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Abstract 
The Transferrins are homologous monomeric bilobal glycoproteins of approximately 
8OkDa that can reversibly exhibit a high affinity for iron. There are four main 
members of this family: the serum transferrins, involved in iron transport around the 
body, the lactoferrins that possess a number of functions, including antimicrobial 
properties, the ovotransferrins and the melanotransferrins. However, the mechanisms 
by which iron is taken up and released is poorly understood. 
The first part of this project was the design of an efficient expression system to 
obtain routinely the substantive amount of protein necessary for the 
structure/function study of these proteins, in order to elucidate their mechanism of 
action and role. The expression of hSTf and hLf was first explored in Escherichia 
cola, where it was shown to be unsuccessful, and then in Saccharomyces cerevisiae 
where, for the first time, a very high level of expression of the full-length hSTf was 
achieved at levels up to 1.8 mg/ml. The expression of the G394R hSTf mutant was 
therefore also obtained using the same system. 
Following the purification of both recombinant hSTf proteins using a three-step 
procedure, a four-way structure-function comparison between native WT, native 
mutant (G394R), recombinant WT and recombinant mutant (G394R) was carried 
0 
out. Structural identity between these recombinant proteins with their native forms 
was shown by CD analysis, dynamic light scattering and immunodiffusion assays 
against anti-hSTf. The ability of the recombinant proteins to bind iron was confirmed 
by urea-PAGE, UV scanning spectroscopy, along with exhibiting similar 
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thermodynamic characteristics, calculated through ITC. EPR analysis of the iron- 
saturated recombinant proteins revealed the characteristic holo-transferrin spectrum. 
Biophysical comparisons between the WT and mutant proteins revealed significant 
changes in the tertiary structure for the variant's C-lobe upon binding iron, which 
explains a 6-7-fold reduction in the C-lobe affinity for iron. However, such decrease 
in binding affinity is proposed, with use of homology modelling, not to be due 
directly to a decreased affinity in the binding site, but more to further interaction of 
residue R394 elsewhere in the C-lobe. Contradictory to the results published by 
Evans et al, 1994, these interactions are shown not to be involving the residues of the 
C-lobe iron-binding site, but to be restricting the flexibility of the lobe's two domains 
therefore preventing them from efficiently closing over the iron atom. Not only has 
the mutation been shown to affect the C-lobe, but these studies have also shown its 
subtle repercussions on the N-lobe. It is worth noticing that since the site of these 
interactions is located near to the regions of the C-lobe involved in interaction with 
the helical domain of TfR1, it is proposed that they are responsible for the 10-fold 
reduced affinity of the variant in its diferric form for the TfRI (Young et al, 1984). 
Concomitantly to the characterisation, conditions for crystallisation of native hLf and 
recombinant hSTf were also investigated. Crystals were obtained for both proteins 
and used in obtaining initial x-ray diffraction data. Such preliminary results, in 
combination with the experimental characterisation, have brought us undoubtedly 
one step further towards the full understanding of the mechanism(s) of iron uptake 
and release of Transferrins. 
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1. Introduction 
1.1. Iron 
With rare exceptions, virtually all studied organisms from Archaea to man are 
dependent on iron for survival (Aisen et al, 2001). One organism found not to require 
iron is Lactobacillus plantarum (Archibald, 1983). These metabolic functions 
include: provision of a specific binding site for oxygen in the Haem moiety of 
haemoglobin and conferment of redox activity on the cytochromes of the respiratory 
chain, and on numerous other enzymes, some of which are involved in DNA 
synthesis (Andrews, 2000). Iron's ability to confer redox activity is due to it 
possessing unfilled d atomic orbitals and is able to undergo changes in oxidative 
states (Fe2+, ferrous and Fe 3+ ferric) involving one electron. However, this 
characteristic can also lead to the formation of unstable intermediates with unpaired 
electrons, i. e. free radical formation. Examples of these include the generation of the 
superoxide radical 02 by the reaction 02 + Fe 2+ -º 02 + Fe 
3+ and the formation of 
OH- (hydroxyl) radical through the Fenton reaction (Fe 2+ + H202 --ý 0H" + Fe 
3+ + 
OH"). It is important to note that H202 in the Fenton reaction is itself generated by 
superoxide dismutase catalysing 202 --º 02 + 022-, then 022" reacting with 2H+. 
These hydroxyl radicals are so reactive they will attack and destroy cell membranes, 
as well as DNA. This shows that iron homeostasis needs to be tightly controlled, as 
even though iron is essential for metabolism, it is also toxic in its free form. 
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1.2. Iron Homeostasis 
Peter J Sargent 
As previously discussed, iron is an important requirement in our diet. Cellular iron 
deficiency is known to arrest cell growth and ultimately lead to cell death (Hentze et 
al, 2004). Because of its importance, organisms have evolved highly sophisticated 
mechanisms to control iron homeostasis in order to provide the amounts required for 
life, but at the same time, minimising its toxic effect. In mammals, this regulation is 
controlled at many levels. 
1.2.1. Iron Requirement 
The daily iron requirement for a healthy individual is approximately 25mg. This 
varies from person to person. For instance, growing children and menstruating 
women have much higher iron demands. This demand increases even more for 
pregnant individuals. Iron requirements are three times higher in pregnancy than they 
are in menstruating women (Tapiero et al, 2001). On average though, the production 
of 200 billion new erythrocytes every day requires -20mg of iron for haemoglobin 
synthesis, accounting for nearly 80% of the iron demand (Hentze et al, 2004). The 
remaining 20% of the iron demand is used as a constituent in the production of other 
haemoproteins, iron-sulphur (Fe-S) proteins, and proteins that use iron in other 
functional groups. 
A typical Western diet provides on average 6mg of this iron (both haem and non- 
haem) per 4120 kJ of energy intake (Beard et al, 2000). However, the amount of iron 
absorbed is regulated depending on the iron status of the individual. An individual 
with high levels of iron will not absorb iron so readily as someone with low levels. 
Also, the form of iron is important. Food iron occurs in two forms, haem iron and 
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non-haem iron. Nearly 50% of iron in meat is of the haem form (Tapiero et al, 2001). 
This form is the most important dietary source of iron, as it is more readily absorbed 
than non-haem iron. This is why vegetarians can be at a relatively greater risk of iron 
deficiency (Beard et al, 2000). 
The majority of this iron is not utilised straight away, but accumulates safely in the 
body. To give an idea how much iron does accumulate, iron represents 
approximately 35 and 45mg/kg of body weight in adult women and men, 
respectively (Leiu et al, 2001). The majority of the total body iron, 60-70%, is 
present in haemoglobin in circulating erythrocytes, 10% in the form of myoglobin, 
cytochromes, and iron-containing enzymes, and the remaining 20-30% is stored in 
ferritins and haemosiderins in hepatocytes and reticuloendothelial macrophages 
(Conrad et al, 1999). This distribution of iron does vary. For example, in situations of 
iron deficiency, erythroid precursors have priority and the production of red blood 
cells continues at the expense of other tissues. 
The body is economical in its handling of iron. Only 0.5-2mg enters and leaves the 
body on a daily basis (Andrews, 2000). The majority of the iron is recycled. For 
instance, when red blood cells reach the end of their lifespan, they are phagocytosed 
by reticuloendothelial macrophages, which recycle the iron from haem in order to be 
used in the production of more erythrocytes, or to be used else where in the body. 
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1.2.2. Iron Absorption and Transport 
Peter J Sargent 
Intestinal absorption of iron is thought to be the critical step in iron homeostasis (De 
Freitas et al, 2001). The enterocytes found in the epithelial cell layer of the 
duodenum are specialised for absorption and transportation of iron. These cells differ 
from other cells in that they express a number of proteins related to iron uptake and 
transport (Figure 1.1). This figure shows a model for iron transport across duodenal 
epithelial cell proposed by Andrews, 2000. 
It is proposed that non-haem iron (Fe3) in the duodenum is reduced by a ferric 
reductase (Dcytb: duodenal cytochrome b) in the brush border, before being 
transported into the enterocyte through the transmembrane iron transporter DMT1 
(divalent metal transporter 1). Once inside the cell, the iron (Fe 2) is either stored in 
ferritin, or passes through the basolateral membrane to reach the plasma by an iron 
exporter known as ferroportin. This step is thought to be followed by the reoxidation 
of Fe 2+ by the plasma ferroxidase ceruloplasmin (or its membrane-associated 
homologue, hephaestin) (Pantopoulos, 2004). Fe 3+ is then picked up by apo- 
transferrin, to make holo-transferrin, through a mechanism that is not yet understood. 
In normal individuals, this extracellular iron circulates in the plasma bound to serum 
transferrin. Iron, bound in this way is no longer toxic, in that it no longer has the 
ability to produce free radicals. 
1.2.3. Iron Uptake 
In vertebrates, the major protein involved in iron uptake of iron-loaded transferrin 
into cells is the plasma membrane transferrin receptor (TfR) (De Freitas et al, 2001). 














f ')rortl^ 1 
Peter J Sargent 
Figure 1.1. A model for iron transport across duodenal epithelial cells, 
proposed by Andrews, 2000. Shown are the proteins thought to be involved 
in the absorption and transport of iron from the diet into the body's circulatory 
system. 
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been identified and its function remains unclear (Kawabata et al, 1999). What is 
known, is that both receptors bind diferric transferrin in a pH-dependent manner and 
delivers iron to the cells. However, TfR2 has a much lower binding affinity (25 times 
lower) and its distribution around the body varies significantly (Trinder and Baker, 
2003). The best characterised of the two is TfR1 (Cheng et al, 2004). This receptor is 
a 760-amino-acid glycoproteins. The functional receptor is composed of two such 
monomers, linked by two disulphide bridges to form a molecule of 190,000 Da. 
Figure 1.2 shows the crystal structure of the ectodomain of the transferrin receptor 
resolved at 3.2A. Virtually all cells, except mature red blood cells, have this receptor 
on their surface, but the largest numbers are in the erythron, placenta and liver 
(Beguin, 2003). 
At physiological pH, this transferrin receptor has a high binding affinity for diferric 
serum transferrin. Following binding of the two proteins, the complex internalises 
through clathrin-coated pits into specialised endosomes (Figure 1.3). Upon 
maturation and loss of the clathrin coat, the endosome becomes competent to pump 
protons in a process energised by ATPase (Qian et al, 2002). This causes the 
endosomal lumen to rapidly acidify to a pH around 5.5. At this pH, the binding of the 
iron to serum transferrin is weakened, leading to iron release. The free Fe 3+ is then 
reduced to Fe 2+ on the cis-side of the endosomal membrane, before being transported 
out of the endosome by DMT1 (section 1.2.2). Once in the cytosol, iron is either 
stored or utilised by the cell. Following release of the iron, the transferrin-TfR 
complex is then recruited through exocytic vesicles back to the cell surface. At 
physiological pH, apo-transferrin is dissociated from the receptor and enters back 
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Apical Domain 
Plasma Membrane 
Figure 1.2. The crystal structure of the ectodomain of TfR resolved at 3.2 Ä. 
(Lawrence et al, 1999). Each TfR monomer can be divided up into a number of 
domains; Cytoplasmic domain, N-terminus consisting of 61 amino acids; 
Transmembrane domain, 26 amino acids long hydrophobic region; and the 
transferrin binding domain, 671 amino acids long. One monomer is depicted in 
blue, whilst the other monomer is divided up into the protease domain, apical 
domain and helical domain, shown in red, green and yellow, respectively. 
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Figure 1.3. A model for iron uptake via the transferrin receptor-mediated 
endocytosis pathway (Andrews, 2000). Shows the internalisation of diferric 
transferrin, following binding to TfRI, followed by the release of iron from 
transferrin and its transport into the cytosol for either storage or utilisation. 
Finally, the transport of the trans ferrin-TfR I complex to the cell membrane and 
the subsequent release of transferrin back into circulation. 
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into the circulation, and reutilised (Morgan, 1996). Transferrin has been calculated 
to be recycled between 100-200 times during its lifetime (Aisen et al, 2001). 
Cells may also take up iron in other protein-bound forms, such as acidic isoferritin, 
or haemoglobin, or through phagocytosis of red blood cells by macrophages. 
Biochemical data also suggests that additional iron uptake mechanisms may exist 
(Hentze et al, 2004). This shows that even though the transferrin-mediated 
endocytosis is thought to be the major uptake system of iron, cells have evolved 
many mechanisms for the uptake of iron. 
1.2.4. Iron Storage and Release 
Not all the iron in the body is being used in metabolic processes. Some of it is stored 
as a reserve in case iron levels drop too low. However, free iron would aggregate into 
toxic precipitates (Arosio and Levi, 2002). To overcome this, iron in the body is 
stored in ferritins and haemosiderins in hepatocytes and reticuloendothelial 
macrophages. As discussed in section 1.2.1, this stored iron makes up 20-30% of the 
total iron in the body. 
Ferritin is a ubiquitous and highly conserved iron-binding protein. A number of 
different forms exist. Examples of these include, cytosol ferritin, mitochondrial 
ferritin and serum ferritin. The structure of the cytosolic form of L-chain horse 
apoferritin is shown in Figure 1.4. Mammalian ferritins are all heteropolymers of 24 
subunits of two types, designated H for heavy (21,000 Da), or heart (but also 
kidney), the tissue in which it abounds, and L for light (19,500 Da) or liver (but also 
spleen) (Aisen et al, 2001). These molecules have the ability to sequester up to 
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Figure 1.4. A ribbon diagram of L-chain horse apoferritin (1.95A) 
(1AEW) created using Deep Viewer / Swiss PDB Viewer. Each of the 24 
subunits is coloured differently to give an idea of the complexity of the 
molecule. 
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approximately 4500 iron atoms in the form of Fe 3+ (Chasteen and Harrison, 1999). 
An important feature of ferritin is its ability to catalyse the oxidation of Fee+, the 
predominant iron form in the cytosol, converting it to Fe 3+ before it is sequestered in 
the ferritin mineral core. 
Haemosiderin is a poorly defined iron-protein complex that forms an insoluble iron 
storage system, thought to derive from the lysosomal degradation of the ferritin 
protein shell. Under normal iron homeostatic conditions, the body tissues contain 
only low amounts of haemosiderin; however, under conditions of primary and 
secondary iron overload, the tissue haemosiderin content dramatically increases, 
particularly in organs such as the liver, pancreas, and heart (Testa, 2002). 
1.2.5. Regulation of Cellular Iron Homeostasis 
Many of the proteins discussed previously and other proteins involved in iron 
homeostasis are under tight genetic control. Their expression can be up- or down- 
regulated depending on the availability of iron. This control involves modulation of 
transcription, mRNA stability, translation, and post-translational modification. 
Post-transcriptional modification is the best characterised. This involves the iron 
regulatory proteins (IRPs) and iron responsive elements (IREs). IRP1 and IRP2 are 
involved in the coordinated post-transcriptional regulation of iron metabolism by 
binding to IREs (Wang et al, 2002). These IREs are stem-shaped structures located 
in the 5' and 3' untranslated regions (UTRs) of mRNA. Their structure comprises a 
terminal hexanucleotide loop region with the sequence 5'-CAGUGX-3', where X 
can be A, C, or U, but never G, and a base-paired stem structure that is interrupted by 
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a conserved unpaired cytosine, six nucleotides down from the loop. Table 1.1 shows 
examples of some of the proteins under IRE control. These include proteins involved 
in iron storage, erythroid heure synthesis, the TCA cycle, iron export and iron uptake. 
The binding of IRPs to single IREs in the 5' UTRs of mRNA has been found to 
block translation. Whereas, binding of IRPs to IREs in the 3' UTRs stabilises the 
mRNA, therefore having a positive effect on translation. Figure 1.5 shows some of 
the proteins regulated in such a way, and also the effect iron levels have on their 
translation. 
The actual binding of IRPs to IREs is regulated by a number of different factors. 
When iron levels are high, a cubane iron sulphur cluster assembles in IRPI, 
inhibiting IRE binding and converting IRP 1 to an aconitase (Pantopoulos, 2004). 
Under iron limiting conditions this iron sulphur cluster does not form, and IRP 1 is 
able to bind to IREs. This is different for IRP2 as this protein does not contain an 
iron sulphur cluster. IRP2 has been found to contain an iron-dependent degradation 
domain. In the presence of iron, proteosomes bind to this protein and degrade it, thus 
preventing its interaction with IREs. Even though these two IRPs have been 
identified, little is known about their individual contribution to the maintenance of 
cellular iron homeostasis. In in vitro experiments, it has been shown that both 
proteins do not differ in their ability to be able to regulate ferritin and TfR expression 
(Erlitzki et al, 2002). However, Meyron-holtz et al, 2004, suggest that IRP2 
dominates post-transcriptional regulation of iron metabolism in mammals. The actual 
control of IRP expression is poorly understood. A number of factors that influence 
their expression are known. These include the influence of reactive oxygen species, 
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Gene 
Single IREs 
IRE location Function Reference 
Ferritin L chain 5' Iron Store Hentze and 
Ferritin H chain 5' Iron Store Kühn, 1996 
Mitochondrial 
Aconitase 




5' Specific key enzyme in 
heure synthesis 




5' Iron Exporter Mok et al., 2004 
DMT 1 3' Iron Transporter Hentze, 2004 
Succinate 
dehydrogenase 









Table I. I. Examples of Iron Responsive Element (IRE)-containing genes and 
their function. The location of the IRE, whether in the 3' or 5' untranslated region 
(UTR), is also stated. Only the TfR1 mRNA contains multiple IREs. 
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Figure 1.5. The IRP-IRE regulation system showing the effect iron, NO, H202 
and 02 levels has on the binding of IRPs to IREs, and the subsequent effect 
this has on translation on a number of proteins. IRPs binding to IREs in the 3' 
UTR portion of mRNA has been found to protect the mRNA from degradation, 
whereas, the binding of IRPs to IREs in the 5' UTR portion has been found to 
block translation. 
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shown to disassemble the iron sulphur cluster of IRP1, as well as nitric oxide and 
hypoxia having an effect on both IRPs (Hentze et al, 2004). 
Many other regulatory mechanisms exist that are independent of the IRP/IRE 
mechanisms. A number of cytokines have been reported to have an effect on the 
expression of some of the proteins involved in iron homeostasis. For example, tumor 
necrosis factor-a, interleukin-1, interleukin-6, and interferon-y all stimulate H- 
ferritin expression but reduce TfRl expression (Torti and Torti, 2002). Interferon-y 
has also been shown to induce DMT-1 expression and inhibit ferroportin expression. 
Another example of regulation is the proposed role of HFE in the regulation of iron 
homeostasis. HFE is a heterodimeric membrane protein that has the ability to form 
noncovalent associations with 02-microglobulin and has been shown to bind to TfR. 
Two molecules of HFE can bind to the dimeric TfR, or just one molecule 
simultaneously with a diferric Tf. When both proteins are bound, HFE has been 
found to reduce the binding affinity of Tf. Two possible reasons for this reduction in 
affinity exist. Either HFE, on binding to one polypeptide chain of the TfR dimer, can 
transmit structural changes to other TfR chains, or it competes with Tf for the TfR 
binding site (Giannetti et al, 2004). However, how HFE actually contributes to the 
regulation of cellular iron homeostasis is still unknown. Roy et al, 1999 showed that 
the expression of HFE in the cell reduces iron uptake by 33%, but does not affect the 
endocytic or exocytic rates of TfR cycling. 
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1.2.6. Iron Metabolism Disorders in Humans 
Iron metabolism-related diseases in humans fall into three major categories: (I) 
diseases associated with defective regulation of iron absorption, (II) diseases caused 
by erroneous tissue and/or subcellular compartmentalisation of iron, and (III) 
secondary disorders induced by altered iron content in cells and/ or other tissues 
(Lieu et al, 2001). Just a few examples of these diseases are listed in Table 1.2, along 
with the gene involved and the defect. 
Haemochromatosis is the most common genetic disorder known in Caucasians of 
European ancestry. In the United States, as much as 10% of the population is 
heterozygous for this condition, and the homozygous state is believed to be as much 
as 0.5% of the population (Sheth and Brittenham, 2000). In this disorder, the control 
of iron uptake is abnormal causing an increase in iron uptake and the progressive 
build-up of body iron, ultimately becoming fatal if not treated. The iron overload 
firstly accumulated in hepatocytes, but subsequently the iron builds up in the 
pancreas, heart and other organs. Five known types of haemochromatosis exist. Type 
1, or hereditary haemochromatosis, is caused by a mutation in the gene encoding 
HFE. Even though the exact mechanism is still a mystery, this protein has a unique 
perinuclear localisation in cells in the deep crypts of the small intestine where it is 
thought to interact with ß2-microglobulin and aid in iron absorption. HFE has also 
been found to interact with the TfR. Type II, or Juvenile haemochromatosis, is an 
autosomal recessive disease very distinct from hereditary haemochromatosis. In this 
disorder, the onset of iron overload is much earlier and is more severe, with 
endocrine dysfunction, joint disease and cardiac abnormalities. Even though the 
exact cause of this disease is unknown, mutations in the hepcidin and haemojuvilin 
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Point mutation, insertion, 
deletion 
African dietary overload - - 
Congenital Transferrin - 
atransferrinaemia 
Congenital - - 
d ser hro oietic anaemia 
Erythropoietic Ferrochelatase Point mutation 
roto oh ria 
Familial hypoferremic - - 
microcytic anaemia 
Friedreich's ataxia FRDA Point mutation 
Hereditary Hfe Point mutation 
haemochromatosis 
HFE 3 type TfR2 Point mutation 
haemochromatosis 
Hyperferritinaemia with Ferritin L Point mutation in IRE 
cataract 
Juvenile - - 
haemochromatosis 
Menkes disease ATPase 7A Point mutation 
Porphyria cutanea tarda URO-D Point mutation, insertion, 
deletion 
Sideroblastic anaemia ALAS2 Point mutation 
Sideroblastic anaemia and ABC7 Point mutation 
ataxia 
Wilson's disease ATPase 7B Point mutation 
Table 1.2. Iron metabolism disorders in humans, the gene involved and the 
defect. Where the gene and / or the defect is unknown a (-) is used. (Adapted 
from Lieu et al, 2001). 
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genes are thought to play a role. Type III is a rare form of the disease thought to be 
cause by mutations in the TfR2 gene and type IV is again rare, and is thought to 
occur due to mutations in the ferroportin gene. The fifth type is neonatal 
haemochromatosis. This again is very rare and the exact cause is unknown. 
Atransferrinaemia is a rare autosomal recessive disorder in which plasma transferrin 
is absent, or almost absent in the case of hypotransferrinaemia. Only about eight 
cases have been described in six families (Beutler et al, 2000). A severe microcytic 
anaemia, present from birth, only responds to transferrin infusion. Without this, or 
blood transfusions, patients are at great risk of iron-overload and usually die early in 
life. 
Aceruloplasminaemia, like atransferrinaemia, is a newly recognised, rare autosomal 
recessive disorder. This disorder results from the deficiency, or complete lack of 
ceruloplasmin ferroxidase activity as a consequence of mutations in the 
ceruloplasmin gene. Clinically, the disease consists of the triad of adult-onset 
neurological disease, retinal degeneration and diabetes mellitus (Miyajima, 2003). 
Ceruloplasmin deficiency is also linked to Wilson's disease and Menke's disease. 
Hyperferritinaemia with autosomal congenital cataract is a disorder characterised by 
early-onset, bilateral nuclear cataracts and moderately elevated serum ferritin 
concentrations. In contrast with normal individuals, serum ferritin in patients with 
this disorder is mainly composed of L-ferritin, with H-ferritin levels being sometimes 
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too low to detect. This disorder is caused by multiple point mutations in the IRE of 
the L-ferritin mRNA, therefore affecting the regulation of its synthesis. 
Friedreich's Ataxia (FRDA) and sideroblastic anaemia (SBA) are disorders that are 
associated with aberrant mitochondrial iron homeostasis (Roy and Andrews, 2001). 
In FRDA, patients show evidence of mitochondrial iron overload and loss of activity 
of iron-sulphur cluster-containing enzymes. They frequently die from 
cardiomyopathy. This disorder is thought to be due to point-mutations in the gene 
encoding frataxin, a protein involved in the mediation of mitochondrial iron 
homeostasis. SBA is quite different. Even though there are many different causes of 
SBA, they all affect the efficiency of haem production within erythroblast 
mitochondria. There are two forms of SBA: SBA with ataxia (muscular problems), 
caused by point mutations in the ABC7 gene and SBA without ataxia, caused by a 
mutation in ALAS2. 
Some disorders actually have a secondary effect on iron metabolism. One such 
disorder is thalassaemia. This is a disease caused by insufficient synthesis of 
structurally normal a or ß chains of haemoglobin and results in anaemia. There are 
many different types of thalassaemia and even more genetic mutations that cause it. 
The two main types are: (I) a-thalassaemia, caused by relative or absolute deficiency 
of a-chains and (II) ß-thalassaemia, caused by relative or absolute deficiency of ß- 
chains. These two groups can be split further into thalassaemia minor, heterozygous 
a- or ß-thalassaemia where anaemia may be present, but is very mild and 
thalassaemia major, homozygous a- or 0 thalassaemia causing severe anaemia. 
Because thalassaemia causes anaemia, patients with this disease, especially in the 
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major cases, require blood transfusions at frequent intervals throughout their lives to 
provide them with the haemoglobin they require. This is an effective treatment, but 
unfortunately the increased uptake of iron, not through the usual regulatory pathways 
of the gut, but in the form of haemoglobin, leads to iron overload. This is made 
worse due to the fact that iron does not get recycled for use in synthesis of 
haemoglobin as in normal patients. 
1.3. The Transferrins 
1.3.1. Introduction 
The transferrins are a family of homologous monomeric bilobal glycoproteins of 
molecular weight approximately 8OkDa, that have an important role in iron 
homeostasis. Even though the first isolation of a member of the transferrin family 
(ovotransferrin) came in 1900 (Osborne and Campbell, 1900), it was not until 1944 
that it function was elucidated (Schade and Caroline, 1944). Soon after, Schade et al, 
1946, isolated a similar protein from blood plasma, known now as serum transferrin. 
This family has now been found to comprise of four main members. The four main 
members include; the serum transferrins, which are known to transport iron from its 
site of absorption to the site of utilisation, or storage; the lactoferrins, which have 
been found to possess antimicrobial properties; the ovotransferrins, which are known 
to be a major component of egg white; and the melanotransferrins, found on the 
surface of melanoma cells. Each of these members exhibits a high affinity for 
iron(III) (K d- 10-22M)(Aisen et al, 1978) and have been found in a wide range of 
organisms, in both vertebrate and invertebrate groups. Table 1.3 lists a few of the 
transferrins that have either been sequenced, or partially sequenced. 
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Transferrin 
Chordata 
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Mouse Atlantic cod Cockroach 
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Table 1.3. Transferrins that have been identified and sequenced. Partial and 
variants are shown in italics. This data was last updated in 2003 from: 
www chatham edu/under¢raduate/bio/lambert/transferrin/transferrins. htm 
38 
1: Introduction Peter J Sargent 
Although the transferrins have evolved to bind iron(III) with high affinity at neutral 
pH, their metal-binding sites are able to bind a wide range of different metal ions, 
especially tripositive ones. By 1992 thirty elements, in addition to iron, were known 
to be able to bind to one or both of the metal-binding sites in hSTf in vitro (Welch, 
1992). Since then a further four metal ions, cerium(IV) (Smith et al, 1994), 
bismuth(III) (Li et al, 1996), lutetium(III)(Harris et al, 1999) and ytterbium(III)(Du 
et al, 2002) have been shown to bind to members of the transferrin family of 
proteins. The elements now proven to bind to transferrins are highlighted in Figure 
1.6. As serum transferrin in normal individuals is only partially iron-saturated, the 
protein, in theory could be involved in the transport of many other metals around the 
body. 
1.3.2. General Structure 
The transferrin polypeptide is approximately 670 amino acids long with a molecular 
weight of 79,55ODa (MacGillivray et al, 1982) folded into two lobes that exhibit 
high levels of homology, the N- and C-lobes. The two lobes of human serum 
transferrin are 48% homologous (Baldwin, 1993) and for both porcine and rabbit 
serum transferrin, 45.5% and 42.9% respectively (Hall et al, 2002). This high degree 
of homology is consistent with the theory that both lobes arose from a gene 
duplication process (Williams, 1982). 
Within the secondary structure of these proteins, there are six conserved disulphide 
bridges in each lobe, with an extra three semiconserved bridges in the C-lobe 
(Williams, 1982). Chicken and duck ovotransferrin have only fifteen bridges, 
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whereas human lactoferrin (hLf) has a further disulphide bridge in the C-lobe and 
hSTf has a further four bridges, two in the N-lobe and two in the C-lobe. 
Since the earliest report of the structure of transferrins in 1979, from a 6th electron 
density map (Gorinsky et al, 1979), the tertiary structure of these proteins has been 
elucidated at much higher resolution. For example, the crystal structure of holo hen 
ovotransferrin N-lobe has been elucidated recently at 1.65A (Mizutani at al, 2001), 
human apolactoferrin at 2. OA (Jameson et al, 1998) and rabbit serum transferrin at 
2.6A (Hall et al, 2001). However, crystal structures of transferrins complexed to 
metals other than iron(III) are limited to hLf with copper(III)(Smith et al, 1992) and 
cerium(IV)(Baker et al, 2000), and mare lactoferrin with samarium(III)(Sharma et al, 
1999). These maps show that the transferrins are folded into two lobes of 
approximately 330 amino acids that are joined together by a short connecting peptide 
and also make contact via a `cushion' of hydrophobic residues packed between them. 
Each lobe can be further split into two dissimilar domains (CI, CII, NI and NII) 
(Figure 1.7). These domains consist of mixed right-handed ß-sheets (-P25%) and a- 
helices (-40%). 
Most of the transferrins, except for Xenopus laevis transferrin, contain a varying 
number of N-linked glycosylation sites. For example, rabbit serum transferrin has 
only one (Evans et al, 1988), bovine lactoferrin has four (Baker and Lindley, 1992) 
and hSTf has two (N413 and N61 1) (Jamieson et al, 1971). No 0-linked 
glycosylations have been identified on transferrins. The fact that not all transferrins 
are glycosylated, and those which do, have glycosylation sites located at different 





Peter J Sargent 
Figure 1.7. Ribbon diagram of rabbit serum transferrin (1JNFA). Picture 
created using Deep Viewer / Swiss PDB Viewer. Both lobes are labelled and 
both domains highlighted. Domain I: Blue and Domain II: Red. 
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1.3.3. Iron-binding Sites 
Peter J Sargent 
As described previously, transferrins have the capability of reversibly binding two 
ferric ions, one in each lobe. The two iron-binding sites are 42A apart and buried 
deep in the interdomain cleft in a highly polar environment (Anderson et al, 1987). 
The iron-binding sites in both lobes are very similar and comprise a distorted 
octahedral coordination involving four protein ligands and a bidentate synergistic 
carbonate anion (Hall et al, 2002)(Figure 1.8. A). These protein ligands comprise two 
tyrosines, one aspartate and one histidine. Amongst all known transferrins the 
aspartate and the histidine are provided by domain I, whereas the two tyrosines and 
the bidentate carbonate anion is provided by domain II. All four of these ligands, 
along with an arginine involved in the anchoring of the carbonate anion to the 
protein, are conserved between lobes and amongst higher transferrins. Table 1.4 
illustrates the degree in which these five residues, along with their neighbours, are 
conserved amongst the higher transferrins. 
In order to understand the binding of Fe 3+ by transferrin, it is important to note that 
Fe 3+ has the ability to bind six ligands. This ability comes from the fact that the atom 
has five unpaired electrons in its 3d orbital and an empty 4s orbital. When Fe3+ is 
bound by transferrin, a possible way these two orbitals are filled up is by an electron 
from one carboxylate oxygen (aspartate), an electron from each of the two phenolate 
oxygens (two tyrosines), an electron from each of the two oxygens from the anion, 
and one electron from the imidazole nitrogen (histidine) (Figure 1.8. B). It is also 
important to note that the three positive charges of the Fe3+ are matched by the 3 
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Figure 1.8. A. The N-lobe binding-site of hLf (Baker et al, 2002) and B. 
Schematic diagram of the coordination environment and the hydrogen 
bonding network around Fe3+ in the N-lobe of hen serum transferrin (Guha 
Thakurta et a!, 2003). The Fe 3+ ion is bound to the side chains of Asp60, Tyr92, 
Tyr192, and His253 and the bidentate C032- ion, which is hydrogen-bonded to 
Arg 121 and to peptide NH groups from the N-terminus of an a-helix. 
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Serum Phe Tyr Gly Phe 
Transferrin Gly Ser Gly Thr 
Ser Thr Asn Ala 
Gly Arg124 I Ser Gly Arg456 Thr 
Human Leu Gly Leu Gly 
Lactoferrin His Tyr Gly Leu 
Ser Ser Gly Thr 
Ser Ala Asn Ala 













































Camel Leu 0 Gly Leu Gly 
Lactoferrin His Try Gly Leu 
Gly Ser Gly Thr 
Ser Ala Asn Ala 
Gly Ser Asp Thr 
Table 1.4. Comparison of residues involved in iron binding, their position 
and the amino acid either side of it (-1 and +1) for both lobes amongst 
different transferrins. Residues highlighted in red are those directly involved 
in the binding of the ferric ion. Out of these residues, yellow text represents the 
residues involved in carbonate binding. 
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is compensated for by the positively charged arginine side chain and a positive 
charge at the N-terminus of an a-helix (Baker et al, 2003b). 
1.3.4. Iron Binding and Release 
A feature common to all transferrins is the closing of the interdomain clefts upon 
incorporation of iron into the iron-binding sites, in doing so, bringing the iron- 
binding ligands on both domains together, `grasping' the iron. This feature has been 
shown to be the opposite in the apo-form, in that the domains are open (Baker et al, 
1997). 
The actual mechanism of iron binding is still not completely clear. It is thought that 
iron-binding starts with the binding of the anion to domain II, followed closely by the 
binding of the metal by the two tyrosines on the same domain. Once bound, a 
conformational change occurs, causing domain I to close over domain II. This 
closure allows the histidine and aspartate ligands to come into contact with the iron, 
allowing them to bind the iron's remaining two coordinates. 
The extent in which the two domains open and close, along with how highly 
conserved the rotation angle of each of the domains are across the transferrin family 
(Guha Thakurta et al, 2004). They showed that if domain I, from the closed form of 
hen STf N-lobe, was superimposed with the open form, a rotation of 52.7° difference 
can be seen. Similarly in the C-lobe, a rotation of 35° was seen. The rotation in the 
N-lobe of human lactoferrin and human serum transferrin is also similar, 54° and 
630, respectively. 
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The actual affinity for the Fe 3+ ion varies between both lobes and also members of 
the transferrin family. One explanation for this is the iron-ligand bond distances, as 
these distances are known to vary. The longer bond length is thought to be the reason 
why the N-lobe of serum transferrin releases iron more readily than the C lobe. Iron 
is released from the N-lobe of serum transferrin at around pH 5.7, whereas the C lobe 
retains iron until around pH 4.8 (Rinaldo and Field, 2003). This difference can also 
be seen between transferrin family members as, for example, lactoferrin retains iron 
at a pH as low as 3.5. The higher iron-binding affinity seen in lactoferrins could also 
be due to the greater number of interdomain hydrogen bonds (Hall et al, 2002). 
The differences in iron affinity between the serum transferrins and the lactoferrins 
has also been proposed to be due to regions found in the N-terminal lobe of only the 
serum transferrins, away from the iron-binding site, at the interdomain interface. 
Around this region, two lysines (K206 + K296) have been proposed to play a role in 
iron-release. These residues are on opposite faces of the iron-binding cleft and are 
thought to be bridged by a single proton when the protein is in its closed form. The 
theory is, at low pH (section 1.2.3) these two lysines are protonated, leading to the 
subsequent release of the proton bridge and causing the two domains to repel each 
other (Rinaldo and Field, 2003). As the domains flip open, the iron is released. This 
theory is known as the dilysine trigger. The importance of these lysines were 
highlighted by Nurizzo et al in 2001 when they showed that mutating these two 
lysines had a significant effect on iron-binding and release. 
However, a primary role of this dilysine trigger has been questioned. It is thought 
that the protonation of the carbonate anion and the histidine iron-binding ligand 
47 
1: Introduction Peter J Sargent 
constitutes the primary stages of iron release, with the dilysine trigger being 
important once the iron binding ligands are weakened (Hall et al, 2002). However, 
this dilysine trigger does explain, at least in part, the in vitro release of iron more 
readily from the N-lobe compared to the C-lobe of serum transferrin. 
1.3.5. Tf/TfR Interactions 
As described earlier (section 1.2.3), serum transferrin transports iron from the gut 
and delivers it to cells using an endocytotic pathway involving the transferrin 
receptor (TfR). At the slightly alkaline pH of 7.4, two diferric serum transferrin 
molecules can bind to the dimeric transferrin receptor. A model of the Tf/TfR 
complex is shown in Figure 1.9. This figure shows the orientation in which the two 
diferric Tf molecules bind to the TfR. The model also shows the N-lobe to bind 
beneath the receptor, making contact with the protease-like and helical domains, 
therefore being sandwiched between the membrane and the TfR ectodomain, and the 
C-lobe pointing up towards the helical domain (Cheng et al, 2004). On binding, there 
also seems to be a shift of the N-lobe by about 9A with respect to the C-lobe, 
`stretching' the protein onto the receptor, tightening the interactions. Regions on the 
TfR shown to interact in this model are consistent with regions predicted through 
mutagenesis studies (Giannetti et al, 2003). 
In the C-lobe a large interaction is thought to take place between domain I and the 
receptor, leaving domain II to move freely. This would suggest that iron could be 
released from the C-lobe whilst the transferrin is still attached to the receptor. The 
interaction of the N-lobe to the receptor seems to be somewhat different. This lobe 
has been found to make two very localised interactions with the receptor. Domain I is 
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A. Ectodomain of the 
dimeric TfR 
B. Binding of two diferric Tf 
molecules to the TfR 
C. Side-on view of the TfR 
with the two diferric Tf 
molecules bound 
Peter J Sargent 
Figure 1.9. An atomic model of the TfR diferric Tf complex created by 
Cheng et al, 2004. The model was created by fitting the crystal structure of the 
TfR with the crystal structure of the human serum Tf N-lobe (MacGillivray et 
al, 1998) and the crystal structure of rabbit serum Tf (Hall et al, 2002). 
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thought to interact with the helical domain of the receptor and domain II is thought to 
interact with the protease-like domain. Even though both domains in the N-lobe are 
involved in receptor binding, studies have shown that the N-lobe interacts with the 
TfR more weakly than the C-Lobe. Cheng et al, 2004 also showed that the N-lobe 
has a hydrophobic patch that is thought to make it non-specifically `sticky', giving it 
the ability to bind to different regions of the receptor. 
Receptor bound Tf preferentially releases iron from the C-lobe, probably due to the 
freedom of movement of domain II. Cheng et al, 2004 have shown the C-lobe to 
rotate approximately parallel to the membrane on release of the iron. However, 
because the N-lobe interacts with the receptor using both of its domains, it cannot 
release the iron so easily. This could explain the predominance of N-monoferric Tf in 
the serum. However, lobe communication through the bridge connecting the two 
lobes and the interaction of the C-terminal helix with domain I of the N-lobe, is 
thought to be a major key in the release of iron from both lobes and the Tf from the 
receptor. Gumerov et al, 2003, confirm this theory of inter-lobe communication as 
they show that loading of the C-lobe with iron reduces the conformational flexibility 
of the iron-free N-lobe. They then postulate that this in turn could cause a transducer 
effect whereby the receptor could undergo a conformational change and thus forcing 
a transition of Tf from its closed conformation to its open one. Evans and Williams 
also reported this inter-lobe communication in 1980, when they found that C-lobe 
monoferric hSTf had a more stable N-lobe than the N-lobe of apo-hSTf. 
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1.3.6. Transferrin-Iron Uptake by Bacteria 
The ability to sequester iron by bacteria is recognised as a virulence factor since the 
environment in a mammalian host is believed to be iron limited. Mechanisms for this 
iron acquisition fall into two general categories: synthesis of siderophores and 
cognate receptors, or receptor mediated acquisition of iron from host proteins such as 
transferrin (Ratledge and Dover, 2000). 
A number of bacteria are capable of utilising hSTf- and hLf- bound iron. These 
include pathogenic Neisseria, Moraxella catarrhalis, Actinobacillus 
pleuropneumoniae, Haemophilus influenzae and Pasteurella multocida (Comelissen, 
2003). Iron uptake from hSTf is mediated by two proteins, transferrin-binding 
proteins A and B (ThpA and TbpB), while lactoferrin-binding proteins A and B 
(LbpA and LbpB) are associated with iron-uptake from hLf. 
Figure 1.10 shows a schematic representation of the ThpAB/LbpAB system involved 
in iron uptake from transferrins by Neisseria meningitidis. The mechanism of iron 
acquisition is thought to start with the initial binding of TbpB/LbpB with diferric 
transferrin, followed with the binding of this protein complex with TbpA/LbpA. 
Once all three proteins are complexed, the diferric transferrin is in a position 
whereby it sits over the ThpA/LpbA. Once here, iron is released from the Tf 
molecule and passes through TbpA/LbpA. Ferric ion transport through these 
membrane proteins is thought to be dependent on the TonB-protein. TonB, along 
with it cytoplasmic membrane accessory proteins ExbB and ExbD, operates in this 
system as an energy transducer that couples proton-motive force between the two 
membranes (Gorringe and Oakhill, 2002). Following passage through the outer 
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Figure 1.10. A schematic representation of the system involved in iron 
uptake from transferrins by Neisseria meningitidis. Internalisation of iron 
into the bacterial cell is thought to be mediated by TbpAB/LbpAB using energy 
derived from TonB. (Adapted from Gorringe and Oakhill, 2002). 
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membrane, ferric ion is then thought to be taken up by ferric binding protein A 
(FbpA). This protein then shuttles the iron from the outer membrane to the inner 
membrane where it interacts with FbpB, a permease. As FbpC possesses an ATP- 
binding domain, it has been postulated that this protein supplies FbpB with the 
energy required for active transport of iron into the cytoplasm. Once in the 
cytoplasm, the path in which the iron takes, as in the case following eukaryotic cell 
iron uptake, is unclear. 
The actual interaction of transferrins with ThpAB/LbpAB is not well characterised. 
A lot of work has been carried out on which regions of Tbp interact with transferrin, 
but relatively little on what regions of transferrins interact with Thp. What has been 
elucidated is that hSTf has a TbpB-binding site located within both the C-lobe 
(Alcantara et al, 1993) and in the N-lobe (Boulton et al, 1999). Boulton et al, 1999, 
showed that even though both lobes can interact with the receptor, the primary 
receptor-binding site resides in the C-lobe, with the N-lobe site acting as a secondary 
receptor-binding site. These studies also identified the specific region of hSTf 
(residues 255-350) in which it interacts with TbpB. Retzer et al, 1999, identified the 
TbpB binding region in the C-lobe of hSTf to be between residues 589-679. Less is 
known about the regions involved in binding to TbpA/LbpA. However, LbpA has 
been shown to bind to both domains of the C-lobe of hLf (Wong and Schryvers, 
2003). 
1.3.7. Genomic Organisation of hSTf and hLf 
Both hSTf and hLf are located within close proximity from each other in the genome, 
3q22.1 and 3g21-q23, respectively (www. ncbi. nlm. nih. gov/genome). Figure 1.11 
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shows the genomic map of both hSTf and hLf genes. As shown, both genes are quite 
different. The hLf gene spans 73692 base pairs of chromosomal DNA comprising of 
21 exons, with a total exon length of 3194 base pairs. Out of these 3194 base pairs, 
2136 base pairs (17 exons) encode for the protein (including leader sequence). The 
hSTf gene spans over 82676 base pairs of chromosomal DNA and comprises 18 
exons, with a total exon length of 2664 base pairs. Only 2096 of these base pairs 
(spanning 17 exons) encode for the protein (including leader sequence). The sizes of 
the mature hLf and hSTf protein are 691 and 678 amino acids, respectively. 
Following the alignment of these two protein's exons and comparing exon lengths, a 
high degree of similarity can be observed (Table 1.5). This similarity can be seen in 
the number of protein coding exons, the length of aligned exons and the size of the 
leader sequences. These similarities are consistent with the fact that both proteins are 
related. However, these similarities can also be seen when comparing these two 
genes with the genes encoding transferrin in other organisms. 
1.3.8. Transferrin Gene Expression Regulation 
Several studies have been carried out to try and identify mechanisms involved in the 
regulation of hSTf expression. What was found was that the transferrin gene is 
induced by many different factors in tissue specific fashion. For example, in the rat, 
the levels of transferrin mRNAs are 6.5-fold higher in the liver than in the testis and 
the brain (Idzerda et al, 1986). Much lower levels of Tf expression is observed in 
many other tissues such as the heart, stomach and spleen. Expression regulation is 
not just tissue specific, but is also regulated by numerous other factors. In rats and 
chickens, nutritional iron deficiency has been shown to cause a specific induction of 
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5 14 2 14 
6 5,50 3 5,53 
7 36 4 36 
8 61 5 59 
9 50 6 45 
10 18 7 18 
11 60 8 60 
12 58 9 59 
13 52 10 52 
14 31 11 31 
15 18 12 11 
16 52 13 52 
17 48 14 46 
18 22 15 21 
19 62 16 62 
20 63 17 63 
21 11 18 35 
Table 1.5. Alignment of exons and comparing coding exon length (amino 
acids) between hLf and hSTf. Numbers in blue represent the protein's leader 
sequence. Exons highlighted in yellow represent exons of the same length (data 
from www. ncbi. nlm. nih. jzov/penome). 
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transferrin gene transcription in the liver, resulting in a several fold increase in 
transferrin synthesis (Idzerda et al, 1989). Glucocorticoids and oestrogen have also 
been shown to stimulate hepatic transferrin synthesis. In chicken, these hormones are 
known to act at the transcriptional level to increase hSTf synthesis by roughly two- 
fold. 
Idzerda et al, 1989, showed, through deletion analysis of a5 kb pairs region 
upstream of the 5' end of the transferrin gene, four major functionally different 
regions (Figure 1.12. A). These regions include a cell-type specific promoter localised 
between positions -145 and -45 base pairs, a distal promoter from -620 to -125 base 
pairs containing positive and a negative cis-acting elements, a negative acting region 
between -1.0 and -0.6 Kb pairs which functions as a silencer (Ghareeb et al, 1998) 
and a strong enhancer located between -4.0 and -3.3 kb pairs which is known to 
interact with hypoxia-inducible factor-1 (Vyhlidal and Safe, 2002). More 
specifically, the region from +1 to -600 base pairs can be expanded further to include 
a number of different protein-binding regions (Figure 1.12. B). Schaeffer et al, 1993, 
showed that two of these regions include two proximal promoters (PRI and PRII). 
These two are known to make up part of the tissue-specific promoter. For example, 
in the liver, hepatocyte nuclear factor 4 acts at the PRI site, while CCAAT/enhancer- 
binding proteins act at the PRII site. In the testis, Sertoli proteins SP-A and SP-D 
binds to the PRBI site, while SP-cc and SP-ß bind to the PRII site. These two sites 
share a common 10-nucleotide-long inverted repeated sequence with two of the other 
regulatory regions known to make up the distal promoter region (DRI and DRII) 
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Figure 1.12. A schematic representation of the regulatory components 
upstream of the hSTf gene that are thought to be in involved in regulation of 
expression. A: Regions that have been linked to transferrin gene expression 
upstream of 5' end. B: Protein-binding sites in the promoter region. (Modified 
from Testa, 2002). 
58 
$ lZb $ MMý+ 
1: Introduction Peter J Sargent 
and DRII are unknown. A fifth region, known as a central regulatory region (CR), 
has also been identified (Schaeffer et al, 1993), but as yet is poorly characterised. 
1.3.9. Transferrin Mutants 
Since transferrins were discovered in the 1900 (Osborne and Cambell, 1900), a large 
number of naturally occurring mutants have been discovered across the transferrin's 
family. For just hSTf, its gene has been found to be naturally highly polymorphic, 
with over 30 genetic variations known to exist (Lee et al, 1999). However, so far, 
only one variant has been identified that exhibits abnormal properties (Evans et al, 
1982). 
Following the screening of approximately 5000 serum samples by 6M urea-PAGE, a 
heterozygous individual possessing both a variant transferrin, with a differential 
electrophoretic mobility, corresponding to loss of iron from the C-site, and a normal 
transferrin was identified (Evans et al, 1982). This variant was found to contain aG 
to A substitution in the first nucleotide of codon 394, leading to the mutation G394R 
(Evans et al, 1994). This variant was shown to have a reduced affinity for iron in the 
C-lobe and also a reduced affinity for the transferrin receptor (Young et al, 1984). 
Evans et al, 1994, suggested that G394 is not directly involved in iron-binding, nor 
does it seem likely to be involved in receptor binding given that it is buried deep 
within the cleft. In 1994, Evans et al predicted that the effect of G394R on iron 
binding was due to its interaction with the iron-binding residue D392, preventing it 
from interacting with the iron. They showed that the inability of the aspartate ligand 
to bind to iron is consistent with the observed blue shift in the visible spectrum of the 
59 
1: Introduction Peter J Sargent 
C-site as judged by qualitative comparison with the mutants of D63 or the N-lobe 
protein (Woodworth et al, 1991) and with an 18-kDa yellow fragment of duck 
ovotransferrin (Evans and Madden, 1984), which is known to lack the aspartate 
ligand. However, even though their discussion seemed to be conclusive, the reason 
for the reduced affinity for the receptor has yet to be elucidated, and the reduced iron 
binding affinity is still unclear. 
Since the advent of recombinant protein technology, a number of genetically 
engineered transferrin mutants have also been created. The reason for creating such 
variants is to try to gain a better understanding of the structure and function of 
transferrins by mutating residues and regions thought to be important in the structure 
and function of the molecule. Table 1.6 lists a few examples of these genetically 
engineered mutants, along with a few examples of the naturally occurring ones. 
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Native 
G277S A risk factor for iron deficiency anaemia Lee et al, 
2001 




K627E One non-symptomatic hSTf variant Pang et al, 
1998 
G394R Variant of hSTf with abnormal functional 
properties 
Evans et al, 
1982 
Recombinant 
D63S Non-glycosylated transferrin mutants expressed in Mason et al, 
D392S Baby Hamster Kidney (BHK) cells 1998 
D63E N-terminal half transferrin mutant expressed in Baker et al, 
R124A BHK cells 2003 
K206A N-terminal half transferrin mutants expressed in Steinlein et 
K296A Pichia pastoris al, 1998 
K206Q N-terminal half transferrin mutant expressed in Yang et al, 
H207E BHK cells 2000 
H249A N-terminal half transferrin mutant expressed in He et al, 
H249E BHK cells 2000 
H249Q 
M109L N-terminal half transferrin mutant expressed in 
BHK cells 
He et al, 
1999 
W8Y N-terminal half transferrin mutant expressed in He et al, 
W 128Y BHK cells 2001 
_ W264Y 
Y85F N-terminal half transferrin mutant expressed in He et al, 
E83A BHK cells 1998 
Table 1.6. Examples of naturally occurring hSTf mutants and some 
genetically engineered mutants. 
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1.4. Aims and Objectives 
Peter J Sargent 
As described previously in this chapter, hSTf provides not only a means of 
transporting iron from the sites of absorption and storage to the sites of utilisation, 
but is also a protection against the damaging effects of iron-catalysed free radical 
cascades. Its role in iron homeostasis is therefore essential, but although the protein 
was identified more than half a century ago, its full-length crystal structure and its 
complete mechanism of iron-loading and releasing, including receptor interaction, is 
still yet to be elucidated. 
The aim of this thesis is therefore to look deeper into the structure and function of 
hSTf in the hope to gain a better understanding of not only this specific protein, but 
also of the other members of the transferrin family and the whole regulatory network 
of iron metabolism. The scheme of this study is summarised in Figure 1.13. 
The initial aim of this project is to create an expression system for the synthesis of 
full-length hSTf and hLf. Recombinant protein technologies are now one of the main 
tools in research used to gain a better understanding of proteins, enabling the 
identification of functionally and structurally important residues, or regions, in the 
protein. Expression of such proteins enables one to modify the protein in many ways, 
either in the form of specific amino acid mutations, protein region deletions, creation 
of protein-protein fusions, or creating non-glycosylated proteins. In these studies, the 
aim is to concentrate on specific amino acid mutations in and around the iron 
binding-site and theoretical receptor binding sites. Such mutations will include the 
amino acid substitution at position 394 (Gly --º Arg) of hSTf, in a naturally occurring 
















3D Structure, mechanism of iron-binding and 
release, and receptor interactions 









Prediction of Physio- 
chemical changes 
Figure 1.13. Plan of study. The aims are split into protein analysis and computer 
analysis, with the computer analysis results influencing the mutagenesis studies. 
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Once purified, the second aim is to analyse these recombinant proteins, along with 
their native counterparts using a variety of physico-chemical techniques. These 
techniques will focus initially on a comparison of the native and the recombinant 
protein's structural integrity, followed by analysing the protein's functionality. Such 
functional studies will focus in on iron-binding and release, and transferrin-receptor 
interactions. One such structural study will be the crystallisation of both recombinant 
and native proteins in order to try and solve the structure of hSTf and/or use the data 
collected from hLf to help interpret structural and functional characteristics of hSTf. 
As well as having a high degree of homology with hSTf, hLf is a good candidate for 
a model protein, especially as many crystallographic studies have been carried out on 
it, with some of them providing high-resolution structural images. 
In parallel to the expression and physico-chemical characterisation of hSTf and hLf, 
the third aim is to create a 3-dimensional homology model of hSTf. Such modelling 
involves alignment of the target protein with proteins that share a high degree of 
homology and whose structures are known. Using specialist software, a 3- 
dimensional image of the protein is created by following specific rules based on 
biophysical properties of proteins. Such a model will provide a powerful tool in 
visualising the structural layout of the protein, enabling one to predict the location of 
regions and residues of importance, and to help interpret results from physico- 
chemical studies. The model will also provide a tool in the interpretation of mutants 
and help in the design of new mutants. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Bacterial Strains 
The bacterial strains used in these studies are listed in Appendix II.!. All Ecoli 
strains were maintained in LB medium containing 15% (v/v) glycerol at -700C. For 
day-to-day use, cells were maintained on LB agar medium plates and kept at 4°C. 
2.1.2. Yeast Strains 
The Saccharomyces cerevisiae cells used for the expression of hSTf were derivatives 
of the DXY1 strain (Kerry-Williams et al, 1998). This strain contains mutations in 
two of its genes, LEU2 and YAP3. LEU2 encodes an enzyme involved in the leucine 
synthesis pathway. Therefore, cells with a mutation in the LEU2 gene (leu2) are 
unable to grow in the absence of leucine, allowing for the selection of cells that have 
been transformed with yeast expression vectors containing the intact LEU2 gene. The 
disruption in the YAP3 gene (yap3:: LYS2) prevents the expression of a yeast aspartyl 
protease previously shown to proteolytically cut recombinant human albumin if 
expressed by the cell. 
2.1.3. Microbiological Media 
The different media used in these studies is shown in Table 2.1. Bacto-agar, yeast 
extract, yeast nitrogen base (w/o amino acids and ammonium sulphate), bacto- 
tryptone and bactopeptone were purchased from Difco Laboratories. All antibiotics 
were purchased from Sigma Aldrich, together with X-gal and IPTG. The antibiotics 
used in these studies are shown in Table 2.2. 
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Table 2.1. Name and composition of different media used in these studies. 
Media Name Content 
Luria Bertani (LB) l0g/L bacto-tryptone. 10o/L sodium chloride, 5g/L yeast 
extract, adjusted to pH 7.5 with NaOH 
SOC To 950mL MilliQ water, 20 g bacto-tryptone, 5g bacto- 
yeast extract and 0.5g NaCl were added. After dissolving 
the ingredients, lOmL of a 250mM solution of KC1 was 
added and the pH of the medium was adjusted to pH 7 
with NaOH. The volume of the medium was made up to 
IL with milliQ water. Just before use, 5mL of sterile 2M 
MgCl2 and 20mL of sterile 1M glucose was added. 
BMM-D 1.7g/L Yeast Nitrogen Base (w/o amino acids and 
ammonium sulphate), 5g/L ammonium sulphate, 36mL/L 
of IM Citric Acid, 126mL/L of IM di-sodium hydrogen 
orthophosphate and 2% (v/v) D- glucose. 
YEPD 1Og/L yeast extract, 20g/L bacto-peptone and 2% (v/v) 
glucose 
Agar plates were made by the addition of 15g/L of Bacteriological agar to the 
specific media followed by autoclaving. 
2.1.4. Chemical Solutions 
Unless otherwise stated in the text, all chemicals were supplied by BDH Chemicals 
Ltd or Sigma Aldrich and were of Analar grade or equivalent. 
2.1.5. Buffers 
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DNA Agarose Gel TBE Buffer (x]0) -Autoclaved, then adjusted to pH -8.2 -8.4 using 11.6M HC! 
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Citric Acid Buffer -adjusted to pH 4.7 using IOM NaOH 
Citric Acid 100mM 21.014g/L 
Coupling Buffer -adjusted to pH 6.5 using IOM NaOH 
Component Final Concentration 
Citric Acid 200mM 
Quantit. % 
42.028<g L 
DEAE Elution Buffer -ßp11 not ac//u. sted (-pH 9.4) 
Component Final Concentration Quantity 
Potassium Tetraborate I etrah%drate 82.6mM 
DEAE Equilibration Buffer 1- pH not adjusted (-pH 9.3) 
Potassium Tetraborate Tetrahydrate 1I MM /L 3.3605g 
DEAE Equilibration Buffer 2- pH not adjusted (-pH 9.2) 
Potassium Tetraborate Tetrahvdrate 15.7mM 4.8g/L 
FeNTA (0.1 M) - NTA dissolved in 2M NaOH first then made up to lOmL with MilliQ water following 
the addition of Iron(Ill) Chloride-6-Hydrate. 
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Native-PAGE Running Buffer (x10) -Made up to Ilitre with Mi11iQ water. pH not adjusted (-8.8) 
Tris Base 250mM 30.3 /L 
G1 cine 1.92M 144 /L 
Nitrocellulose Blocking Buffer 
PBS-T Ix 250mL 
Bovine Serum Albumin 1% (w/v) 2.5 
PBS-T 
Component 
PBS I\ 250mL 
Polyoxyethylene-sorbitan mono-laurate (Tween20) 0.05% (v/v) 125 L 
SDS-PAGE Running Buffer (x10) -fadc up to 1litre with Mi//iC) water. pH not adjusted ( s' 3) 
Component Final Concentration Quantity 
Tris B isc 250mM 30.3, -, 1. 
Glycine 1.92M 144 /L 
Sodium dodecyl Sulphate 35mM 10 /L 
SP Elution Buffer -adjusted to pH 7 using NaOH 
Component Final Concentration Qualltitý 
Sodium Dihydrogen Phosphate di-hydrate 50mM 7.8g/L 
NaCl 100mM 5.84 /L 
SP Equilibration Buffer -adjusted to pH 5 using 100% glacial acetic acid 
Sodium Acetate Trihydrate 50mM 
SP Washing Buffer -adjusted to pH 5 using 100°/ glacial acetic acid 
Component Final Concentration Quantity 
Sodium Acetate Trihydrate ý, OmM 6.8, -, 
I. 
NaCI 100mM 5.84g/L 
TBS (iris Buffered Saline) and T-TBS (iris Buffered Saline - Tween) -0.5mL of Tween 20 was 
added per litre of TBS in order to make T- TBS 
Component Fimil Concentration Qtjantitý 
Tris Base 50mM 6.05 /L 
Potassium Chloride 2.6mM 0.2 /L 
Sodium Chloride 137mM 8g/L 
Transferrin buffer -adjusted to pH 8 using 11.6.1 HC/ 
Component Final Concentration Quantity 
I ri, Base 10111%1 .4 
2_ I. 
NaHCO; 20mM I. 681'1'L 
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2.1.6. Enzymes 
Restriction endonucleases were supplied by Promega Corporation, New England 
Biolabs, or Roche Applied Sciences. T4 DNA Ligase, T4 Polynucleotide Kinase, 
Calf Intestinal Alkaline Phosphatase, Taq DNA Polymerase and Pfu DNA 
Polymerase were all supplied by Promega Corporation. The optimum conditions 
required for these enzymatic reactions, including choice of buffer, amount of 
enzyme, and temperature, were obtained from the manufacturers' protocols. 
2.1.7. Vectors 
Physical maps of the vectors used in these studies are shown in Appendix 11.2. A 
brief description of these vectors' main features are described in this section, but 
further information can be obtained by visiting the supplier's website. 
pALTER-Exl: 
The pALTER-ExI vector is a phagemid which is part of the Altered Sites II in vitro 
systems (Promega) that uses a straightforward procedure to generate and select 
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oligonucleotide-directed mutants. The system uses antibiotic selection as a means to 
obtain a high frequency of mutants. This vector contains genes for ampicillin and 
tetracycline resistance, but the ampicillin resistance gene has been inactivated. An 
oligonucleotide is provided which restores ampicillin resistance to the mutant strand 
during the mutagenesis reaction, by annealing to the single-stranded DNA (ssDNA) 
template at the same time as the mutagenic oligonucleotide, and subsequent synthesis 
and ligation of the mutant strand links the two. As well as mutagenesis, this vector 
also allows expression of the insert in vivo and in vitro using a novel polylinker. 
Transcription of the insert in controlled by opposing T7 and SP6 promoters. A tac 
promoter is also provided in the same direction as the SP6 promoter. To prevent 
transcription through the tetracycline gene, a T7 transcription terminator is located 
outside of the multiple cloning-site. The tac promoter is induced by the addition of 
IPTG in a lac Iq host, and the expression from T7 can be provided by strains which 
produce T7 RNA polymerase. 
pALTER-Max: 
The pALTER-Max vector (Promega) is a plasmid designed for use with Promega's 
Altered Sites® Mammalian Mutagenesis Systems. It contains the human 
cytomegalovirus (CMV) immediate-early enhancer/promoter region for strong, 
constitutive expression of cloned DNA inserts in a variety of mammalian cell types. 
Mutagenesis using this vector works on the same principal as the pALTER-E1 
vector, except that the gene encoding for tetracycline resistance has been substituted 
with a gene encoding for chloramphenicol resistance. The gene for ampicillin 
resistance in the pALTER-Max vector has also been deactivated. 
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pET-12a: 
Peter J Sargent 
pET12a (Novagen), like all of the other pET vectors, is designed for high-level 
prokaryotic expression of proteins using a T7 promoter. Expression of proteins using 
a pET vector is therefore reliant on strains that possess the T7 RNA polymerase. This 
vector carries an N-terminal ompT sequence for potential periplasmic export of the 
expressed protein. Export into the periplasm is known to provide a more favourable 
environment for folding and disulphide-bridge formation, therefore increasing the 
chance of producing active, soluble proteins. 
pET-21d: 
The pET-21d (Novagen) vector carries an N-terminal T7"Tag® sequence and an 
optional C-terminal His-Tag® sequence for purification of the target protein. 
pDB2514: 
pDB2514 (Delta Biotechnology Ltd) is a basic vector containing a pUC 18 region for 
replication in E. coli, and a gene encoding apramycin resistance and the human 
serum transferrin (N413Q, N611Q) cDNA from the translation initiation methionine 
codon (ATG) to an internal Nhel site. 
pDB2529: 
The pDB2529 (Delta Biotechnology Ltd) vector contains the yeast PRB1 promoter 
(Sleep et al 1991) for nitrogen regulated protein expression in yeast, the yeast ADHJ 
transcription terminator (Sleep et al 1991) and a leader sequence based upon a fusion 
of the first 19 amino acids of the human serum albumin leader sequence and the last 
5 amino acids of the MFa-1 prepro leader sequence from S. cerevisiae for secretion 
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of protein out of the cell (Sleep et al 1990). The vector also carries a gene that 
encodes for ampicillin resistance, a number of restriction sites required for cloning 
and a human transferrin cDNA (N413Q, N61 IQ). 
pDB2536: 
The pDB2536 (Delta Biotechnology Ltd) vector comprises of the transferrin 
(N413Q, N611 Q) Notl expression cassette from pDB2529 cloned into the unique 
Nod site of pSAC35 (Sleep et al 1991). 
2.1.8. Plasmid DNA Purification and DNA Cleanup Kits 
All kits used in these studies were supplied by Qiagen Ltd. These kits included: 
HiSpeed Plasmid Midi, Spin Mini Prep, 96 Turbo MiniPreps, Mini Elute Gel 
Extraction and Mini Elute Reaction Cleanup. The only exception was during the 
cloning of the yeast expression system when a 1310101 Gene Clean III gel extraction 
kit was used. These kits were used in accordance to the suppliers' protocol. 
2.1.9. Loading Buffers 
All loading buffers were made up to 100mL with MilliQ water, then filtered (0.2µ). 
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SDS-PAGE Loading Buffer (2x) 
Peter J Sargent 
Component 





Glycerol 20%(v/v) 20mL 
Sodium Dodecyl Sulphate 4.4% (w/v) 4400mg 
Bromophenol Blue 0.02% (w/v) 20m 
2-Mercaptoethanol 
(For reduced SDS-PAGE only) 
2% (v/v) 2mL 




The addition of 0.05% (w/v) ethidium bromide to gels enabled DNA to be visualised under UV light 
2.1.11. Computer Software 
The different software packages used in these studies are listed below, along with a 
brief description of each one: 
-BioEdit (5.0.9): Sequence alignment editor and sequence analyser. 
-ChromasPro(1.22): DNA sequence chromatogram analyser 
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-Deepview/Swiss-PDB viewer: PDB graphical interface and analysis package 
-SciEd Central Clone Manager 6: Cloning simulator, enzymes operations and 
genetic map drawing package. (A gift from Delta Biotechnology Ltd) 
2.2. DNA Cloning and Analysis Methods 
2.2.1. Glycerol-Stocks 
To 700µL of fresh culture and 300µL of sterile 50% (v/v) glycerol was mixed gently 
in a sterile 1.5mL NUNC cryotubes tube. 
2.2.2. DNA Electrophoresis 
Agarose gel electrophoresis was performed using a 1% (w/v) agarose gel throughout 
these studies. The gel was made by the addition of Ig of electrophoresis-grade 
agarose (Sigma) to 100mL of lx solution of TBE buffer (section 2.1.5) and then 
melted in a microwave at full power for 2 minutes. The solution was then allowed to 
cool to 60°C before the addition of ethidium bromide to a final concentration of 
50ng/ml. This agarose was then poured into plastic formers and allowed to set at 
room temperature. Prior to loading, DNA samples were mixed with 5x DNA loading 
buffer (section 2.1.9). Gels were electrophoresed in lx TBE buffer at 100V constant 
volts until the dye had reached the end of the gel. Following electrophoresis, gels 
were examined by transillumination with UV light and photographed on a SynGene 
GelDoc System. 
2.2.3. Ligation 
Ligation of DNA was achieved using T4 DNA ligase from Promega. When ligating 
DNA together a number of different molar ratios of vector and insert were used. 
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These ratios included 1: 1,1: 3 and 3: 1 (vector: insert). The reactions were either 
incubated overnight at 4°C, 4-18 hours at 15°C, or at room temperature for 3 hours. 
2.2.4. Transformation 
2.2.4.1. Bacterial 
Competent Ecoli cells were removed from -80°C storage and thawed on ice. To 
50µL of these cells, 20µL of chilled ligation mixture was added before being 
incubated on ice for 30 minutes. The cells were then heat shocked at 42°C for 90 
seconds prior to the addition of 0.7mL of LB and then incubation at 37°C for 45 
minutes. Transformants were selected by growing the cells on LB agar plates 
overnight at 37°C with the appropriate selective marker. 
2.2.4.2. Yeast 
Yeast cells grown on YEPD plates were resuspended in a microcentrifuge tube 
containing 0.5mL of transformation buffer (100mM lithium acetate, 10mM Tris-HCI, 
pH 7.5,1mM EDTA pH 8.0). The cells were microcentrifuged for 5 seconds and the 
supernatant removed, leaving 50-100µL of buffer in the tube. A 10µL aliquot of 
salmon testes DNA (10mg/ml) and -1µg of plasmid DNA was added to the cells 
before they were vortexed for 10 seconds. 600µL of Plate buffer (40% PEG, 100mM 
lithium acetate, 10mM Tris-HCI, pH 7.5,1mM EDTA pH 8.0) was then added. The 
mixture was vortexed again before being incubated at room temperature for 15 
minutes. An optional heat shock step for 15 minutes at 42°C can be applied here. 
Following centrifugation for 3 seconds and the removal of the supernatant, the cells 
were resuspended in 300µL of sterile water. The cells were then plated on BMM-D 
media and incubated at 30°C for 2-3 days, or until colonies appeared. 
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2.2.5. PCR DNA Amplification 
Peter J Sargent 
PCR amplification of both hLf and hSTf was accomplished in 50µL reaction 
mixtures containing lx DNA polymerase buffer with 1.5mM MgSO4, of each of the 
four dNTPs (200µM), of each primer(IpM), <0.5µg DNA template, 1.25units DNA 
polymerase and MilliQ water. Both Pfu and Taq DNA polymerase were used in these 
studies. The choice of DNA polymerase and primers is discussed in Chapter 4. Table 
2.3 outlines the thermal cycling conditions used. 
Table 2.3. Thermal cycling conditions for hLf and hSTf amplifitcation 
1. Initial Denaturation 95°C 2 minutes 1 
2. Denaturation 95°C 1 minutes 
3. Annealing 58°C 40 seconds 30 
4. Extension 74°C 2 minutes per 1kb 
of DNA template 
5. Final Extension 74°C 5 minute 1 
6. Soak 4°C Indefinite I 
2.2.6. UV determination of DNA concentration 
DNA concentration of samples was determined by measuring their optical density at 
260nm using a Shimadzu UV-1201 UV-VIS spectrophotometer and a 10mm 
pathlength curvette. Samples were diluted 50-fold using MilliQ water. 
1.0 OD at 260nm = 50µg/mL (Promega) 
2.2.7. Mutagenesis 
Mutagenesis of hSTf cDNA was achieved using a Stratagene Quikchange® Site- 
Directed Mutagenesis Kit. The two oligonucleotides required for mutagenesis were 
designed using Sci Ed Central Clone Manager 6 software and synthesised by Sigma- 
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Genosys. Following the manufacturers' protocol, a 50µL reaction mix comprising 
5µL of QuikChange Reaction buffer (x10 concentration), IOng of template plasmid, 
125ng of both mutagenesis oligonucleotides, 1µL of dNTP Mix, 1µL of PfuTurboO 
DNA polymerase, and MilliQ water was made. This reaction mix was then incubated 
in a DNA Engine DYAD TM Peltier thermocycler using the program described in 
Table 2.4. Following incubation, 1µL of Dpn 1 was added and the mixture incubated 
at 37°C for I hour. 
Table 2.4. The thermocycler program for QuikChange site-directed 
mutagenesis of pDB2514. 
1. Initial Denaturation 95°C 30 seconds 1 
2. Denaturation 95°C 30 seconds 
3. Annealing 55°C 1 minute 16 
4. Extension 68°C 5 minutes 
6. Hold 4°C Indefinite I 
2.2.8. DNA Sequencing 
DNA sequencing was either carried out using a Perkin Elmer ABI Prism 310 Genetic 
Analyser. Each 20µL PCR reaction comprises 500ng of DNA template, 0.8pmol/µL 
of primer, 8µL of ABI Prism Big Dye V3 Terminator and MilliQ water. The 
thermocycle program is shown in Table 2.5. 
Table 2.5. Thermal cycling conditions for ABI Prism Big Dye Sequencing 
1. Denaturation 96°C 10 seconds 
2. Annealing 50°C 5 seconds 25 
3. Extension 60°C 4 minutes 
4. Soak 4°C Indefinite I 
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The reaction from the PCR tube was then transferred into a 1.5mL eppendorf. To this 
reaction was added 2µL of 3M NaOAc, pH 4.6 and 50µL of 95% EtOH. The sample 
was mixed and then left to stand for 15 minutes at RT, before being centrifuged for 
20 minutes at maximum speed. Following centrifugation, the supernatant was 
immediately removed and 750µL of 70% EtOH added to the pellet. The sample was 
vortexed briefly and then centrifuged for 5 minutes, at maximum speed. Once the 
supernatant had been removed, the pellet was allowed to dry rapidly on a 95°C 
heating block, to remove any remaining ethanol. The pellet was resuspended in 12µL 
of Template Suppression Reagent (Perkin Elmer), vortexed briefly, denatured at 
95°C for 2 minutes, and then placed immediately on ice. Samples were centrifuged 
briefly before being loaded onto the ABI Prism 310 Genetic Analyser. 
2.3. Protein Purification and Preparation Methods 
2.3.1. Ion-Exchange Chromatography 
Two ion-exchange chromatography columns were used in these studies to purify 
rhSTf. The first was a 232mL SP-FF sepharose (Amersham Biosciences) column and 
the second was a 94mL DEAE-FF sepharose (Amersham Biosciences) column. The 
methodology described below was created by Delta Biotechnology Ltd. Both 
columns were connected to a Pharmacia Biotech Pump P-1 and a Single Path 
Monitor UV-1 Optical / Monitor Unit measuring at 280nm, with an output to a 
Pharmacia Chart Recorder. Columns were stored in 0.5M NaOH when not in use. 
2.3.1.1. SP-FF Sepharose 
Once the column had been equilibrated with SP Equilibration Buffer at 0.5 cv/min 
for 8 minutes, or until the pH of the eluate was approximately 5, the sample was 
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loaded on to the column at the same rate. The column was then washed at 0.5cv/min 
with SP Equilibration Buffer for 10 minutes, SP Washing Buffer for 16 minutes and 
again with SP Equilibration Buffer for 4 minutes. The last wash was extended if the 
absorbance at 280nm had not yet reached zero. Using a reduced flow rate of 
0.25cv/min, rHSTf was then eluted with SP Elution Buffer, collecting the flow 
through only when the UV spectrophotometer recorded a peak at 280nm. Once the 
absorbance had reached baseline, the column was washed at 0.25cv/min with 1M 
NaCl for 12 minutes, then with 0.5M NaOH for a further 12 minutes. 
2.3.1.2. DEAE-FF Sepharose 
The flow rate in which this column was run was set at a constant 0.5ev/min. Prior to 
loading, the column was equilibrated with DEAE Equilibration Buffer I for 24 
minutes and then with DEAE Equilibration Buffer 2 for a further 6 minutes. Once the 
sample was loaded, the column was washed with DEAE Equilibration Buffer 2 for 
10 minutes, or until the absorbance at 280nm returned to baseline. The rhSTf was 
then eluted with DEAE Elution Buffer, starting collection of the eluate when the UV 
spectrophotometer recorded a peak at 280nm. Following elution, the column was 
washed with 1M NaCl for 6 minutes and then with 0.5M NaOH for 4 minutes. 
2.3.2. Immunoaffinity Chromatography 
CNBr-activated SepharoseTM 4B was purchased from Amersham Biosciences. Each 
affinity column was made using 15g of freeze-dried medium. This amounted to 
approximately 5OmL once the beads had been swollen, by washing in 1mM HCI. 
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Ligand coupling was achieved by dissolving the ligand in Coupling Buffer and then 
adding the required amount of medium. The mixture was incubated at room 
temperature for one hour with gentle mixing, not stirring. Following this, the medium 
was washed clean of any unbound ligands using 5cv of Coupling Buffer and then 
incubated at room temperature for 2 hours in Immunoaffinity Buffer to ensure that 
any remaining active groups are blocked. The final washing step comprised three 
cycles of alternating pH. Each cycle consisted of a wash with Washing Buffer 1 
followed by a wash with Washing Buffer 2. A total of 5 column volumes of each 
buffer was used in the final washing step. The ligand-coupled medium was then 
packed into a Pharmacia XK26 column, connected to a Pharmacia Biotech Pump P-1 
and a Single Path Monitor UV-1 Optical / Monitor Unit with an output to a 
Pharmacia Chart Recorder. 
The affinity column was equilibrated using 8 column volumes of Immunoaffinity 
Buffer Following this, the sample, which had been filtered through a 0.2µm filter and 
diluted 1: 1 with 2x Equilibration Buffer, was loaded onto the column at 4ml. min'. 
The column was then washed with 10cv of Immunoaffinity Buffer, or until the OD at 
280nm reached baseline, before eluting the protein using 1M ammonia. 
2.3.3. Fast Performance Liquid Chromatography 
A Pharmacia Fine Chemical FPLC system was used in these studies. This setup 
consisted of a Gradient Programmer GP-250, two P-500 pumps (pump A and B), a 
Rec-2 Chart Recorder, UV-M monitor with optional 214nm / 280nm filters, a mixer, 
V-7 Valve, a 2mL loading-loop and a RediFrac fraction collector. Before use, the 
two pumps were washed with their respective buffers and the loading-loop washed 
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with MilliQ water. All samples and buffers were filtered through a 0.2µm filter 
before use. 
2.3.4. Protein Concentration and Dialysis 
Protein samples were concentrated and dialysed using an Amicon Ultra-15 
(30,0000MWCO) centrifugal filter units at 4000g for 15 minutes in a swingout rotor. 
Centrifugation was repeated for samples larger than 15mL until the required 
concentration and volume was achieved. Dialysis was achieved by repeatedly 
resuspending and concentrating the sample in the specific buffer. 
2.3.5. Creation of Apo- and Diferric Transferrin 
Apo-hSTf preparations were made by dialysing hSTf against Citric Acid Buffer 
(section 2.1.5) to release the iron from the protein. These samples were then left to 
incubate at room temperature on a roller for 2 hours, before further dialysis against 
the same buffer to remove any free iron. Apo-hSTf was then dialysed into 
Transferrin Buffer (section 2.1.5) before use. Diferric preparations of protein were 
made by dialysing hSTf against Transferrin Buffer and then saturating by addition of 
two-fold excess of FeNTA (section 2.1.5) in excess. Dialysing the samples further 
into the same buffer washed unbound FeNTA away. 
2.3.6. Desalting and Freeze-drying 
Purified proteins were desalted into 50mM NH4HCO3 using a G-25 Sephadex 
(Amersham Biosciences) column. The protein solution was then transferred into a 
round bottom Quick-fit vacuum flask and frozen evenly onto its inner surface using 
liquid nitrogen. The flask was then connected to the Modulyo freeze-dryer 
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(Edwards), previously cooled to -45°C and depressurised to 0.08mBar, and left 
overnight, or until the solvent had been removed. 
2.4. Protein Analysis Methods 
2.4.1. Circular Dichroism (CD) Spectroscopy 
CD spectra for protein samples were acquired on the Jasco J720 spectropolarimeter 
in the 600-230nm (1cm cell path length) and 260-185nm (0.02cm cell path length) 
regions. Protein samples were made to O. 5mg/mL in 0.02M NaHCO3 and filtered 
through a 0.2µm syringe filter. Protein concentrations were calculated after light 
scattering correction had been applied. All spectra were corrected for solvent 
baseline and, where appropriate, normalised for concentration and path length (mean 
molecular weight = 113). Secondary structure analysis of the proteins was calculated 
using the principle component analysis method (Malik, 1997). 
2.4.2. Cell Proliferation Assay 
Cellular proliferation was determined by quantification of 5-bromo-2'-deoxy-uridine 
(BrdU) integrated into cellular DNA. TRVb-1 (McGraw et al, 1987) (kindly 
provided by Dr. H. Kawabata, Kanazawa Medical University Uchinada-machi, 
Ishikawa-ken Japan) or HepG2 cells were seeded in 6-well tissue culture plates at a 
density of 5x 104 cells per well and grown to 50% confluence in F12HAM 
(Invitrogen) and RPMI160 (Invitrogen), respectively supplemented with 10% foetal 
bovine serum (FBS) 2mM Glutamine and Penicillin/Streptomycin. Cells were then 
synchronised by cultivation in the absence of FBS for 24 hours. Immediately after 
addition of transferrin, to a final concentration of 2mg/ml, or 5% FBS to the cells, 
BrdU (Roche Applied Sciences) at a final concentration of 10µM was added and the 
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cells were grown for a further 16 hours. Integration of BrdU into cellular DNA was 
then quantified immuno-metrically using the BrdU detection Kit III (Roche Applied 
Sciences) according to the manufacturer's directions. 
2.4.3. Dot Blot Analysis 
Dot blots were used in these studies to determine levels of protein expression and to 
visualise protein-protein interactions. Nitrocellulose Membrane from BioRad (Trans- 
Blot Transfer Medium) was cut to size and marked with a pencil for orientation and 
location of drops. For each drop, 4µL of protein sample was pipetted onto the 
membrane and allowed to dry at room temperature. The membrane was then washed 
in Nitrocellulose Blocking Buffer for 1 hour on a rocking platform to block the 
remaining membrane surface. Excess Nitrocellulose Blocking Buffer was removed 
by 3x5 min washes with PBS-T before the membrane was incubated for 2 hours in 
l OmL of PBS containing 1 gg/mL FITC labelled IgG specific for the protein of 
interest. A final wash with PBS to remove any unbound FITC-IgG was carried out 
before visualisation of the bound FITC-IgG under UV light. 
2.4.4. Dynamic Light Scattering 
Protein samples were prepared at O. lmg/mL in Transferrin Buffer and filtered 
through a 0.21im syringe filter prior to analysis. Samples (l00µ1) were analysed in a 
sealed quartz curvette using a DynaPro99 and Temperature Controlled Microsampler 
(Protein Solutions Inc). Using the DynaPro Dynamic Ligtht Scattering instrument 
control software, each sample was initially cooled to 5°C and then held at this 
temperature for 2 minutes. The machine then took 20 photon count recordings before 
heating the sample up to the next temperature and holding it a further 2 minutes. 
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After 5°C, the machine ramped the sample up to 15°C and then 5°C increments up to 
95°C. Results were analysed automatically using the Dynamic (V5.26.37) Software 
package. 
2.4.5. Electron Paramagnetic Resonance (EPR) Spectroscopy 
EPR spectra were obtained using a Bruker ELEXSYS E500 spectrometer. The 
protein samples (40mg/ml) in 50mM NaHCO3, were frozen in an EPR tube at 77°K 
in liquid nitrogen. The microwave frequency was maintained at 9.38GHz and the 
field set at 2499G with modulation amplitude at 5G. The sample was then scanned 
twice using a microwave power of 10mW over 4000G (400mT) with a receiver gain 
of 2x103G. 
2.4.6. Fluorescein Isothiocyanate (FITC) Protein Labelling 
FITC Isomer 1 on Celite from Sigma was used to label immunoglobulin G (IgG) 
molecules specific for Transferrins. Freeze dried immunoaffinity chromatography 
purified IgG was resuspended in O. 1M sodium carbonate pH 9 at 2mg/ml. To this 
solution, FITC-celite resuspended in DMSO was added in 5µL aliquots to the protein 
solution to a molarity three times that of the protein. The amount of FITC required 
was multiplied ten times to compensate for the mass of the celite. Following 
overnight incubation at 4°C on a roller machine, ammonium chloride was added to a 
final concentration of 50mM before incubation for a further 2 hours at 4°C on a roller 
machine. All incubations were carried out in the dark. Xylene Cyanol to 0.1 % (w/v) 
and glycerol to 5% (v/v) was then added before the mixture was span at 5000g for 30 
min to pellet the Celite. Unbound FITC was separated from the conjugate by gel 
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filtration of the supernatant on a G-25 Sephadex column wrapped in aluminium foil 
to block out the light. Samples were stored in the dark at 4°C. 
Determination of Fluorescein: IgG Molar Ration 











2.4.7. High Performance Liquid Chromatography (HPLC) 
To work out protein concentrations and to determine relative protein purity, samples 
were separated by size-exclusion chromatography using a G3000SWXL (Tosoh 
Biosciences) column and a Shimadzu LC2010 HPLC. A Shimadzu-SIL-HTA 
Autosampler was used to load samples. The HPLC machine was calibrated using 
hSTf (Calbiochem) as an internal reference to allow the elution time and protein 
concentration to be determined. Protein concentration was determined by measuring 
the area of the curve created by plotting absorption at 280nm against time. 
2.4.8. Immunodiffusion 
A thin layer of 1% (w/v) Agar (VWR) and 20mM Tris molten solution was gently 
poured onto a clean glass microscope slide, and left to set at room temperature. Once 
set, a template was used to accurately cut five holes in the agar in the same pattern as 
on the fifth-side of a dice. In to each hole, 10µL of sample (1 mg/mL) was pipetted 
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and the slide sealed, along with a small piece of moist filter paper, in a petri dish with 
parafilm. The slide was then incubated at 4°C for 24-48 hours. 
2.4.9. Isothermal Titration Calorimetry (ITC) 
All protein samples to be analysed were prepared in ITC sample buffer (section 
2.1.5) at 2mg/mL (-26µM) and then filtered using a 0.2µm syringe filter. O. 1M 
FeNTA (section 2.1.5) was diluted into ITC sample buffer to 500µM and then 
filtered using a 0.2µm syringe filter. Both protein samples and the FeNTA were 
degassed and heated to 25°C using a ThermoVac Degasser/thermostat (MicroCal). 
Experiments were performed using the VP-ITC (MicroCal, USA) in the buffer 
conditions given above. Before titration, the machine was allowed to heat both cells 
to exactly 25°C. For each titration 1.463mL of protein, in the cell, was titrated with 
19 injections of 500µM FeNTA. The volume of each injection was 15µL, except for 
the first injection, which was 2µL. Injections were continued beyond saturation 
levels to allow for determination of heats of ligand dilution. The resulting data were 
fit to a double-site binding isotherm using the ORIGIN software supplied with the 
calorimeter. All thermodynamic data was generated automatically by the software. 
2.4.10. Native-PAGE 
Discontinuous non-denaturing (native) PAGE was carried out using the BioRad 
Mini-Protean II system. The resolving gel (8%) comprised 2.5mL of 1.5M Tris (pH 8 
with HCI), 2.66mL of Acrylamide stock solution (30% acrylamide, 0.8% Bis- 
acrylamide) and 50µL of 10% ammonium persulfate, made up to lOmL with MilliQ 
water. The stacking gel (5%) comprised 0.67mL of Acrylamide stock solution, 1mL 
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of 0.5M Tris (pH 6.8 with HCI) and 30µL of 10% ammonium persulfate, made up to 
4mL with MilliQ water. 5µL of TEMED was added to each solution before gels were 
poured. Samples were prepared by addition of an equal volume of native-PAGE 
loading buffer (section 2.1.9) prior to loading on the gel. The gels were run at 20mA, 
constant current, in a BioRad tank with lx Native-PAGE Running buffer (section 
2.1.9) until the loading dye reached the bottom of the gel. As with SDS-PAGE, 
bands were visualised by submerging the gels in PAGE stain (section 2.1.10) for 15 
minutes on a rocking platform and then destained by replacing the stain with PAGE 
Destain solution (section 2.1.10) and rocking the gel for a further 45 minutes, or until 
the background was clear. 
2.4.11. Protein Crystallisation 
Purified protein was concentrated to the relevant concentration using the method 
described in section 2.3.4 and filtered using a 0.2µm syringe filter. The precipitant 
solutions were prepared to the relevant concentration in MilliQ H2O and passed 
through a 0.2µm syringe filter following adjustment to the appropriate pH. 
2.4.11.1. Hanging Drop (Vapour diffusion) Method 
Hanging drops were set up using 24-well Limbro plates (Hampton Research). 
Aliquots (1mL) of precipitant buffer were added to each of the 24 wells. Grease was 
then applied to the top of each well using an air pump. A drop (3µl) of protein 
sample was pipetted onto a siliconised cover slip and immediately mixed with 3µL 
of the relevant precipitant buffer. Care was taken not to introduce any air bubbles 
into the drop. The cover slip was then inverted and placed over the relevant well, 
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ensuring that an airtight seal had formed around the grease. The trays were then 
stored at either 277K or 293K until crystals appeared. 
2.4.11.2. Microbatch Method 
Microbatch assays were set up using 74-well Terasaki Plates (Hampton Research). 
Mineral oil was poured onto the plate to cover all wells by at least 2mm. For each 
crystallisation trial, the protein sample of interest (l µl) was mixed with the relevant 
crystallisation agent (1µl) and then dropped through the oil into the relevant well 
using an automatic pipette. Microbatch plates were then at either 277K or 293K until 
crystals appeared. 
2.4.12. SDS-PAGE 
SDS-PAGE analysis used a discontinuous method adapted from Laemmli (1970). 8% 
acrylamide resolving gels and 5% stacking gels were used with the BioRad Mini- 
Protean II system. Samples were prepared by adding an equal volume of SDS-PAGE 
loading buffer (section 2.1.9) followed by boiling for eight minutes prior to loading 
on the gel. The gels were run at 20mA, constant current, in a BioRad tank with lx 
SDS running buffer (section 2.1.5) until the loading dye reached the bottom of the 
gel. To visualise the bands, the gels were submerged in PAGE stain (section 2.1.10) 
for 15 minutes on a rocking platform and then destained by replacing the stain with 
PAGE destain solution (section 2.1.10) and rocking the gel for a further 45 minutes, 
or until the background was clear. 
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2.4.13. SPOTs Peptide Library Mapping 
Before use, each of the SPOTs membranes (Sigma Genosys) was allowed to warm to 
room temperature and then rinsed in methanol. Each membrane was then sealed in a 
polypropylene box and rocked for 10 minutes in 5OmL of TBS. This washing 
procedure was repeated twice.. The membrane was then incubated at room 
temperature overnight, in 5OmL of Ix SPOTs Blocking Buffer (Sigma Genosys), 
before being washed for 10 minutes in 5OmL of T-TBS. The membrane was then left 
to incubate for 4 hours on a rocking platform in 5OmL of SPOTs blocking buffer 
containing Fluorescein (FITC)-conjugated Chromopure hSTf (Jackson 
ImmunoResearch) at a final concentration of 5µg/mL. Unbound FITC-hSTf was 
removed by washing the membrane three times for 10minutes in 5OmL of T-TBS. 
The binding of FITC-hSTf to the SPOTs membrane was visualised using a UV 
SynGene GelDoc System and quantified using SynGene Genetools. Membranes 
were cleaned following the manufacturers' guidelines. 
2.4.14.6M Urea PAGE 
Polyacrylamide gel electrophoresis in 6M urea was carried out using the method 
described in Evans et al, 1978 and Evans et al, 1982. Table 2.6 shows the 
composition of a 6M urea gel. This solution was made up to 40mL with MilliQ water 
and the components dissolved by vortexing. Prior to pouring the gel between a two- 
plate setup, 60µL of TEMED was added and the solution inverted quickly several 
times to mix. All components, except for the Urea and TBE, were supplied by 
National Diagnostics. 
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Table 2.6. The composition of a 6M urea gel. 
Peter J Sargent 
Component 
Urea 




Bis-Ac laGe1TM 0.32% (w/v) 6.4m1 
Protogel 6.5% (w/v) 8.7m1 
Urea Gel TBE Buffer (20x) 1x 2ml 
Ammonium Persulfate 0.1 % (w/v) 40m 
Once the gel had set, the comb removed and the wells washed with water, 501AL 
samples (25µL of 0.65mg/mL protein sample and 25µL of Urea Gel loading buffer) 
were loaded onto the gel. The gel was then run at 100V (constant) for 16hrs, before 
being removed from the plates and stained and destained in an identical manner to 
the SDS gels. 
2.4.15. UV-Visible Scanning Spectroscopy 
Apo-hSTf was prepared at -I Omg/mL in Transferrin Buffer and scanned in a 10mm 
path length quartz cuvette from 350-600nm using a Perkin Elmer Lambda 2 UV- 
visible spectrometer. The protein was then titrated with 5µL aliquots of 0.01M 
FeNTA, repeating the scan between aliquots, until the protein reached saturation. In 
order to determine protein concentration throughout these studies, the extinction 
coefficients at 280nm for apo and diferric hSTf as 88200M-'cm' and 114000M-'cm- 
', respectively (Aisen et al, 1980), and at 470nm for diferric hSTf, 4620M"'cm-' 
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To determine the absorbance of a sample at a known protein concentration, the 
following equation was used: 
A=B( c) Mw 
Where: c extinction coefficient 
B path length of quartz cuvette (1 cm) 
C protein concentration (mg/ml) 
Mw Molecular Weight (hSTf =79,55ODa) 
A280 Absorbance at 280nm 
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3. Computational Analysis of Transferrins 
Peter J Sargent 
This chapter focuses on the `in silico' characterisation of hSTf through sequence 
analysis and homology modelling. The information from this is then to be used as a 
tool to help in the interpretation of the in vitro data obtained from both the 
recombinant and native proteins, which are described in the later chapters. The 
compilation of theoretical predictive modelling with the experimental results will 
take us a step forward towards a complete understanding of the mechanisms of iron- 
uptake/release of transferrin. 
3.1. Sequence Analysis and Homology Modelling 
Even though much is known about hSTf, no crystallographic structure of the full- 
length hSTf molecule is available yet. This prevents us from answering a number of 
important questions concerning the mechanism of iron binding and release and also 
the mechanism of delivering iron to the cells. Therefore, in order to visualise this 
molecule and gain a better understanding of it, the initial aim of this chapter is to 
create a reliable computer 3D model of the protein. Such a model will be an essential 
tool to be used for the interpretation of the results obtained in structural and 
functional experiments carried out later on in these studies on native and 
recombinant hSTf, with both wild-type and mutant variants. 
3.1.1. Primary Sequence Analysis 
As described in Chapter 1, hSTf is a monomeric bilobal glycoprotein consisting of 
679 amino acids with a 19 amino acid leader that is processed off in the mature 
protein (Appendix I). This protein can be divided into two lobes, the N-lobe and the 
92 
3: Computational Analysis of Transferrins Peter J Sargent 
C-lobe, which spans form residues 1-336 and from residues 337-679 respectively 
(MacGillivray et a! 1983), and are connected by a bridge region from residues 331 to 
339 (Ugo Testa, 2002). 
3.1.1.1. Blast Search 
The first step in the creation of a model is to identify solved structures of proteins 
that are homologous to hSTf. From these results, the molecule with the highest 
degree of homology can then be used as a template onto which the model can be 
based. In order to find solved structures of proteins that share a high degree of 
sequence homology with hSTf, its sequence was extracted from the NCBI website 
(Accession number: NP_001054) and a similarity search was carried out using 
BLASTp (NCBI website) over the PDB database (Brookhaven Protein Data Bank). 
The results of this search (Figure 3.1) identified rabbit serum transferrin (rSTf) with 
the highest identity score of 78%, followed by porcine serum transferrin (pSTf) with 
an identity score of 70%. Below pSTf, the next four closest molecules are all 
lactoferrins. It is noteworthy a lower identity score was obtained with human 
lactoferrin (hLf) than with the other lactoferrins from different organisms. 
A phylogram of these six proteins, hSTf and eighteen other transferrins was created 
using ClustaiW (Phylip) (www. ebi. ac. uk/clustalw) and edited using TreeviewX 
(Figure 3.2). From the results obtained with the phylogram, which illustrates the 
evolutionary relationship of these twenty-five proteins, it can be concluded, in 
agreement with the BLASTp results, that out of these Transferrins, rSTf is the closest 
relative to hSTf. 
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1JNFA: Chain A, Rabbit Serum Transferrin At 2.6 A Resolution. 
Length = 676 
Score =1114 bits (2881), Expect = 0.0 
Identities = 532/678(78%), Positives = 595/678(87%), Gaps = 3/678(0%) 
ii. 1H76A: Chain A, The Crystal Structure Of Diferric Porcine Serum Transferrin 
Length = 696 
Score = 986 bits (2548), Expect = 0.0 
Identities = 484/686(70%), Positives = 560/686(81%), Gaps = 12/686(1%) 
iii. 1F9BA: Chain A, Melanin Protein Interaction: X-Ray Structure Of The Complex 
Of Mare Lactoferrin With Melanin Monomers 
Length = 695 
Score = 858 bits (2218), Expect = 0.0 
Identities = 432/693(62%), Positives = 527/693(76%), Gaps = 22/693(3%) 
iv. 1JW1A: Chain A, Crystallization And Structure Determination Of Goat 
Lactoferrin At 4.0 Resolution: A New Form Of Packing In Lactoferrins With A 
High Solvent Content In Crystals 
Length = 689 
Score = 839 bits (2168), Expect = 0.0 
Identities = 421/690(61%), Positives = 510/690(73%), Gaps = 20/690(2%) 
v. IBIY: Structure OfDiferric Buffalo Lactoferrin 
Length = 689 
Score = 838 bits (2165), Expect = 0.0 
Identities = 422/690(61%), Positives = 508/690(73%), Gaps = 20/690(2%) 
vi. 1CB6A: Chain A, Structure Of Human Apolactoferrin At 2.0 
Length = 691 
Score = 834 bits (2155), Expect = 0.0 
Identities = 420/692(60%), Positives = 509/692(73%), Gaps = 22/692(3%) 
Figure 3.1. The six most similar molecules in the PDB database 
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3: Computational Analysis of Transferrins 
3.1.1.2. Sequence Alignments 
Peter J Sargent 
To visualise the regions of hSTf that are homologous to regions in the other six 
transferrins listed in Figure 3.1, the program ClustalW was used to create a multiple 
alignment of the seven protein sequences (Figure 3.3), using Gonnet 250 matrix and 
the default option for all other parameters. The alignment was carried out over the 
full-length protein sequences, but the graphical view was then divided into each lobe, 
with one lobe per page. Portions of the sequences highlighted in red, which identify 
residues that are 100% conserved amongst the seven transferrins, indicate large 
regions of conserved sequence, especially around residues involved in iron binding. 
Such high degree of conservation suggests an important role for these residues in the 
structure and function of the protein. From this, the iron-binding residues for hSTf 
can be predicted. By comparing the two lobes separately and identifying their 
conserved regions, it is also possible to see a high degree of homology between 
them. There are many of these regions, but a few examples include ADA at position 
63-65 and 400-402, SCH at position 123-125 and 470-472, and GDVAF at position 
213-217 and 553-557. Such a phenomenon is consistent with the theory that suggests 
the evolution of the transferrin family proteins by gene-duplication events (Park et al 
1985). 
Using the same ClustaIW parameters, an alignment of hSTf and rSTf was generated 
(Figure 3.4) to determine how good a template rSTf would be for homology 
modelling of hSTf. The high degree of sequence homology between these two 
proteins suggests that rSTf would be an ideal template for the modelling of hSTf. 
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N-Lobe 
Peter J Sargent 
10 20 30 40 50 60 
humanSTf ------VPDK VSEH SFRD H SVIPSDG V KKAS Y 54 
rabbitSTf ------VTEK VNDH FRD S KVLPEDG II KKAS Y 54 
porcineSTf ------VAQK ISNQ SFRE NIS KAVK-NG VS KKSS Y 53 
mareLf LGLCLAAPRK ISPA QR NIKKVRG VS IRKTS SF 57 
goatLf ------APRK ISLP QWQR RJRKLGA I TS VL G 51 
buffaloLf ------APRK ISQP WQW RIKKLGA I VL 51 
humanLf ------GRRR S VSQP QWQR NIRKVRG VS IKRDS PI 51 
70 80 90 100 110 120 
humanSTf NE SKEDIQJF S MN 114 
rabbitSTf HE VH L SKENIKIF S LNE 114 
porcineSTf 
IVFTLI 
QKD S WN 113 
mareLf NY TRG S LN 117 
goatLf EYI TEKS S LD 111 
FIQJR 
buffaloLf FE YI TKES s 111 
humanLf I TER G 111 
130 140 150 160 170 180 
IMNML rabbitSTf KSII LCDLPEP ESA AD 172 
humanSTf II [FLNWTGP YCDLPEP RKILEKIW TD 172 
porcineSTf II YDQLPEP IE A PVN 171 
mareLf VII YLNWTGP PQA KQ 177 
goatLf Q -SIMNI"I PLSWTES AEJL KA 171 
buffaloLf II YLSWTES L QA 171 
humanLf LIPIA GQ 171 
190 200 210 220 230 240 
humanSTf -- G LN G KH S IK 
1 
227 
rabbitSTf ----- G SVQ G KQ E I SK DE 227 
porcineSTf GAE AED DK 231 
mareLf A QE NG KD S PDE 237 
1 
goatLf GEN A QE DG KE EK 231 
buffaloLf GEN A RE DG KE PEK 231 
humanLf E QE G IRE S DE AE 231 
250 260 270 280 290 300 
anSTf hum 
... . ... .... ... ... LYG ... N 
... ... . 
287 




mareLf PDi F 297 
goatLf LN' FKE 291 
buffaloLf LN F sl 291 
humanLf PF R 
lM 
291 
310 320 330 
ý ý 
340 350 
humaaSTf . ... " PHG P I .. I .... I GTCPEAPT 
. ... 336 
rabbitSTf PHG- P GICPDPLQ ... ... 336 porcineSTf SHG- KI SSY EISPDSSK ... ... 340 mareLf TPEEQ I SQI G TAAEVA 345 
goatLf PEG ISS --TAEEVK ... ... 339 buffaloLf PPGQ ISS --TAEEVQ ... ... 339 humanLf PSGQ IR PRI GS I --SEEEVA .... .. 339 
Figure continues on 
the next page.... 
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C-Lobe 
Peter J Sargent 
360 370 380 390 400 410 
humanSTf DECK LS ElIVNIV GKI TTED I 760 
rabbitSTf DEC LG LI S TPED IS 760 
porcineSTf NEC IGH I NJIGG KI ES NTED IV SI 760 
mareLf ARRE VGPE QWVIP KV TTEE VL I 760 
goatLf ARC VGP QNV TTDD VL SI 760 
buffaloLf VGP QIV TTDD VL I 
j[j 
760 
humanLf VGE GSV TIED VL 760 
420 430 440 450 460 470 
humanSTf I -KSDN-- D KSA-SDL NL 813 
rabbitSTf I -STD--- KES KSN-PDI NINNL 812 
porcineSTf I T-- -EGEN-- SSGPDL NBWL 815 
mareLf KSQN SNAPD-- E SD-ADL SLS 817 
goatLf KSSK HSSLD-- L KAN-EGL SL 817 
buffaloLf SSK HSSLD-- LE KAN-EGL SL 817 
humanLf KSQQ SSDPDP SD-TSL SV 819 
480 490 500 510 520 530 
I 
humanSTf .... ...... .... ... ... I .... ... ý .... ý.... KI FEK G--- 870 
rabbitSTf RI FQ -----5 867 
porcineSTf KIN F EQI ERAPG 875 
mareLf 
J 
QTG QP N-EN 876 
goatLf I QTG FQP DQG-LD 876 
buffaloLf I QTGS F QS P DQG-LD 876 
humanLf QTG YQDPI EQG-EN 878 
540 550 560 570 580 590 
humanSTf E Q MID E lcU4llllLD 929 
rabbitSTf A Q NSE E EIFEMIlLD 926 
porcineSTf Q NKD QEN JF M 934 
mareLf m NSE QE IFEIIELD 936 
goatLf V DD SS RE IFRJIIIM 936 
buffaloLf V DD ST REIFRIIJILD 936 
humanLf V N 938 
600 610 620 630 640 650 
humanSTf ... . ... .... ý.... ý .... I.... .... ý.... .... .... ý MjrRKDKEA CVHKI QH SG 989 
rabbitSTf 
ý 
RKDKAA CVKQ SS 986 
porcineSTf 
t 
DKVT CVAE KA SSS 994 
mareLf S QSDRAQ HLK LD NGP PG 996 
goatLf S RSDRAA HVEQ HG PD 996 
buffaloLf Q S LSERAA HVEQ NG PD 996 
humanLf s RMDKVE RLKQ GS PD 998 8 
660 
ý 
670 680 690 700 710 
ý 
humanSTf 
. ....... .... 
L 
... .... .... .... .... HDRN VKAV P 1043 
rabbitSTf L RGKN IKAVKH 1040 






goatLf L GGRP VTAI TR 1050 
buffaloLf EL GGRP VTAI TR 1050 
humanLf EL HGKT VAGI il" RK 1052 
Figure 3.3. Multiple alignment created by ClustalW of hSTf and the six most 
similar molecules determined following BLASTp. The N- and C-lobes are 
divided between the two pages. Sequence in red highlights regions of 100% 
identity. The eight iron-binding residues for all of the seven transferrins are 
marked above in yellow. 
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10 20 30 40 50 60 
humanSTf E in 60 
rabbitSTf 60 
70 80 90 100 110 120 
humanSTf 120 
rabbitSTf E 120 
Mi" AW 





Mimi wimý shmi Mimi 
180 
180 
190 200 210 220 230 240 
humanSTf TLN SS 240 
rabbitSTf SVQ Q 240 
250 260 270 280 290 300 




310 320 330 340 350 360 
humanSTf I 360 
rabbitSTf 
tili 
I PL 360 
370 380 390 400 410 420 




430 440 450 460 470 480 
rabbitSTf 









S IN 479 
490 500 510 520 530 540 
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Figure 3.4. Sequence alignment of hSTf and rSTf generated by ClustaiW. 
Sequence in red highlights regions of 100% identity. The eight iron-binding 
residues for both proteins are marked above in yellow. 
99 
3: Computational Analysis of Transferrins Peter J Sargent 
3.1.2. Secondary Structure Prediction 
3.1.2.1. Secondary Structure Prediction Overview 
To predict the secondary structure of hSTf, three different secondary structure 
prediction servers, using three different methods, were used. The first one, GORIV, 
is based on the information theory (Gamier et al, 1978). This method considers the 
information carried by a residue about its own secondary structure (its tendencies to 
form a particular structure), in combination with the information carried by other 
residues in a local window of seventeen residues on the either side of the residue 
concerned (Westhead et al, 2002). After cross validation on a database of 267 
proteins, GORIV is known to have a mean accuracy of 64.4% (Gamier et al, 1996). 
The second method used is from the Advanced Protein Secondary Structure 
Prediction Server (APSSP2). This method uses three different steps to predict 
secondary structure. Firstly, it uses the standard neural network and multiple 
sequence alignment generated by PSIBLAST (biology. westl. edrrlgcg/psiblast. html. 
instead of just the single sequence as with GORIV. In the second step, it uses the 
modified Example Based Learning (EBL) technique, which compares short segments 
of sequence with that from known protein structures. Finally, in the third step, the 
results from the first two steps are combined in order to predict the final structure. 
This method is known to predict secondary structure with a mean accuracy of 82.9% 
(ivwwforcasp. org). The third method used was PSlpred 
(www bioinf. cs. ucl. ac. uk/zpsizrred). This method is similar to APSSP2 in that it uses 
neural networks to perform analysis on output obtained from PSIBLAST. The data 
collected from four separate neural networks is averaged out in the prediction 
process to increase accuracy (-78% accurate) (McGuffin et al, 2000). 
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3.1.2.2. Secondary Structure Prediction Analysis 
Figure 3.5a, shows the sequence of hSTf aligned with rSTf and the results from the 
three secondary structure prediction programs discussed above. The secondary 
structure of rSTf (IJNF) is also shown in this figure. As both hSTf and rSTf are 
highly homologous, it is reasonable to suggest that these two molecule's secondary 
structure will be similar. When comparing the predictions from the three methods, 
they all share a high degree of similarity, especially with APSSP2 and PSIPred. In 
the majority of cases, these predictions are also homologous with the actual 
secondary structure of rSTf. This is consistent with the idea both molecules are very 
closely related in evolutionary terms and therefore should have a similar secondary 
structure. 
However, this does not always have to be the case as two identical sequences can 
sometimes have different secondary structures due to long-range interactions 
(Kihara, 2005). This means that such methods as APSSP2 and PSIPred, despite their 
accuracy in predictions, could actually skew the results. The reason for this is 
because these two methods use PSIBLAST to predict the secondary structure by 
analysing the secondary structure of molecules similar to the query sequence. As 
PSIBLAST is similar to the BLAST search engine used in section 3.1.1.1 there is 
high probability that rSTf would therefore have been used in the prediction 
processes. This is the reason why GORIV was also used as this method produces a 
prediction purely from the amino acid sequence. Even so, as discussed before, 
APPSP2 and PSIPred have both been shown to be more accurate than GORIV. 
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Figure Continued.... 
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Figure 3.5. a) Sequence alignment of hSTf and rSTf showing the 
secondary structure of rSTf and the predicted secondary structure using 
GORIV, APSSP2 and PSIPred. b) Percentage of a-helices and ß-sheets in 
each prediction and for rSTf. Sequence highlighted in blue is sequence that 
is homologous with rSTf. Red regions: helix (a- or 31o) and yellow regions: 3- 
sheet. * indicates iron-binding residues 
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To be able to compare the three predictions with the rSTf structure, the percentage of 
cc-helices and ß-sheets were calculated for each one (Figure 3.5b). These results 
showed that the percentages of these two secondary structures are very similar 
between APSSP2 (30.3% a and 17.5% ß), PSIPred (30.8% a and 16.2% ß) and rSTf 
(29.3% (x and 18.8% ß). However, their percentage predicted using GORIV (21.1% 
a and 23.9% ß) is quite different. 
Figure 3.5a also shows the secondary structure around each iron-binding site residue 
to be conserved between each lobe. D63 and D392 are both predicted to be flanked at 
either side between an a-helix and a ß-sheet. Y95 and Y426 are both predicted to be 
in regions of predominantly ß-sheet. Y188 and Y517 are both in regions of a- 
helices. Finally, H249 and H585 are both in regions of ß-sheet. However, the overall 
percentage of a-helix and ß-sheet does vary between lobes to as much as 8%, 
showing that the secondary structure of both lobes is significantly different. 
3.1.3. Homology Modelling 
From the results obtained in section 3.1.1. and section 3.1.2, rSTf was found to be the 
best candidate for a template to create a homology model of hSTf due to its high 
degree of homology with hSTf, at both the primary and predicted secondary structure 
levels. To create this model, a Silicon Graphics Indy Workstation and Modeller 6 
(salilab. org) were used. The core modelling procedure begins with the alignment of 
the sequence to be modelled (target) with related known 3D structures (template). An 
alignment of these two sequences is given as an input to the program, with the output 
being a 3D model. 
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3.1.3.1. Creation of hSTf Model 
Peter J Sargent 
A model of hSTf was created as described in the Modeller 6 manual (Sali et al, 
2001). The three input files to this program included the alignment (PIR database 
format) of hSTf with rSTf (Figure 3.4), the PDB file of rSTf (IJNF) and the sequence 
of hSTf (NP_001054). After the fully automated modelling program had been 
processed, two output files had been created. The first of these is a PDB file 
(Appendix I) of the model and the second one is a log file describing the information 
about the run (Appendix I). This latter file was checked to ensure no additional 
violations had occurred during the modelling process. 
The PDB file created was viewed using Deep Viewer/Swiss PDP Viewer 
(us. expasv. or 7 spdby/) (Figure 3.6). This figure shows a ribbon diagram of the model 
with the ß-sheets highlighted in yellow and the a-helices highlighted in red. A 
diagram of the two iron-binding sites is also shown with the eight iron-binding 
residues labelled. The percentage of a-helices and ß-sheets of the model, shown in 
Figure 3.7, are quite similar to the percentages obtained for rSTf and hSTf 
predictions in section 3.1.2. 
3.1.3.2. Model Validation 
The first validation test was to create a Ramachandran plot of the hSTf model and of 
rSTf using Deep Viewer/Swiss PDB Viewer (Figure 3.8). Three main regions can be 
seen on these plots. The top left hand corner of these plots represents ß-sheet, below 
this region represents right handed a-helix and in the top right quarter represents left 
handed a-helix. Each white cross or square represents a particular residue within the 
3D model and its position according to the phi and psi angles that it possesses. Areas 
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A. 
B. 
Peter J Sargent 
Figure 3.6. The 3D model of hSTf created using Modeller 6 and a Silicon 
Graphics Indy Workstation and viewed using Deep Viewer / Swiss PDB 
Viewer. Red: a-helix. Yellow: ß-sheet. Grey: Random coil. A: A ribbon diagram 
of the model with the two lobes highlighted. B: A picture of the iron-binding site 
of each lobe with the eight iron-binding residues labelled. 
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Figure 3.7. a) Sequence alignment of the hSTf model with rSTf, b) 
Percentage of a-helices and ß-sheets. Sequence highlighted in red: a-helices 
and highlighted in yellow: ß-sheets. * indicates iron-binding residues. 
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A. 
B. 
Peter J Sargent 
Figure 3.8. Ramachandran Plots created using Deep Viewer / Swiss 
PDP Viewer. A: Plot of rSTf PDP (IJNF). B: Plot of the hSTf model. 
Square: Glycines. Crosses: all other residues. 
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enclosed by a yellow line represent the most favoured phi and psi angle combinations 
within the protein backbone, whereas those areas within the blue lines represent 
additionally allowed phi and psi angle combinations. Anything outside either of these 
two regions represents residues with disallowed phi and psi angle combinations. To 
calculate the frequency of residues in each region, an on-line program known as 
Procheck (www. biochem. ucl. ac. uk/-roman/procheck) was used. A score of 91.4% of 
hSTf residues were found to be located in the most favoured regions compared with 
85.6% for rSTf. Of the remaining portion, 8.2% of hSTf reside in the additionally 
allowed regions compared with 13.9% for rSTf. The remaining residues for both 
proteins reside in the disallowed regions. What is noticeable is that hSTf has more of 
its residues in the most favoured regions, even though the data for rSTf is from a 
crystal structure. There are two possible reasons for this. Firstly, the data collected 
for rSTf is from a protein crystal, and therefore describing a static state of the 
protein. This means that the protein may not be in its most natural configuration and 
therefore some bond angles could be strained. Secondly, within the rules used by 
Modeller to create a model, the ones including the optimum phi and psi angles will 
tend to lead to a high percentage of residues located into the preferred Ramachandran 
plot regions. However, in general, the majority of residues for both proteins reside in 
the favoured regions and when comparing the two proteins, a lot of similarity can be 
seen. 
Knowing that the Ramachandran plots of both proteins are similar, the similarity in 
the overall 3D structure of both proteins was checked by aligning the hSTf model to 
the rSTf template using Deep Viewer/Swiss PDP Viewer (Figure 3.9). By viewing 
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Figure 3.9. Structural alignment of rSTf (IJNF) with the hSTf model. 
The alignment of the two molecules without their side-chains was 
viewed using Deep Viewer / Swiss PDB Viewer. Red: rSTf and white: 
hSTf model. A-C: different views of the alignment. 
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the alignment from different angles it is possible to see that the backbone from both 
proteins are quite superimposed. 
In order to validate the model further, another on-line program was used. This 
program, known as WHATIF (biotech. ebi. ac. uk: 8400/cgi-bin/sendquerx), runs 54 
different structural analysis checks on an inputted PDB file. Both the PDB file of the 
model and also the rSTf (IJNF) were analysed using this program. For the majority 
of these checks very few errors were noticed. The first error was showing abnormally 
short interatomic distances, or atomic bumps. Two atoms are said to bump when they 
are closer than the sum of their Van der Waals radii minus 0.4tß. For hydrogen- 
bonded pairs, a tolerance of 0.55A is used. The atomic pairs that bump in both 
proteins are shown in the Appendix 1.4 and 1.5.418 atomic pairs in the model are 
shown to bump and 180 atomic pairs in rSTf. However, the vast majority of atomic 
pairs are labelled as BF, meaning that the B-factor average for both atoms is greater 
than 80 and therefore there is a high probability the atoms are not there. The second 
error was histidine, asparagine, glutamine side-chain flips. Six residues (Q18, Q109, 
H205, N323, H533, H640) were shown through hydrogen-bonding analysis to form 
energetically more favourable hydrogen bonds if the terminal group is rotated by 
1800. The remaining errors picked up by WHATIF program were more related to the 
PDB file than to the model itself. Following these model validation checks, it can be 
concluded that the accuracy and suitability of the model of hSTf created was 
acceptable. 
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3.2. Structure Prediction 
Peter J Sargent 
Sali et al, 1995, stated that with a template structure of more than 40% sequence 
identity to the target protein, the model is likely to have about 90% of the main-chain 
atoms modelled with a root mean squared (rms) deviation from the X-ray structure of 
approximately 1 A. Therefore, since the sequence identity of hSTf to rSTf (template) 
is 78% (section 3.1.1.1) the accuracy of the model should be greater than 90%. 
3.2.1. Conserved Regions 
As discussed in section 3.1.1 a high proportion of residues amongst the Transferrins 
are conserved. Figure 3.10 highlights the residues of the hSTf model that are found 
to be conserved amongst the six Transferrins listed in Figure 3.1 and hSTf. From 
this, important regions of the protein can be determined. From this figure it can be 
concluded that the conserved residues make up a core skeleton, defining clearly the 
two domains in each lobe, and the residues that are not conserved, and therefore can 
be described as variable, surround the outside of the molecule. This is consistent with 
the transferrins having a similar iron-binding mechanism, but having specificity for a 
variety of receptors. 
3.2.2. Proposed Regions and Residues of Importance 
As described in section 1.3.3 all of the iron-binding residues are conserved amongst 
the majority of the transferrin family, especially between the serum transferrins and 
lactoferrins. These residues are highlighted in red in Figure 3.10. When visualising 
the iron-binding residues in relation to secondary structure, all these residues are 
located, usually towards the end, of a-helix or ß-sheets, and never in regions of 
random coil, or loop (Figure 3.7, section 3.1.3.1). A possible reason for this is so 
112 







Peter J Sargent 
A: All residues shown. B: Only conserved residues shown. All iron-binding 
resiudes are conserved and are highlighted in red. Both lobe and the four 




Figure 3.10. PDB image of the hSTf model highlighting residues (blue) that 
are conserved amongst the six Transferrins listed in section 3.1.1. and hSTf. 
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stability is brought to these residues by the secondary structure, as well as still 
remaining accessible to bind the iron. The idea that transferrins have evolved through 
gene duplication is also reflected here since the corresponding residues constituting 
the iron-binding sites in each lobe are found in regions of the same secondary 
structure. 
The two arginines (R124 and R456) involved in carbonate binding, which are also of 
great importance in the binding and release of iron, are not located in regions 
containing a-helix or ß-sheet, but in regions of random coil. Figure 3.11 shows the 
position on the 3D model of these two residues in relation to the iron binding 
residues and the secondary structure around that area. Such a lack of defined rigid 
secondary structures suggests an increase in flexibility for these two residues that 
could be necessary for the protonation of the carbonate anion in the release of the 
iron. 
Two other important residues thought to be involved in the mechanism of iron- 
release are the two lysines (K206 and K296) located in the N-lobe of hSTf. As 
described in section 1.3.4, these two lysines are located on opposite domains so that 
when the two domains are closed, an interaction through a proton bridge is formed. It 
has been proposed that at low pH, this proton bridge is released, allowing the two 
domains to flip open (Rinaldo and Field, 2003). Figure 3.12 shows the location of 
these two lysines in relation to the two domains of the N-lobe. It is possible to see in 
this figure that these two lysines come into close contact when the two domains Ni 
and N2 are in the closed configuration shown in the model. The distance between the 
nitrogen and the hydrogen of both amino acid side-chains is shown in this model to 
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N-Lobe 
C-Lobe N 
Peter J Sargent 
Figure 3.11. PDB image showing the two iron-binding sites of the hSTf 
model and the secondary structure around those regions. Yellow: ß-sheets. 
Red: a-helix. Grey: random coil, or loop. Red residues: directly involved in 
iron binding. Green residues: involved in carbonate binding. 
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N-Lobe C-Lobe 
Peter J Sargent 
Figure 3.12. PDB image showing the location of the `dilysine-trigger' in 
the N-lobe of the hSTf model, minus all side-chains (apart from K206 and 
K296). The two are highlighted in red, the C-lobe in grey and the N-lobe in 
blue. The four domains are also labelled (Ni, N2, C1 and C2). 
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be -3A (measured using the atomic ruler in Deep Viewer/Swiss PDB viewer) which 
is equivalent to the typical length of hydrogen bonds (Kyte, 1995). 
TfR/hSTf interactions are of great interest for the understanding of receptor-mediated 
iron uptake into cells. Although it is totally not clear which residues in hSTf interact 
with the transferrin receptor 1 (TfR1) Cheng et al, 2004 has proposed ten residues on 
the C-lobe domain I (H349, R352, L353, D356, E357, S359, V360, E367, S370 and 
G372) that interact with the helical domain of TfR1. These residues are highlighted 
in yellow in Figure 3.13. Apart from S359, none of the residues are conserved 
amongst all seven Transferrins listed in section 3.1.1. However, all of these ten 
residues are conserved in rSTf and five are conserved in pSTf. Residue S370 is also 
conserved in mare STf and hLf. Cheng et al, 2004 also proposes an interaction 
between the hSTf and TfRI through a hydrophobic patch on the N-lobe. The regions 
of interaction on the N-lobe are less well defined than in the C-lobe. Figure 3.13 also 
highlights the areas in the N-lobe that are seen to interact in the PDB file of the 
hSTf/TfR complex (Accession number: 1SUV) downloaded from RCSB PDB 
Protein Databank (www. resb. org/pdb). This shows the N-lobe making two localised 
contacts with TfR1. As shown by Cheng et al, (2004) the Ni domain interacts with 
the helical domain of TfRI and the N2 domain interacts with the protease-like 
domain. 
3.2.3. Surface Characterisation 
The surface-characteristics of any ligand molecule are of great importance, since it is 
at this interface that interactions with other molecules occur. Not only can this help 
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Figure 3.13. PDB image of the hSTf model highlighting regions that are 
thought to interact with the TfR (yellow) and conserved residues (blue). 
A: All residues shown. B: Only conserved residues and TfR interacting residues 
are shown. Both lobe and the four domains are labelled. (Generated using Deep 
Viewer / Swiss PDB Viewer) 
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to identify regions involved in binding, but it can also reveal characteristics that can 
be of considerable importance in protein function and stability. 
The surface profile of the hSTf model, coloured in relation to surface accessibility 
(a), charge (b) and hydrophobicity (c), is shown in Figure 3.14. This figure was 
generated using Deep Viewer/Swiss PDB Viewer, presuming a fixed radius of 1.4A 
for all atoms. When comparing accessibility (Figure 3.14a) with residue homology 
amongst transferrins (section 3.1.1), it is noticeable that the most accessible of 
residues are also generally the most variable. The opposite is true for the most 
conserved of residues. Figure 3.14b shows the surface residues of hSTf to be 
predominantly positively charged, with one very large region of positivity in the C- 
lobe and a slightly smaller region in the N-lobe. Both of these regions are surface 
exposed and therefore could be involved in molecular interactions. Since hSTf is a 
soluble protein, its surface is expected to be mainly hydrophilic. However, quite a 
few hydrophobic patches can be identified (Figure 3.14c) which could be involved in 
protein-protein interactions. 
3.2.4. Analysis of hSTf mutants 
As discussed in section 1.4, one of the aims of this study is to investigate specific 
hSTf mutants using a variety of physico-chemical techniques and to interpret the 
results using the model created in this chapter. Comparing these results with the ones 
obtained for the wild type transferrin should help to solve its mechanism of iron 
uptake and release by transferrin. 
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N-Lobe C-Lobe C-lobe N-lobe 
A. 
Figure 3.14. PDB image showing the surface accessibility, charge and 
hydrophobicity of the hSTf model. A: Surface accessibility (yellow most 
accessible > green > blue less accessible). B: Charge distribution through the 
protein (red positive, blue negative). C: Hydrophobicity (Blue: Hydrophilic, 
yellow: hydrophobic). Surface generated using Deep Viewer / Swiss PDB Viewer. 
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3.2.4.1 G394R Variant 
Peter J Sargent 
One particular variant of interest is the G394R mutant protein, discussed in section 
1.3.9. Evans et al, suggested in 1994 that since G394 was buried, it was neither 
directly involved in iron-binding, nor did seem likely to be involved in receptor 
binding. These results are consistent with the location of G394 within the hSTf 
model created in section 3.1.3. The close proximity of residue 394 with the five 
residues involved in iron binding can also be seen in Figure 3.15. In this model, the 
arginine sidechain seems to point into the iron-binding site, close to R456 and D392. 
This could have two possible effects: due to its positively charged sidechain, R394 
could either interact with the negatively charged sidechain of D392, or/and repel the 
sidechain of R456. Either way, this would probably lead to structural alteration of the 
iron-binding site that might lead to a reduction in affinity for iron. 
In order to further investigate how this mutation might affect the overall structure 
and function of the protein, the hydropathicity (Kyte and Doolittle, 1982) and % 
accessibility (Janin, 1979) of residues 350 - 450 were calculated using ProtScale 
(us expasy. orv, /tools/T)rotseale. html ). A secondary structure prediction of the same 
region was also carried out on the same region using PSlpred (section 3.1.2). Figure 
3.16 compares all three data sets collected, comparing the G394R mutant to the WT 
protein. 
A noticeable difference between both proteins was identified when comparing both 
secondary structure prediction profiles. In the WT protein, G394 is shown to be on a 
four-residue section of random coil, sandwiched between two regions of ß-sheet. 
However, in the G394R protein, the secondary structure around this region is 
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Figure 3.15. Location of G394R mutation within the hSTf model. A: Overview 
of hSTf and location of the mutant in the C-lobe. B: Location of G394 in relation 
to the C-lobe iron-binding site. C: Location of R394 in relation to the C-lobe iron- 
binding site. Red: Residues directly involved in iron-binding. Yellow: Arg456 
(involved in binding of the synergistic carbonate anion). Blue: residue 394. 
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dramatically altered. Instead of residue 394 being sandwiched between two regions 
of ß-sheet, a region of a-helix is predicted between residues 393 and 401. The 
secondary structure further along the protein also seems to be affected by the G394R 
mutation, including the lengthening of a ß-sheet region around residues 405 and 412 
and a shortening of a ß-sheet region around residues 426 and 433. 
Minor differences around residues 390 and 400 can also be seen between the two 
proteins when comparing hydropathicity and % accessibility. The data shows this 
region to have a higher degree of hydrophobicity and % accessibility in the WT 
protein than in the mutant protein, suggesting that the mutation causes these residues 
to be buried deeper within the protein. This could possibly cause the deformation of 
the inner structure of the C-lobe and in turn, its iron-binding site. 
3.2.4.2. N413Q and N611Q Variants 
As defined in see section 1.4 one of the purposes of this project is to express hSTf in 
yeast, more specifically, in Saccharomyces cerevisiae. One of the foreseeable 
problems using such a system is protein hyper-glycosylation, which might lead to 
increased protein heterogeneity that could possibly affect downstream analysis and 
crystallisation. 
Mason et al, (2001) discuss the mutagenesis of the N-linked glycosylation residues 
on hSTf (N413D and N611D) in order to express non-glycosylated hSTf in baby 
hamster kidney (BHK) cells. In order to achieve the same effect, it was decided to 
mutate both N-linked glycosylation asparagine residues to glutamines (N413Q and 
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N61 IQ), which is the residue of choice due to their close similarity, as shown by 
Dayhoff Table in Appendix I. 
To study how these mutations might affect the overall structure and function of the 
protein, the predicted secondary structure, hydropathicity and % accessibility of the 
residues around these mutations was compared with the wild type protein, as 
described for G394 variant (Figure 3.17 and Figure 3.18). The predicted secondary 
structure and the hydropathicity profile were found to be superimposable for the 3 
variants suggesting no changes in secondary structure and hydropathicity for the 
mutant proteins. However, for both mutants, there is a change in % accessibility 
around their corresponding regions suggesting that the accessibility of the region 
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3.3. Transferrin - Transferrin Receptorl Interactions 
In the previous section, the interaction of hSTf with TfR1 is discussed in relation to 
the model created in section 3.1 and data published by Cheng et al, 2004. The 
purpose of this section is to attempt to further identify regions on TfRI that interact 
with hSTf. Such data, along with previously published data, can then be used to 
locate regions on hSTf that are involved in the receptor interactions. 
To find which regions of TfRI interact with hSTf, a peptide library of the full 760 
amino acids of TfR1 was purchased from Sigma Genosys. This library comprises of 
108 13-mer peptides (Appendix I), with an overlapping length of 6 residues. By 
overlapping each peptide, every residue, apart from the first and last seven residues, 
are present in one peptide along with at least the seven residues upstream, and in 
another peptide, along with at least the seven residues downstream of it. This reduces 
the chance for a specific length of sequence that may interact with hSTf being 
missed. The library was probed using FITC conjugated hSTf, which allowed the 
spots containing the specific peptides that bound hSTf to be visualised under UV. 
The sequence of these peptides can then be mapped back to the TfRI pdb image, so 
that regions of the protein that interact with hSTf can be highlighted. 
Using the protocol described in section 2.4.13, the 108 spot peptide library was 
probed with FITC-conjugated hSTf. The membrane was then scanned using a UV 
SynGene GelDoc System and the fluorescence quantified, in terms of mean 
fluorescence count (MFC), using Syngene Genetools (Figure 3.19a). In order to take 
into account the background fluorescence count, the MFC of each spot was 
subtracted by the minimum MFC (630.58). Figure 3.19b compares the adjusted 
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1 11 21 31 41 51 61 71 81 91 101 
Spot Number 
Figure 3.19. TfR1 Peptide library probed with FITC-hSTf. A: Peptide library 
scanned under UV using a SynGene GelDoc System and quantified using 
SynGene Genetools. Values represent the mean fluorescence count per spot with 
the minimum highlighted in yellow. B: Plot of mean fluorescence count minus the 
minimum spot fluorescence (630.58). Yellow line: Mean. Blue, green and brown 
line: Mean +1, +2 and +3 standard deviation respectively. 
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fluorescence of each spot, highlighting the average MFC and also the MFC at +1, +2 
and +3 standard deviation (SD) above the average. By determining which spots 
fluoresce above +1 SD, +2 SD and +3 SD gave an indication of how significant this 
fluorescence is in terms of hSTf-TfRI interaction. Taking all spots that have a MFC 
greater than +1 SD above the average ensures that only the top 16% of all spots, in 
order of brightness, are chosen. A MFC greater than +2 SD above the average, this 
percentage is reduced to 2.3% and greater than +3 SD, the percentage is reduced 
further to 0.15% (Harris et al, 2005). 
Only 13 spots were detected with a MFC greater than 1 SD above the average. These 
include spots 46,58,59,64,65,66,67,75,76,91,92,101 and 105. By highlighting 
these areas on the pdb image of the TfRl-hSTf complex (Accession number: 1 SUV), 
the regions of TfRl shown to interact with hSTf can be visualised (Figure 3.20). 
These results show that a large majority of these regions lie within the helical domain 
of TfR1, with a few around the protease-like domain. It can also be seen in this 
figure that the majority of the interactions are occurring through the C-lobe of hSTf, 
with only a small number of interactions occurring through the N-lobe. Apart from 
the lack of interactions form the N-lobe, the C-lobe interaction is consistent with the 
results published by Cheng et al, 2004. 
In order to characterise these regions further, their average hydrophilicity (calculated 
using the Hopp and Woods method, 1981) and their charge was calculated (Figure 
3.21a). These characteristics were then mapped onto the receptor image so they 
could be compared with the characteristics of their corresponding hSTf interacting 
regions (Figure 3.21b). As expected, the majority of residues on the surface of the 
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Figure 3.20. Molecular surface images of the TfRl dimer (A and D) and the 
hSTf-TfRI complex (B, C, E and F), highlighting regions shown by peptide 
library analysis to interact with hSTf. The TfRI dimer is coloured red with 
interacting regions in yellow and hSTf coloured blue. Surface generated using Deep 
Viewer / Swiss PDB Viewer and using PDB Accession Number: 1 SUV, Cheng et 
al, 2004. 
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58 DHYVVVGAQRDAW 1 2 -1 -0.2 
59 AQRDAWGPGAAKS 2 1 +1 0.3 
64 FQPSRSIIFASWS 1 0 +1 -0.6 
65 IFASWSAGDFGSV 0 1 -1 -0.7 
66 GDFGSVGATEWLE 0 3 -3 -0.1 67 ATEWLEGYLSSLH 0 2 
-2 -0.5 
75 GQFLYQDSNWASK 1 1 0 
-0.3 
76 SNWASKVEKLTLD 2 2 0 0.3 
91 DIKEMGLSLQWLY 1 2 -1 -0.4 92 SLQWLYSARGDFF 1 1 0 
-0.6 
101 FWGSGSHTLPALL 0 0 0 
-0.9 
105 TLFRNQLALATWT 1 0 +1 -0.8 
B. 
Figure 3.21. Calculated hydrophilicity and charge of TfRI regions proposed to 
interact with hSTf (A) and their location on the molecular surface of TfRI (B). 
The TfRI dimer is coloured red with hydrophilic and hydrophobic interacting 
regions in blue and yellow, respectively (BI) and positive, negative and neutral 
interacting regions in green, grey and white, respectively (BII). Interacting regions 
are labelled corresponding to their peptide number (BII). Surface generated using 
Deep Viewer / Swiss PDB Viewer and using PDB Accession Number: I SUV, 
Cheng et al, 2004. 
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protein are hydrophilic. However, two of the regions that are shown to interact are 
hydrophobic (peptides 59 and 76). These two regions could possibly be involved in 
hydrophobic interactions with hSTf, especially peptide 76 as it has a MFC greater 
than +3 SD above the mean. With relation to charge, the majority of interacting 
regions are neutral with only three regions being positively charged. However, apart 
from region 64, these positively charged regions have all a MFC below +2 SD above 
the mean, which suggests that they might not be significant. 
By creating a 3D image using Deep Viewer/Swiss PDB Viewer and the PDB file of 
the TfRI-hSTf complex (Accession Number: 1SUV), the TfR1 dimer and one of the 
hSTf molecules can be disintegrated away to reveal the possible binding sites on one 
hSTf (Figure 3.22). Figure 3.22c highlights the 10 hSTf residues which are discussed 
in section 3.2.2 and that are proposed by Cheng et al, 2004 to interact with TfRI. 
These two main regions in the Cl domain of hSTf are shown to interact with 
peptides 75,76 and 92. A third interacting region in the Ni domain is also shown to 
interact with peptides 58 and 64. 
By comparing the proposed TfR1 binding regions of hSTf with the surface 
characteristics of the hSTf model in section 3.2.3, the characteristics of these specific 
binding sites can be visualised. From this it can be seen that 8 out of the 10-hSTf 
residues that are proposed by Cheng et al, 2004 to bind TfR1 are hydrophilic, 
although interspersed with numerous hydrophobic residues. Therefore, one possible 
interaction could be with the large hydrophobic region (peptide 76) of TfR1 and a 
number of these hydrophobic residues. Peptide 76 had the highest MFC in these 
studies, which implies that this interaction with hSTf might be one of the strongest. 
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Figure 3.22. Disintegrating molecular images (A- *C) of hSTf-TfRI 
complex, unveiling the receptor binding regions of hSTf. TfRI dimer is 
coloured red with interacting regions in yellow. The transferrin is coloured 
blue with the published TfRI binding residues in white. Surface generated 
using Deep Viewer / Swiss PDB Viewer and using PDB Accession Number: 
I SUV, Cheng et al, 2004. 
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Another possible interaction could involve the hSTf residues D356 and E357. These 
two negatively charged residues are present just below where the TfR1 peptide 92 
binds hSTf and in a region that would line up with the positively charged TfR1 
peptide 46, following binding of the two molecules. TfR1 peptide 58 and 64 are also 
shown by these studies to be involved in hSTf binding. As with peptide 76, these two 
are predominantly hydrophobic, and as they are shown here to bind to a region of 
hSTf that is also predominantly hydrophobic, this could be the form of this 
interaction. The high degree of hydrophobicity identified in many of these regions 
proposed to be involved in the interaction between hSTf and its receptor TfRI, 
suggests a strong hydrophobic nature of this interaction. Since both molecules 
present mainly hydrophilic surfaces, such interactions involve regions of both 
proteins which are not exposed, and therefore implies structural/conformational 
changes upon interaction. 
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4. Protein Expression and Mutagenesis 
Peter J Sargent 
This chapter focuses on the expression of hLf and hSTf using E. coli and S. cerevisiae 
cells. There are many advantages and disadvantages for using either of these very 
different cells for recombinant protein expression. A few reasons for using E. coli is 
that these cells are relatively low maintenance, they have a quick generation time, 
much is know about them and they are relatively easy to use in cloning. In addition, a 
large number of different strains are readily available from companies such as 
Novagen and Promega. S. cerevisiae cells are also well known, relatively easy to 
grow and maintain, and not easily outgrown by contaminants. However, one of the 
main advantages of using Scerevisiae over E. co1i is that these are eukaryotic cells 
and therefore have very similar protein processing pathways as mammalian cells. 
4.1. Expression of hSTf and hLf in Esc/ierichia coli 
4.1.1. Introduction 
Three different strains of E. coli were used in the following hLf and hSTf expression 
studies. BL21 (DE3), Origami (DE3) Plys and Origami were all purchased from 
Novagen (section 2.1.1). Both of these Origami strains have mutations in both the 
thioredoxin reductase (trxB) and glutathione reductase (gor) genes, which greatly 
enhances disulfide bond formation in the cytoplasm (Xiong et al, 2005). 
4.1.2. hLF Expression 
The source of hLf eDNA for these studies was in the form of a pUC 18 vector, kindly 
donated by Delta Biotechnology Ltd. Before using this vector in any experiments, an 
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RFLP study was carried out to check its integrity. This study comprised five different 
digests: BamHI, PstI, HindIII, BamHI / PstI and Ndel. These digests were visualised 
on a 1% (w/v) agarose gel (Figure 4.1). This gel shows the hLf insert to be flanked 
by two BamHI sites and also two HindIIl sites. These two sites, including other sites, 
were confirmed by sequencing the entire hLf cDNA (Cytomyx, Cambridge). The 
sequence was also used to ensure that no mutations were present in the coding frame. 
Only two silent mutations were found. 
4.1.2.1. Constructs 
Two vectors were explored for the expression of hLf in E. coif: pET12a and 
pALTER-Exl (section 2.1.7). Both plasmids contain a T7 promoter, a ß-lactamase 
gene for ampicillin resistance, an OriR region for plasmid replication in E. coil and 
their own unique multiple cloning sites. There are also a number of differences: 
pALTER-Exl also contains a gene encoding tetracycline resistance, a tac promoter 
and an SP6 promoter, whereas pET12a contains an ompT leader for potential 
periplasmic export of the target protein. The main reason for wanting to export the 
protein to the periplasm is that it is thought to improve protein folding and solubility. 
However, in order to compare protein expression with and without this leader, two 
separate constructs were made: hLf-pET12a and hLf-modpETl2a. 
4.1.2.2. Creation of hLf pALTER-Exl 
Since pALTER-ExI is a multifunctional vector used for both protein expression and 
mutagenesis, this was therefore the ideal plasmid for preliminary attempts to express 
hLf. The hLf cDNA was digested out of pUC18-hLf using BamHI and purified from 
an agarose gel using a Qiagen Mini Elute Gel Extraction Kit (section 2.1.8) 
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Figure 4.1. An RFLP study of the pUC18-hLf construct on a 1% (w/v) 
Agarose Gel. M: EcoRl / HindHI lambda marker, 1: BamHI, 2: PstI, 3: Hindill, 
4: BamHI / Pstl and 5: Ndel. 
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following electrophoresis. At the same time, pALTER-Exl was also digested with 
BamHI, treated with phosphatase to remove the phosphate group from the 5' end and 
then purified using a Mini Elute Reaction Cleanup kit (see section 2.1.8). The hLf 
cDNA was then ligated into pALTER-Exl before being transformed into JM109 
cells and grown at 37°C overnight on LB agar plates containing 100µg/mL 
ampicillin. Five transformants were then selected, grown up overnight at 37°C in 
5mL LB broth containing 100µg/mL ampicillin, and then plasmids were then 
extracted using a Spin Mini Prep kit (section 2.1.8). 
Because hLf was ligated into pALTER-Exi using a single restriction site, the insert 
could be orientated in two different ways (Figure 4.2). To check its orientation, 2µL 
plasmid prep samples from each transformant were digested using HindIIl and then 
run on a 1% (w/v) agarose gel (Figure 4.3). One of the T7 orientated constructs was 
selected for expression studies in E. cola (DE3) carrying the T7 polymerase gene. 
4.1.2.3. Creation of hLf-pET12a (with OmpT leader) 
The hLf cDNA from the hLF-pUC18 vector was cloned into the BamHI site of 
pET12a using the same procedure as for the ligation of hLf into pALTER-Ex1. As 
before, twelve transformants were selected, grown up overnight at 37°C in 5mL LB 
broths containing 100µg/mL ampicillin, and their plasmids were then extracted using 
a Spin Mini Prep kit. 
Because hLf was ligated into pET12a using a single restriction site, the insert can be 
present in two orientations (Figure 4.4). The hLf orientation for all twelve 
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Peter J Sargent 
Fl T7 
urdlll 5748 Hindill 7927 
T7 F1 tac 
AmpR TetR HLf 
BamHl BamHI 
Figure 4.2. Linear vector maps of the two possible ligation products 
following the cloning of hLf into pALTER-Exl using the BamHI 
restriction site. The two orientations can be visualised following digestion 
with HindII1. T7 ori: 7851bp and 99bp, tac ori: 5771bp and 2179bp. 
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Figure 4.3. Agarose Gel Electrophoresis showing the orientation of the hLf 
cDNA in pALTER-Exl following digestion of five transformants with 
HindIIl. M: EcoR 1/ HindIII lambda marker and 1-5: transformants. 
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Orientation 1 
Ec, R1 2184 
am HI 2204 
108 I &oRl 2716 
OmpT HLf 
Orientation 2 
Peter J Sargent 
BamHl 108 ßm HI 2204 
1F. co RI 128 IF: coRl 
2716 
Om, pT HLf 
Figure 4.4. Linear vector maps of the two possible ligation products 
following the cloning of hLf into pET12a using the BamHI restriction site. 
The two orientations can be visualised following digestion with EcoR 1. The 
correct orientation for expression using the T7 promoter is Oril. Oril: 6238bp 
and 532bp, Ori2: 4182bp and 2588bp. 
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transformants was checked by observing the fragment sizes produced following 1% 
(w/v) agarose gel electrophoresis of BamHI and EcoRI hLf-pET12a plasmid digests 
(Figure 4.5). Out of the twelve, only transformant eleven carried the hLfpET12a 
plasmid with the hLf cDNA in the correct orientation. The sequence of the first 500 
bases of this construct, including the T7 promoter, was confirmed by DNA 
sequencing (Randall Centre, Kings). 
4.1.2.4. Creation of hLf-modpETl2a (without OmpT leader) 
To knock out the OmpT leader present in the hLf-pET12a construct, two 
oligonucleotides were designed (LFPompTK5-3 and LFPompTK3-5, see appendix 
II) so that when hybridised together can be ligated into the hLf-pET12a construct to 
replace the OmpT sequence (Figure 4.6). 
Before the two oligonucleotides were hybridised together, a phosphate group was 
added to the 5'-terminus of each one, using a T4 Polynucleotide Kinase (Promega). 
This reaction was carried out for each oligonucleotide separately by mixing 2µL of 
100µM oligonucleotide, 2.5µL of lOx Kinase buffer, 2.5µL of lOnM ATP, lp. L of 
T4 Polynucleotide Kinase with 17µL of MilliQ water. The mixture was then 
incubated at 37°C for 30 minutes, then heated at 70°C for 10 minutes to deactivate 
the enzyme. These two 25µL reaction mixtures were then mixed together and heated 
to 75°C for 5 minutes and then cooled at 1°C/min to allow the two oligonucleotides 
to slowly hybridise. 
Following hybridisation of the two oligonucleotides, hLf-pET12a was digested with 
Xbal and Sall to excise the OmpT leader. The digested plasmid was then purified by 
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Figure 4.5. Agarose Gel Electrophoresis showing the orientation of the 
hLf cDNA in pET12a following digestion of five transformants with 
BamHI and EcoRI. M: EcoRI / HindIII lambda marker, 1-12: Transformants 
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hLf-pET12a Construct 
XbaI RBS NdeI 
TCT. AGA. AAT. AAT. TTT. GTT. TAA. CTT. TAA. T. ATA. CAT. ATG. 
M 
OmpT Leader 
CGG. GCG. AAA. CTC. CTA. GGA. ATA. GTC. CTG. ACA. ACC. CCT. ATC. GCG. ATC. 
RAKLLGIVLTTPIAI 
BamHI Sall 
AGC. TCT. TTT. GCG. TCG. ACG. GGA. TCC. AAA. AAA. ATG. GGT. CGA. CGG. AGA 
SSFASTGSKKMGRRR 
AGG...... Human Lactoferrin... 
R 







Ligation of hybridised oligonucleotides 
into Xbal / SaII cut hLf-pET I2a 
XbaI RBS 
TCT. AGA. AAT. AAT. TTT. GTT. TAA. CTT. TAA. T. ATA. CAT. ATG. G 
M 
Sall 
GT. CGA. CGG. AGA. AGG ...... Human Lactoferrin... 
GRRRR 
Figure 4.6. Creation of the hLf-modpETl2a construct by replacing the 
OmpT leader sequence with a 50 base long double-stranded oligonucleotide. 
Sequence in black: pET12a, red: OmpT, blue: hLf insert and green: the 
hybridised LFPompTK5-3 and LFPompTK3-5 insert. The lactoferrin isoform 
used in these studies included four arginines after residue 1 (glycine), unlike the 
three arginines observed in other isoforms. 
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agarose gel electrophoresis and gel extraction before being ligated with an equal 
molarity of hybridised oligonucleotides. This ligation was transformed into JM109 
cells and grown at 37°C overnight on LB agar plates containing 100pg/mL 
ampicillin. Ten transformants were selected from these plates and their plasmids 
extracted following overnight growth in 5mL of LB containing 100µg/mL 
ampicillin. To check that the plasmid had been correctly modified, the ten 
transformants were digested with BamHI and also with EcoRI. The digests were run 
on a 1% agarose gel to visualise the fragment (Figure 4.7). Unmodified plasmids 
contain two BamHI sites, whereas the modified plasmid only contains one site due to 
the replacement of the OmpT leader with the hybridised oligonucleotides. Both 
plasmid types contain two EcoRI sites 532 bases apart. All of the ten transformants 
were correctly modified. Two of these transformants were DNA sequenced (Randall 
Centre, Kings) around the modification site to check sequence integrity. Both were 
correct, but only one transformant was selected by random. 
4.1.2.5. Expression Study 1 
The selected T7 orientated hLf pALTER-Exl plasmid and a pALTER-Exl plasmid 
without hLf, were transformed into BL21 (DE3) cells (section 2.1.1). Transformants 
were selected for on LB agar plates containing 10µg/mL tetracycline. From these 
plates, one transformant from each of the two clones were selected and used to 
inoculate 5mL LB broth (10µg/mL tetracycline) and incubated overnight at 37°C. 
The following day, 6x 5mL LB broth were inoculated with 50µL of hLf pALTER- 
Exl overnight culture and 1x 5mL LB broth was inoculated with 50µL of pALTER- 
Exl overnight culture. After incubation for 3 hours at 37°C on a shaking platform, 
IPTG was added to three of the hLf constructs to a final concentration of 
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Figure 4.7. Agarose Gel Electrophoresis of 10 hLf-modpETl2a 
transformants following BamHI and EcoRI digestion. M: EcoRl / HindIIl 
lambda marker, 1-10: hLf-modpETl2a transformants and A-B: hLf-pET12a. 
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1mM. All seven cultures were then placed back in the incubator. After a further two 
hours, two of the hLf construct cultures were taken out and centrifuged at 2000 g for 
10 minutes. The supernatant was poured off and the pellet frozen. This was repeated 
at three and at four hours, with the pALTER-Exl culture being taken out on the 
fourth hour. Frozen pellets were then defrosted at room temperature before being 
resuspended in lmL of Cell Suspension buffer. Each lmL suspension was then 
sonicated for 30 seconds using a Mullard Ultrasonic Powerunit and then centrifuged 
at 10,000g for 20 minutes to spin down any debris. Samples (5 t1) of supernatant 
from each sample were run on a reducing 8% (w/v) PAGE SDS gel (Figure 4.8). 
4.1.2.6. Expression Study 2 
hLf-pET12a, hLf-modpETl2a and pET12a were transformed into BL21 (DE3) and 
Origami (DE3) pLys cells and selected on LB agar plates containing IOOpg/mL 
ampicillin. One transformant was selected from each of the three construct plates and 
each of the two E. coli strains plates and used to inoculate 5mL of LB broth 
containing 100µg/mL ampicillin. After overnight growth at 37°C in a shaking 
incubator, 1mL from each of these six cultures were tested for the presence of its 
expression vector using a Spin Mini Prep kit, leaving the remaining culture for 
expression studies. Once all had been confirmed to contain an expression vector, 
three different inductions were set up for each of the six cultures (Table 4.1 number 
1-18). Each induction experiment was carried out using SmL of LB broth containing 
I OOtg/mL ampicillin and 100µl of the specific inoculum in a temperature-controlled 
shaking incubator. Cells were induced by the addition of IPTG to a concentration of 
1mM. After induction, cells were harvested, sonicated and their protein expression 
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Figure 4.8. Reducing SDS-PAGE of IPTG induction experiments 
using BL21 (DE3) cells containing hLf pALTER-Exl. hLf was used as 
a reference band in order to locate any E. coli expression of hLf. 1: 2 hrs 
non-induced, 2: 2 hrs induced, 3: 3 hrs non-induced, 4: 3 hrs induced, 5: 
4 hrs non-induced, 6: 4 hrs induced and 7: pALTER-Ex 1 negative 
control. All samples run were extracted from their soluble fractions. 
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E. coli No. Expression 
strain Construct 
Mm M_Wpressiofi`ý 
Origami 1 hLf-mod ET 12a 




gtidy 2: IFfM 
1 hr 
Post-induction Incubation 
Cirowth Temp (*C) 
ndU'q4 
4 hrs 37 
4 hLf-mod ET12a 
5 hLf- ET12a 0 hrs Overnight 37 
6 ET12a 
7 hLf-mod ET12a 
8 hLf- ET12a 0 hrs Overnight 25 
9 ET12a 
BL21 10 hLf-mod ET12a 
(DE3) 11 hLf- ET12a 1 hr 4 hrs 37 
12 ET12a 
13 hLf-mod ET12a 
14 hLf- ET 12a 0 hrs Overnight 37 
15 ET12a 
16 hLf-mod ET12a 





Expression S tudy 3: 1 PTC In 
3 hrs 
duction 
(DE3) 20 hLf-modpETl2a 4 hrs 
21 5 hrs 
22 3 hrs 2 hrs 37 
23 hLf-pET 12a 4 hrs 






xpression Study 4: 
hLf-mod ET 12a 
5 his 
Bacterio hage X CE6 Induction 
27 hLf- ET12a 2 hrs 3 hrs 
28 ET12a 37 
29 hLf-mod ET 12a 
30 hLf- ET12a 2 his 5 his 
31 ET12a 
Table 4.1. Induction plan for hLf expression using pET12a in E. coli Origami 
(DE3) pLys, BL21 (DE3) and Origami cells. 
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profile visualised on an SDS-PAGE (Figure 4.9 numbers 1-18) using the same 
method as for hLf PALTER-Exl induction experiments. 
4.1.2.7. Expression Study 3 
Using the same method, three more inductions were set up (Table 4.1 number 19- 
25). Once again, protein expression profiles were visualised using SDS-PAGE 
(Figure 4.10 numbers 19-25). 
4.1.2.8. Expression Study 4: XCE6 Bacteriophage Induction 
DE3 deficient cells containing the hLf-modpETl2a, hLf-pETl2a and pET12a were 
grown in duplicate (Table 4.1 numbers 26-31) in LB broth containing 0.2% maltose 
and the appropriate antibiotic. When the OD600 of each culture reached between 0.6 
and 1 (after approximately 2 hours), MgSO4 was added to a final concentration of 
10mM and the XCE6 stock (Novagen) was added to a final concentration of 2-4 x 109 
pfu/mL. One set of cells was allowed to grow for 3 hours at 37°C, whilst the other 
set was allowed to grow for a further 2 hours at 37°C. Cells were harvested, 
sonicated and their protein expression profile visualised on an SDS-PAGE (Figure 
4.10 numbers 26-31) using the same method as before. 
4.1.2.9. Dot-Blots 
Using the method described in section 2.4, four dot-blots were set up using samples 
1-31 (Table 4.1). Drops (3µl) of each sample, including two positive controls and a 
negative control, were used in this study. These dot-blots were then probed with 
FITC-conjugated Anti-hLf IgG (section 2.4) to look for hLf expression (Figure 4.11). 
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11 
Figure 4.9. Reducing SDS-PAGE of IPTG induction experiments, 
numbers 1-18. hLf was used as a reference band in order to locate any 
E. coli expression of hL£ Numbers 1-9: Origami (DE3) plys, 10-18: 
BL2 (DE3) (see table 4.1). All samples run were extracted from their 
soluble fractions. 
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OWN 
Figure 4.10. Reducing SDS- PAGE of hSTf expression studies 3 and 
4, experiment numbers 19-31. hLf was used as a reference band in 
order to locate any E. coli expression of hLf. Numbers 19-25: Origami 
(DE3) plys IPTG induction, 10-18: Origami (DE3) XCE6 induction 
(table 4.1). All samples run were extracted from their soluble fractions. 
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Figure 4.11. Dot Blot analysis of samples 1 to 31 with FITC-conjugated 
anti-hLf IgG to detect hLf expression. hLf: 1 mg/ml hLf positive control, 
hLf/2: 0.5mg/ml hLf positive control, -ve: water and 1-31: samples from 
expression studies 2,3 and 4 (table 4.1). 
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4.1.2.10. Discussion 
Peter J Sargent 
As described earlier, three expression constructs and four different expression studies 
were used to try and express hLf in E. coli. 
In expression study 1, the protein profiles shown on the SDS gel are the same for 
each of the six cultures and also for the negative control. This suggests that no hLf 
was being expressed in any of the seven cultures. However, cell growth in the 
induced cultures was significantly reduced when comparing with the non-induced 
cultures, suggesting that induction was having some effect on the cells. This could be 
due to the cells expressing hLf at levels too low to be detected by SDS 
electrophoresis, but high enough to be toxic to the cells. 
In expression study 2, no hLf expression could be detected in any of the eighteen 
cultures. A reason for this could be the same reason used for the hLf pALTER-Exl 
studies, in that hLf is actually toxic to the cells. Even when induced at 25°C, when 
cells should be under less pressure due to a reduced metabolic rate, no hLf 
expression could be observed. 
To try and overcome this possible selective pressure that causes cells not to express 
hLf, pre-induction growth in expression study three was lengthened to allow the cell 
mass to reach greater levels in order to increase the chance that protein will be 
expressed following induction. As before, no extra bands corresponding to hLf were 
visible. What could be noted however, was hLf-modpETl2a cells grew much slower 
than that for hLf-pET12a. This could be due to hLf-modpETl2a expressing hLf at 
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higher levels than hLf-pET12a due to the lack of the fusion leader. However, as 
expression was not detected in either of the cells, this is not conclusive. 
A problem with transforming T7 controlled expression vectors into DE3 lysogenic 
hosts is that; even without IPTG induction there will always be low-level expression 
or leak of the target protein. Therefore, if the target protein is toxic to the cell, there 
will always be a selective pressure against expressing it. This could be a reason for 
the lack of hLf expression in expression studies one to three. 
In expression study 4, the bacteriophage induction system from Novagen was 
employed. Bacteriophage ? CE6 is a recombinant lambda phage containing the T7 
RNA polymerase gene. The polymerase gene is cloned into the int gene such that it 
is constitutively transcribed from the PL and p, promoters of the phage during 
infection. Using this, it is therefore possible to selectively induce cells containing the 
T7 expression construct during exponential phase by infecting them with the 
bacteriophage. Unfortunately though, even using this induction system, no hLf 
expression could be detected. 
As protein expression may not be easily detected using SDS-PAGE, especially when 
at low levels, all 31 samples, from expression studies two to four, were blotted onto a 
nitrocellulose membrane and then probed with FITC-conjugated anti-hLf IgG. None 
of the 31 samples reacted with the FITC-conjugated anti-hLf IgG. As discussed in 
Chapter 7, these results, taken together with the SDS-PAGE results, suggest that no 
hLf was expressed in any of these four studies. 
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4.1.3. hSTf Expression 
Peter J Sargent 
The source of hSTf cDNA for these studies was in the form of a pcG13 vector, 
kindly donated by Christopher Joannou (King's College London). The presence of 
the hSTf cDNA in the plasmid was confirmed by sequencing either ends of the clone 
using hTrfFwd and hTrfBck oligonucleotides (appendix II). Using these 
oligonucleotides, 400 bases at either end of hSTf were sequenced, thus confirming its 
presence. 
4.1.3.1. Constructs 
Two vectors were used for the cloning and expression of hSTf in E. coli. The first 
one, pALTER-max (section 2.1.7), is a mutagenesis vector that can be used to 
express target proteins in mammalian cells as well as being able to be replicated in E. 
coli. The second vector, pET21 d, is designed for high-level prokaryotic expression of 
proteins using a T7 promoter (section 2.1.7). 
4.1.3.2. Creation of hSTf pALTERmax 
In order to clone the hSTf cDNA from the pcGl3 vector into pALTER-max, hSTf 
was PCR amplified (section 2.2.5) using Pfu DNA polymerase for high-fidelity DNA 
synthesis and the same two oligonucleotides used to sequence its ends. These two 
oligonucleotides, hTrfFwd and hTrfBck, are designed to complement either end of 
the hSTf cDNA, with overhanging sequence that will create two new restriction sites 
following PCR amplification (Figure 4.12). Extra sequence was added to the ends of 
the oligonucleotides to optimise cleavage of these two new sites. This is 
recommended by NewEngland Biolabs for restriction sites close to the end of DNA 
fragments. 
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hTrfFwd 
XhoI 
Peter J Sargent 
PCR---* 
3' 5' 
MetArgLeu AlaValGly AlaLeuLeuVal.......... 
hTrfBck 




Figure 4.12. A Diagram to show the binding of hTrfFwd and hTrfBck 
oligonucleotides to hSTf and the creation of two restriction sites at each end 
during PCR amplification. The sequence highlighted in red represents hSTf, 
whilst the sequence highlighted in turquoise represents the oligonucleotides. 
The start codon and stop codon are highlighted in yellow and the two new 
restriction sites in blue. 
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The amplified hSTf was purified from the PCR reaction mix by agarose gel 
electrophoresis and gel extraction before digestion with NotI and XhoI. At the same 
time, pALTER-max was digested using the same two enzymes. Both digestions were 
run on an agarose gel to purify hSTf and pALTER-max from their reaction mixture 
by gel extraction. The digested hSTf was then ligated into the digested pALTER-max 
and transformed into JM109 cells and then plated onto LB agar plates containing 
20µg/mL chloramphenicol. Following overnight incubation at 37°C, four 
transformants were picked and used to inoculate 5mL samples of LB broth 
containing 20gg/mL chloramphenicol. These cultures were incubated overnight at 
37°C in a shaking incubator before their plasmids were extracted using a Spin Mini 
Prep kit. Two separate restriction digests were carried out on each of the 
transformants to check that the ligation was successful. Both the NotI / XhoI and the 
HindIII digests, for each of the four transformants, were run on an agarose gel 
(Figure 4.13). The NotI / XhoI digest cuts the hSTf back out of pALTER-max and 
HindIII digestion should generate three bands (3918bp, 2187bp and 1502bp). All 
four transformants were shown to contain hSTf-pALTER-max. 
One of these transformants was selected for use in the creation of the hSTf- 
modpET21d expression vector. However, before being used, the hSTf region of this 
transformant was DNA sequenced (Cytomyx, Cambridge) to check for gene 
integrity. The sequence was also used to ensure that no mutations were present in the 
coding frame which would cause an amino acid substitution. Only three silent 
mutations were found. 
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Figure 4.13. Agarose gel electrophoresis of Not! / Xhol and HindIII hLf 
pALTER-max digests. M: EcoRl / HindIIl lambda marker, 1-4: hLf pALTER- 
max transformants, A: Notl /Xhol digest and B: HindIII digest. 
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4.1.3.3. Creation of hSTf-modpET21d 
Peter J Sargent 
Rather than PCR cloning hSTf out of pALTER-max and ligating it into pET21 d, a 
three step cloning strategy was used. There were two reasons for doing this: firstly 
PCR of any large DNA fragment is prone to introduce mutations and secondly, no 
suitable restriction sites were available for ligation. 
Step one was the modification of pET21 d. Using the same method used for the 
modification of pET12a, two oligonucleotides were designed to modify the multiple 
cloning site of pET21d by replacing part of its multiple cloning site with sequence 
containing new restriction sites (Figure 4.14). The sequence of these two 
oligonucleotides, PET21d-insert53 and PET21d-insert35, can be found in the 
appendix II. Following ligation and transformation, three transformants were selected 
and their plasmids purified using a Spin Mini Prep kit. 
The modification of these plasmids was confirmed by observing the fragments 
generated by agarose gel electrophoresis following Sacl / EcoRV digestion (Figure 
4.15). An unmodified pET21d will produce two bands (1321bp and 4119bp), 
whereas the modified pET21 d will only produce one band (5440bp). All three 
transformants contained the insert, but only one was used in further cloning steps. 
The second step was to clone into the modified pET21 d (modpET21 d) the back 7/8 of 
hSTf. The modpET21 d plasmid and hSTf pALTER-max were digested with BamHI 
and NotI. BamHI cuts hSTf 266bp in from the start whilst Nod cuts hSTf straight 
after its stop codon. The modpET21d digest was cleaned up using a Mini Elute 
Reaction Cleanup kit, whilst the fragment of hSTf released from hSTf pALTERmax 
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T7 Promoter Lac Operator 
5' GAA. ATT. AAT. ACG. ACT. CAC. TAT. AGG. GGA. ATT. GTG. AGC. GGA. TAA. CAA. TTC. C 
XbaI RBS NcoI 
CC. -. AAT. AAT. TTT. GTT. TAA. CTT. TAA. GAA. GGA. GAT. ATA. -. CT 
BamHI 
A. GCA. TGA. CTG. GTG. GAC. AGC. AAA. TGG. GTC. GAA. TTC. GAG. CTC. C  
Sall NotI XhoI 
. GCT. T . A-CA. CCA. CCA. CCA..... pET21d..... 3' 
Digestion of pET21 d with Xbal 
and SaII 
XbaI RBS BamHI Sall 
5 AT 
3' I'TATT AAAAACTAAATT GAAAATTCTTC CTCT TAC` 5' 
Ligation of hybridised oligonucleotides 
into Xbal / Sall cut pET2l d 
T7 Promoter Lac Operator 
5' GAA. ATT. AAT. ACG. ACT. CAC. TAT. AGG. GGA. ATT. GTG. AGC. GGA. TAA. CAA. TTC. C 
XbaI RBS BamHI Sall 
CC. -. AAT. AAT. TTT. GTT. TAA. CTT. TAA. GAA. GGA. GAT_-_ATG. _ 
NotI XhoI 
 . AAG. CTT. . 
-. CAC. CAC. CAC. CA..... pET21d..... 3' 
Figure 4.14. Modification of pET21d by replacing part of its multiple cloning 
site with a 49 base long double-stranded oligonucleotide. Black sequence: 
unmodified pET21d; red sequence: oligonucleotides; yellow highlighted 
sequence: regions important for protein expression; and turquoise highlighted 
sequence: restriction sites. 
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Figure 4.15. Agarose Gel Electrophoresis of three modified pET21d 
transformants digested with Sac! / EcoRV. M: EcoRI / HindIIl lambda 
marker, 1-3: Transformants and C: pET21d digested with Sad / EcoRV 
163 
4: Protein Expression and Mutagenesis Peter J Sargent 
was purified using a Mini Elute Gel Extraction kit. Both were then ligated together 
before being transformed into JM109 cells and plated onto LB agar plates containing 
100µg/mL ampicillin. The plasmids from eight transformants were purified and 
digested with Pstl to confirm the presence of the hSTf fragment in modpET21d 
(Figure 4.16). Plasmids containing the hSTf fragment will generate a 5211bp 
fragment and a 1933bp fragment when cut with PstI, whilst modpET21 d will only 
produce one fragment. All of the eight transformants carried the modpET21d 
containing the hSTf fragment (BhSTfmodpET21 d). Only one was selected for further 
cloning steps. 
The final step in the cloning of hSTf into pET21d was the PCR amplification of the 
first 271bp of hSTf and its ligation into BhSTfmodpET21d (Figure 4.17). The 
amplification of this region using hSTfp2IdFwd and hSTfp21dBck primers generates 
a 291bp fragment flanked by a BamHI site at the start and a Bg1II site at the end. 
Following PCR amplification of this fragment (section 2.2.5) the product was 
purified by agarose gel electrophoresis and gel extraction before being digested with 
BamHI and Bg1II. At the same time, BhSTfmodpET21 d was digested with BamHI 
and treated with phosphatase to remove the phosphate group from the 5' end. Both 
digests were then purified using a Mini Elute Reaction Cleanup kit before being 
ligated together. The reason for creating a BgIII site is that it can be directly ligated 
to ends generated using BamHI without affecting the coding frame, but following 
ligation, the site cannot be recut. Following transformation of this ligation into 
JM109 cells and overnight growth on LB agar plates containing 100µg/mL 
ampicillin, 12 transformants were selected and their plasmids purified. All 12 
transformants were digested with NdeI and then run on an agarose gel (Figure 
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Figure 4.16. Agarose Gel Electrophoresis of eight modpET2l d 
transformants containing the back 7/g of the hSTf cDNA following 




5' CGC. GGA. TCC. ATG. GTC. CCT. GAT. AAA. ACT. GTG. AGA-> 
-. CAG. GGA. CTA. TTT. TGA. CAC. TCT. ACC. ACA... hSTf. 5' 
Met Val Pro Asp Lys..... 
5'. hSTf... GTG. GTG. GCA. GAG. TTC. TAT. GGG. TCA. AAA. G 
E CGT. CTC. AAG. ATA. CCC. AGT. TTT. CTT. CTA. GAA. GTC 5' 
hSTfp21dBck 
PCR amplification using hSTfp2ldFwd 
and hSTfp2ldBck primers 
BamHI 
CGC. GGA. TCC. -. GTC. CCT. GAT. AAA. ACT. GTG. AGA. TGG. TGT. GCA. GTG. TCG. 
Met Val Pro Asp Lys... hSTf.. 
GAG. CAT. GAG. GCC. ACT. AAG. TGC. CAG. AGT. TTC. CGC. GAC. CAT. ATG. AAA. AGC. 
GTC. ATT. CCA. TCC. GAT. GGT. CCC. AGT. GTT. GCT. TGT. GTG. AAG. AAA. GCC. TCC. 
TAC. CTT. GAT. TGC. ATC. AGG. GCC. ATT. GCG. GCA. AAC. GAA. GCG. GAT. GCT. GTG. 
ACA. CTG. GAT. GCA. GGT. TTG. GTG. TAT. GAT. GCT. TAC. CTG. GCT. CCC. AAT. AAC. 
Bg1II 
CTG. AAG. CCT. GTG. GTG. GCA. GAG. TTC. TAT. GGG. TCA. AAA. GAA. GAT. CTT. CAG 
Figure 4.17. PCR amplification of the first 271bp of hSTf and the creation 
of BamHI and BglHI restriction sites using hSTfp2ldFwd and 
hSTfp2ldBck primers. Black sequence: hSTf pALTER-max; red sequence: 
oligonucleotides; blue sequence: PCR product; yellow highlighted sequence: 
generated restriction sites and turquoise highlighted sequence: hSTf start 
codon. 
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4.18) to determine the orientation of the PCR insert. Following NdeI digestion, three 
different plasmids can be visualised. Transformants that are only cut once do not 
contain the PCR fragment. Transformants that are cut twice to produce one 1864bp 
fragment and one 5555bp fragment contain the PCR fragment in the correct 
orientation. Transformants that are cut twice to produce one 1751bp fragment and 
one 5668 fragment contain the PCR fragment in the wrong orientation. Out of the 12 
transformants, only transformants 9 and 12 contained the PCR fragment in the 
correct orientation. Both of these constructs were sequenced for 500 bases from the 
T7 promoter region, through the RBS and into the hSTf gene to check for any 
mutations that may have occurred. Both transformants were shown not to contain any 
mutations, but only one was used in the expression studies. 
4.1.3.4. Expression Study 5 
hSTf-modpET21d and pET21d were transformed into BL21 (DE3) and Origami 
(DE3) pLys cells and selected on LB agar plates containing 100µg/mL ampicillin. As 
in the hLf-pET12a expression studies, one transformants was selected from each 
plate and used to inoculate 5mL of LB broth containing 100µg/mL ampicillin. After 
overnight growth at 37°C in a shaking incubator, 1mL from each of the four cultures 
was tested for the presence of its expression vector using a Spin Mini Prep kit, 
leaving the remaining culture for expression studies. Once all had been confirmed to 
contain an expression vector, three different inductions were set up for each of the 
four cultures (Table 4.2 numbers 32-43). After induction, cells were harvested, 
sonicated and their protein expression profile visualised on an SDS-PAGE (Figure 
4.19 numbers 32-43) using the same method as used for all the previous expression 
studies. 
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Figure 4.18. Agarose gel electrophoresis of Ndel digested hSTfmodpET21d 
transformants. M: EcoRl / HindIIl lambda marker and 1-12: Ndel digested 
transformants. 
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Table 4.2. Induction plan for hSTf expression using pET21d in E. coli 
Origami (DE3) pLys, BL21 (DE3) and Origami cells. 
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Figure 4.19. SDS-PAGE, under reducing conditions, of IPTG induction 
experiments, numbers 32-43. Native hSTf was used as a reference band in 
order to locate any E. coli expression of hSTf. Numbers 32-37: Origami 
(DE3) plys, 38-43: BL2 (DE3) (table 4.2 numbers 32-43). All samples run 
were extracted from their soluble fractions. 
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4.1.3.5. Expression Study 6 
As in expression study 3, three more inductions were set up (Table 4.2 numbers 44- 
47). Again, protein expression profiles were visualised using SDS-PAGE (Figure 
4.20. numbers 44-47). 
4.1.3.6. Expression Study 7 
As in expression study 4, three more inductions were set up (Table 4.2 numbers 48- 
51) using the bacteriophage XCE6 induction method. Protein expression profiles 
were visualised using SDS-PAGE (Figure 4.20 numbers 48-51). 
4.1.3.7. Dot-blots 
As for the hLf expression studies, four dot-blots were set up. Again, 3µL drops of 
samples 32 to 51, including two positive controls and a negative control, were used 
in this study. These dot-blots were then probed with FITC-conjugated anti-hSTf IgG 
(section 2.4) to look for hSTf expression (Figure 4.21). 
4.1.3.8. Discussion 
As described, only one expression construct and three different expression studies 
were explored to look for expression of hSTf in E. coli. 
Similar expression studies to the ones explored for the expression of hLf in E. coli 
were used for the expression of hSTf in E. coli. Expression studies five and six 
explored IPTG induction, whereas expression study seven used the bacteriophage 
induction system described before. As for hLf, no expression could be detected in 
any of these three studies, either using SDS-PAGE or Dot-blot analysis. 
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Figure 4.20. Reducing SDS-PAGE of hSTf expression studies 6 and 7, 
experiment numbers 44-51. hSTf was used as a reference band in order to 
locate any E. coli expression of hSTf. Numbers 44-47: Origami (DE3) plys 
IPTG induction, 48-51: Origami (DE3) XCE6 induction (table 4.2). All 
samples run were extracted from their soluble fractions. 
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Figure 4.21. Dot Blot analysis of samples 32 to 51 with FITC-conjugated 
Anti-hSTf IgG to look for hSTf expression. hSTf: 1 mg/ml hSTf positive 
control, hSTf/2: 0.5mg/ml hSTf positive control, -ve: water and 32-51: 
samples from expression studies 5,6 and 7 (table 4.2). 
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4.2. Expression of hSTf in Saccharomyces cerevisiae and 
mutagenesis 
4.2.1. Introduction 
Using an in-house protein expression system designed and constructed by Delta 
Biotechnology Ltd, it was possible to express hSTf in S. cerevisiae at levels greater 
than Ig per litre in a fermentor. The expression vector used was based on a 2µ 
plasmid containing a PRBJ yeast promoter, a fusion leader for protein secretion, the 
hSTf insert, a gene encoding ampicillin resistance and a pUC9 region for plasmid 
replication in E. coll. A unique feature of this plasmid is its ability to release its 
pUC9 region through site-specific recombination once it has been transformed into a 
yeast cell. This increases plasmid stability within the cell by eliminating any 
unnecessary sequence (Chinery and Hinchliffe, 1989). 
4.2.2. Constructs 
Three vectors were used for the cloning and expression of hSTf in S. cerevisae 
DXY1 derived cells (section 2.1.2). Two of the vectors, pDB2514 and pDB2529, 
were used purely for cloning and modification steps, whilst pDB2536 was the actual 
expression vector (section 2.1.7). All three vectors contained the hSTf cDNA insert 
(appendix II). 
In order to produce a homogenous population of deglycosylated proteins, which 
would improve the crystallisation conditions (Pace, 1990; Mason et al. 2001), the 
double mutant (N413Q, N611Q) was generated using site-directed mutagenesis 
kindly donated by Christopher Finnis (Delta Biotechnology). Insertion of both 
mutations is unlikely to compromise the structural integrity of the protein or its 
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function, since previous studies have shown that the glycan chains have no functional 
role in transferrin (Mason et al. 1993). The reason for substituting an asparagine with 
a glutamine is due to their close structural similarity, as shown by Dayhoff et al, 
1978, and as discussed in section 3.2.4, the fact that these mutations are predicted not 
to affect the structure or function of the protein. Mason et al, 1998 were also able to 
express non-glycosylated human transferrin in BHK cells following mutagenesis of 
the hSTf cDNA. However, instead of mutating N413 and N611 to two glutamines, 
they mutated these two residues to aspartates. 
4.2.3. Mutagenesis of hSTf 
The reason behind developing an hSTf expression system was to be able to express a 
number of specific mutants, primarily the G394R mutation (section 1.3.9). This 
mutation is found in the C-lobe of transferrin (hSTf sequence, appendix I), lying 
close to the iron binding-site. 
4.2.3.1. Mutagenesis Design 
Mutagenesis of the hSTf construct was achieved using a QuikChange site-directed 
mutagenesis kit from Stratagene. To create a substitution from glycine to an arginine 
at position 394 two oligonucleotides (CF125 and CF124) were designed (appendix 
II). CF125 was designed to bind to a 35 bases region around codon 394 on the 5' to 
3' strand, whilst CF124 was designed to bind the same region but on the 3' to 5' 
strand (Figure 4.22). Both oligonucleotides complement a region from codon 388 to 
399 of hSTf, except codon 394 where two bases have been changed so that an 
arginine is encoded rather than a glycine. The reason for mutating codon 394 from 




Asp Ala Met Ser Leu Asp Gly Gly Phe Val Tyr Ile Ala Gly 
387 5' 
1266 3' 
Oligonucleotide-Template (hSTf) Hybridisation 
oligo CF125 GG TAC TCG AAC CTA CCT TCT AAA CAG ATC TAT CGC 
oligo CF124 CC ATG AGC TTG GAT GGA AGA TTT GTC TAC ATA GCG 
G394R hSTf 
394 
Asp Ala Met Ser Leu Asp Gly Arg Phe Val Tyr Ile Ala Gly 
387 5' 
1266 3' 
Figure 4.22. Creation of the G394R mutation in hSTf using a Stratagene 
QuikChange site-directed mutagenesis kit. Mutated residues are highlighted 
in yellow. 
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most commonly used codon by S. cerevisae to encode arginine (ftp: // enome- 
ftp. stanford. edu/pub/codon/vsc. orf. cod). 
4.2.3.2. Mutagenesis 
Using the protocol described in section 2.2.7 and oligonucleotides CF125 and 
CF124, the hSTf cDNA insert of pDB2514 was mutated at residue position 394. 
Mutagenesis was achieved in two steps. Step one uses PfuTurbo 0 DNA polymerase 
and a DNA Engine DYADTM Peltier thermocycler to denature the template DNA 
from double-stranded to single-stranded, hybridise the two oligonucleotides to their 
specific strands, and then synthesise new molecules that are complementary to these 
strands using the hybridised oligonucleotides as primers. The second step then uses 
the endonuclease Dpnl to digest the parental DNA template, leaving only the 
mutated synthesised DNA. This works because Dpnl is specific for methylated and 
hemimethylated DNA, therefore will not digest DNA synthesised during step one. 
4.2.3.3. Transformation of pDB2514 
Using the transformation protocol described in section 2.2.4, the pDB2514-G394R 
mutant was transformed into XL1-Blue E. coli along with a pDB2514 positive 
control and a negative control (water). Transformants were selected on LB agar 
plates containing 35jig/mL apramycin, 30gg/mL X-Gal and 60µg/mL IPTG 
following incubation overnight at 37°C. 
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4.2.3.4. Mutagenesis Check 
To check that the desired mutations have been made, six transformant colonies were 
picked and individually grown at 37°C overnight in lOOmL of LB broth containing 
35µg/mL apramycin. The pDB2514-G394R constructs were then purified from each 
clone using a Qiagen HiSpeed Plasmid Midi Kit (section 2.1.8). Plasmids were 
eluted in 350µL of MilliQ water and the DNA concentration determined using a 
Shimadzu UV-1201 UV-VIS Spectrophotometer measuring the OD at 260nm 
(section 2.2.6). A 728bp sequence between restriction sites Asp718I and BspEl 
found in the hSTf insert of each pDB2514-G394R clone was sequenced with a 
Perkin Elmer ABI Prism 310 Genetic Analyser (section 2.2.8) using six specific 
oligonucleotides to confirm the two base mutations in codon 394 and to make sure 
no other mutations have occurred. Out of the six transformants, five of them 
contained the desired mutations, but only one transformant was selected for further 
cloning experiments. 
4.2.3.5. Cloning of G394R fragment from pDB2514 into pDB2529 
The selected transformant was digested with Asp718I and BspEI to release a 728bp 
fragment. At the same time, pDB2529 was digested with the same two enzymes. 
Following electrophoresis of the two digests on a 1% (w/v) agarose gel (Figure 4.23), 
a BIO101 Gene Clean III gel extraction kit (section 2-1-8) was used to extract the 
728bp fragment from pDB2514 and the 5757bp fragment from pDB2529. Once 
purified, these two fragments were ligated together (section 2.2.3) before being 
transformed into DH5a cells and plated onto LB agar plates containing 50µg/ml, 
ampicillin. Following overnight incubation at 37°C, two transformants were selected. 
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Figure 4.23. DNA gel electrophoresis of pDB2514 and pDB2529 following 
digestion with Asp7181 and BspEl. M: 1Kb Marker, 1: pDB2514 and 2: 
pDB2529. 
179 
The modified plasmids from both pDB2529 transformants were purified using a 
Qiagen HiSpeed Plasmid Midi Kit following their inoculation into 100mL LB 
cultures containing 50µg/mL ampicillin and overnight incubation at 37°C. As before, 
Plasmids were eluted in 350µL of MilliQ water and the DNA concentration 
determined using a Shimadzu UV-1201 UV-VIS Spectrophotometer measuring the 
OD at 260nm. 
4.2.3.6. Cloning of G394R Insert from pDB2529 Into pSAC35 
In order to express the G394R hSTf gene it was necessary to clone it together with 
all other features of the Nod expression cassette from pDB2529, into pSAC35 
(pDB2536 without the Notl hSTf expression cassette). 
The plasmids from both pDB2529 transformants were digested using Noll and ScaI 
and run on a 1% (w/v) agarose gel (Figure 4.24). The two identical 3274bp 
fragments, corresponding to the Notl hSTf expression cassette, were then extracted 
using a BIO101 Gene Clean III gel extraction kit before being ligated into Notl 
digested and dephosphorylated pSAC35 plasmids. Both ligations were then 
transformed into DH5a cells and plated onto LB agar plates containing 50pg/mL 
ampicillin, 30µg/mL X-Gal and 60pg/mL IPTG. Following incubation of these 
transformants overnight at 37°C, 96 colonies were picked and used to inoculate a 96 
well plate containing 1.3mL of LB broth and 50µg/mL ampicillin per well. This 
block was incubated overnight on a shaking platform at 37°C. A plasmid prep of 
each transformant was then carried out using a Qiaprep 96 Turbo kit (section 2-1-8). 
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Figure 4.24. DNA Gel Electrophoresis of G394R pDB2529, following Nod / 
Scal digestion. M: 1Kb Marker, A: pDB2529 transformant 1 and B: pDB2529 
transformant 2. 
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Figure 4.25. DNA gel electrophoresis of G394R pDB2536, following HindIII 
digestion. M: 1 Kb Marker. The 96 plasmid prep digests were run in groups of 
16 with a marker lane in between. 
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To check whether the NotI hSTf expression cassette has been ligated into pSAC35 in 
the correct orientation, 5µL samples of each of the 96 plasmid preps were digested 
using HindIII and run on a 1% (w/v) agarose gel (Figure 4.25). Two different 
orientations are possible (Figure 4.26): the LEU2 orientated (optimal for expression), 
or the AMP orientated. Out of the 96 transformants, 44 contained the correctly 
orientated expression cassette. 
From these results, three correctly orientated constructs and two incorrectly 
orientated constructs were picked. Carrying out an RFLP study using five different 
endonucleases, the integrity of these five plasmids were checked by electrophoresis 
on a 1% (w/v) agarose gel (Figure 4.27). The theoretical fragment sizes for all 
digests matched up to what can be seen on the gel, showing that all the plasmids had 
maintained their integrity. 
4.2.4. Transformation and Stock Set up 
4.2.4.1. Yeast Transformation 
Six separate yeast transformation reactions were set up. These included, three 
correctly orientated pDB2536-hSTf plasmids (section 4.2.3), two positive controls 
(pSAC35 and a Sigma control vector pR536) and a negative control (no DNA). 
Following transformation (section 2.2.4) five colonies from each of the pDB2536- 
hSTf plates and five colonies from the pSAC35 plate were used to inoculate separate 
flasks containing 10mL BMM-D broths. Using the same twenty colonies, each 
colony was streaked in a patch on BMM-D agar plates. The flasks were shaken 
incubated at 30°C for 4 days and the plates were incubated at 30°C for 2 days. 
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Figure 4.26. Maps of the two possible ligation products following cloning of 
the Nod hSTf expression cassette into pSAC35 and the theoretical fragment 
sizes produced following HindIIl digestion. Because the two largest fragments 
from product one are of a similar size, they will not resolve on a gel and 
therefore it will appear that there is only one fragment. 
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Figure 4.27. An RFLP study of four correctly orientated and one incorrectly 
orientated G394R pDB2536 transformant using five different restriction 
endonucleases. 1-2: Amp orientated, 3-5: LEU orientated and M: 1Kb Marker. 
Fragments highlighted in the blocked area correspond to the pUC9 region of 
pDB2536 following its disintegration from the vector. 
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4.2.4.2. Trehalose Stocks for Fermentation 
After two days of growth, two colonies from each of the BMM-D pDB2536-hSTf 
plates and two from the BMM-D pSAC35 plate were used to inoculate lOmL of 
BMM-D broth. These cultures were incubated at 30°C for 2 days before being spun 
at 3000 rpm for 10 min. For each culture, 5mL of the supernatant was taken off and 
replaced with 5mL of 40% (v/v) D(+) trehalose (Sigma). Following resuspension of 
the pellet, lmL aliquots were taken and frozen at -80°C in 1.8mL NUNC Cryotubes. 
One aliquot from each transformant was used to inoculate 100mL of LB broth to test 
for bacterial contamination. No contamination was observed. 
4.2.4.3. Immunoprecipitation Agar Plate 
To confirm that the cells were expressing hSTf, the same eight colonies picked to 
make trehalose stocks were also inoculated in small patches onto a BMM-D agar 
plate containing Anti-Human Transferrin serum (Calbiochem). After four days of 
incubation at 30°C, precipitation halos appeared around the transformants containing 
the hSTf contructs but not around the two containing just the pSAC35 (Figure 4.28). 
4.2.5. Transferrin Expression 
The conditions required for the production of cloned proteins by S. cerevisiae need to 
be very tightly controlled in order to optimise expression levels whilst maintaining 
cell growth. 
To understand the reasoning behind the choice of conditions used, it is important to 
note that S. cerevisiae cells are known to exhibit a diauxic type of growth. Rather 













Figure 4.28. Immunodiffusion BMM-D agar plate. The plate was stained by 
firstly gently washing off the Yeast colonies off the agar with distilled water 
and then laying a GelBond® Film (BMA), hydrophilic-side down, onto the 
agar under a layer of filter paper and tissues. The next day, the film and agar 
were stained using the same protocol as for SDS-PAGE. 
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phase, stationary phase and then sporulation, or death, S. cerevisiae has been shown 
to exhibit an extra phase of growth separated from the first one by a short stationary 
phase. The reason for this is due to S. cerevisiae's ability to adapt to use the ethanol 
and acetate produced from the fermentation of sugars in the first exponential phase as 
a carbon source. 
The expression of the cloned protein is very sensitive to the conditions within the 
fermenter. If too much carbon source is present, fermentation products such as 
ethanol and acetate accumulate to levels that become toxic to cells, inhibiting cell 
growth and ultimately leading to cell death. If there is not enough carbon, cell growth 
will be restricted. To achieve the correct balance, cells were grown under carbon- 
limited conditions by using a batch medium and a feed medium. The batch medium 
is the initial source of nutrients for the cells. When all of the carbon has been used 
up, including ethanol and acetate, a feed medium is added at such a rate that the 
carbon source concentration is kept limiting. 
Yeast growth is also very sensitive to pH, with cells growing optimally at pH 5.5. 
The CO2 produced following carbohydrate metabolism forms carbonic acid in 
solution and causes the pH to drop in the fermenter. Also, during acetate utilisation 
the pH increases. To ensure optimum growth, the fermenter has a feedback system to 
detect pH change, adding 17.5% ammonia to increase it, or 2M H2SO4 to decrease it, 
maintaining the pH at the optimum 5.5. 
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4.2.5.1. Fermentation 
Before inoculation, the batch medium was prepared in a 10 L fermenter. 200mL of 
an autoclaved 50% (w/v) sucrose solution was added to 2560mL of distilled water 
and filtered, using a 0.22µm SuporCapTM sterile capsule, into the fermentor. To this, 
a mixture containing 50mL of a vitamin stock solution (6g/L calcium pantothenate, 
1Og/L nicotinic acid, 6g/L m-inositol, 1.5g/L thiamine-HC1 and 30mg D-Biotin), 
600mL of a salt mixture (28g/L KOH, 40g/L H3PO4,7.17g/L MgS04'7H20 and 
0.75g/L CaC12 H20) and 40mL of distilled water was added following filtration 
through a 0.22µm Durapore filtration unit. A trace element solution (4SmL 
containing 63.07g/L H2SO4,3g/L ZnSO4'7H20, lOg/L FeSO4.7H20,2.42g/L 
MnSO4*H2O, 79mg/L CuSO4*5H20,0.5g/L Na2Mo04'2H20 and 0.56g/L CoCl2'6H2O) 
was also added to the fermenter, again following filtration through a 0.22µm 
Durapore filtration unit. Both Durapore filtration steps included a flush-through with 
125mL of distilled water. 
Inoculation of the batch medium with S. cerevisae cells containing the respective 
construct was achieved by growing up the specific trehalose stock in IOOmL of 
BMMS to approximately lg of cells per litre and then adding approximately 60mg of 
these cells to the batch medium. 
Following batch growth, the feed medium was added at a rate that maintained carbon 
limitation conditions. The feed medium comprised 5L of sterile 62.5% (w/v) sucrose 
containing a mixture of 120mL of vitamin stock, 250mL of salt solution and 30mL of 
distilled water, filtered using a 0.22µm Durapore filtration unit. The filter was 
flushed with 100mL of distilled water. The feed medium also contained a mixture of 
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105mL of trace element solution and 295mL of distilled water, filtered and flushed in 
the same way as for the vitamin stock-salt solution. The fermentation was complete 
once the entire feed medium had been added. 
In total, four fermentations were carried out. Two with S. cerevisiae cells containing 
the WT pDB2536-hSTf and two with S. cerevisiae cells containing the G394R 
mutated pDB2536-hSTf. Following fermentation, cultures were centrifuged at 
5000rpm for 15 minutes and then the supernatant divided into 3 litre aliquots. These 
3 litre aliquots were either processed straight away, or frozen at -20°C. 
4.2.5.2. Protein Concentration Determination 
The protein concentration and relative purity of transferrin in the post-fermentation 
supernatant was determined by HPLC (section 2.4). Samples of supernatant (200µl) 
from both WT rhSTf and G394R rhSTf fermentations were loaded and run on the 
HPLC. The elution profile, shown in Figure 4.29, shows that the transferrin yield for 
WT rhSTf fermentation 1 was -1.82mg/mL and for G394R rhSTf fermentation 1 
was -1.7mg/mL. 
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Figure 4.29. The protein concentration and relative purity of transferrin in 
the post-fermentation cultures, determined by HPLC. The amount of rhSTf 
in mg/ml was adjusted to take into account dilution and sample volume. 
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This chapter primarily focuses on the purification of the recombinant proteins 
(rhSTf) expressed in Chapter 4, along with the purification of native wild type (WT) 
hSTf, native G394R hSTf and native hLf. The production of highly pure preparations 
of these proteins is very important, since many of the structural and functional 
characterisation methods used later on in these studies were dependant on it. 
As well as purification, this chapter also discuses the crystallisation of recombinant 
hSTf and native hLf-In3+ in the hope to solve their structures. The crystallisation of 
hSTf is of particular interest since only a high-resolution image of its N-lobe has so 
far been solved. As for hLf, even though this protein's structure has been solved at 
high-resolution, it has not been solved with indium bound to it. 
5.1. Purification 
5.1.1. Introduction 
In order to characterise both the WT and G394R recombinant hSTf (rhSTf) and to 
compare them with both WT and G394R native hSTf, pure preparations of each of 
the four proteins is essential. Purification of both recombinant proteins was achieved 
using a number of chromatography steps. These steps are described in the following 
sections, along with the purification of both native proteins. Native G394R hSTf was 
purified from serum kindly donated to Dr R Evans by the individual who is 
heterozygous for this variant (section 1.3.9). Purification of this variant was a two- 
step process. The first step involved the isolation of hSTf from the serum and the 
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second step was the resolution of the variant from the WT. Native WT hSTf was 
bought from Scipac Ltd but further purified by immunoaffinity chromatography. 
5.1.2. Recombinant hSTf Purification using Ion-Exchange Chromatography 
The first step in the purification of WT rhSTf and G394R rhSTf involved the use of 
two separate ion-exchange chromatography columns. A SP-FF sepharose column 
was used first, followed by a DEAE-FF sepharose column. The difference between 
these two columns is the charge they carry at a specified pH. SP-FF sepharose is 
strongly cationic, whereas DEAE-FF sepharose is weakly anionic. The use of two 
differently charged matrices, one after the other, allowed rhSTf to be purified 
without the use of salt gradients. 
5.1.2.1. SP-FF Purification 
For each fermentation, only one 3 litre aliquot (section 4.2.5) was processed at a 
time. Prior to loading of this aliquot onto the SP-FF column, the supernatant was 
conditioned by firstly reducing its conductivity to -3mS. cm"1 by the addition of 
MilliQ water and then lowering its pH to -5 by the addition of 100% glacial acetic 
acid. Once conditioned, it was important to process the sample immediately so to 
reduce the chance of any protein degradation. 
This conditioned supernatant was then purified using the protocol described in 
section 2.3.1, collecting the elution when the UV spectrophotometer recorded a peak 
at 280m-n. 1mL samples were also taken from the load, the load flow-through, the 
wash flow-through, the elution and the 1M NaCI wash flow-through. The eluate was 
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collected, filtered through a Millipore-DuraporeTM 0.22µm filter and stored at 4°C for 
a maximum of 2 days before being processed further. 
The lmL samples were run on a non-reducing SDS PAGE gel (section 2.4.12) to 
determine the efficiency of the column (Figure 5.1). This figure shows samples 
collected from four different SP-FF runs, two WT rhSTf fermentations and two 
G394R rhSTf fermentations. The four SP-FF elution samples were also analysed 
using HPLC (section 2.4.7) to determine relative protein purity and concentration 
(Figure 5.2 and 5.3). 
5.1.2.2. DEAE-FF Purification 
The SP-FF elute was further purified using a DEAE-FF column (section 2.3.1). Prior 
to loading the SP-FF eluate onto this column, it was first conditioned by bringing its 
conductivity down to -3mS. cm"1 with MilliQ water and increasing its pH to -9 with 
1OM NaOH. As soon as the DEAE-FF eluate had been collected it was filtered 
through a Millipore-DuraporeTM 0.22µm filter and stored at 4°C for a maximum of 2 
days before being processed further. 
As with the SP-FF run, lmL samples were taken from the load, the load flow- 
through, the wash flow-through, the eluate and the iM NaCl wash flow-through from 
each DEAE-FF run. These samples were then visualised on a non-reducing SDS 
PAGE gel to determine the efficiency of the column (Figure 5.4). This figure shows 
samples collected from four different DEAE-FF runs, two different WT rhSTf 
fermentations and two different G394R rhSTf fermentations. As with the SP-FF 
elutes, these four DEAF-FF eluates were also analysed using HPLC 
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Figure 5.1. Non-reducing SDS PAGE of samples collected during SP-FF 
rhSTf purification. Tf: 1µg of native hSTf (Calbiochem), 1: load (diluted 
1: 10), 2: load flow-through, 3: wash flow through, 4: elution (50mM sodium 
dihydrogen phosphate di-hydrate, 100mM NaCl, pH 7) and 5: IM NaCI 
wash flow-through 
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Figure 5.2. The protein concentration and relative purity of transferrin in 
the SP-FF eluate, determined by HPLC. The amount of rhSTf in mg/ml was 
adjusted to take into account dilution and sample volume. 
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Figure 5.3. The protein concentration and relative purity of transferrin in 
the SP-FF eluate, determined by HPLC. The amount of rhSTf in mg/ml was 
adjusted to take into account dilution and sample volume. 
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Figure 5.4. Non-reducing SDS PAGE of samples collected during 
DEAE-FF rhSTf purification. Tf: 1µg of native hSTf (Calbiochem), 1: 
load (diluted 1: 10), 2: load flow-through, 3: wash flow through, 4: elution 
(82.6mM potassium tetraborate tetrahydrate, pH 9.4) (diluted 1: 10) and 5: 
1M NaCl wash flow-through 
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(section 2.4.7) to determine relative protein purity and concentration (Figure 5.5 and 
5.6). 
5.1.2.3. Dialysis and Concentration 
Using a PALLfiltron LV CentramateTM and a Pall CentramateTM 10,000 MWCO 
Cassette, powered using a Watson Marlow 313 peristaltic pump, the DEAE eluate 
for each fermentation was dialysed into 10mM HEPES (pH 8) and then concentrated 
to around 5mg/ml. This solution was then filtered through a Millipore-DuraporeTM 
0.22µm filter before being frozen at -20°C. 
5.1.2.4. Discussion 
Following purification using an SP-FF column, most contaminants have been 
removed from the rhSTf sample. However, Figure 5.1 shows that a number of non- 
transferrin proteins still remained in the SP-FF eluate (lane 4). It can also be seen that 
this purification step is relatively efficient, as all of the rhSTf seemed to bind to the 
column, and no rhSTf was visible in either the load- or wash flow-through. 
Upon comparison of the HPLC traces, showing the protein profiles of the fermenter 
supernatants (Figure 4.29) with that of the SP-FF elutes (Figure 5.2 and 5.3), it can 
be seen that a large proportion of the non-transferrin proteins have been removed. 
These traces also show roughly how much transferrin has been lost during the 
purification step by comparing the transferrin concentration (mg/mL) in the 
fermenter supernatant and the SP-FF elute, taking volume into account. Using these 
concentrations, the average percentage of protein recovered following SP-FF 
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Transferrin 9.79 1659876 78 63876 1.28 mg/ml 
Figure 5.5. The protein concentration and relative purity of transferrin in 
the DEAE-FF elute, determined by HPLC. The amount of rhSTf in mg/ml 
was adjusted to take into account dilution and sample volume. 
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Figure 5.6. The protein concentration and relative purity of transferrin in 
the DEAE-FF elute, determined by HPLC. The amount of rhSTf in mg/ml 
was adjusted to take into account dilution and sample volume. 
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chromatography purification of the fermenter supernatant can be calculated. On 
average, 82% (88% for WT rhSTf and 76% for G394R rhSTf) of transferrin loaded 
onto the column was recovered in the eluate. 
After the SP-FF eluate had been further purified on a DEAE-FF column, no real 
change in the purity of rhSTf was observed. Furthermore, a lot of rhSTf failed to 
bind to this column as large amounts were seen in the load flow-through (Figure 5.4). 
rhSTf was also seen in the wash flow-through of the G394R rhSTf DEAE-FF 
purification. The presence of rhSTf in both the load and wash flow-throughs 
indicates that in each case the DEAE-FF column was overloaded. 
The protein profile seen in the HPLC charts (Figure 5.5 and 5.6) is also consistent 
with the SDS-PAGE results, in that a large portion of the rhSTf has been lost. This 
loss can be again calculated by comparing rhSTf concentration, taking into account 
volume, in the SP-FF eluate and the DEAE-FF eluate. For the two WT rhSTf 
purifications, the average protein recovery was approximately 78%. The recovery for 
the G394R rhSTf purification was even lower at 73%. This difference between the 
WT and G394R can also be seen on the SDS-PAGE gel in that substantially more 
protein seems to be present in the load and wash flow-through of the G394R 
purification than the WT purification. The average protein recovery using the DE-FF 
column can therefore be calculated to be 75.5%. This is 8% lower than that 
calculated for the SP-FF purification step. 
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5.1.3. Recombinant hSTf Purification using Immunoaffinity Chromatography 
Following SP-FF and DEAE-FF chromatography, an immunoaffinity column was 
created to further purify rhSTf. The reason for creating such a column is so rhSTf 
can be purified efficiently, and without the need for gradients or complex buffers. 
This column was made using sheep anti-hSTf IgG coupled to cyanogen bromide 
activated Sepharose 4B (Amersham Biosciences). When the sample to be purified is 
run through this column, only rhSTf will bind to the IgG, leaving other proteins to be 
washed off. The rhSTf is then eluted off the column producing a very pure sample. 
5.1.3.1. Creation of an Anti-hSTf Immunoaffinity Column 
In order to make such a column, it was first necessary to purify sheep anti-hSTf IgG 
from the serum of sheep that have been immunised with hSTf. A very pure 
preparation of hSTf-specific IgG is important as if there were any other proteins 
present, they may interact with non-transferrin proteins and therefore reduce the 
efficiency of the column. To produce this pure preparation of IgG, a 50mL hSTf- 
coupled affinity column was first created using the protocol described in section 
2.3.2 and 400mg of hSTf (Scipac). 40mL of sheep serum (Micropharm) was then 
loaded on to this column to purify IgG specific for hSTf. The purity of IgG in the 
eluate was checked using reducing and non-reducing SDS PAGE (section 2.4.12) 
(Figure 5.7). This process was repeated until approximately 400mg of IgG had been 
purified. The quantity of IgG was determined using UV spectroscopy and the same 
principals described in section 2.4.15, but using the extinction coefficient of 
210,000M'1cm" and knowing the molecular weight of IgG is 150kDa. This 400mg of 
IgG was then used in the creation of a 5OmL anti-hSTf immunoaffinity column using 
the same protocol for the creation of the hSTf-immunoaffinity column. 
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Figure 5.7. SDS PAGE showing the purity of IgG purified from sheep 
serum using an hSTf-immunoaffinity column. IgG eluted using IM 
ammonia. By breaking the disulphide bridges using a reductant, the molecule's 
2 light-chains (25KD) separate from the 2 heavy-chains (5OKD). If IgG is not 
reduced, then the 4 chains remain bound to each other as a molecule with a 
molecular mass of 150kDa. 
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5.1.3.2. Purification of Recombinant hSTf 
Using the protocol described in section 2.2.3,40mL of each of the DEAE-FF eluates, 
in 10mM HEPES (pH 8 with 10M HCI), were run on the column. Samples were 
taken from the load, the load flow-through, the wash flow-through and the elution for 
each run. The protein profiles of each sample were visualised using SDS-PAGE 
(section 2.4.12) (Figure 5.8) to determine the efficiency of the column. Eluted 
protein was desalted using a G-25 column and freeze-dried (section 2.3.6) 
immediately after purification. 
5.1.3.3. Native -PAGE Analysis and Discussion 
Purification of rhSTf using immunoaffinity chromatography proved to be very 
efficient. Figure 5.8 shows the purity of rhSTf in the eluate is approaching 100% and 
that almost all the rhSTf loaded, binds to the column. The latter can be concluded as 
no rhSTf can be seen in the load flow-through, or the wash flow-through. By 
purposely overloading the column with hSTf, its binding capacity could be 
calculated. The binding capacity was calculated to be between 100 to 150mg. 
Because the electrophoretic mobility of proteins using SDS-PAGE depends primarily 
on their molecular mass, only limited information can be obtained about these 
proteins. In order to look at heterogeneity in the protein's charge and its 
hydrodynamic size, immunoaffinity column purified samples of each protein were 
made diferric using the protocol described in section 2.3.5 and then run on native 
PAGE gels (section 2.4.10). This gives a rough indication of whether all of the 
proteins in the population have been correctly processed and whether there is any 
protein aggregation. SDS-PAGE shows the protein population of both rhSTf samples 
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Figure 5.8. Reducing SDS-PAGE of samples collected during two rhSTf 
purifications using an anti-hSTf immunoaffinity column. Gel A: WT rhSTf 
and Gel B: G394R rhSTf. M: HMW-SDS marker, 1: Load, 2: Load flow-through, 
3: Wash and 4: Eluate (eluted using 1M ammonia). hSTf: 1µg of native hSTf 
(Scipac Ltd) 
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to be homogeneous, whereas when using native-PAGE, a number of different forms 
were visible (Figure 5.9). Also noticeable on this gel is the difference in mobility of 
WT and G394R rhSTf. The WT sample is shown to migrate faster than the mutant. 
One explanation for this could be the extra positive charge created following the 
substitution of a glycine to an arginine at position 394 in the mutant. The mutant 
would therefore not be attracted to the cathode as strongly as the WT. However, 
looking at the hSTf model (section 3.1.3), glycine 394 is relatively buried in the 
protein. If the model is correct, this would mean that even if the residue is mutated to 
an arginine, the positive charge would not have any effect on the net surface charge 
and therefore the protein's mobility. Another possible cause for a change in mobility 
is a difference in the folding of the two proteins. As larger molecules migrate slower 
than smaller ones, it could be postulated that the mutation has possibly caused the C- 
lobe of the rhSTf to adopt a more open structure. 
5.1.4. Analysis of the Heterogeneous rhSTf Samples 
In order to elucidate why some many different bands can be seen on a native-PAGE 
gel, samples from both WT and G394R rhSTf DE-ff eluate preparations were 
analysed using a VG Quattro 1 electrospray mass spectrometer (Delta Biotechnology 
Ltd). Figure 5.10 shows the profile of proteins in these two samples. From this figure 
it can be concluded that a large number of other molecular masses varying between 
75kDa and 77kDa are present in both samples. This variety is most likely to be due 
to different forms of rhSTf, rather than many different non-transferrin proteins. The 
reason for this is that the chances of so many proteins with a similar molecular mass 
still being present in the sample following SP-FF and DEAE-FF chromatography is 
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Peter J Sargent 
,. 
Figure 5.9.8% Native PAGE of WT and G394R rhSTf following 
affinity chromatography. 1: WT rhSTf (4µg), 2: G394R rhSTf (4µg), 
3: WT rhSTf (2µg) and 4: G394R rhSTf (2µg). 
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5: Purification and Crystallisation Peter J Sargent 
very low. A possible explanation for this heterogeneity could be due to variations in 
the amount of 0-linked glycosylations present on each protein. 
The theoretical molecular weight of the WT and G394R rhSTf proteins are labelled 
on this Figure, minus 38 hydrogens to take into account of the 19 disulphide bonds. 
Also labelled, are three major peaks that are present in both spectra. When 
comparing the three peaks between the two samples, a -99Da difference can be seen. 
This difference is consistent with the increase in weight caused by the substitution of 
glycine with an arginine. However, peak one is about 760Da less than the other two 
peaks, with peaks two and three being roughly the same size. This points to the fact 
that two major forms of the protein exist, whether due to extra amino acids being 
present, or due to extra sugars. 
5.1.5. Recombinant hSTf Purification using Fast Performance Liquid 
Chromatography (FPLC) 
In order to investigate the different forms of the recombinant proteins identified by 
electrospray mass spectrometry, a final purification step was used. WT and G394R 
rhSTf samples that had been purified using immunoaffinity chromatography were 
run on a MonoQ HR 5/5 using a Pharmacia Fine Chemical FPLC system (section 
2.3.3). This system allows high-resolution separation of proteins by accurately 
controlling the buffer composition passing through the column. The MonoQ HR 5/5 
is a pre-packed, high resolution, anion exchange column with a bed volume of 1 ml. 
Even though it has the ability to hold up to 20-50 mg of protein, for high-resolution 
separation of proteins it is advisable to only load 5mg (Amersham Biosciences). 
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5.1.5.1. Purification 1 
Peter J Sargent 
To start, 5mg of freeze-dried WT rhSTf was made diferric following the protocol 
described in section 2.3.5. This sample was then filtered through a 0.211 filter before 
being injected onto the 2mL loading-loop. Using program 1 (Table 5.1), a 2mL 
sample was loaded onto the column, washed and then eluted using a gradient of 0- 
250mM NaCl (Figure 5.11a). Samples from nine fractions spanning over the elution 
peak were collected and analysed using native PAGE (Figure 5.11 b) as described in 
section 5.1.3.3. 
From these two figures, it can be concluded that only fraction 1 contained a 
homogeneous sample of rhSTf. All other fractions still contained heterogeneous 
samples. Following closer inspection of these nine fractions, it can be seen that the 
band in sample 1 corresponds with the top band of sample 2 and the bottom band in 
sample 2 corresponds to the bottom band in sample 3. Also present in sample 3, is 
another band that migrates halfway between the other two. These three bands appear 
to correspond to the first three peaks on the elution trace. In the remaining six 
fractions, a fourth band can be visualised lower down than any of the other three. 
Because no other bands are clearly visible, it can be concluded that approximately 
four main forms of the protein exist in the rhSTf preparation. 
5.1.5.2. N-Terminal Sequencing 
In order to elucidate the first two peaks, the protein in fraction 1 and 2 were N- 
terminal sequenced (Delta Biotechnology Ltd). N-terminal sequence data for both of 
these fractions are shown in Figure 5.12 and 5.13. This data reveals that in fraction 
one, only one protein exists that has an N-terminus that starts with arginine, followed 
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Program 
1 0 Set port 3.0 and 6.0 
Buffer B= 0% 
5 BufferB=0% 
Set port 3.1 and 6.1 
125 BufferB=50% 
Set port 3.0 and 6.0 
Buffer B= 100% 
130 Buffer B= 100% 
Buffer B= 0% 
135 BufferB=0% 
2 0 Set port 3.0 and 6.0 
Buffer B= 0% 
5 Buffer B= 0% 
Set port 3.1 and 6.1 
125 BufferB=25% 
Set port 3.0 and 6.0 
Buffer B= 100% 
130 Buffer B= 100% 
Buffer B= 0% 
135 BufferB=0% 
3 0 Set port 3.0 and 6.0 
Buffer B= 0% 
5 Buffer B=0% 
Set port 3.1 and 6.1 
125 Buffer B= 25% 0.4M NaCI) 
Set port 3.0 and 6.0 
BufferB= 100% 
130 Buffer B= 100% 
Buffer B= 0% 
135 Buffer B= 0% 
4 0 Set port 3.0 and 6.0 
Buffer B= 0% 
5 Buffer B= 0% 
Set port 3.1 and 6.1 
145 BufferB=40% 
Set port 3.0 and 6.0 
Buffer B= 100% 
150 Buffer B= 100% 
Buffer B= 0% 
155 BufferB=0% 
Table 5.1. The programs executed for the purification of rhSTf using a GP- 
250 controlled FPLC system and a lml MonoQ HR 5/5 column. At the start 
of each program the flow rate is set to 0.5m1/min and the chart speed to 
0.25cm/min. Fractions were collected every 2 minutes. Buffer A: 20mM Tris 
(pH8), buffer B: 20mM Tris, 0.5M NaCl (pH8) (except for program 3 where 
NaCl is at 0.4M), port 3: fraction collector and port 6: Valve V-7. 
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Figure 5.11. FPLC purification of WT rhSTf using a lml MonoQ HR 5/5 
column and a NaCl gradient of 0- 250mM (Program 1). a) A trace showing 
absorbance of eluate at 214nm and percentage of buffer B versus time. Blue 
line: absorbance and black line: percentage of buffer B. b) Native PAGE 
showing the protein profile of nine fractions spanning over the major elution 
peaks. 
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Figure 5.12. N-terminal sequencing of fraction 1 from FPLC MonoQ 
purification of rhSTf using Program 1. 
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Figure 5.13. N-terminal sequencing of fraction 2 from FPLC MonoQ 
purification of rhSTf using Program 1. 
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by serine and then leucine. This sequence is part of the fusion leader used for the 
secretion of rhSTf out of the S. cerevisiae cell following expression (Figure 5.14). 
This suggests that the protein is not correctly processed. If these three amino acids 
are on the N-terminus, so must the other three amino acids of the fusion leader that 
lead up to first residue of the mature hSTf. These amino acids are aspartate, lysine 
and arginine. All six of these amino acids (RSLDKR) gave this isoform an extra, two 
positive charges. The data from fraction 2 shows that two proteins with different N- 
terminus sequences were detected. This can be concluded as two amino acids were 
released per cycle. In cycle one, arginine and valine were detected, cycle 2, serine 
and proline were detected and in the final cycle, aspartate and leucine were detected. 
As only one of the two amino acids per cycle can correspond to one protein, the 
sequence of both isoforms can be elucidated. One form is the same as the protein in 
fraction 1 and the second one has an N-terminus starting with valine, then proline 
and then aspartate. By comparing this sequence with that shown in Figure 5.14 it can 
be seen that this second isoform is correctly processed rhSTf. 
5.1.5.3. Purification 2 
In order to purify these two forms further, Program 2 was used (Table 5.1). Another 
2mLs of 5mg/mL diferric rhSTf was loaded onto the column, washed and then eluted 
using a gradient of 0- 125mM NaCl (Figure 5.15). As this gradient was stretched 
over the same amount of time as the gradient in Program 1, but the final NaCl 
concentration was halved, the different isoforms should elute off the column at a 
greater resolution. This was shown to be successful. Fractions one, two and four 
contained homogeneous samples of rhSTf. The only difference between these 
fractions was that number four contained an isoform that migrated further than the 
216 
5: Purification and Crystallisation Peter J Sargent 



















































Figure 5.14. Amino acid sequence of WT rhSTf, including the fusion 
leader. Mature rhSTf sequence: blue and fusion leader: black. Sequence 
corresponding to the N-terminus of proteins in fraction 1 and 2 are 
highlighted in yellow. 
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Figure 5.15. FPLC purification of WT rhSTf using a lml MonoQ HR 5/5 
column and a NaCl gradient of 0- 125mM (Program 2). a) A trace showing 
absorbance of eluate at 214nm and percentage of buffer B versus time. Blue 
line: absorbance and black line: percentage of buffer B. b) Native PAGE 
showing the protein profile of ten fractions spanning over the major elution 
peaks. 
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one seen in the other two fractions. Both of these isoforms are present in fraction 3 at 
low concentrations. This is expected as fraction 3 is a sample of the eluate between 
the first two peaks of the trace and as the absorbance did not reach baseline, both 
isoforms will be present. The remaining six fractions each contained at least two 
isoforms at low concentrations. 
Even though this purification only produced a small amount of homogeneous 
protein, sufficient protein was purified for the majority of the structural and 
functional characterisation studies. 
5.1.5.4. G394R Purification 
The last purification (Program 2) was repeated for G394R rhSTf (Figure 5.16). 
Unfortunately though, the different isoforms did not resolve as well as for the WT 
rhSTf. Fractions 1 and 2 both contained a homogeneous sample of the same rhSTf 
isoform. All other fractions contained at least two different isoforms, The migration 
of these isoforms on native PAGE, in relation to the time at which they elute off the 
column, is similar to the elution pattern of WT rhSTf. 
In order to resolve the isoforms further, the program was modified (Program 3, Table 
5.1) to make the NaCl gradient shallower. By decreasing the NaCl concentration of 
buffer B from 0.5M to 0.4M, the gradient was reduced from 0- 100mM over 
120min from 0- 125mM over the same amount of time. Both the elution trace and 
native PAGE analysis of fractions from this purification are shown in Figure 5.17. 
Using this new gradient, a second major isoform was purified. This isoform, which 
eluted off in fraction 4, migrated further on a native PAGE when compared with the 
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Figure 5.16. FPLC purification of G394R rhSTf using a lml MonoQ HR 
5/5 column and a NaCl gradient of 0- 125mM (Program 2). a) A trace 
showing absorbance of eluate at 214nm and percentage of buffer B versus 
time. Blue line: absorbance and black line: percentage of buffer B. b) Native 
PAGE showing the protein profile of seven fractions spanning over the major 
elution peaks. 
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Figure 5.17. FPLC purification of G394R rhSTf using a lml MonoQ HR 
5/5 column and a NaCl gradient of 0- 100mM (Program 3). a) A trace 
showing absorbance of eluate at 214nm and percentage of buffer B versus 
time. Blue line: absorbance and black line: percentage of buffer B. b) Native 
PAGE showing the protein profile of eight fractions spanning over the major 
elution peaks. 
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isoform in fractions 1 and 2. Again, this is consistent with the elution pattern of WT 
rhSTf using program 2, in that two different isoforms were purified. 
5.1.5.5. Analysis of the Homogeneous rhSTf Samples 
In order to understand more about the four homogeneous isoforms of WT and 
G394R rhSTfs further, all four were analysed using electrospray ionisation (ESI) 
mass spectroscopy (MS) (The Babraham Institute, Cambridge) (Figure 5.18 and 
5.19). All of the samples run on the mass spectrometer were shown to be still 
heterogeneous, even though on native and SDS PAGE gels they were seen to be 
homogeneous. 
To work out the reason behind this heterogeneity, the theoretical MW for the protein 
in each fraction was first calculated. The theoretical MW of both WT and G394R 
rhSTf is stated in section 5.1.4. However, as described previously, N-terminal 
sequencing revealed that two forms of WT rhSTf existed. This second form has six 
amino acids (RSLDKR) of the leader sequence still attached, increasing the protein's 
MW by 756Da. Even though the mutant rhSTf has not been N-terminal sequenced, 
its mobility on a native gel is similar to that of the WT, therefore suggesting that a 
proportion of the mutant also contains these six amino acids. The theoretical MW of 
the WT and G393R partially processed forms are therefore 75965Da and 76064Da, 
respectively. For the WT rhSTf, fraction 2 is the partially processed protein and 
fraction 4 is the fully processed protein. This is the same for the mutant, with fraction 
1 being the partially processed protein and fraction 4, the fully processed protein. 
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Figure 5.18. Electrospray Ionisation Mass Spectroscopy Analysis of WT 
rhSTf FPLC fractions using Program 2. Samples were prepared in 20mM 
ammonium bicarbonate. 
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Figure 5.19. Electrospray Ionisation Mass Spectroscopy Analysis of 
G394R rhSTf FPLC fractions using Program 3. Samples were prepared 
in 20mM ammonium bicarbonate. 
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Knowing these masses, it was possible to calculate the degree of heterogeneity by 
calculating the difference between the theoretical mass for each fraction and the mass 
of each peak in that fraction. This shows that all four fractions contain proteins with 
masses ranging from 68 to 485Da above their theoretical mass. As the amino acid 
sequence of all four proteins are known, and the residues involved in N-linked 
glycosylation have been mutated, only two other possible reasons could account for 
this heterogeneity. 
The first reason could be due to varying numbers of Fe 3+ bound to each protein, as 
one Fe3+ atom weighs -56Da and one C032- weighs -60Da, the difference between 
apo and diferric is -232Da. The second reason could be varying levels of 0-linked 
glycosylation. 0-linked glycosylation in S. cerevisiae is different to that in 
mammalian cells. The first step of O-linked protein glycosylation in mammals is the 
attachment of an N-acetylgalactosamine (GaINAc) to a serine or a threonine (Van 
den Steen et al, 1998). Instead of using Ga1NAc, O-linked glycosylation in S. 
cerevisiae starts by adding a mannose to either a serine or a threonine. After this first 
mannose, the glycan chain can be elongated through the binding of additional 
mannose sugars (Hausler et al, 1992). Every time a mannose is added to a serine or 
threonine, or to another mannose, the overall MW will increase by -162Da. The 
reason for this MW increase is because mannose has a MW of -180Da, but every 
time one is added, a water molecule (-18Da) is released. 
By working out the differences between the mass of the first peak and the theoretical 
mass (calculated using Compute pUMW tool, us. expasy. org and then between 
each peak from then on, the number of 0-linked mannoses attached to each protein 
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and the iron status of that protein can be determined (Table 5.2). Between six to eight 
peaks per fraction are labelled. The smallest peak in each fraction relates to the 
protein with no mannoses attached, but with one Fe 
3+ ion bound. This protein is 
-116Da larger than its theoretical MW. The largest peak in each fraction usually 
represents protein with more than one mannose attached and varying numbers of 
Fe3+ ions bound. It should be noted that on average a 6Da (0.007% of total mass) 
error in the accuracy of the ESI-MS occurs. One reason for the varying numbers of 
iron ions bound could be due to the low pH solvent used in preparing the samples for 
mass spectroscopy. Therefore, some of the protein in the diferric preparation of 
protein analysed will have lost either one, or both of its Fe 
3+ ions. 
By comparing the MW of proteins with the same number of mannoses and Fe3+ ions 
attached, a mass difference of -756Da can be observed between the two fractions of 
the same protein. The difference between peak 2 and 10 is 754Da and the difference 
between peak 17 and 24 is 758Da. These differences are consistent with the presence 
of the partially processed leader sequence RSLDKR in fraction 2 of the WT and 
fraction 1 of the mutant. 
5.1.5.6. Scaled-up MonoQ FPLC Purification of rhSTf 
In order to purify a larger quantity of the four isoforms described above, the 1mL 
monoQ column was replaced by a lOmL monoQ column. A number of modifications 
were made to these purifications. The flow rate was increased from 0.5ml/min to 
2ml/min, and instead of loading 5mg of diferric protein, 20mg was loaded. All other 
parameters were kept the same. 
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2 76135 0 1 +8 
3 76198 2 0 +1 
4 76246 1 1 +3 
5 - - - - 
6 76357 2 1 +2 
7 - - - - 
8 76450 0 3 -1 
75209 4 9 75332 1 0 +7 
10 75381 0 1 +10 
11 75441 2 0 0 
12 75487 1 1 0 
13 75550 0 2 +17 
14 75599 2 1 -4 
15 75642 1 2 -7 
G394R 76064 2 16 76186 1 0 +6 
17 76234 0 1 +8 
18 76295 2 0 -1 
19 - - - - 
20 76401 0 2 +13 
21 76453 2 1 -5 
75308 4 22 75376 - - - 
23 75428 1 0 -4 
24 75476 0 1 +6 
25 75538 2 0 -2 
26 75567 1 1 -19 
27 75642 0 2 +10 
28 75698 2 1 -4 
Average error +/-Da) 6 
Table 5.2. Theoretical number of 0-linked mannoses attached to each protein 
visualised using ESI mass spectroscopy (figure 5.18 and 5.19) and their 
theoretical iron status. This was calculated by firstly working out the difference 
between the peak mass and its theoretical mass. The number of mannoses (I 6213a), 
and or Fe 
3+ + C032- (116Da) that could make up this mass difference was calculated 
empirically. 
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5.1.6. Native G394R hSTf Purification 
5.1.6.1. Immunoaffinity Chromatography 
50mL of serum from the individual who is heterozygous for the G394R hSTf 
mutation was centrifuged at 10,000g for 10min and then filtered through a 0.2µ filter. 
The serum was then diluted 1: 2 with immunoaffinity chromatography equilibration 
buffer before being run on the anti-hSTf affinity column described in section 5.1.3.2 
As with previous purifications using this column, samples from the load, the load 
flow-through, the wash flow-through and the elution were analysed using SDS- 
PAGE (Figure 5.20). This Figure shows that a pure preparation of hSTf was purified 
from the serum. As before, eluted protein was desalted using a G-25 column and 
freeze-dried immediately following purification. 
5.1.6.2. Fast Performance Liquid Chromatography Purification 
In order to separate the mutant transferrin from the WT transferrin from this affinity 
purified preparation, 5mg of it was run on a 1mL monoQ column (section 5.1.5.1). 
Using the same protocol described in section 2.3.5, this preparation was made 
diferric and then filtered through a 0.2µ filter before being injected onto the 2mL 
loading-loop. Program 4 (Table 5.1) was then used to load and purify this sample 
using a gradient of 0- 200mM NaCl (Figure 5.21a). Samples from nine fractions 
spanning over the elution peak were collected and visualised using native PAGE 
(Figure 5.21b). The first four fractions visualised on a native PAGE contained a 
single isoform that migrated faster than the isoform in the last four fractions. Fraction 
5, contained a mixture of the two isoforms. These two isoforms correspond to the 
WT (fractions 1-4) and mutant (fractions 6-9) transferrin. The fact that the mutant 
runs slower on a native PAGE is discussed in section 5.1.3.3. However, the fact that 
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Figure 5.20. Reducing SDS PAGE of samples collected during native 
G394R hSTf purification using an anti-hSTf affinity column. M: HMW- 
SDS marker, 1: load, 2: load flow-through, 3: wash, 4: Eluate and hSTf: 1 µg 
of native hSTf (Scipac Ltd) 
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Figure 5.21. FPLC purification of native G394R hSTf using a lml MonoQ 
HR 5/5 column and a NaCl gradient of 0- 200mM (Program 4). a) A trace 
showing absorbance of eluate at 214nm and percentage of buffer B versus 
time. Blue line: absorbance and black line: percentage of buffer B. b) Native 
PAGE showing the protein profile of nine fractions spanning over the major 
elution peaks. 
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the mutant elutes of the monoQ column later than the WT protein is a mystery since 
its extra positive charge should make it bind weaker. These results therefore suggest 
that the mutant's surface is more negatively charged than the WT. 
5.1.7. Native WT hSTf purification 
Native WT hSTf (90% pure) was purchased from Scipac Ltd in a freeze-dried form. 
In order to purify it further, 100mg of it was resuspended in affinity chromatography 
equilibration buffer and run on the anti-hSTf immunoaffnity column used for the 
purification of the recombinant proteins. As before, eluted protein was desalted using 
a G-25 column and freeze-dried immediately following purification. 
5.1.8. Native WT hLf Purification 
In order to purify hLf quickly and efficiently, an immunoaffinity chromatography 
column was created using purified sheep anti-hLf IgG. IgG was purified using 
exactly the same principal used for the purification of sheep anti-hSTf (section 
5.1.3.1). The only difference being was that an hLf affinity column was created for 
the purification of the sheep anti-hLf IgG, rather than the hSTf immunoaffinity 
column. In order to create such a column, hLf (a gift from Dr L Moriarty) was used. 
Following the creation of the anti-hLf affinity column, 200mL of unpasteurised 
human milk (donated by King's College Hospital Neonatal Unit, London) was 
centrifuged at 5000g for 40mins. The resulting cream layer was removed by filtration 
through glass wool. Using the protocol described in section 2.3.2, hLf was then 
purified from the resulting supernatant. The purity of hLf in the eluate was 
determined by SDS PAGE (Figure 5.22) to be highly pure. 
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Figure 5.22. Reducing SDS-PAGE of samples collecting during hLf 
purifications using an anti-hLf affinity column. M: HMW-SDS marker, 1: 
Load, 2: Load flow-through, 3: Wash and 4: Eluate. 
232 
5: Purification and Crystallisation Peter J Sargent 
5.2. X-ray Crystallography of hLf and hSTf 
X-ray crystallography is perhaps the most powerful technique for determining 
protein structure and has been used extensively for decades. This technique relies on 
the interference, or diffraction, caused by X-rays being scattered by electrons 
surrounding atoms aligned within the protein crystals. 
In order to use this technique, suitable crystals of the protein need to be first grown. 
These crystals should ideally be transparent, well defined with no cracks and be 
between 0.2-0.5mm in length. Once grown, these crystals are then bathed in an X-ray 
beam, typically generated in a laboratory by accelerating a beam of electrons into a 
cooled anode. In some cases, the anode is rotated to produce brighter images, or in 
the case of synchrotron radiation generators, the beam of electrons can be focused 
using magnets. In the latter, the X-ray beams produced are several thousand times 
more intense and of shorter wavelengths than those produced from conventional 
generators. Diffracted X-rays are visualised as a diffraction pattern on an X-ray 
detector plate. The data collected from this plate can then be used to generate an 
electron density map. These maps represent regions that are occupied by atoms 
within the protein. 
As discussed in section 1.3.2 the tertiary structure of many of the transferrins have 
been elucidated using X-ray crystallography. However, to date, no high-resolution 
image of hSTf has been obtained. The reason for the failure to stabilise hSTf is still a 
bit of a mystery, but one possible reason could be the heterogeneity in the N-linked 
glycosylation found on the protein. Therefore, the initial aim of this aspect of the 
study is to explore conditions for the crystallisation of recombinant hSTf. 
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The second aim of this study is to explore conditions for the crystallisation of hLf 
bound to indium(III). Even though hLf has been crystallised previously in both its 
apo- (Jameson el al, 1998) and diferric form (Haridas et al, 1995) there are still many 
questions yet to be answered which could help us understand the mechanics of all 
proteins in the Transferrin family. 
One of these questions is how both domains, in each lobe, close to bind the metal 
ion, whether they do open or close at all. As discussed in section 1.3.1, the 
Transferrins are known to be able to bind a wide range of metal ions of varying sizes. 
One of the smallest known is aluminium(III) which has a molecular radii of 57pm 
and the largest is cerium(III), a lanthanide with a molecular radii of 99pm. This 
shows the residues involved in iron binding are able to adapt to different size metal 
ions. How they are able to do this is a question, which we attempt to answer in these 
studies. 
5.2.1. Introduction to Protein Crystallisation 
Crystallisation of proteins is achieved by the gradual removal of solvent around the 
protein leading to state known as supersaturation. This state can be split up into three 
phases. The first phase is known as the Metastable phase and is where crystals may 
not form for a long time, but the conditions are suitable to sustain growth. Phase two, 
or the Nucleation phase, is where protein crystals nucleate and grow and finally, the 
Precipitation state. This is where proteins will precipitate out of solution. The rate at 
which this supersaturation is attained is dependent on many variables. These include 
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protein concentration, pH, temperature, as well as the nature and concentration of 
precipitant present. 
Two main methods are commonly used for the crystallisation of serum transferrins 
and lactoferrins: the dialysis and the vapour diffusion method. The latter is the most 
common, but both of these methods work using the same principal. With the dialysis 
method, the protein is dissolved in buffer and precipitant and then dialysed against a 
higher concentration of precipitant. This gradually removes the water around the 
protein causing supersaturation. The rate of attainment of supersaturation can be 
controlled by varying the difference in concentration of precipitant on either side of 
the dialysis membrane. With the vapour diffusion method (Hanging Drop), a droplet 
of protein solution containing precipitant is equilibrated with a reservoir of 
precipitant containing a higher concentration of precipitant. Equilibration proceeds in 
this case by the diffusion of solvent from the drop to the reservoir, thus achieving 
supersaturation in the drop. This occurs until the vapour pressures in the drop and the 
reservoir are equal. 
During this study, only vapour diffusion was explored for the crystallisation of hLf. 
However, a third technique was used in attempts to crystallise hSTf. This third 
technique, known as Microbatch, involves mixing the protein sample with the 
crystallisation agent and then placing a drop of this under oil. Unlike vapour 
diffusion and the dialysis method, the concentration of the ingredients in the 
crystallisation agent is such that supersaturation is achieved immediately upon 
mixing, thus the composition and the volume of a trial remain constant and crystals 
will only form if the precise conditions have been correctly chosen. The benefits of 
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this technique are that very small amounts of sample are required and crystallisation 
conditions are less prone to experimental error. 
5.2.2. Crystallisation of Diferric Recombinant hSTf 
As discussed previously, to date, no high-resolution image of diferric-hSTf has been 
obtained. Therefore, in this section, conditions for the crystallisation of recombinant 
hSTf were explored in the hope of obtaining a high-resolution image of this protein. 
The growth of hSTf crystals and subsequent X-ray diffraction analysis in this study 
was carried out in collaboration with Dr Claire Naylor and Dr Bernard O'Hara, 
Department of Crystallography, Birkbeck College, London. 
Recombinant WT hSTf, purified and fractionated in section 5.1.5.6, was iron loaded, 
as described in section 2.3.5, and then desalted and freeze-dried as described in 
section 2.3.6. Prior to use, proteins were then resuspended into the relevant buffer. 
All hSTf crystallisation assays were carried out using the Microbatch assay described 
in section 2.4.11. 
The first screen used the Hampton Research Crystal Screen 1 (Appendix III), with a 
protein concentration of 3mg/mL. It should be noted that since 1µL of protein is 
mixed with Ipl of crystallisation agent, the final concentration of protein is around 
1.5mg/ml. These crystallisation screens were incubated at 293K for 2 weeks, but no 
crystals grew. 
In order to try and increase the chance of crystal growth, this first screen was 
repeated, but with the protein concentration at 5.5mg/ml. Also, using the same 
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protein concentration, a second screen (Hampton Research Crystal Screen 2, 
Appendix III) was also explored. From these two screens, crystals grew in two of the 
crystallisation conditions, following incubation at 293K for approximately 2 weeks 
(Figure 5.23). These two conditions are screen 1, buffer 40: 0.05M tri-sodium citrate 
dihydrate pH 5.6,20 %v/v iso-propanol and 20% (w/v) PEG 4000 and screen 2, 
buffer 39: 0.2M magnesium chloride hexahydrate, 0.1M tris (pH 8.5), 3.4M 1,6 
hexanediol. It should be noted that as hSTf has a pI of around 5.2 (tasialotransferrin) 
to 5.7 (disialotransferrin), with tetrasialotransferrin and trisialotransferrin residing in 
between (Chang et al, 2005), the ideal pH for crystallisation should be around pH 5.5 
Therefore, it is not surprising that crystals grew in buffer 40, screen 1, but it is 
surprising that they grew in buffer 39, screen 2. However, all crystals grown from 
both conditions were long rod shaped and around 0.2-0.3mm in size. All crystals 
looked to be of a good enough quality to be used to get initial diffraction data. 
Before any diffraction attempts were carried out, all crystals were soaked in mother 
liquor containing 10-20% (v/v) glycerol as a cryoprotectant and then mounted on a 
heated Goniometer head in a stream of liquid nitrogen using a Nikon Microscope and 
wire loop. Initial X-ray diffraction data was collected using a Rigaku RU-H3R 
rotating anode X-ray generator and a 300mm Mar image plate running on a Silicon 
Graphics workstation. Unfortunately, the diffraction data collected from this run only 
went up to a 7A resolution. Since diffraction at this resolution would only be able to 
be used to determine protein domains and overall shape, it was decided that an 
alternative X-ray source was needed. However, it was possible from this data to 
calculate the space group to be P222 with cell dimensions a=89.1447A, 
b=102.8808A and c=198.1554A. 
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Figure 5.23. Examples of diferric rhSTf crystals grown in these studies. 
Crystals were visualised using a Leica MZFLIII microscope and photos taken 
using a mounted Carl Zeiss Axiocam. 
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In order to obtain higher resolutions, crystals were taken to the Synchrotron facility 
in Grenoble, France. Using the facilities available there, a 4A resolution data set was 
collected, taking diffraction images every 1° for 900 (Figure 5.24). The data collected 
from all of these images was analysed using the CCP4 (Collaborative Computational 
Project Number 4) UNIX-based software suite. This software showed that there is 
likely to be two molecules of recombinant hSTf in each asymmetric unit and 
confirms the space group to be P222. Even though 4A resolution is not good enough 
to solve the structure of hSTf by itself, molecular replacement analysis with rabbit 
serum transferrin (1JNF) and the N-lobe of hSTf (1N84) is currently under way. 
5.2.3. Crystallisation of Native hLf-In3+ 
This section discusses the screening of conditions for the crystallisation of hLf bound 
to indium(III), a metal shown by Battistuzzi et al, 1995 to bind to transferrin with an 
affinity on par with that of Iron(III). The reason for choosing indium(III) is due to its 
large atomic radii of 92pm, compared to iron(III)'s 67pm, the fact that iron does not 
have the ability to displace indium from transferrin, and due to its availability. 
Solving the structure of hLf-In 3+ will enable us to compare the structural differences 
around both metal-binding sites with that of hLf-Fe 
3+ and give us an insight into the 
conformational changes that occur in metal binding and release. 
Recombinant WT hLf purified in section 5.1.8 was dialysed into 20mM NaHCO3 
(pH 8 with 10M HCl) and In3+ (Sigma) added at twice the protein's molarity. This 
protein solution was left on a rolling platform for lhr at room temperature before 
being desalted and freeze-dried using the protocol described in section 2.3.6. 
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Figure 5.24. Examples of X-ray diffraction images of recombinant hSTf 
crystals using Synchrotron radiation (Grenoble, France). A: An example of 
an unprocessed diffraction image. B-D: diffraction images looking down the 
three axes (1, k and h) of the crystal. 
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As discussed before, hLf has been crystallised in its apo- and diferric form. A 
number of lactoferrins from other species have also been crystallised. Such species 
include, buffalo (Karthikeyan et al, 2000), bovine (Moore et al, 1997), equine 
(Kumar et al, 2002) and camel (Khan et al, 2001). From this published data, a 
relatively focused initial screen of conditions for the crystallisation of hLf-In 3+ was 
therefore possible. This screen (screen 3, appendix III) was carried out using the 
hanging-drop method described in section 2.4.11. Three different precipitants 
(ethanol, isopropanol and PEG6000) were used at six different concentrations in 
10mM Tris at either pH 7.5,8.0,8.5, or 9 making up a total of 72 buffers. The reason 
for choosing this range of pH was due to the fact that hLf has a pI of 8.6 (Pulina et 
al, 2002). These 72 buffers were then used along with four different protein 
concentrations (10,20,30 and 40mg/ml) and two different temperatures (277K and 
293K). 
From this screen a number of crystals were grown (appendix III). These crystals only 
grew on plates using ethanol or isopropanol as a precipitant. The use of PEG6000 
was shown to by unsuccessful in these studies. It can also be seen from these results 
that most of the crystals grew at pH 8.0 when the isopropanol and ethanol 
concentrations were between 5-15% (v/v). High protein concentration was also 
shown to favour crystal growth. However, precipitation did occur around these 
conditions, especially when precipitant concentration was above 15% (v/v). A few 
crystals did grow outside these conditions, but these were usually small and irregular 
in shape. 
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Photographs of eight crystals grown in this screen are shown in Figure 5.25. All 
these crystals were of similar shape and ranged in size from 0.2-0.5mm in length. It 
is possible to see from this figure that there is a morphological difference between 
the crystals grown using ethanol as a precipitant rather than isopropanol. This 
difference is seen in the presence of striations in the isopropanol grown crystals. 
These striations are characteristic of crystal cracking. One possible reason for this 
could be that the drops became too dehydrated, causing the crystals to become 
unstable. It was concluded from this screen that the best hLf-In 
3+ crystals grew using 
buffer 8,40mg/ml protein and at a temperature of 277K. 
The collection of crystal diffraction data was attempted using an in-house rotating 
anode X-ray diffractor (45kV, 45mA, detector distance 200mm, 10min exposure per 
image). Unfortunately, crystals were found to be unstable and cracked easily during 
mounting. In an attempt to overcome this problem, a cryoprotectant was tried. This 
involved adding 1 µl of 2-methyl-2,4-pentanediol (MPD) (Sigma) to the relative drop. 
The crystal was then passed through this solution before mounting. Again, crystals 
were found to be unstable and no diffraction data could be collected. 
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Figure 5.25. Examples of hLf-In3+ crystals grown in these studies. Crystals 
were visualised using a Leica MZFLIII microscope and photos taken using a 
mounted Carl Zeiss Axiocam. 
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Peter J Sargent 
This chapter focuses on the structural and functional comparison not only between 
the recombinant and the native forms for each variant of the protein, but also 
between the WT and the mutant the proteins. The first comparison is to ensure that 
the recombinant proteins are functionally and structurally indistinguishable from the 
native proteins for the recombinants to be used to investigate the mode of action of 
hSTf. Only when true homology can be shown, can the data collected from the 
analysis of recombinant mutant proteins be thought to be an accurate representation 
of the native forms. In the case of the G394R mutant, a native form exists enabling a 
direct comparison of the recombinant and native hSTf G394R mutants. In summary, 
this chapter is therefore a four-way comparison of two native hSTf proteins (WT and 
G394R) and two recombinant hSTf proteins (WT and G394R). In addition, further 
comparison between both the fully processed and partially processed recombinant 
proteins are to be made to ensure that the extra six additional amino acids discussed 
in section 5.1.5 do not affect the structure or functionality of the protein. 
6.1. Structural Characterisation 
Four different techniques were used in this section to compare the structural 
characteristics of these four proteins: circular dichroism spectroscopy (CD), electron 
paramagnetic resonance (EPR), dynamic light scattering and immunodiffusion. 
6.1.1. Circular Dichroism Spectroscopy 
Circular dichroism spectroscopy measures differences in the absorption of left- 
handed circularly polarized light versus right-handed circularly polarized light, 
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which arise due to structural asymmetry. The absence of regular structure results in 
zero CD intensity, while an ordered structure results in a spectrum, which can 
contain both positive and negative signals. The most commonly used units of CD 
intensity are mean residue ellipticity (degree cm2 dmol") and the difference in molar 
extinction coefficients, called the molar circular dichroism (Ac) (M"' cm-1). 
In relation to proteomics, proteins possess a number of chromophores, which can 
give rise to CD signals. In the far UV region (240-180nm), which corresponds to 
peptide bond absorption, the CD spectrum can be analysed using reference data to 
give the content of regular secondary structure features such as a-helix and ß-sheet. 
For an a-helix, a negative Ae at -222nm, a positive Ae -190 and a negative Ac at 
-208nm occurs. ß-sheets are 
known to cause a negative Ac - 215nm, a positive Oe 
198 and a negative As -175nm. Finally, for random coil, a negative As -212 nm and 
a negative Ae - 195 nm is seen (Wallace et al, 2001). The CD spectrum in the near 
UV region (320-260nm) reflects the environments of the aromatic amino acid side 
chains and the presence of disulphide bonds, thus giving information about the 
tertiary structure of the protein (Kelly and Price, 2000). More specifically, the near 
UV absorption of the disulphide bond occurs near 260nm, tryptophan (290 and 
305nm), tyrosine (275 and 283nm) and phenylalanine (255 and 270nm). However, 
like all spectroscopic techniques, the CD signal reflects an average of the entire 
molecular population. It cannot determine which specific residues are involved in 
certain structures. CD is therefore a very powerful tool in proteomics and is 
particularly suited for such studies. In this section, CD is used as a `fingerprint' to 
compare all the different forms of protein. 
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Using the protocol described in the section 2.4.1, apo and diferric preparations of the 
six different transferrins, including the recombinant isoforms, purified in the 
previous chapter were analysed in both the far and near UV range. Apo and diferric 
preparations were made following the protocol described in section 2.3.5. 
Figure 6.1,6.2,6.3 and 6.4 show the spectra for both CD and UV from 190 - 260nm, 
and the relative a-helix, ß-sheet and irregular secondary structure percentages 
calculated from data averaged from two scans per protein. Results obtained indicate 
that the recombinant forms of both variant proteins produce spectra which are 
superimposable to the ones obtained with their respective native forms, and for both 
apo and diferric forms. This indicates, along with the percentage of secondary 
structure calculated, that the four recombinant proteins are correctly folded and show 
minor changes in absorption in the near UV. 
In order to look at the overall differences in secondary structure between the apo and 
diferric forms of the WT and G394R proteins, each data set from both variants were 
averaged (Figure 6.5). These results show that both the WT and G394R hSTf 
produce very similar CD spectra in the far UV range regardless of their iron content. 
This similarity can also be seen in the variation of percentage secondary structure 
calculated (v). These secondary structure percentages only vary by +/. -1% from the 
average. In terms of the number of residues (equation 1), this variation is 
approximately +/. -2 residues, out of a total of 679 residues. From this, it can 
therefore be seen that this variation is probably not significant and more likely to be 
due to experimental error rather than resulting from structural differences between 
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Figure 6.1. Far-UV (190-260nm) CD (A) and UV (B) spectra of native and 
recombinant WT apo-hSTf. All scans were carried out in duplicate with the 
average shown above. Black line: Native WT hSTf, red line: partially processed 
WT recombinant hSTf and yellow line: fully processed WT recombinant hSTf. 
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Figure 6.2. Far-UV (190-260nm) CD (A) and UV (B) spectra of native and 
recombinant G394R apo-hSTf. All scans were carried out in duplicate with the 
average shown above. Grey line: Native G394R hSTf, blue line: partially 
processed G394R recombinant hSTf and green line: fully processed G394R 
recombinant protein. 
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Figure 6.3. Far-UV (190-260nm) CD (A) and UV (B) spectra of native and 
recombinant WT diferric-hSTf. All scans were carried out in duplicate with the 
average shown above. Black line: Native WT hSTf, red line: partially processed 
WT recombinant hSTf and yellow line: fully processed WT recombinant hSTf. 
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Figure 6.4. Far-UV (190-260nm) CD (A) and UV (B) spectra of native and 
recombinant G394R diferric-hSTf. All scans were carried out in duplicate with 
the average shown above. Grey line: Native G394R hSTf, blue line: partially 
processed G394R recombinant hSTf and green line: fully processed G394R 
recombinant protein. 
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Figure 6.5. Far-UV (190-260nm) CD spectra (CD) and Near-UV (249-320) 
UV spectra (B) of WT and G394R hSTf, in both apo and diferric forms. Data 
compiled from averaged data from all six proteins. Black line: apo hSTf WT, Red 
line: diferric hSTf WT, blue line: apo hSTf G394R and Yellow line: diferric hSTf 
G394R. 
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the four proteins. This conclusion is consistent with the observation of Zhang et al, 
2004, who showed the secondary structure of hSTf did not vary upon metal binding. 
n xm 
residue var iance = 
100 
-x v Iii 100 
n= total number of residues (679) 
m= mean percentage secondary structure 
v=m- (maximum, or minimum percentage secondary structure) 
After measurement of CD and UV absorbance over the near UV range from 249 - 
320nm, (Figure 6.6,6.7,6.8 and 6.9), the spectra obtained for each isoform of the 
recombinant proteins were found to be superimposable to the spectra of their 
respective native protein, for both their apo or diferric forms. As indicated by 
spectral data from the far UV (190-260nm), these data confirm that the recombinant 
proteins are correctly folded and display structural variation identical to the native 
variants upon iron binding. 
In order to look at the overall difference in tertiary structure between the apo and 
diferric forms of the WT and G394R proteins, the data from each of the three 
proteins, for both variants, were averaged (Figure 6.10). Although identical spectra 
were obtained for both apo proteins, considerable differences can be seen after iron 
binding, not only between the spectra obtained for the apo and the holo-forms, but 
also between both spectra obtained for both holo-forms of the variants. 
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Figure 6.6. Near-UV (249-320nm) CD (A) and UV (B) spectra of native and 
recombinant WT apo-hSTf. All scans were carried out in duplicate with the 
average shown above. Black line: Native WT hSTf, red line: partially processed 
WT recombinant hSTf and yellow line: fully processed WT recombinant protein. 
253 
249 252 251 2L1 2[6 2« 271 277 2" 2ts 299 29) 747 )K 2ti )09 )0 )ti 
W iueh(mn) 
6: Characterisation of Recombinant/Native hSTf 
A. ý., 













zp W3 757 2i1 26s z5 ii? 21 ZM 246 tM 2s3 217 341 Xs )S 30 317 
WaNeIh (mtt) 
Figure 6.7. Near-UV (249-320nm) CD (A) and UV (B) spectra of native and 
recombinant G394R apo-hSTf. All scans were carried out in duplicate with the 
average shown above. Grey line: Native G394R hSTf, blue line: partially 
processed G394R recombinant hSTf and green line: fully processed G394R 
recombinant protein. 
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Figure 6.8. Near-UV (249-320nm) CD (A) and UV (B) spectra of native and 
recombinant WT diferric-hSTf. All scans were carried out in duplicate with the 
average shown above. Black line: Native WT hSTf, red line: partially processed 
WT recombinant hSTf and yellow line: fully processed WT recombinant protein. 
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Figure 6.9. Near-UV (249-320nm) CD (A) and UV (B) spectra of native and 
recombinant G394R diferric-hSTf. All scans were carried out in duplicate with 
the average shown above. Grey line: Native G394R hSTf, blue line: partially 
processed G394R recombinant hSTf and green line: fully processed G394R 
recombinant protein. 
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Figure 6.10. Near-UV (249-320nm) CD spectra (A) taken from the inset scan 
(249-600nm) and Near-UV (249-600nm) UV spectra (B) of WT and G394R 
hSTf, in both apo and diferric forms. Data compiled from averaged data from 
all six proteins. Black line: apo hSTf WT, Red line: diferric hSTf WT, blue line: 
apo hSTf G394R and Yellow line: diferric hSTf G394R. 
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For WT hSTf, both forms show peaks at 253,283 and 291nm, corresponding to 
phenylalanine, tyrosine and tryptophan, respectively. However, except for the 283nm 
peak, the differential molar CD value (differential molar circular dichroic extinction 
coefficient Ac) of the other two peaks increases quite significantly in the diferric 
form. For example, the peak at 253nm has a negative differential molar value in the 
apo form, but then rises to a positive value in the diferric form, whereas even though 
the 291nm peak increases, it remains positive in both forms. Other differences 
between the apo and diferric WT hSTf includes an increase in differential molar CD 
value at 270nm in the diferric protein, along with an increase from a negative 
differential molar CD value to a positive one in the 300-320nm range. These 
characteristic peaks are almost identical to the results published for the near UV CD 
spectra of WT porcine serum Tf (Shen et al, 1992), WT hen serum Tf (Thakurta et 
al, 2004) and WT hSTf (Zhang et al, 2004). 
The spectra obtained for diferric G349R hSTf is very different from that for diferric 
WT hSTf. Even though the overall spectral pattern remained very similar, G394R 
hSTf differs by having a lower differential molar CD value in the 249-260nm region 
with a significantly higher one in the 260-31 Onm region. Such a difference suggests a 
different orientation of these aromatic chromophores in the mutant that could relate 
to a change in tertiary structure. Due to the difficulty in calculating such a variation, 
the degree of tertiary structural change could not be verified. Shen et al, 1992, 
postulated that the binding of the Fe 
3+ with the side chains of the two tyrosines, the 
histidine and the aspartate could significantly affect the absorbance of these tyrosines 
as well as the neighbouring tryptophan residues. Therefore, rather than a direct major 
structural alteration due to the presence of the mutation G394R, the difference 
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between both spectra could be the indirect result of fine structural differences around 
the iron-binding site. 
6.1.2. Electron Paramagnetic Resonance 
Electron paramagnetic resonance (EPR), also known as electron spin resonance 
(ESR), is the name given to the process of resonant absorption of microwave 
radiation by paramagnetic ions or molecules, with at least one unpaired electron spin, 
and in the presence of a magnetic field. 
Electrons possess spin magnetic moments that can assume two quantum mechanical 
orientations. In electron pairs, the net moment is zero and thus the application of an 
external magnetic field will not affect electron spin. However, in compounds with 
unpaired electrons, such as transition metals (i. e. iron) and free-radicals, the electron 
has the ability to change spin orientation, or resonate, between spins with moments 
parallel or anti-parallel to an externally applied magnetic field. Transition between 
electron spin states, of which only two are allowed, according to Planck's law 
involves the absorption of a comparatively small amount of energy (when DE = hv, 
where h is Planck's constant (6.626x10-34) and v is the frequency of the radiation). 
In EPR, an unpaired electron is held in a specific spin orientation by the application 
of a magnetic field. Energy, in the form of microwave radiation, is then applied to 
the system. In relation to the Bruker EPR spectrometer used in these studies, this 
microwave radiation is kept at a constant frequency (hv) (9.38GHz) whilst the 
magnetic field strength (Bo) is then scanned until transition between electron spin 
states occurs. The strength of magnetic field required to do this is known as the field 
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for resonance. However, this field for resonance is not a unique fingerprint for 
identification of a compound because spectra can be acquired at several different 
frequencies. In order to overcome this, the g-factor is used. This g-factor is a 
proportionality constant approximately equal to 2 for most samples, but which varies 
depending on the electronic configuration of the radical or ion. The g-factor was 
calculated using the following equation (2), where p is the Bohr Magneton 






Measurements of the g-factor provide some useful information, but do not reveal 
very much about the molecular structure of our sample. However, when 
paramagnetic ions are present within molecules, a number of factors can influence 
the transition between electron spin states once a magnetic field has been applied. 
The magnetic moment of these electrons can be influenced by the molecules own 
magnetic field, or by the magnetic field of surrounding molecules, or even by 
interactions with nearby spinning nuclei (known as hyperfine interactions). These 
influences manifest themselves in a change in the g-value and are useful for the 
identification of the source of resonance. 
For molecules such as transferrin, the task of quantitative spectra interpretation is an 
immense and highly problematic one. Therefore, the purpose of EPR in these studies 
was more of a qualitative tool, to compare the environments surrounding the Fe 3+ 
ions in each of the transferrins under investigation. 
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Figure 6.11 shows a comparison of EPR spectra for both WT diferric proteins and 
Figure 6.12 a comparison of EPR spectra for both the G394R diferric proteins. All 
proteins were made diferric following the protocol described in section 2.3.5. The 
two recombinants used were from the fully processed fractions (section 5.1.5). The 
superimposable spectra obtained for both WT proteins are indicative of an identical 
chemical environment around the ferric iron for both native and recombinant 
proteins, with a resonance occurring at a g-value of 4.3, which is consistent with the 
g-value shown for the typical high-spin ferric iron-bicarbonate complex in WT hSTf 
(Pinkowitz and Aisen, 1972). Similarly, the EPR spectra obtained for the native and 
recombinant G394R proteins, are also both almost identical, with the resonance still 
fixed at a g-value around 4.3, and indicate therefore an identical chemical 
environment around the ferric iron. 
When comparing the WT protein spectrum to the G394R mutant protein spectrum, a 
number of differences can be observed (Figure 6.13). These differences include a 
reduction in size of peak a in the G394R protein, along with the lowering of a shelf 
in the spectrum at point b, 155mT. When comparing the spectrum of this G394R 
mutant to the published hSTf spectrum, a close resemblance to the published spectra 
produced for the N-monoferric transferrin (Aisen et al, 1978) can be observed. This 
suggests that the positively charged side-chain of R394 is either interacting directly 
in some way with the ferric ion in the C-lobe, or indirectly perturbing the iron 
binding site. Either way, this indicates that the normal rhombic symmetry of the 
bound iron has been affected. Other differences can also be noticed in the magnetic 
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Figure 6.11. EPR Spectrum of diferric WT native (A) and recombinant (13) 
hSTf, scanning a magnetic field from 100 to 245 mT. 'I'hr (i-factor valucs for 
the main spectral features are also labelled. 
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Figure 6.12. EPR Spectrum of diferric G394R native (C) and recombinant 
(D) hSTf, scanning a magnetic field from 100 to 245 mT. The G-factor values 
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field in the range 180 to 362mT. However, these differences could be due to the 
signal strength rather than direct change difference in chemical behaviour around the 
ferric ions. 
6.1.3. Dynamic Light Scattering 
Dynamic Light Scattering is a technique used to determine the size of molecules. 
This technique works by shining red laser light (675nm) through a cuvette containing 
the sample of interest. When such a light is shone at a sample of particles such as 
proteins, their Brownian motion causes a Doppler Shift when the light hits them, 
changing the wavelength of the incoming light. In turn, this causes a change in the 
intensity of light, which can be measured. In the case of the DynaPro99 Light 
Scattering machine used in this study, a detector at 90° from the light source 
measures this change in light intensity by counting photons emitted from the sample. 
The photon count, or intensity, can then be used to calculate particle size. 
However, the reason for using this technique is not to calculate the size of particles 
per se, but to determine the thermo-stability of all four proteins. This was achieved 
by gradually heating each of the protein samples to initially 5°C, then to 15°C and 
then in 5°C increments up to 95°C. At each temperature increment, the number of 
photons were recorded and used by the software to calculate particle (protein) 
diameter. From this, the temperature at which each protein started to denature could 
be determined by a significant increase in particle diameter. 
Using the protocol described in section 2.4.4, the four proteins, native WT, 
recombinant WT, native G394R and recombinant G394R were analysed in both their 
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apo- and diferric forms. The results from this study (Figure 6.14) indicate that all 
four proteins are stable up to at least 55°C, in both their apo- and diferric forms, and 
that both recombinants behave very similarly to their native counterparts. Between 
60-65°C, the average radius of all four apo-proteins almost simultaneously increases 
significantly in size, indicating protein denaturation. Towards 70°C, there is a slight 
increase in the average radius for the native and recombinant G394R diferric 
proteins, but between 80-85°C these proteins are seen to fully denature. Finally, the 
native and recombinant WT proteins denature at 85-90°C, indicating that these are 
the most heat-stable. It can therefore be concluded from this study that the binding of 
iron to hSTf stabilises its structure, and provides a higher resistance to heat. 
These findings are consistent with the work published by Ikemoto and Ventura, 
1979, who found through Differential Scanning Calorimetry that apo-hSTf denatured 
between 60-70°C and diferric hSTf denatured around 83°C. However, unlike the 
results obtained in our study, they actually observed that the apo-hSTf denatured in 
two steps (60.1 °C and 70.7°C), as also descirbed by Evans et al, 1982, who found 
apo-hSTf denatured at 64.4°C and then 74.4°C. Such two-step denaturation of apo- 
hSTf could be masked by the 5°C increments used in our study, which prevents the 
resolution of two separate denaturation events, which appear as a single event. 
The fact that both recombinant and native G394R hSTf in their apo forms denature 
around 60-65°C is also consistent to previously published work. Evans et al, 1982 
showed that native G394R hSTf denatures at 63.4°C and then 75.3°C in its apo form. 
This is only around 1°C less than the temperature they published for the WT protein. 
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Figure 6.14. Dynamic Light Scattering data showing the thermostability of 
apo- and diferric hSTf. Native WT: red, recombinant WT: blue, native G394R: 
yellow and recombinant G394R: green. Apo samples are shown here as solid lines, 
whereas the diferric samples are shown here as dotted lines. Reading with a radius 
of >_8 indicates complete denaturation. 
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These results therefore suggest that there is no significant difference in stability 
between the WT and G394R apo-proteins. 
The only real difference shown by light scattering is between the diferric WT and 
G394R proteins. These studies show the G394R mutant to be less thermostable than 
the WT by approximately 5°C. Even though no work has been published on the 
thermo-stability of diferric G394R hSTf, these findings could be explained by a 
weaker binding to the iron atom for the mutant protein than for the WT protein, 
which could lead to a release of iron in this mutant at lower temperatures than for the 
WT, and thus an earlier denaturation. 
6.1.4. Immunodiffusion 
Immunoprecipitation, or immunodiffusion, is a technique that can be used to 
compare the antigenicity of many proteins. Information from this can give an 
indication into whether proteins are folded correctly, or have been modified in a way 
that has affected the properties of its surface. However, like the previous two 
techniques described in this section, immunoprecipitation is more of a qualitative 
than a quantitative tool. 
This technique relies upon the diffusion of a multivalent antigen towards either a 
divalent (IgG) or multivalent (IgM) antibody in agar. If both molecules 
immunochemically react, large antibody-antigen complexes give rise to a molecular 
lattice that is too large to remain in solution, causing the formation of an 
immunoprecipitin line. In double immunodiffusion, when two antigens are diffused 
towards a single antibody, two immunoprecipitin lines can form if both antigens 
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react with the antibody. How both of these lines meet gives an indication of how 
immunochemically similar the two antigens are. If both lines meet, the two antigens 
are suggested to be immunochemically identical, whereas, if both lines cross, the two 
antigens are suggested to be immunochemically non-identically. When one line fuses 
and one does not, this suggests partial identity. The antigen that fuses shares all its 
determinants with the second one. However, all the determinants on the second one 
are not all shared with the first one (Wilson and Walker, 2000). 
Using the protocol described in section 2.4.8, immunodiffusion slides were set up to 
compare the immunochemical similarity of all four proteins: native WT, native 
G394R, recombinant WT and recombinant G394R proteins in both their apo- and 
diferric- forms. All proteins were made either apo or diferric following the protocol 
described in section 2.3.5. As with the EPR study, both of the recombinants used 
were fully processed. The results from this study are shown in Figure 6.15. 
Slides A, B and C are double diffusions of the four proteins in their apo form. 
Although the immuno-precipitin lines obtained are not that sharp, it can be seen that 
all lines fuse together, implying immunochemical identity for all four proteins. Slide 
C, D and E are also double diffusions of the four proteins, but in their diferric forms. 
Again, all lines fuse together infer immunochemical identity. Slide G and H 
compares the apo- and diferric proteins. The reason for repeating the 
immunodiffusion, with apo- and diferric proteins, is to see whether proteins show a 
conformational change between the two forms that could result in the antigenic 
determinants on their surface being altered. No difference could be seen between the 
two forms. 
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Figure 6.15. Immunodittusion study of both native and recombinant, WT 
and G394R mutant hSTfs. S: Sheep Anti-hSTf serum, -ve: MilliQ Water, 1: 
Native WT hSTf, 2: Native G394R hSTf, 3: Recombinant WT hSTf, 4: 
Recombinant G394R hSTf and -Fe: Diferric. 
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From this immunodiffusion study, it can be concluded that all four of the proteins 
have the same immunochemical determinants on their surface under either their apo- 
or diferric forms. This therefore suggests that both recombinants are correctly folded 
and that the surface antigenic determinants on WT and G394R proteins are identical 
in agreement with Evans et al, (1982) who previously reported that the structural 
change present in the C-lobe of the G394R mutant could not be detected by 
immunological tests. 
6.2. Functional Characterisation 
Four different techniques were used in this section to compare the functional 
characteristics of these four proteins: Urea PAGE, UV-Visible Scanning 
Spectroscopy, Isothermal Titration Calorimetry (ITC) and a Cell Proliferation Assay. 
6.2.1.6M Urea PAGE Analysis 
Urea PAGE electrophoresis is a technique (Makey and Seal 1976, Williams et al 
1978) whereby the four forms of hSTf, iron-free, C-terminal monoferric, N-terminal 
monoferric, and diferric hSTf, can be resolved due to their increasing mobility 
through the gel. 
This difference in migration is a result of variations in charge and shape between the 
four forms of the protein. The binding of each ferric ion decreases the charge on the 
protein by 1 due to the ionisation of the tyrosine residues, along with the binding of 
the bicarbonate anion, thus increasing the proteins mobility. The presence of 6M- 
urea causes the iron-free domains to unfold, which decreases the mobility of iron- 
free transferrin, and the two monoferric transferrins, relative to that of the iron- 
271 
6: Characterisation of Recombinant/Native hSTf Peter J Sargent 
saturated protein. Even though both monoferric forms are located in between the apo 
and diferric forms, Evans and Williams showed in 1980 that, due to the structure of 
transferrin, they both migrate slightly differently from each other, with the N-lobe 
monoferric having the highest mobility. The technique of 6M urea PAGE can 
therefore be used to study the binding of iron to and the release of iron from 
transferrin. 
Using the protocol described in section 2.4.14 all six of the proteins in both their apo 
and diferric forms, including the fully and partially processed fractions of the 
recombinant proteins, were analysed by 6M Urea gel PAGE (Figure 6.16). In order 
to test these proteins for their ability to bind and release iron, all proteins were 
initially fully saturated with iron using the protocol described in section 2.3.5 and 
then a fraction of this diferric protein was then made apo using the protocol 
described in that same section. 
Gel A (Figure 6.16) illustrates the different forms of the WT native and recombinant 
proteins, which imply the ability to bind and release iron for all three proteins. 
However, all three of the proteins migrate slightly differently from each other. Both 
of the recombinant proteins do not migrate as far as the native protein and fraction 1 
does not migrate as far as fraction 2 of the recombinants. A probable reason for these 
differences could be the absence of the N-linked glycosylations on the recombinant 
proteins. Of the total serum hSTf, 80% is under tetrasialotransferrin form, carrying 
therefore 4 supplementary negative charges due to the four terminal sialic acid 
groups (Rosalki, 2004 and Jamieson et al, 1971). As a result, the net charge of 
recombinant transferrin molecules on 6M urea PAGE (pH 8.4), which do not have 
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Figure 6.16.6M Urea PAGE to study the iron-binding capabilities of native 
and recombinant, WT and G394R hSTfs. Gel A: Recombinant and native WT. 
Gel B: Recombinant and native G394R. Apo: Apo-transferrin. 2Fe: Diferric- 
transferrin. 
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any sialic acids, will be increased by four extra positive charges, reducing the 
mobility of molecules during electrophoresis towards the cathode. The difference 
between the two recombinant fractions could also be due to a charge difference. As 
discussed in section 5.1.5, the recombinant protein fraction 1 contains the partially 
processed leader sequence (RSLDKR) and has therefore two extra charges when 
compared to the correctly processed protein. Such a difference could also result in 
the shorter migration distance observed in these results. 
Gel B (Figure 6.16) illustrates the different forms of the iron bound G394R native 
and recombinant proteins. The behaviour of these proteins on this gel can be seen to 
be very different to the proteins on Gel A. All apo-forms of these proteins are shown 
to run normally when compared to the WT native protein, with the exception of the 
recombinant forms running slightly behind the native forms as expected from the 
above discussion. However, all of the G394R diferric samples run more like 
monoferrics. This is consistent with previous work on the naturally occurring G394R 
mutant by Evans et al, 1982 who reported that the variant was able to bind two atoms 
of iron, but that the iron in the C-terminal binding site was bound abnormally and 
was released from the protein during electrophoresis in the presence of 6M-Urea. 
These results therefore suggest that the recombinant mutants are binding iron in a 
similar way to the native mutant. 
6.2.2. UV-Visible Scanning Spectroscopy 
UV-Visible scanning spectroscopy is a common technique used to study iron binding 
and release by transferrins. Lehrer (1969) reported that, following scanning of hSTf 
over the spectral range from 250 to 600nm, characteristic peaks in the region of 
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tyrosine and tryptophan absorption indicated perturbation of these chromophores by 
the binding of metal ions. More specifically, binding of Fe3i' and Cu 2+ yielded peaks 
at around 470nm and 440nm respectively. Therefore, it is possible to obtain a 
characteristic fingerprint of ironbound transferrin and also to determine the iron- 
binding capacity of the protein by titration of iron until saturation occurs. 
Using the protocol described in section 2.4.15 each of the four proteins: WT native, 
WT recombinant, G394R recombinant and G394R native were scanned from 350 to 
600nm, repeating the scan for each titration of FeNTA (Figure 6.17 and 6.18). 
Proteins were made apo using the protocol described in section 2.3.5. These spectra 
show a characteristic peak in absorbance around the 420-480nm region for all four 
proteins, with each titration causing an increase in absorbance around this range until 
protein saturation occurs. This stepped increase in absorbance, following FeNTA 
titration, is indicative of the protein's ability to bind iron. 
When comparing the spectral data collected from the iron-saturated proteins (Figure 
6.19), a number of differences can identified between the proteins. One major 
difference was the final absorbance attained, which can be explained by a slightly 
different concentration for each sample. Measuring the absorbance of each protein in 
its apo-form at 280nm, and using the equations in section 2.4.15, its protein 
concentration could be calculated. It was then possible to calculate the theoretical 
absorbance at 470nm using the same equations. This theoretical absorbance value 
can give an indication of how much of the protein is binding iron. If there is 100% 
binding, the observed absorbance at 470nm should be close to the calculated 
theoretical value (approximately 19 times less than the absorbance of the apo protein 
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Figure 6.17. Scanning UV-visible spectra (350-600nm) of iron-free WT 
native (A) and WT recombinant (B) hSTf following titration with 5µI 
aliquots of 0.01M FeNTA until proteins become iron saturated. 
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Figure 6.18. Scanning UV-visible spectra (350-600nm) of iron-free 
G394R native (A) and G394R recombinant (B) hSTf following titration 
with 5µl aliquots of 0.01M FeNTA until proteins become iron 
saturated. 
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Figure 6.19. Scanning UV-visible spectra (350-600nm) of diferric WT 
native (black), WT recombinant (red), G394R recombinant (blue) and 
G394R native (green) hSTf. The actual absorbance of apo protein at 
280nm and peak absorbance between 440-470nm when iron saturated is 
stated in the above table, and the theoretical 470nm maximum for all four 
proteins, based on their 280nm absorbance, is highlighted on the chart. 
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at 280nm). For each of the four proteins, the theoretical absorbance at 470nm was 
therefore compared with the actual peak absorbance between 440-470nm. These 
results showed that on average, approximately 96% of all proteins bound iron. 
However, this data was skewed slightly, since the WT native hSTf only had an 
88.6% binding capability. Since this protein is known to be of a high degree of 
purity, the reason for this observation is unclear, but could probably be due to the 
way this protein was handled during or after purification. 
The second major difference seen between the four proteins is a shift in the peak 
wavelength. Both WT proteins had an absorbance maximum between 460 to 465nm, 
whilst both mutants had an absorbance maximum further to a lower wavelength, 
around the 443nm. This observation is consistent with the findings of Evans et al, 
(1982) who found the fractionated native G394R protein to have an absorbance 
maximum at 435nm. In the case of unfractionated native G394R hSTf, it was shown 
that the absorption maximum was at 448nm. Evans et al, (1994) proposed later that 
this blue shift in the visible spectrum could be due to the interaction of R394 with 
D392. This explanation is consistent not only with the spectral data obtained for a 
D62 mutant by Woodworth et al, in 1991, but also with data for the N-lobe 
equivalent of D392 and an 18Kda fragment of duck ovotransferrin that was yellow in 
colour (Evans and Madden in 1984). 
6.2.3. Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) is a thermodynamic technique for monitoring 
any chemical reaction initiated by the addition of a binding component. In this 
system, when two molecules interact, heat is either generated or absorbed, depending 
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on whether the interaction is exothermic or endothermic. By accurately measuring 
this change in heat, ITC can allow accurate determination of the association 
constants (Ka), reaction stoichiometry (n), free energy (OG), enthalpy (tH) and 
entropy (OS). Therefore ITC can provide a complete thermodynamic profile of 
molecule interactions. 
The ITC machines works by maintaining the temperature of two cells using a 
feedback system. These two cells are designated the sample cell, containing the 
macromolecular solution of interest, and the reference cell, containing either buffer 
or water. During the injection of titrant into the sample cell, heat is taken up or 
evolved depending on whether the macromolecular association reaction is 
endothermic or exothermic. In an exothermic reaction, the temperature of the sample 
cell will increase and the feedback power will be deactivated to maintain equal 
temperatures between the cells. For an endothermic reaction, the opposite will take 
place. That is, the feedback power will be turned on (Pierce et al, 1999). During an 
ITC experiment, the direct observable measurement is the time-dependent input 
required to maintain equal temperatures in the sample and reference cells (pcal/s). As 
successive amounts of the ligand are titrated into the cell, the quantity of heat 
absorbed or released is directly proportional to the amount of binding occurring with 
time. As the system reaches saturation, the signal diminishes until only heats of 
dilution are observed. A binding curve is then obtained from a plot of the `heats' 
from each injection against the ratio of ligand and binding partner in the cell. From 
this curve, thermodynamic data for the molecular interactions and stoichiometry can 
be calculated. 
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Before analysing of the four proteins, apo preparations of native WT, native G394R, 
recombinant WT and recombinant G394R were made using the protocol described in 
section 2.3.5. Using the protocol described in section 2.4.9, all four hSTf proteins 
were then titrated separately with FeNTA in a VP-ITC (MicroCal, USA) calorimeter 
and the energy required to stabilise the temperature of the two cells, following each 
titration, recorded. The results from each titration are shown in Figure 6.20,6.21, 
6.22 and 6.23, for each of the four proteins, respectively. Each of these figures shows 
the differential power signal recorded during each experiment (gcal/sec versus time) 
(top) and a sigmoidal plot of kcal/mole versus molar ratio (below). This sigmoidal 
plot data was calculated from the integration of each differential power signal peak. 
The line of `best fit' was generated automatically using the ORIGIN software, with 
slight manual adjustments to take into account experimental error. 
The four figures show two major characteristics of these reactions. Firstly, the 
differential power signal indicates that iron binding by each protein is an exothermic 
event, since the ITC machine reduces its power input into the cell following each 
titration. This is indicative of the machine attempting to compensate for heat 
generated by the reaction. These results are consistent with published data for 
ovotransferrin (Mason et al, 1996). It can also be concluded from these figures that 
more than one binding event is occurring since the molar ratio at the point of 
inflection of the sigmoidal curve is greater than 1.5. A theoretically value of 2, which 
should have been obtained, is in fact rarely achieved due to experimental error and 
data interpretation difficulties. In reality, the number of binding events is generally 
calculated by rounding-up the molar ratio at this point. 
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Figure 6.20. ITC data of native WT hSTf being titrated with FeNTA up 
to and beyond saturation. A: Differential power signals during titration of 
hSTf with FeNTA. B: Integrated differential power signal data plotted as a 
sigmoidal curve. 
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Figure 6.21. ITC data of recombinant WT hSTf being titrated with 
FeNTA up to and beyond saturation. A: Differential power signals during 
titration of hSTf with FeNTA. B: Integrated differential power signal data 
plotted as a sigmoidal curve. 
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Figure 6.22. ITC data of native G394R hSTf being titrated with FeNTA 
up to and beyond saturation. A: Differential power signals during titration 
of hSTf with FeNTA. B: Integrated differential power signal data plotted as a 
sigmoidal curve. 
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Figure 6.23. ITC data of recombinant G394R hSTf being titrated with 
FeNTA up to and beyond saturation. A. Differential power signals during 
titration of hSTf with FeNTA. B: Integrated differential power signal data 
plotted as a sigmoidal curve. 
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From these sigmoidal curves, the ORIGIN software automatically calculates the 
thermodynamic parameters for each reaction. A comparison of these parameters is 
shown in Table 6.1 along with iG parameters and dissociation constants (Kd). OG 
(Gibbs free energy) can be calculated using either equation 3, or equation 4) 
(Jelesarov and Bosshard, 1999) and Kd is simply 1/KA. Two sets of parameters are 
shown for each protein (e. g. N1 and N2), corresponding to the two binding sites. 
OG=-RTInKA [31 Or... 
OG = AH-TOS [4] 
-R = gas constant (8.314 J K-1 mol-1) 
-T = Absolute temperature 
in degrees kelvin 
-AH = Change in Enthalpy 
-AS = Change in Entropy 
The first observation from these parameters is that the values of N1 and N2 vary quite 
substantially between proteins. Apart from the N1 parameters for recombinant WT 
and native G394R proteins, all other N parameters are above 0.68. This is consistent 
with the observation made from the sigmoid curve that more than one binding event 
is occurring. The reason for the Ni parameters for recombinant WT and native 
G394R proteins being lower than 0.5 is most likely due to experimental error and 
difficulties in fitting the sigmoid curve to the data points. Taking into account the 
margins of error stated in Table 6.1, N1+N2 for all four proteins can be calculated to 
be close to 2. 
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hSTf Native Error Recomb Error Native Error Recomb Error 
Paramaters 
Temperature 25.0161 - 25.0145 ? 5.0125 '>. 0086 - 
(°C) (T) 
Temperature 298.176 - 298.174 - 298.172 - 298.168 - 
(Kelvin) 
Tl, 0.7124 0.1993 0.4421 0.1180 0.4833 0.1358 0.6884 0.0243 
K, (M") 7.95x10 6.0x10 1.99x10 2.5x10 5.97x10 3.2x10 1.56x10 1.4x10 
Kd (M") 1.3x10" 5.0x10 1.7x10' 6.4x10' 
AH, -4340 3106 -4229 1815 -5914 1187 -6407 198.6 
(J mol") 
AS, 17.02 - 19.22 - 11.17 - 11.43 - 
(J K" Mol") 
OG, -39.3 008 1.4 -41.6717 2.0 -38.6801 1.1 -41.0713 0.2 
(kJ mol") 
N2 0.9185 0.2174 0.9822 0.1236 1.234 0.1449 0.7708 0.0259 
K2(M" 4.16x10 4.1x10 8.42x10 9.3x10 5.82x10 2.5x10 1.42x10 3.0x10 
Kd (M' 2.4x10" 1.2x10" 1.7x10" 7.0x10" 
AH2 -7674 1275 -8051 468 -7828 179 -9131 103.9 
(J mol") 
OS2 9.124 - 9.259 - 4.7 - 6.687 - 
(J K" Mol' I) 
A G2 -43.4954 1.7 -45.2410 1.8 -38.6146 1.1 -40.8412 0.5 
(kJ mol-') 
Table 6.1. Calculated parameters for ITC titration of FeNTA into native WT-, 
recombinant WT-, native G394R- and recombinant G394R hSTf. All parameters 
and margin of error, apart from OG data, were calculated automatically by ORIGIN 
(MicroCal) software. 
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From these experiments, association constants (KA) and dissociation constants (Kd) 
can be calculated. However, for very tight binding reactions, when KA is higher than 
109 M"1, even the most sensitive of ITC instruments cannot accurately calculate 
binding constants (Jelesarov and Bosshard, 1999). Therefore, these results are more 
for comparative purposes rather than accurate measurement of binding constants. 
Even so, the results obtained in these studies for both the WT recombinant and native 
proteins are very similar to the results published by Lin et al, 1993. The small 
differences between the two studies are probably due to slight differences in 
experimental temperature (25°C vs 27°C) and buffers. 
When both the KA and Kd for both WT proteins, and for each binding event are 
compared, it can be seen that there is on average a 10 fold difference in binding 
affinity between the two binding sites. This is again consistent with the results 
published by Lin et al, 1993 and can possibly be explained by the C-lobe having a 
stronger affinity for iron than the N-lobe (Aisen et al, 1978). Therefore, in the case of 
these WT proteins, Kl is likely to correspond to the N-lobe, whilst K2 probably 
corresponds to the C-lobe. In the mutant proteins however, even though the values 
for Kl are similar to the KI values for the WT proteins, their K2 values are between 6 
to 7 times lower than the WT proteins K2 values. In fact, the K2 values for the mutant 
proteins are actually lower than their Kl values. These findings are consistent with 
the work published by Evans et al, 1982, in that the G394R mutation seems to have 
reduced the iron binding affinity of the C-lobe. There also seems to be a slight 
difference between the native and recombinant proteins. For both the WT and mutant 
proteins, the recombinant proteins are shown here to have on average a 2.4x stronger 
iron binding affinity. 
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When the OH values for each protein and for both binding sites are compared, it can 
be seen that all iron-binding events are exothermic. However, the amount of energy 
produced from each binding event varies. iHl for the WT proteins is shown to be on 
average 2-fold higher than OH2 and 1.4-fold greater than AH2 for the mutant proteins. 
This is again consistent with Lin et al, 1993, and not with the observations of Binford 
and Foster, 1974, who suggest that the binding enthalpies for the N- and C-lobes are 
the same. Therefore, since both lobes are different, this suggests that they are both 
thermodynamically and kinetically different. When comparing the mutant to the WT 
proteins, the G394R mutation is shown to decrease OH for both lobes by 
approximately 1.2-fold. Interestingly this decrease is not just in the C-lobe, where the 
mutation is present, but actually can be seen in both lobes, which suggests that that 
both lobes are probably interconnected and influenced by each other. 
Since enthalpy (OH), expressed as J mole t, can be related directly to the amount of 
energy required to break one mole of bonds between pairs of atoms, it can be 
concluded that a negative AH indicates the net increase in atomic interactions. From 
this, it can then be postulated that more molecular interactions are occurring in the 
G394R protein upon binding iron. 
The values for entropy (OS) also varies between proteins and between sites. These 
studies show approximately a 2-fold decrease in AS between the N-lobe and C-lobe 
for all four proteins. This suggests that more disorder is occurring in the N-lobe 
during iron binding, compared to the C-lobe. Another way of looking at this is the N- 
lobe could be seen to be more flexible than the C-lobe on binding iron. A possible 
reason for this could be due to the C-lobe having a tighter binding affinity for iron 
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(section 1.3.4), therefore restricting movement of the two domains. Another reason 
could be the larger number of atomic interactions in this lobe on iron binding, shown 
by a lower iH. It is known however, that the N-lobe is more stable than the C-lobe 
to themal-denaturation (Donovan and Ross, 1976) and during electrophoresis on a 
6M-urea gel (Evans et al, 1980), probably due to it having a higher number of 
disulphide bonds. Therefore, the stability of the N-lobe is probably more to do with 
the folding of the individual domains, rather than the flexibility of both domains 
together. It can also be seen by this study that the G394R mutation has resulted in a 
1.6 fold decrease in AS in both lobes. Since a decrease in AS is indicative of an 
increase in molecular rigidity, it can therefore be interpreted as the G394R mutation 
restricting the movement of both domain in the C-lobe, but also reducing movement 
in the N-lobe. 
Finally, the last parameter calculated from these ITC studies is OG. Since iH is 
negative for all binding events and AS is positive, OG will always be negative at any 
temperature of the reaction. Such a reaction will be spontaneous at all temperatures 
(Sutton et al, 2000). Since the WT proteins have a lower OG than the G394R mutant 
proteins, this suggests that the WT proteins have a greater ability to bind iron. This 
data also shows that for the WT proteins, the C-lobe has a greater tendency to bind 
iron than the N-lobe. However, for the mutant protein, this is reversed. 
6.2.4. Cell Proliferation Assay 
The abilities of the recombinant proteins to bind and release iron has been 
established in this study, but their ability to deliver iron to cells through receptor- 
mediated endocytosis has not yet been demonstrated. Therefore, the aim of this 
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section was to test the recombinant and native proteins in their ability to fulfil such a 
function. However, due to the lack of native G394R hSTf, this protein was not 
included in this part of the study and the only proteins to be investigated were the 
native WT hSTf, recombinant WT hSTf and the recombinant G394R hSTf. 
Since iron is essential for cellular proliferation, its availability has a direct effect on 
growth rate (Trowbridge and Shackelford, 1986). Therefore, by using these three 
different hSTfs as the main source of iron in cell culture, their efficiency to deliver 
iron to the cells by receptor-mediated endocytosis can be determined by measuring 
levels of cell proliferation. In order to measure these levels of cell proliferation, a 
BrdU cell proliferation assay (Roche Applied Sciences) was used. This assay is 
based on the measure of DNA replication in cell proliferation before the cell divides 
into two daughter cells. By adding a labelled DNA precursor such as 5-Bromo-2'- 
deoxyuridine (BrdU) to the cell culture during cellular proliferation, cells take it up 
and incorporate it into the newly synthesised DNA. Therefore, as cellular 
proliferation increases, so will the amount of DNA and so will the amount of BrdU 
incorporated. This incorporated BrdU can then be detected by a quantitative cellular 
enzyme linked immunoassay using monoclonal antibodies directed against BrdU. 
Using the protocol described in section 2.3.5, diferric preparations of the three 
different proteins were made together with an apo preparation of the native WT hSTf 
to be used as a negative control. These four proteins, together with a control of foetal 
bovine serum (FBS), were tested individually in collaboration with Dr Heinz Zoller 
(Department of Medicine, University of Cambridge), using the protocol described in 
section 2.4.2, for their ability to stimulate cell proliferation in two different cell lines. 
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The first cell line were Chinese hamster ovary (CHO) (TRVb-1) cells that lack both 
endogenous transferrin receptors, but since being transfected with TfRl cDNA, 
stably expresses only TfR1 (Carlson et al, 2005). This allows the study to focus on 
protein interactions with only one receptor. The second cell line used was a human 
hepatoma cell (HepG2). These cells were used as a control as they express both 
human receptors for transferrin and human asialoglycoprotein receptor (Popovic and 
Templeton, 2004). Each of these studies were repeated five times, with each data set 
then averaged. 
Figure 6.24 shows that all three diferric proteins significantly stimulate TRVb-1 and 
HepG2 cell proliferation more than apo-hSTf indicating that both of the recombinant 
proteins and the native protein are able to deliver iron to cells. However, their 
efficiency is shown to vary slightly with the most efficient being the native WT, 
followed by the recombinant WT and then the recombinant mutant. This result is 
consistent with published data from Evans et al, 1994, where they suggest that native 
G394R hSTf has a reduced affinity for the transferrin receptor. Alternatively, this 
difference may not be significant as the error bars for each of the three proteins are at 
similar levels. Therefore, no major difference can be seen from these results that 
show that all three proteins are able to deliver iron to TRVb-1 and HepG2 cells 
through receptor-mediated endocytosis. The ability of the recombinant protein to 
deliver iron to cells is important, since a pathogen free replacement of native 
transferrin in cell line supplements is advantageous. 
It is worthy of notice that the proliferation stimulation observed with FBS on HepG2 
cells is not observed with TRVb-1 cells. The effect of FBS on TRVb-1 proliferation 
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Figure 6.24. A BrdU assay to show the effect of using native and 
recombinant hSTf, including recombinant G394R hSTf, on the cellular 
proliferation of TRVb-1 (blue) and HepG2 (brown). The data shown is an 
average of five data sets. 
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is similar to that of apo-hSTf, suggesting that HepG2 cells have a greater ability than 
TRVb-1 cells in taking up iron and other essential nutrients from FBS. One possible 
reason for this could be due to the HepG2 human cells having a closer similarity to 
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Amongst the Transferrin family, hSTf is now one of the best-characterised proteins. 
However, the mechanism by which it binds and releases iron, together with how it 
interacts with its receptors, is still poorly understood. Therefore, in order to further 
elucidate the structural and functional characteristics of hSTf, these studies focussed 
on the use of techniques such as computational analysis, recombinant expression and 
biophysical / biochemical analysis to attempt to address these fundamental questions. 
As discussed in Chapter 4, two different cell types were explored for the creation of a 
recombinant expression system able to provide routinely the high amount of hSTf 
necessary to study its structure and function. The first to be explored was E. coli, due 
to the ease with which it can be manipulated and grown, and also the plethora of 
expression vectors available for use in such a system. The second type of system 
explored was S. cerevisiae. Even though these are not as easy to manipulate, as E. coli 
and only few expression vectors are available for use with such cells, a highly 
developed expression system provided by Delta Biotechnology Ltd was available. 
The expression of the full-length (De Smit et al, 1995) and separate lobes (Steinlein 
and Ikeda, 1993) of hSTf has been reported in E. coli. However, this published work 
suggests that the expressed hSTf forms inclusion bodies and that protein refolding 
and purification of functional protein was difficult. The formation of such inclusion 
bodies probably occurs due to incorrect protein folding and is either due to the cells 
attempting to express hSTf at too high a level, or the fact that hSTf contains nineteen 
disulphide bonds that cannot be formed in E. coli. 
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The fact that these proteins have formed inclusion bodies due to improper folding 
could be one of the reasons why hSTf expression in E. coli was unsuccessful in this 
study. Since the majority of expression attempts in E. coli were carried out using 
Origami® cells, strains that carry mutations in both the thioredoxin reductase (trx13) 
and glutathione reductase (gor) genes, the formation of disulfide bonds in the 
cytoplasm is supposedly `greatly enhanced'. If disulphide-bond formation is 
occurring in these cells, there is a chance that correctly folded active hSTf is being 
expressed within the cytoplasm. However, these active proteins could actually be 
having a bacteriostatic effect on the cells by chelating all the surrounding iron, 
inducing a selective pressure that would prevent them from expressing either hSTf or 
hLf, even as inclusion bodies. Using constructs containing the OmpT leader 
sequence could also increase this selective pressure, since this fusion leader directs 
expressed proteins into the periplasm, increasing protein solubility and enhancing 
protein folding. However, this phenomenon does not explain the lack of expression 
by the BL21 strains. 
Unlike attempts using E. coli, hSTf expression was successful using S. cerevisiae. 
Following analysis of the culture supernatant, the transferrin yield for WT rhSTf 
fermentation was -1.82mg/mL and for G394R rhSTf fermentation was -1.7mg/ml. 
These levels are higher than any previously reported for transferrin, with the closest 
being by Mizutani et al, 2004, who reported levels up to 100mg/L of ovotransferrin 
using Pichia pastoris. However, these levels were achieved in a shake flask and not 
under the tight control of a fermenter as in these studies. 
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The purification of recombinant hSTf was achieved using a variety of 
chromatographic techniques. Initial purification, used two ion-exchange columns, but 
produced an eluate that still contained contaminants and only retained an average of 
54% of the recombinant protein loaded. This loss of hSTf can be attributed to the 
overloading of the columns and their limit binding capacity. In contrast with the first 
one, the second purification step, using the immunoaffinity column, was very 
efficient. By determining a more accurate binding capacity, very little protein was 
lost and a degree of purity close to 100% was achieved. Such results confirmed that, 
for research purposes, recombinant hSTf could in the future be purified in a one step 
process using immunoaffinity chromatography. 
Following native PAGE, mass spectrometry and N-terminal sequencing, the pure 
preparations or recombinant hSTf were shown to comprise of two species. One of 
these species was fully processed whereas the second one was only partially 
processed, with a six amino acid residual fragment of the fusion leader on its N- 
terminal. Paradoxically, the incomplete processing of all expressed proteins could be 
due to the extreme efficiency of the system at the transcription and translation levels. 
The presence of these two species could be that the cells express hSTf faster than 
they are able to process it. In the future, this could possibly be prevented by either 
reducing the growth rate or, at a genetic level, by experimenting with different fusion 
leader sequences. For our purpose, the two species were resolved using FPLC 
MonoQ ion-exchange chromatography. 
Even though only -20% of proteins loaded onto the FPLC MonoQ were recovered a 
homogeneous sample of each form was achieved. This low level of protein recovery 
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was due to incomplete resolution of the hSTf forms. In fact, the elution profiles show 
each fraction to contain varying amounts of both species as the salt gradient 
increases. This suggests that these proteins are not just separated on the base of their 
charge differences due to the partially processed leader sequence, but also due to 
other factors. The heterogeneous glycosylation of the proteins should not have any 
effect since the glycosylations are 0-linked mannoses that do not carry charges. 
However, these sugars could be interacting in a non-specific manner with the gel 
matrix due to the age of the column and therefore the build up of material within it. 
When the native and recombinant forms of WT and G394R mutant proteins were 
compared, all structural and functional characteristics explored in this study, suggest 
that these recombinant proteins, even with partially processed fusion leaders, mimic 
almost identically their native form. The only difference seen is a 2-fold increase in 
iron-binding affinity exhibited by the recombinant proteins. Since it is unlikely that 
the presence of N-linked glycosylations on the native proteins would reduce their 
affinity for iron, the most likely reason would be experimental error. In fact, the 
amount of error calculated for the recombinant Kd values is on average significantly 
higher than the values for native hSTf. Regardless of this, these results imply that the 
S. cerevisiae expression system obtained is an ideal tool for the production of 
functional hSTf, in both WT and variant forms. 
As expected, differences in structural and functional characteristics can be observed 
when comparing the WT and the G394R forms. Even though there is no significant 
change in secondary structure, far UV CD spectra suggests that there is a significant 
change in the tertiary structure of hSTf upon binding to iron with a stronger effect 
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detected with the G394R mutation. These differences between mutant and WT hSTf 
are also confirmed by EPR spectroscopy and the blue-shift seen in the scanning UV 
spectra of the two diferric proteins. By compiling the EPR data from this study with 
spectra published by Aisen et al, in 1978, it can be postulated that these changes are 
directly related to distortions in the C-lobe's iron-binding site. 
Results obtained using light scattering and 6M urea PAGE, show that the presence of 
R394 has reduced the protein's structural stability. Possible reasons for this could be 
either the 6-7-fold reduction in the C-lobe Kd, obtained by ITC analysis, or the 
weakening of residue interactions holding the C-lobe domains together. However, 
Evans et al, 1982 reported that the C-lobe of the iron-free variant is less stable than 
the C-lobe of the iron-free WT protein, suggesting that the reduction in stability is 
not directly due to a lowered affinity for iron, but possibly also due to residue 
interactions elsewhere in the C-lobe. This could also explain why the ITC data show 
a reduction in the LH for variant's C-lobe, since more energy would be produced 
taking the iron-free C-lobe from its more unstable open form, to its iron-bound, 
closed form. 
The model created in Chapter 3 confirms that R394 is not directly involved in iron 
binding, nor does it seem to be involved in receptor binding. Evans et al, 1994 
suggested that residue R394 is interacting with residue D392, one of the iron-binding 
residues, thus perturbing the iron-binding site. However, these studies suggest that 
the mutation is causing a much larger effect, not only on the iron-binding site, but on 
the whole C-lobe, with subtle repercussions on the N-lobe. 
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Since the AS of the variant's C-lobe indicates an increase in domain rigidity and the 
lowered AH indicates an increased number of molecular interactions, rather than 
R394 interacting with D392, it can be postulated from the hSTf model that the 
positive side chain of R394 could be interacting with residues away from the iron- 
binding site and towards the region where domains 1 and 2 hinge in the C-lobe 
(figure 3.15). These interactions could in turn be restricting the flexibility of the two 
domains, preventing them from efficiently closing over the iron atom. If the two 
domains are being obstructed, this could explain the distortion of the tertiary 
structure seen when the protein binds iron. 
Interestingly, it is also around this region of the C-lobe (region 91, Figure 3.21) that 
hSTf is thought to interact with the helical domain of TfR1 (Cheng et al, 2004). This 
could therefore explain the 10-fold reduced affinity of the variant for the TfR1 (6.25 
± 2.53x107 mol"1) in its diferric form (Young et al, 1984a). In fact, the binding 
affinity for the receptor is similar to that shown for monoferric hSTf (2.5-4.6x101 M" 
1) (Young et al, 1984b). The suggestion that the variant's C-lobe is adopting a more 
open structure, as suggested in section 5.1.3.3 based on the proteins mobility on 
native PAGE, the interaction with the receptor could be comparable to that of an N- 
monoferric. However, since the C-lobe of diferric G394R hSTf is not as open as it 
would be in the apo-form, this could explain why the affinity for the receptor is 
slightly stronger than that for the N-monoferric. 
The proposal that the G394R mutation is perturbing the N-lobe can also be explained 
by this hypothesis, since the proposed distorted region is in close proximity to where 
both lobes make contact via a `cushion' of hydrophobic residues packed between 
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them. A distortion in the tertiary structure of the C-lobe on binding iron could 
therefore possibly affect this interaction, causing the subtle alterations in the N-lobe 
suggested by the thermodynamic data collected during these studies. 
To briefly summarise the work presented in this thesis, it can be said that after 
having established an extremely successful expression system, which is envisaged 
can be exploited for the expression of numerous other eukaryotic proteins, the 
comparative analysis and characterisation of both WT and mutant proteins, in 
combination with the predicted 3D model obtained by computer study, have enabled 
a step close to be made towards solving the mechanism of iron-uptake and -release 
by transferrin. Further in depth investigations are necessary to solve the entire 
mechanism, and the most obvious extension to these studies would be to obtain a 
high-resolution crystal structure of diferric and apo-hSTf, followed by the elucidation 
of the structure of the G394R hSTf variant. Unfortunately, the difficulties 
encountered in the crystallisation of these proteins suggest that it is necessary to 
explore alternative approaches towards gaining a full understanding of hSTf. One of 
the main tools now available at the conclusion of our study is the yeast expression 
system and the access to literally unlimited number of variants obtainable by site- 
directed mutagenesis. One of the numerous example of such an approach would be to 
express mutant proteins in an attempt to recreate the same effect as the one observed 
with G394R variant, but without being in such a close proximity to the iron-binding 
site. Such results would confirm that residue R394 does not directly interact with the 
iron-binding site, but causes the C-lobe domains to adapt a less dynamic and open 
structure. Several mutant variants could also be designed in order to investigate 
further the inter-dependence of both lobes. For example, the different 
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thermodynamics obtained for each lobes following ITC analysis, could be further 
investigated using such variants. Any variation of the data attributed to one lobe 
following mutation introduced in the other one would confirm and define 
thermodynamically such interdependence. The availability of specific variants will 
also be an invaluable tool for the comparative studies of interactions between hSTf 
and chelators, and their competitive iron binding properties. Variants could also be 
used to define hSTf/TfR1 interactions, which still remain unclear. Probing the TIRI 
peptide library with the variant protein could also help in the interpretation of the 
variants abnormal properties by seeing whether there is a reduction in the affinity of 
hSTf to region 91 (Figure 3.21). Defining receptor/protein interactions will be 
important not only for understanding the mechanism for fundamental and medical 
purposes, but also as a research tool since hSTf in now widely used as growth factor 
in cell culture. Indeed, a better understanding of their interactions might provide a 
better tuning and monitoring of growth. 
It is satisfying that, although this work has not provided a complete deciphering of 
the mechanism of iron-uptake and -release, it has undoubtedly produced the most 
essential tools for such an aim, and has allowed us to move one step closer to the 
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Appendix I: Computational Analysis 
1.1. Human Serum Transferrin Sequence 
The sequence of hSTf with the leader, the two lobes, the bridge and the two domains 
highlighted. Also highlighted, are the 38 cysteines thought to be involved in 
disulphide-bridge formation (grey), the eight residues theorised to be involved in 
Fei' binding (red) and the eight residues thought to be involved in the carbonate 
binding (turquoise). 
1 gcacagaagc gagtccgact gtgctcgctg ctcagcgccg cacccggaag 
ThrGlu AlaSerProThr ValLeuAla AlaGlnArg ArgThrArgLys 
51 atgaggctcg ccgtgggagc cctgctggtc tgcgccgtcc tggggctgtg 
-19 MetArgLeu AlaValGly 
AlaLeuLeuVal CysAlaval LeuGlyLeu 
start -------------- Leader Sequence------------------- 
101 tctggctgtc cctgataaaa ctgtgagatg gtgtgcagtg tcggagcatg 
-3 CysLeuAlaVal ProAspLys 
ThrValArg TrpCyaAlaVal SerGluHis 
--------- t ---------- N Lobe ----------------------------- 
151 aggccactaa gtgccagagt ttccgcgacc atatgaaaag cgtcattcca 
15 GluAlaThr LysCysGlnSer PheArgAsp HisMetLys SerValIlePro 
201 tccgatggtc ccagtgttgc ttgtgtgaag aaagcctcct accttgattg 
32 SerAspGly ProSerVal AlaCyiValLys LysAlaSer TyrLeuAsp 
251 catcagggcc attgcggcaa acgaagcgga tgctgtgaca ctggatgcag 
48 CysIleArgAla IleAlaAla AsnGluAla AspAlaValThr Leu-Ala 
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301 gtttggtgta tgatgcttac ctggctccca ataacctgaa gcctgtggtg 
65 GlyLeuVal TyrAspAlaTyr LeuAlaPro AsnAsnLeu LysProValVal 
------------------------------------------------------- 
351 gcagagttct atgggtcaaa agaggatcca cagactttct attatgctgt 
82 AlaGluPhe TyrGlySer LysGluAspPro GlnThrPhe laryrAla 
401 tgctgtggtg aagaaggata gtggcttcca gatgaaccag cttcgaggca 
98 ValAlaValVal LysLysAsp SerGlyPhe G1nMetAsnGln LeuArgGly 
451 agaagtcctg ccacacgggt ctaggcaggt ccgctgggtg gaacatcccc 
115 LysLysSer CyaHis-Gly LeuGly- Ser TrpAsnllePro 
501 ataggcttac tttactgtga cttacctgag ccacgtaaac ctcttgagaa 
132 IleGlyLeu LeuTyrCyl AspLeuProGlu ProArgLys ProLeuGlu 
551 agcagtggcc aatttcttct cgggcagctg tgccccttgt gcggatggga 
148LysAlaValAla AsnPhePhe SerGlySer Cy*AlaProCys AlaAspGly 
601 cggacttccc ccagctgtgt caactgtgtc cagggtgtgg ctgctccacc 
165 ThrAspPhe ProGlnLeuCyi G1nLeuCya ProG1yCys G1ySerThr 
651 cttaaccaat acttcggcta ctcgggagcc ttcaagtgtc tgaaggatgg 
182 LeuAsnGln TyrPheGly 
0SerGlyAla PheLysCys LeuLysAsp 
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701 tgctggggat gtggcctttg tcaagcactc gactatattt gagaacttgg 
198G1yA1aGlyAsp ValAlaPhe Va1LysHis SerThrllePhe GluAsnLeu 
751 caaacaaggc tgacagggac cagtatgagc tgctttgcct ggacaacacc 
215 AlaAsnLys AlaAspArgAsp GlnTyrGlu LeuLeuCyi LeuAspAsnThr 
801 cggaagccgg tagatgaata caaggactgc cacttggccc aggtcccttc 
232 ArgLysPro ValAspGlu TyrLysAspCya HisLeuAla G1nValPro 
851 tcataccgtc gtggcccgaa gtatgggcgg caaggaggac ttgatctggg 
248Serlrhrval ValAlaArg SerMetGly GlyLysGluAsp LeulleTrp 
901 agcttctcaa ccaggcccag gaacattttg gcaaagacaa atcaaaagaa 
265 G1uLeuLeu AsnGlnAlaGln GluHisPhe GlyLysAsp LysSerLysGlu 
951 ttccaactat tcagctctcc tcatgggaag gacctgctgt ttaaggactc 
282 PheGlnLeu PheSerSer ProHisGlyLys AspLeuLeu PheLysAsp 
1001 tgcccacggg tttttaaaag tcccccccag gatggatgcc aagatgtacc 
298 SerAlaHisGly PheLeuLys Va1ProPro ArgMetAspAla LysMetTyr 
1051 tgggctatga gtatgtcact gccatccgga atctacggga aggcacatgc 
315 LeuGlyTyr GluTyrValThr AlaIleArg AsnLeuArg GluGlyThrCys 
---------------------------------------------------- 
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1101 ccagaagccc caacagatga atgcaagcct gtgaagtggt gtgcgctgag 
332 ProGluAla ProThrAsp GluCysLysPro ValLysTrp CysAlaLeu 
=Bridge Region===========-? ---------- C Lobe- 
1151 ccaccacgag aggctcaagt gtgatgagtg gagtgttaac agtgtaggga 
348 SerHisHisGlu ArgLeuLys CysAspGlu TrpSerValAsn SerValGly 
1201 aaatagagtg tgtatcagca gagaccaccg aagactgcat cgccaagatc 
365 LyslleGlu Cy8ValSerAla GluThrThr GluAspCy$ IleAlaLysIle 
1251 atgaatggag aagctgatgc catgagcttg gatggagggt ttgtctacat 
382 MetAsnGly GluAlaAsp AlaMetSerLeu -GlyGly PheValTyr 
1301 agcgggcaag tgtggtctgg tgcctgtctt ggcagaaaac tacaataaga 
398 IleAlaGlyLys CysGlyLeu Va1ProVal LeuAlaGluAsn Tyr-Lys 
1351 gcgataattg tgaggataca ccagaggcag ggtattttgc tgtagcagtg 
415 SerAspAsn CysGluAspThr ProGluAla Gly-Phe AlaValAlaVal 
1401 gtgaagaaat cagcttctga cctcacctgg gacaatctga aaggcaagaa 
432 Va1LysLys SerAlaSer AspLeuThrTrp AspAsnLeu LysGlyLys 
1451 gtcctgccat acggcagttg gcagaaccgc tggctggaac atccccatgg 
448 LysSerCysHis 
-A1aVa1 Gly- AlalWrpAsn IleProMet 
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1501 gcctgctcta caataagatc aaccactgca gatttgatga atttttcagt 
465 GlyLeuLeu TyrAsnLysIle AsnHisCyS ArgPheAsp G1uPhePheSer 
1551 gaaggttgtg cccctgggtc taagaaagac tccagtctct gtaagctgtg 
482 G1uGlyCys AlaProGly SerLysLysAsp SerSerLeu ILysLeu 
1601 tatgggctca ggcctaaacc tgtgtgaacc caacaacaaa gagggatact 
498 Cy. MetGlySer GlyLeuAsn LeuCy$Glu ProAsnAsnLys GluGlyTyr 
1651 acggctacac aggcgctttc aggtgtctgg ttgagaaggg agatgtggcc 
515 TyrGly- ThrGlyAlaPhe ArgCy®Leu ValGluLys GlyAspValAla 
1701 tttgtgaaac accagactgt cccacagaac actgggggaa aaaaccctga 
532 PheValLys HisGlnThr ValProGlnAsn ThrGlyGly LysAsnPro 
1751 tccatgggct aagaatctga atgaaaaaga ctatgagttg ctgtgccttg 
548 AspProTrpAla LysAsnLeu AsnGluLys AspTyrGluLeu LeuC"Leu 
1801 atggtaccag gaaacctgtg gaggagtatg cgaactgcca cctggccaga 
565 AspGlyThr ArgLysProVal GluGluTyr AlaAsnCya HisLeuAlaArg 
1851 gccccgaatc acgctgtggt cacacggaaa gataaggaag cttgcgtcca 
582 AlaProAsn 
-A1aVa1 Va1ThrArgLys AspLysGlu AlaCyaVal 
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1901 caagatatta cgtcaacagc agcacctatt tggaagcaac gtaactgact 
598 HisLyslleLeu ArgGlnGln G1nHisLeu PheGlySer- ValThrAsp 
1951 gctcgggcaa cttttgtttg ttccggtcgg aaaccaagga ccttctgttc 
615 CysSerGly AsnPheCy$Leu PheArgSer GluThrLys AspLeuLeuPhe 
2001 agagatgaca cagtatgttt ggccaaactt catgacagaa acacatatga 
632 ArgAspAsp ThrValCye LeuAlaLysLeu HisAspArg AsnThrTyr 
2051 aaaatactta ggagaagaat atgtcaaggc tgttggtaac ctgagaaaat 
648 G1uLysTyrLeu GlyGluGlu TyrValLys AlaValGlyAsn LeuArgLys 
2101 gctccacctc atcactcctg gaagcctgca ctttccgtag accttaa 
665 CysSerThr SerSerLeuLeu G1uAlaCys ThrPheArg ArgPro--- 
- -------------------------------------------- -- T End 
1.2. The hSTf model PDB output file 
Due to the large volume of text associated with this file, it has been decided not to 
include it in this thesis. However, this file can be provided on request. 
1.3. Modeller Log File 
This file was created following the creation of the hSTf model using Modeller 6v2. 
PROTEIN STRUCTURE MODELLING BY SATISFACTION OF SPATIAL RESTRAINTS 
Copyright(c) 1989-2002 Andrej Sali 
All Rights Reserved 
Kind, OS, HostName, Kernel, Processor: 4, IRIX evanssgl 6.5 IP22 
Date and time of compilation : 07/05/2002 17: 12: 26 
Job starting time (YY/MM/DD HH: MM: SS): 2004/08/25 12: 03: 19.255 
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check_ali_> Checking the sequence-structure alignment. 
Implied target CA(i)-CA(i+l) distances longer than 8.0 angstromst 
ALN_POS TMPL RID1 RID2 NAM1 NAM2 DIST 
---------------------------------------------- 
END OF TABLE 
patch_ 
_s 
522_> Number of disulfides patched in MODELS 19 
delete443 > Restraints marked for deletion were removed. 
Total number of restraints before, now, 72348 67436 
Peter J Sargent 
» ENERGY, Differences between the models features and restraints: 
ID1, ID2 : 9999 1 
Number of all residues in MODEL 677 
Number of all, selected real atoms 5252 5252 
Number of all, selected pseudo atoms 0 0 
Number of all static, selected restraints 67436 67436 
COVALENT_CYS F 
NONBONDED_SEL_ATOMS 1 
Number of non-bonded pairs (excluding 1-2,1-3,1-4)s 11393 
Dynamic pairs routine 2, NATM x NATM cell sorting 
Atomic shift for contacts update (UPDATE DYNAMIC) 0.390 
LENNARD_JONES_SWITCH 6.500 7.500 
COULOMB_JONES_SWITCH 6.500 7.500 





LENNARD, MODELLER T T F 
SCHEDULE_STEP, N_SCHEDULE 13 13 
SPHERE_STDV 0.050 
RADII FACTOR 0.820 
Current energy , 409 8.1191 
symmetry term within energy 0.0000 
Summary of the restraint violations: 
HUM ... number of restraints. 
NOMVI ... number of restraints with RVIOL s VIOL_ REPORT C[Tf(i). 
RVIOL ... relative difference from the best value . 
NUMVP ... number of restraints with -Ln(pdf) > VIOL_REPORT_CUT2(i). 
RMS_1 ... RMS(feature, minimally_violated basis_restraint, NUMB). 
RMS2 ... RMS(feature, best value, NUMB). _ MOL . PDF ... scaled contribution to -Ln(Molecular pdf). 
8 RESTRAINT_GROUP NUM NUMVI NUMVP RMS 1 RMS_2 
--------------------------------------------------------------------- 




Bond length potential 5371 000.005 0.005 42.525 1.000 
2 Bond angle potential : 7260 7 36 2.689 2.689 769.50 1.000 
3 Stereochemical cosine torsion potent 3343 0 105 48.160 48.160 1217.9 1.000 
4 Stereochemical improper torsion pot: 2213 031.426 1.426 106.70 1.000 
5 Soft-sphere overlap restraints 11393 000.002 0.002 5.1942 1.000 
6 Leonard-Jones 6-12 potential :0000.000 0.000 0.0000 1.000 
7 Coulomb point-point electrostatic p: 0000.000 0.000 0.0000 1.000 
8 H-bonding potential 0000.000 0.000 0.0000 1.000 
9 Distance restraints 1 (CA-CA) 15570 000.096 0.096 165.64 1.000 
10 Distance restraints 2 (N-0) 15650 040.151 0.151 397.38 1.000 
11 Mainhain Phi dihedral restraints 0000.000 0.000 0.0000 1.000 
12 Mainchain psi dihedral restraints 0000.000 0.000 0.0000 1.000 
13 Mainhain omega dihedral restraints: 
676 054.478 4.478 158.32 1.000 
14 Sidechain Chi_l dihedral restraints: 570 07 57.713 57.713 94.010 1.000 
15 Sidechain Chi_2 dihedral restraints: 455 07 68.652 68.652 171.53 1.000 
16 Sidechain Chi_3 dihedral restraints: 202 01 65.499 65.499 105.58 1.000 
17 Sidechain Chi 4 dihedral restraints: 84 00 73.123 73.123 47.956 1.000 
18 Disulfide distance restraints 19 000.015 0.015 0.73262 1.000 
19 Disulfide angle restraints 
38 002.247 2.247 4.2370 1.000 
20 Disulfide dihedral angle restraints: 0000.000 0.000 0.0000 1.000 
21 Lower bound distance restraints 0000.000 0.000 0.0000 1.000 
22 Upper bound distance restraints 0000.000 0.000 0.0000 1.000 
23 Distance restraints 3 (SDCH-MNCH) 9645 000.345 0.345 227.20 1.000 
24 Sidechain Chi_5 dihedral restraints: 0000.000 0.000 0.0000 1.000 
25 Phi/PSi pair of dihedral restraints: 675 18 68 26.673 31.926 227.08 1.000 
26 Distance restraints 4 
(SDCH-SDCH) 5665 000.636 0.636 356.63 1.000 
27 Distance restraints 5 (x-Y) 0000.000 0.000 0.0000 1.000 
28 NMR distance restraints 6 (x-Y) 0000.000 0.000 0.0000 1.000 
29 NMR distance restraints 7 (X-Y) 0000.000 
0.000 0.0000 1.000 
30 Minimal distance restraints 
0000.000 0.000 0.0000 1.000 
31 Non-bonded restraints 0000.000 0.000 0.0000 1.000 
32 Atomic accessibility restraints 
0000.000 0.000 0.0000 1.000 
33 Atomic density restraints 0000.000 0.000 0.0000 1.000 
A restraint is violated when the relative difference 
from the best value (RVIOL) is larger than CUTOFF. 
ICSR ... index of a restraint in the current set. 
RESNO ... residue numbers of the first two atoms. 
ATM ... IUPAC atom names of the 
first two atoms. 
FEAT ... the value of the feature in the model. 
restr ... the mean of the basis restraint with the smallest 
difference from the model (local minimum). 
viol ... difference from the local minimum. 
rviol ... relative difference from the local minimum. 
RESTR ... the best value (global minimum). 
VIOL ... difference from the 
beat value. 
RVIOL ... relative difference 
from the best value. 
Feature 2: Bond angle potential 
List of the RVIOL violations 
larger than 4.5000 
g ICSR RESNO1/2 ATM1/2 INDATM1/2 FEAT restr viol rviol RESTR VIOL RVIOL 
1 11308 553N 553N ND2 CG 4250 4248 139.04 122.50 16.54 4.60 122.50 16.54 4.60 
Feature 25 1 Phi/Psi pair of 
dihedral restraints 
List of the RVIOL violations 
larger than 6.5000 
8 ICSR RESNO1/2 ATM1/2 INDATM1/2 FEAT restr viol rviol RESTR VIOL RVIOL 
1 18253 9V JOS 
CN 73 75 82.60 -136.60 144.17 4.97 -64.10 -155.24 16.77 
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1 lOS 103 N CA 75 76 -177.86 151.20 -35.00 
2 18369 1250 126W CN 950 952 -108.61 -63.00 46.85 8.18 -63.00 46.85 
2 126W 126W N CA 952 953 -54.89 -44.20 -44.20 
3 18396 152F 1533 CN 1172 1174 -105.85 -136.60 93.52 4.00 -64.10 106.41 
3 153$ 1533 N CA 1174 1175 62.87 151.20 -35.00 
4 18574 330P 331E CN 2556 2558 56.68 -69.30 134.21 11.61 -69.30 134.21 
4 331E 331E N CA 2558 2559 -171.22 142.50 142.50 
5 18578 334T 335D CN 2584 2586 -100.67 -96.50 8.30 0.35 54.50 174.50 
5 335D 335D N CA 2586 2587 121.38 114.20 40.90 
6 18580 336E 337C CN 2601 2603 -67.80 -63.00 72.38 8.51 -63.00 72.38 
6 337C 337C N CA 2603 2604 31.12 -41.10 -41.10 
7 18581 337C 338K CN 2607 2609 -69.15 -62.90 83.38 10.50 -62.90 83.38 
7 338K 338K N CA 2609 2610 42.34 -40.80 -40.80 
8 18582 338K 339P CN 2616 2618 71.31 -64.50 135.86 13.71 -64.50 135.86 
8 339P 339P N CA 2618 2619 143.28 147.20 147.20 
9 18589 345L 3463 CN 2672 2674 47.74 -72.40 124.03 9.59 -64.10 -179.42 
9 3463 346S N CA 2674 2675 -176.77 152.40 -35.00 
10 18604 3603 361V CN 2799 2801 64.89 55.90 10.95 1.34 -125.40 -164.25 
10 361V 361V N CA 2801 2802 45.75 39.50 143.30 
11 18624 380M 381N CN 2944 2946 -104.23 -63.20 83.58 8.99 -63.20 83.58 
11 381N 38100 N CA 2946 2947 31.71 -41.10 -41.10 
12 18658 414D 415N CN 3189 3191 60.51 55.90 28.25 1.65 -63.20 134.47 
12 415N 415N N CA 3191 3192 11.63 39.50 -41.10 
13 18684 440D 441N CN 3386 3388 -107.78 -63.20 85.41 9.18 -63.20 85.41 
13 441N 441N N CA 3388 3389 31.75 -41.10 -41.10 
14 18701 4570 458W CN 3505 3507 -111.26 -63.00 50.49 8.88 -63.00 50.49 
14 458N 458W N CA 3507 3508 -59.04 -44.20 -44.20 
15 18742 498G 499S CN 3826 3828 -31.82 -136.60 105.11 4.39 -64.10 168.57 
15 4993 4993 N CA 3828 3829 159.55 151.20 -35.00 
16 18743 4993 5000 CN 3832 3834 -58.69 -62.40 9.68 1.64 82.20 146.67 
16 5000 5000 N CA 3834 3835 -32.27 -41.20 8.50 
17 18782 538Q 53900 CN 4137 4139 -123.82 -119.90 94.27 4.37 -63.20 103.52 
17 539N 539N N CA 4139 4140 42.81 137.00 -41.10 
18 18794 550K 55100 CN 4227 4229 -106.32 -63.20 85.54 9.19 -63.20 $5.54 
18 551N 55100 N CA 4229 4230 32.78 -41.10 -41.10 
report > Distribution of short non-bonded contacts: 
DISTANCE1: 0.00 2.10 2.20 2.30 2.40 2.50 2.60 2.70 2.80 2.90 3.00 3.10 3.20 3.30 3.40 
DISTANCE2: 2.10 2.20 2.30 2.40 2.50 2.60 2.70 2.80 2.90 3.00 3.10 3.20 3.30 3.40 3.50 
FREQUENCY; 00000 25 83 257 360 461 469 659 746 B51 891 
<c end of ENERGY. 


















Dynamically allocated memory at finish IB, kB, MBI: 29583587 28890.223 28.213 
Starting time 2004/08/25 12: 03: 19.255 
Closing time 2004/08/25 13: 12i32.963 
Total CPU time (seconds] 0.00 
1.4. Human serum transferrin model bump table 
A table of atomic pairs that bump according to WHATIF analysis of the hSTf model. 
Key. A: Bump Number. B+C: Residue One. D: Atom. E+F: Residue Two. G: 
Atom. H: How much shorter the contact is than the accepted limited (A). I: Distance 
(A) between the two centres of the atoms. J: Status of the atomic pair. K: Explanation 





















































































































































































































































































































29 24 MET CB 272 PHI C92 0.25 2.95 INTRA BP 
30 24 MET 0 25 LYE C 0.062 2.738 INTRA BP 
31 28 ILS C02 29 PRO N 0.319 2.781 IN77U BP 
32 28 ILE C02 32 DLY CA 0.259 2.941 INTRA BP 
33 28 ILB C02 29 PRO CD 0.169 3.031 INTRA BP 
34 28 ILB CA 29 PRO CD 0.024 2.776 INTRA BP 
35 31 ASP 0 32 OLY C 0.108 2.692 INTRA BP 
36 32 OLY 0 33 PRO C 0.035 2.765 INTRA BP 
37 32 OLY CA 33 PRO CD 0.02 2.78 INTRA BP 
38 33 PRO CD 264 LBU CD2 0.167 3.033 INTRA BP 
39 42 8BR CB 177 CYS 80 0.125 3.275 INTRA BP 
40 43 TYR Co 44 LEU N 0.13 2.97 INTRA BP 
41 50 ILE CD1 56 ASP C 0.058 3.142 1 N7RA BP 
42 52 ALA 0 53 558 CS 0.065 2.735 INTRA 8P 
43 53 AM 0D1 252 ARG CO 0.056 2.744 INTRA BP 
44 61 ASP CO 62 ALA N 0.11 2.99 INTRA BP 
45 65 VAL CO1 77 PRO CO 0.04 3.16 INTRA BP 
46 66 TYR CEO 318 VAL CO2 0.2 3 INTRA BP 
47 69 TYR CB 309 ALA CB 0.222 2.978 INTRA BP 
48 69 TYR CD1 309 ALA CB 0.18 3.02 INTRA BP 
49 69 TYR CO 309 ALA C8 0.122 3.078 INTRA BP 
50 71 ALA CA 74 ASH ND2 0.237 2.863 INTRA SP 
51 73 ASN 0 74 ASN C 0.023 2.777 INTRA BP 
52 78 VAL C02 79 VAL. N 0 129 2.971 INTRA BP 
53 78 VAL C01 258 OLU CC 0.124 3.076 INTRA BP 
54 79 VAL Cal 80 ALA N 0.188 2.912 INTRA By 
55 82 PHI C82 299 OLY C 0.255 2.945 INTRA By 
56 82 PHI CB1 298 HIS CB 0.251 2.949 INTRA BP 
57 82 PHE CE2 299 GLY CA 0.206 2 994 1N7RA BP 
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58 82 PHB CZ 299 GLY CA 0.085 3.115 INTRA BF 
59 82 PHE CD2 299 GLY C 0.038 3.162 INTRA BF 
60 82 PNB CE2 300 PHE N 0.008 3.092 INTRA BP 
61 84 GLY N 298 HIS CD2 0.226 2.874 INTRA BP 
62 84 GLY C 298 HIS NE2 0.215 2.885 INTRA SF 
63 84 OLY C 298 MIS CD2 0.091 3.109 INTRA BP 
64 84 GLY 0 298 HIS NE2 0.08 2.62 INTRA OF 
65 85 SEE CO B7 OLU CD 0.015 2.785 1NNTAA BP 
66 87 OLU C 89 PRO CD 0.04 3.16 INTRA RF 
67 88 ASP N 89 PRO CD 0.037 2.963 INTRA OF 
68 88 ASP CA 89 PRO CD 0.01 2.79 INTRA BF 
69 92 PHB CB1 677 PRO 0 0.044 2.756 INTRA BF 
70 95 ALA CB 128 ILE CDR 0.253 2.947 INTRA OF 
71 98 VAL CO1 99 VAL N 0.062 3.038 INTRA BF 
72 99 VAL 002 100 LYS N 0.282 2.818 INTRA RF 
73 99 VAL CG2 230 ARG NH2 0.192 2.908 INTRA BP 
74 99 VAL CG1 230 ARG NH2 0.01 3.09 INTRA OF 
75 101 LYS 0 102 ASP CO 0.064 2.736 INTRA OF 
76 103 SER 03 105 PHB CE2 0.019 2.781 INTRA BP 
77 105 POE CB 109 GLU NE2 0.232 2.868 INTRA OF 
78 105 PHE CA 109 GIN CD 0.141 3.059 INTRA BP 
79 105 PHE CB 109 ME CD 0.02 3.18 INTRA BF 
80 105 PHE CA 109 GLN NE2 0.014 3.086 INTRA BP 
81 106 GLN N 109 00N 081 0.078 2.622 INTTü BP 
82 106 OLN 0E1 228 ASN C 0.019 2.781 INTRA BP 
83 110 LEO 0 111 ARG C 0.082 2.718 INTRA BP 
84 111 ARG CO 151 PHE CE1 0.258 2.942 INTRA BP 
85 111 ARG CO 151 PHE Cl 0.246 2.954 INTRA BF 
86 114 LYS CE 153 SER 0 0.026 2.774 INIRA OF 
87 116 CY9 90 171 LEO CD1 0.206 3.194 INTRA BP 
Be 116 CYS SG 156 CYS CB 0.116 3.284 INTRA BF 
89 123 SEE CB 317 TYR OH 0.021 2.779 INTRA BP 
90 126 TRP CZ2 144 LEU 001 0.251 2.949 INTRA BF 
91 128 ILE CD1 244 VAL col 0.25 2.95 INTRA BP 
92 128 ILE N 129 PRO CD 0.107 2.893 INTRA OF 
93 128 ILE CB 129 PRO CD 0.056 3.144 INTRA BF 
94 133 LEO 0 136 ASP CG 0.059 2.741 INTRA OF 
95 134 TYR CD1 329 CYS SO 0.369 3.031 INTRA OF 
96 134 TYR CE2 144 LE0 CD2 0.122 3.078 INTRA BP 
97 134 TYR OH 141 ARC CB 0.018 2.782 INTRA BP 
98 134 TYR CD2 144 LOU CD2 0.013 3.187 INTRA BP 
99 134 TYR 0 135 CYS C 0.01 2.79 INTRA BF 
100 135 CYS SO 330 PRO CD 0.025 3.375 INTRA BP 
101 137 LEO CB 138 PRO CD 0.069 3.131 INFRA BF 
102 137 LEO CD2 151 PHE CD1 0.057 3.143 INTRA OF 
103 137 LEO 0 138 PRO C 0.054 2.746 INTRA BP 
104 137 LOU CA 138 PRO CD 0.024 2.776 INTRA BF 
105 138 PRO 0 139 OLO C 0.052 2.748 INTRA BP 
106 139 GLO CB 140 PRO CD 0.046 3.154 INTRA SF 
107 142 LYS CA 143 PRO C 0.088 3.112 INTRA BP 
108 142 LYS CA 143 PRO CA 0.075 2.725 INTRA BF 
109 145 GLU CS 165 PHE CE2 0.249 2.951 INTRA BF 
110 145 GLU CB 165 PHE CD2 0.072 3.128 1N17ü BP 
111 148 VAL C01 149 ALA N 0.272 2.828 INTRA up 
112 156 CYS 90 183 TYR CB 0.007 3.393 INTRA BP 
113 157 ALA 0 158 PRO C 0.032 2.768 INTRA OF 
114 161 ASP OD1 163 THR CG2 0.058 2.742 INTRA OF 
115 162 GLY CA 169 CYS SO 0.084 3.316 INTRA BP 
116 162 GLY 0 163 THE C0 032 2.768 INTRA By 
117 163 T HR 002 164 ASP N 0.282 2.818 INTRA BP 
118 165 9H8 CB 168 LOU CD2 0.246 2.954 INTRA RF 
119 169 CYS 0 170 GLN C 0.053 2.747 INTRA BF 
120 169 CY9 0 172 CYS C 0.04 2.76 INTRA BF 
121 171 LEO C 172 CYS SG 0.093 3.307 INTRA OF 
122 172 CYS SG 183 TYR CB 0.422 2.978 IN77U BF 
123 172 CYO 0 173 PRO C 0.057 2.743 INTRA OF 
124 172 CYS SG 183 TYR CG 0.051 3.349 INTRA SP 
125 174 GLY 0 175 CYS C 0.053 2.747 INTRA BF 
126 176 OLY C 181 ASN ND2 0.239 2.861 INTRA Be 
127 178 SER 0 181 ASN 9602 0.045 2.655 INTRA BP 
128 179 TOR N 180 LBO N 0.009 2.591 INTRA OF 
129 183 TYR C 188 GLY CA 0.19 3.01 INTRA OF 
130 184 PHE CO 185 GLY N 0.138 2.962 INTRA SP 
131 190 POE CR1 208 ILE C02 0.121 3.079 INTRA BF 
132 190 PHE Cl 212 LEG CM 0.097 3.103 INTRA EP 
133 193 1. E0 CD1 221 TYR CE2 0.254 2.946 INTRA BP 
134 194 LYS CD 221 TYR OH 0.018 2.782 INTRA BP 
135 200 VAL C02 201 ALA N 0.144 2.956 0815k SF 
136 204 LYS NZ 294 LYS NZ 0.135 2.865 INTRA SF 
137 205 HIS CO 206 SER N 0.037 3.063 INTRA BP 
138 206 SEE 0 207 THE C 0.063 2.737 INTRA BF 
139 207 THR 0 208 ILE C 0.031 2.769 INTRA BP 
140 208 ILE CD1 233 VAL 
CG1 0.258 2.942 INTRA BP 
141 208 ILE 001 218 ARG CG 0.249 2.951 INTRA RF 
142 208 ILE 001 233 VAL CG2 0.239 2.961 INTRA OF 
143 209 PHB 0E1 218 ARG NE 0.107 2.993 INTRA BF 
144 223 LOU CD2 233 VAL CA 0.248 2.952 INTRA BP 
145 227 ASP 0 228 ASH CB 0.055 2.745 INTRA OF 
146 229 THR C02 230 ARG N 0.274 2.826 19FRA SF 
147 231 LYS CD 239 
CYS SG 0.369 3.031 INTRA BF 
148 231 LYS CB 232 
PRO CD 0.096 3.104 INTRA SF 
149 231 LYS CA 232 
PRO CD 0.053 2.747 INTRA SF 
150 235 GLU 0 236 
TOR C 0.022 2.778 INTRA OF 
151 236 TYR 001 237 LYS N 0.098 3.002 INTRA BF 
152 236 TYR 0 237 LYS 
C 0.059 2.741 INTRA RF 
153 237 LYS NZ 238 ASP CG 0.189 2.911 INTRA OF 
154 237 LYS CO 238 
ASP N 0.182 2.918 INTRA BF 
155 237 LYS CD 238 
ASP OD1 0.055 2.745 INTRA BF 
156 244 VAL C, '1 317 
TOR CE1 0.101 3.099 INTRA BF 
157 244 VAL CA 245 
PRO CD 0.028 2.772 INTRA OF 
158 247 HIS CD2 294 
LYS CD 0.136 3.064 INTRA OF 
159 247 HIS C 248 
THR CG2 0.086 3.114 INTRA BF 
160 248 THE 002 
312 TYR Cl 0.112 3.088 INFRA BF 
161 248 THR 002 
312 TYR OH 0.017 2.783 INTRA 9F 
162 259 ASP CG 260 
LEO N 0.225 2.875 INTRA SP 
163 259 ASP CG 
260 LHU 001 0.135 3.065 INTRA BP 
164 259 ASP OD1 260 
LEO CD1 0 054 2.746 INTRA BF 
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165 260 LOU 0 264 LBU 002 0.047 2,753 INTRA or 
166 260 LEU 0 261 ILE C 0.023 7.777 INTAA Bº 
167 266 ASN 0 269 OLE CO 0.011 2.789 INTRA  F 
168 267 OLE 0 268 ALA C 0.016 2.784 1NTRA 
169 269 OLE 0 270 OLU C 0.055 2.745 INTRA Bº 
170 275 ASP CO 276 LYS N 0.237 2.863 INTRA BF 
171 276 LYS CO 277 SEA N 0.098 3.002 INTRA BF 
172 278 LYS CO 279 OLD N 0.271 2.827 INTRA BF 
173 291 LEU C 292 LED CD1 0.006 3.114 INTRA BF 
174 303 VAL CA 304 PRO CD 0.056 2.744 INTRA BP 
175 303 VAL COO 304 PRO N 0.028 3.072 IN7RA OF 
176 304 PRO CA 305 PRO CD 0.093 2.707 INTRA SF 
177 306 ARG CD 668 LSU CA 0,083 3.117 INTRA or 
178 306 ARG 501 311 MET CE 0.078 3.022 INTRA OF 
179 307 NET CE 671 ALA 0 0.059 2.741 INTRA BF 
160 309 ALA 0 313 LEU CD1 0.059 7.741 INTRA SF 
161 309 ALA 0 310 LYS C 0.013 2.787 INTRA OF 
182 310 LYS CE 301 ASH ND2 0.234 2.866 INTRA OF 
183 310 LOS NO 381 ASS CO 0.17] 7.977 INTRA OF 
184 310 LOS CB 381 ASN CO 0.158 3.042 INTRA BP 
185 310 LYS CD 381 ASH CB 0.056 3.142 INTRA RF 
186 311 MET SD 671 ALA CB 0.279 3,121 INTRA OF 
187 316 OLU 0 319 THR CO2 0.057 2.743 INTRA or 
188 315 VAL COS 319 OHR N 0.773 2.827 114M BP 
189 318 VAL 0 321 ILE 002 0.063 2.737 INTRA OF 
190 319 THR CO2 320 ALA N 0.28 2.82 INTRA BF 
191 321 ILE C02 322 ABO N 0.247 2.853 INTRA BF 
192 322 ARG 0 326 OLD CO 0.053 2.747 INTRA BP 
193 327 OLY N 328 THR N 0.033 2.567 INT2A OF 
194 329 CY8 CA 330 PRO CD 0.093 2.707 INTRA or 
195 329 CYS 0 330 PRO C 0.057 7.743 INTRA BF 
196 330 PRO C 331 OLD 0 0.085 2.715 INTRA BF 
197 330 PRO 0 331 OLD C 0.022 2.778 INTRA OF 
198 330 PRO CO 331 GLU N 0.02 3.08 INTRA BF 
199 331 OLU 0 332 ALA C 0.076 2.724 INTSA BP 
200 331 OLD C 332 ALA C 0.008 2.792 INTRA BF 
201 332 ALA CA 333 PRO CD 0.11 2.69 INTRA BF 
202 334 THR C02 335 ASP N 0.272 2.828 INTRA OF 
203 336 OLD CO 594 COB 80 0,249 3.151 INTRA OF 
204 336 OLD 0 338 LYS N 0.083 2.617 INTRA Bp 
205 338 LYS C 339 PRO CD 0.125 2.175 INTRA OF 
206 339 PRO CD 363 LOS C 0.009 3.191 INTRA SF 
207 340 VAL CG1 341 LOS N 0.117 2.983 INTRA PF 
208 341 LYS CD 394 ALA CA 0.249 2.951 INTRA BF 
209 341 LYS CO 385 ASP N 0,094 3.006 INTRA or 
210 341 LY8 CD 363 OLD 0 0.062 2.738 INTRA BP 
211 343 CYS SO 387 MET SD 0,449 3.151 INTRA OF 
212 345 LEU CD1 3117 MET co 0.254 2,946 INTRA BP 
213 347 HIS CR1 351 LSU CD1 0.167 3.033 INTRA or 
214 349 OLD CO 627 LEU CD1 0.161 3.039 INTRA OF 
215 351 LEU 0 357 LYS C 0.001 2.799 INTRA 
216 353 CYS C 366 COB 80 0.188 3.212 INTRA BF 
217 353 CYS 0 354 ASP C 0.031 2,769 INTRA or 
218 355 OLD CO 617 PHI CD1 0.012 3,188 INTRA OF 
219 357 SRR 0 358 VAL C 0.066 2,734 INTRA OF 
220 360 SHE 0 361 VAX. CO2 0.083 2.717 INTRA OF 
221 367 VAL CO 368 SER N 0.159 2.941 INTRA OF 
222 369 ALA CB 378 LYS CB 0.025 3.175 INTRA OF 
223 372 THR C02 373 OLD N 0.278 2.822 INTRA OF 
224 372 THR 0 376 ILE CD1 0.064 2,736 INTRA BP 
2221 372 THR C02 393 PHE C61 0.062 3.138 INTRA all 
226 375 COB SO 387 MET 8D 0.394 3.206 INTRA OF 
227 375 CYS CB 387 MET SD 0.154 3.246 INTRA OF 
228 377 ALA CA 380 MET CB 0.252 2.948 INTRA BP 
229 379 ILE 0 588 ARG CD 0.069 2.731 INTRA BF 
230 380 MET BD 400 CYS CB 0.159 3.241 INTRA OF 
231 381 ASH OD1 383 OLU CO 0.055 2.745 INTRA OF 
232 390 ASP CO 391 01.0 N 0.229 2.871 INTRA BF 
233 391 GLY 0 394 VAL COO 0.065 2.735 INTRA BF 
234 394 VAL CG1 395 TYR N 0.174 2,926 INTRA OF 
235 394 VAL CO1 649 LOU CD1 0.124 3.076 INTRA OF 
236 398 GLY 0 399 LOS C 0.02 2.78 INTRA OF 
237 399 LYS N 400 COB N 0.019 2.581 INTRA OF 
238 403 VAL CO1 589 LYS CD 0.237 2.963 INTRA BF 
239 405 VAL COO 406 LSO N 0.283 2.817 INTRA BF 
240 409 ASH CB 415 ASH ND2 0.005 3.095 INTRA OF 
241 410 TYR CR2 582 ASN CO 0.064 3.136 INTRA OF 
242 411 ASN CB 421 OLD 082 0.054 2.746 INTRA By 
243 412 LOS CO 414 ASP N 0.28 2.82 INTRA BF 
244 412 LOS CD 413 SER N 0.278 2.822 INTRA OF 
245 412 LYS 0 634 VAL COO 0.06 2.74 INTRA BF 
246 412 LYS CB 415 ASN 001 0.058 2.742 INTRA BF 
247 413 SER CA 634 VAL C01 0.255 2.945 INTRA BP 
248 413 SER N 414 ASP N 0.083 2.517 INTRA OF 
249 413 SER C 414 ASP 0 0.075 2.725 INTRA SP 
250 414 ASP CO 415 AMN N 0.273 2.827 INTRA BP 
251 414 ASP C 416 COB N 0.139 2.761 INTRA BP 
252 414 ASP 0 415 ASH CG 0.1 2.7 INTRA BP 
253 414 ASP OD1 415 ASH N 0.078 2.622 INTRA BF 
254 414 ASP 0 415 ASH C 0.062 2.738 INTRA SP 
255 415 ASN CB 418 ASP CB 0.28 2.92 INTRA OF 
256 415 ASN CA 416 ASP N 0.276 2.824 INTRA OF 
257 415 ASN C 418 ASP N 0.265 2.835 INTRA PF 
258 415 ASN CA 418 ASP CB 0.199 3.001 INTRA OF 
259 415 AMN C 416 CY9 C 0.133 2.667 INTRA OF 
260 415 ASH 0 416 CYO C 0.069 2.731 INTRA BF 
261 415 ASN C 417 OLU N 0.06 2.84 INTRA SF 
262 416 CYS N 417 OLD N 0.182 2.418 INTRA OF 
263 419 THR CA 420 PRO CD 0.059 7.741 INTRA SF 
264 419 THR CB 420 PRO CD 0.01 3.19 INTRA BP 
265 421 GLU CG 582 A. 98 ND2 0.234 2.866 INTRA OF 
266 427 VAL 002 428 ALA N 0.278 2.822 INTRA OF 
267 427 VAL C02 559 LEU CD1 0.256 2 942 INTRA OF 
268 429 VAL C02 559 LEU CD1 0.25 2.95 INTRA OF 
269 429 VAL CG1 430 VAL N 0.118 2.982 INTRA OF 
270 430 VAX. CO1 437 LEU CD1 0.254 2.946 INTRA OF 271 430 VAL 0131 560 LOU 002 0.131 3 069 INTRA BF 
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272 430 VAL CB 437 LEU CD1 0.07 3.13 INTRA By 
273 432 LYS 0 433 SER C 0.024 2.776 INTRA SF 
274 434 ALA 0 437 LEU CD2 0.054 2.746 INTRA SF 
275 438 THR C02 439 TRP N 0.294 2.806 INTRA BF 
276 438 THR CG2 564 GLY 0 0.071 2.729 INTRA BF 
277 439 TRP CZ2 464 LEU CD2 0.248 2.952 INTRA BF 
278 441 ASH CA 443 LYS HZ 0.139 2.961 INTRA BF 
279 441 ASH 0 445 LYS CE 0.057 2.743 INTRA BF 
280 442 LEU 0 443 LYS C 0.075 2.725 INTRA BF 
281 443 LYS N 477 PHB CZ 0.046 3.054 INTRA BF 
282 448 CYS SG 521 COB C 0.095 3.305 INTR. 5 BF 
283 450 TSR 0G1 454 ARG CD 0.013 2.787 INTRA BF 
284 452 VAL CGl 453 GLY N 0.07 3.03 INTRA BF 
285 455 THR C02 580 ALA CB 0.071 3.129 INTRA BP 
286 460 ILS CB 461 PRO CD 0.169 3.031 INTRA BF 
287 460 ILS N 461 PRO CD 0.092 2.908 INTRA SF 
288 462 MET CE 474 PHE CO 0.198 3.002 INTRA BP 
289 462 MET CB 474 PHS CB 0.123 3.077 INTRA BF 
290 464 LEU CD2 562 LSO CD2 0.003 3.197 INTRA SP 
291 466 TYR 0 467 ASH C 0.06 2.74 15CRA SP 
292 471 HIS CE1 473 ARG CO 0.166 3.034 INTRA SP 
293 471 HIS ND1 473 ARG N 0.1 2.75 INTRA BP 
294 471 HIS 5101 473 ARG CO 0.068 
3.032 INTRA SP 
295 473 ARG CD 476 GLU CD 0.254 2.946 INTRA BP 
296 473 ARG CD 476 GLU OE1 0.054 
2.746 INTRA BF 
297 473 ARG CO 476 GLU CB 0.001 3.199 INTRA SF 
298 475 ASP CA 492 LEU C02 0.265 2.935 INTRA BP 
299 475 ASP CB 492 LBG CD2 0.171 3.029 INTRA BF 
300 480 GLU CD 494 LYS CD 0.105 3.095 INTRA BF 
301 480 GLU 082 494 LYS CB 0.054 2.746 INTRA BF 
302 480 OLU 0112 494 LYS CO 0.054 2.746 INTRA BP 
303 480 GLU CB 495 LEU CD1 0.024 
3.176 INTRA BF 
BP 304 481 OLY N 495 LBU CDI 0.28 2.82 INTRA 
305 481 GLY CA 495 LEG CD1 0.033 3.167 INTRA BP 
306 482 CYS SO 512 TYR CB 0.089 
3.311 INTRA BF 
307 483 ALA 0 484 PRO C 0.049 2.751 INTRA BF 
308 483 ALA CA 484 PRO CD 0.005 
2.795 INTRA BF 
309 496 CYS SO 504 CYS CB 0.064 3.336 INTRA BF 
310 496 CYS 0 503 LBU CD1 0.058 
2.742 INTRA SF 
311 497 BET 0 498 GLY C 0.09 2.71 INTRA BP 
312 499 SER C 501 LEU N 0.081 
2.819 INTRA BF 
313 499 SER 0 500 GLY C 0.062 2.738 INTRA SF 
314 499 SER C 500 GLY C 0.014 2.786 INIRA BP 
315 500 GLY N 501 LSG N 
0.092 2.508 INTRA SP 
316 500 GLY 0 501 LEO C 
0.026 2.774 INTRA SP 
317 501 LEU C 502 ASH C?. 
0.009 2.291 INTRA BF 
318 502 ASH CS 509 LYS 
CB 0.196 3.004 INTRA SP 
319 502 ASH OD1 509 LYS 
CO 0.056 2.744 INTRA SF 
320 502 ASH CB 505 GLU CB 0.025 3.175 INTRA BP 
321 502 ASH OD1 509 LYS 
CB 0.013 2.787 INTRA SP 
322 505 GLU CG 507 ASH ND2 0.234 2.866 INTRA BP 
323 505 GLU CG 506 PRO CD 
0.168 3.032 INTRA SP 
324 505 GLO CA 506 PRO CD 
0.093 2.707 INTRA SP 
325 505 GLU CD 506 PRO CD 
0.073 3.127 INTRA SP 
326 505 GLU CG 506 PRO N 
0.068 3.032 INTRA SF 
327 508 ASH C 510 GLU N 0.008 2.892 INTRA BF 
328 512 TYR CD2 521 CYS CB 
0.258 2.942 INTRA BF 
329 512 TYR CD2 521 CYS SG 0.151 3.249 INTRA BF 
330 512 TYR CE2 521 COB 
CA 0.027 3.173 INTRA SF 
331 516 THR 001 625 LOS CD 0.015 2.785 INTRA BP 
332 516 THR 0 517 GLY C 0.011 2.769 INTRA BP 
333 519 PHS CZ 557 TYR 
C82 0.261 2.939 INTRA BP 
334 519 PHS CO 557 TYR 
CO 0.222 2.978 INTRA SP 
335 519 PHS CD2 539 ASH 001 
0.056 2.744 ISTIU BF 
336 520 ARG 0 521 CYS C 0.066 2.734 I"r", BF 
337 520 ARG 0 523 VAL 
CG1 0.057 2.743 INTRA BF 
338 522 LEU 0 523 VAL C 0.02 2.78 INTRA BY 
339 523 VAL CG1 524 GLU N 0.281 2.819 INTRA BF 
340 528 VAL CG2 529 ALA N 0.069 3.031 INTRA SP 
341 530 PHE C 531 VAL 
CG1 0.061 3.139 INTRD BP 
342 532 LYS CO 535 THR 
CG2 0.195 3.005 INTRA SP 
343 533 HIS CD2 534 GIN 
N 0.233 2.867 INTRA BF 
344 535 THR 0 536 VAL 
C 0.021 2.779 INTRA SP 
345 536 VAL CB 537 
PRO CD 0.174 3.026 INTRA SP 
346 536 VAL N 537 
PRO CD 0.092 2.908 INTRA SF 
347 537 PRO 0 543 LYS 
CD 0.058 2.742 INTRA SF 
348 539 ASH CB 544 ASH 
CS 0.057 3.143 INTRA SF 
349 542 GLY N 543 LYS N 
0.008 2.592 INTRA B3 
350 544 ASH 5102 625 
LYS NZ 0.174 2.826 INTRA SF 
51 544 ASH CA 545 PRO CD 
0.101 2.699 INTRA SF 
352 553 ASH 0 556 
ASP CO 0 04 2.76 INTRA SP 
I. S. Rabbit serum transferrin bump table 
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353 556 ASP 001 557 TYR C52 0.084 2,716 INTRA Sº 
354 556 ASP 001 567 TYR CD2 0.061 2.739 INTRA SF 
355 559 LOU CD2 569 VAL CA 0,250 2.942 INTRA  º 
356 561 CYS 80 565 THR C02 0.132 3.268 INTRA  º 
357 S61 CYS CS 565 TOR C02 0.035 3.165 INTRA OF 
358 561 CYS N 575 CYS SO 0.004 3.296 INTRA SP 
359 564 SLY N 565 THR N 0.094 2.506 INTRA SP 
360 567 LYS CA 568 PRO CD 0.038 2.762 INTRA SP 
361 566 PRO 0 571 ULU Co 0.017 2.783 INTRA OF 
362 569 VAL 001 570 00.3 N 0.109 2.991 INTRA HP 
363 571 OLU 0 572 TYR C 0.078 2.722 INTRA HP 
364 572 TYR 001 573 ALA N 0.276 2.624 INTRA RP 
365 572 TYR CO 573 ALA N 0.065 3.015 INTRA Sº 
366 572 TYR 0 573 ALA C 0.074 2.726 INTRA HP 
367 585 VAL 001 586 VAL N 0.082 3.018 INTRA HP 
368 587 THR C02 S58 ARG N 0.01 3.09 INTRA HP 
369 567 1148 C02 592 ULU CA 0 3,2 INTRA HP 
370 588 ARG 9041 591 LYS CS 0.234 2.866 INTRA BY 
371 589 LYS 0 590 ASP C 0.064 2.736 INTRA SP 
372 590 ASP CO 591 LYS N 0.232 2.068 INTRA HP 
373 591 LYS 0 592 01.3 C 0.066 2.734 INTRA HP 
374 593 ALA CA 596 HIS CD2 0.21 2.99 I. NT1U HP 
37S 593 ALA 0 594 CYS C 0.071 2.729 INTRA HP 
376 593 ALA 0 596 HIS CD2 0.015 2.785 INTRA 11P 
377 595 VAL 0 598 ILS C02 0.04 2.76 INTRA SP 
378 596 HIS ND1 597 LYS N 0.209 2.791 INTRA HP 
379 596 HIS CS1 597 LYS C0 0.17 3.03 IN7RA NP 
380 596 HIS CO 597 LYS N 0.154 2.946 INTIUI lip 
381 596 HIS 0 597 1.08 C 0.063 2.737 INTRA HP 
382 598 11.8 C02 599 LED N 0.275 2,825 INTRA ZIP 
383 S99 LOU 0 602 OLN CO 0.055 2.745 INTRA ZIP 
384 599 LSU 0 600 ARG C 0.055 2.745 INTRA NP 
385 602 00H CD 603 Oiti N 0.17 2.93 IN771A lip 
386 602 01.04 N22 606 PHI CS 0.082 3.018 INTAA HP 
387 602 OLN CO 603 01.04 N 0.05 3.05 INTRA HP 
388 603 0104 0 604 HIS C 0.047 2.753 INTRA HP 
389 609 ASN CO 610 VAL N 0.138 2.962 INTRA HP 
390 609 ASH 0 610 VAL C 0,062 2.738 INTRA lip 
391 610 VAL 001 613 CYO 00 0.127 3.273 1NTIU HP 
392 619 LEU CD2 629 PHS CD1 0.260 2,932 INTRA HP 
393 619 LEU CD2 629 PHS C81 0.143 3.057 INTRA HP 
394 619 LOU CD1 629 PHS CS1 0.102 3.095 INTRA HP 
395 623 ULU CO 624 TOR N 0.262 2.535 INTRA lip 
396 624 THR CS 625 LYS N 0.05 2.65 INTRA lip 
397 624 TOR 001 627 LSU CD2 0.032 2.768 INTRA HP 
398 627 LOU C 629 PN8 N 0.007 2.693 INTRA UP 
399 638 LYS CO 639 LEU N 0.20 2.82 INTRA lip 
400 638 LYS CD 640 HIS N 0.23 2.87 INTRA 8P 
401 639 LOU 0 640 HIS C 0.037 2.763 INTRA 8P 
402 644 TOR C02 645 TYR N 0.213 2.867 INTRA lip 
403 644 THR C8 647 LYS CO 0.025 3.175 INTRA lip 
404 645 TYR CO 646 01,3 N 0.159 2.941 0908A OF 
405 645 TYR 0 649 LOU CD2 0.063 2.737 INTRA HP 
406 651 01.3 0 654 VAL Cal 0.065 2.735 INTRA 8P 
407 651 OLD 0 652 OLD C 0.056 2.744 INTRA up 
408 654 VAL 001 655 LYS N 0.273 2.827 INTRA SP 
409 654 VAL 0 655 LYS C 0.04 2.76 INTRA lip 
410 658 GLY 0 659 ASH C 0.007 2.793 INTRA 
411 659 ASN 0 662 LYS CD 0.052 2.748 INTRA NP 
412 660 LSU 0 661 ARG C 0.055 2.745 IN197A OP 
413 661 ARG 0 662 LYS C 0.032 2.768 INTRA HP 
414 663 CYS 0 664 88R C 0.061 2.739 INTRA 8P 
415 667 SER 0 670 OLU CO 0.054 2.746 INTHA 
416 670 OLU CO 671 ALA N 0.1 3 INTRA HP 
417 670 ULU 0 673 THR C02 0.07 2.73 INTHA HP 
418 674 PHE 0 67S ARG C 0.006 2.794 INTRA RP 
A table of atomic pairs that bump according to WHATIF analysis of rSTf. Key. A: 
Bump Number. B+C: Residue One. D: Atom. E+F: Residue Two. G: Atom. H: 
How much shorter the contact is than the accepted limited (A). I: Distance (Ä) 
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between the two centres of the atoms. J: Status of the atomic pair. K: Explanation of 
bump (BF: B-factor > 80, HB: Hydrogen Bonding). 
BCDSP0HIJR 
11 GLU CO 2 LYS N 0.471 2.629 INTRA OF 
21 GLU OE1 34 ARG NN1 0.174 2.376 INTRA OF 
31 OLO CB 2 LYS N 0.069 2.631 INTRA OF 
45 ARG NHl 56 ASP CO 0.392 2.708 INTRA BF 
55 ARG NH2 53 HIS 0 0.3 2.25 IN'lRR OF 
65 ARG NN1 56 ASP OD1 0.221 2.329 INTRA BP 
75 ARG NH1 56 ASP OD2 0.154 2.396 INTRA OF 
86 TRP B 36 ILE 0 0.005 2.545 INTRA HB 
9 11 ASP OD1 39 LYS NZ 0.005 2.545 INTER HB 
10 14 ALA 0 15 SBR C 0.007 2.793 INTER 
11 16 LYS 0 17 CYS C 0.016 2.784 INTER 
12 17 CYS C 37 CYS SO 0.144 3.256 INTER 
13 24 MET 0 25 LYS C 0.086 
2.714 INTRA OF 
14 29 PRO 0 31 ASP N 
0.226 2.474 INTEL SF 
15 29 PRO C 31 ASP N 0.047 
2.853 IN17ü OF 
16 31 ASP 0 32 GLY C 0.508 
2.392 INTRA BP 
17 31 ASP 0 32 GLY 0 0.399 
2.001 INTER OF 
18 31 ASP C 32 GLY 0 
0.39 2.41 INTER OF 
19 31 ASP C 32 OLY C 0.225 
2.575 INTER OF 
20 35 ILE CG2 36 ILE N 0.078 
3.022 INTRA OF 
21 43 TYR CO 44 LOU N 0.174 
2.926 INTRA 
22 44 LOU 0 45 ASP C 0.019 2.781 INTER OF 
23 49 ALA 0 54 OLD N 0.02 2.53 INCUR OF 
24 52 ALA 0 53 HIS CB 0.049 2.751 INTRA By 
25 56 ASP OD1 252 ARG NH2 0.102 2.448 INTRA OF 
26 61 ASP Co 62 ALA N 0.006 3.094 INTER 
27 71 THE C02 72 PRO CA 0.112 3.088 INTRA OF 
28 72 PRO C 74 ASH ND2 0.238 2.862 INTRA OF 
29 73 ASN 0 74 ASN C 0.103 2.697 INTER OF 
30 79 VAL CGl 80 ALA N 0.021 3.079 INTRA 
31 103 SBR N 104 ANN H 0.039 2.561 INTRA B3 
32 106 01.8 0161 229 THE C 0.011 2.789 INTRA 
33 110 LEU 0 111 GIN C 0.114 2.686 INTRA 
34 115 SER 00 155 SBR OG 0.031 2.219 INTRA HB 
35 116 CYO SO 192 CYS C 0.043 3.357 INTER 
36 128 ILS CS 129 PRO CD 0.131 3.069 IN71tA 
37 128 ILS 0 129 PRO C 0.026 2.774 INTRA 
38 135 CYS 0 141 ARG 
NH2 0.269 2.431 INTRA OF 
39 137 LOU Co 138 PRO 
CD 0.018 3.182 INTER OF 
40 137 LBU 0 138 PRO 
C 0.009 2.791 INTRA BF 
41 138 PRO 0 139 
GLU C 0.046 2.754 INTRA OF 
42 142 LYS CA 143 PRO 
CA 0.016 2.784 INTER or 
43 143 PRO 0 144 
LOU C 0.06 2.74 INTER OF 
44 157 VAL 0 158 PRO 
C 0.108 2.692 INTRA 
45 158 PRO C 159 CYS SO 0.112 
3.288 INTER 
46 164 ASP C 165 PHR CO 
0.001 3.199 INTER OF 
47 172 CYS 0 173 PRO C 
0.009 2.791 INTRA 
48 175 CYS 0 176 GLY C 
0.055 2.745 INTRA 
49 178 SBR C 180 VAL N 0.006 
2.894 INTER 
50 183 TYR C 188 GLY CA 
0.038 3.162 INTRA 
51 184 PHB CO 185 GLY N 0.083 3.017 INTRA 
52 186 TYR OH 247 HIS 
NE2 0.076 2.474 INTRA HB 
53 188 OLY 0 189 ALA 
C 0.002 2.798 INTRA 
54 202 PHE C 203 VAL 031 0.001 3.199 INTER 
55 204 LYS NZ 294 LYS NZ 0.486 2.514 INTRA 
56 204 LYS NZ 294 LYS CE 0.017 3.083 INTRA 
57 206 GLU 0 207 THE C 0.114 2.686 INTRA 
58 212 LOU CA 213 PRO CD 
0.086 2.714 INTRA B3 
59 252 ARG 881 255 ASP 0 0.375 
2.175 INTER OF 
60 252 ARG NH1 255 ASP C 0.133 2.967 INTER OF 
61 254 VAL 0 255 ASP CD 0.019 2.781 INTRA OF 
62 260 LOU 0 261 ILB C 0.002 2.798 INTRA OF 
63 263 GLU 0 267 GIN Co 0.065 2.735 INTRA OF 
64 267 GLN 0 268 ALA C 0.031 2.769 INTRA 
65 275 ASP CG 276 LYS N 0.104 2.996 INTRA OF 
66 279 ASP N 280 PHE N 0.02 2.58 INTRA OF 
67 284 SBR 0 285 SER CB 0.014 2.786 INTRA 
68 302 LYS CD 303 VAL 
N 0.051 3.049 18CR 1 OF 
69 304 PRO CA 305 PRO 
CD 0.137 2.663 INTRA OF 
70 314 OLY 0 318 
VAL 032 0.01 2.79 INTRA OF 
71 316 GLU 0 317 
TYR C 0.021 2.779 INTER OF 
72 323 ANN 0 324 
LEO C 0.021 2.779 INTER OF 
73 330 PRO C 331 
ASP 0 0.212 2.588 INTRA OF 
74 331 ASP 0 333 
LEG N 0.321 2.379 INTRA OF 
75 331 ASP 0 332 PRO 
C 0.185 2.615 INTRA OF 
76 331 ASP CB 332 
PRO CD 0.022 3.178 INTRA OF 
77 334 0117 0 335 
ASP CB 0.08 2.72 INTRA OF 
78 336 GLU N 337 
CYS N 0.036 2.564 INTRA BF 
79 337 CYS SG 
595 LYS CD 0.041 3.359 INTRA OF 
80 342 TRP N 365 
GLU 0 0.096 2.454 INTRA BP 
81 345 LBG 0 
346 GLY 0 0.274 2.126 INTER OF 
82 345 LBG 0 346 
GLY C 0.17 2.63 INTER OF 
83 345 LBG C 
346 GLY 0 0.009 2.791 INTRA OF 
84 351 LOU 0 
352 LYS C 0.04 2.76 INTER OF 
85 352 LYS NZ 
616 MET 0 0.04 2.51 INTRA OF 
86 353 CYS C 366 
CYS SG 0.233 3.167 INTRA BF 
87 353 CYS 0 354 
ASP C 0.099 2.701 INTRA BP 
88 354 ASP 0 355 
GLU C 0.008 2.792 INTRA OF 
89 355 GLU CG 614 
POE CD1 0.026 3.174 INTRA BP 
90 357 SER 0 358 
VAL C 0.305 2.495 INTRA BP 
91 357 SER C 358 
VAL C 0.029 2.771 INTRA BF 
92 370 GLU C 
371 THE 002 0.037 3.163 INTRA OF 
93 371 THE CB 
372 PRO CD D. 024 3.176 INTRA BP 
94 373 GLU 082 
663 SRR 00 0.187 2.063 INTER OF 
95 373 GLU 0 374 
ASP C 0.009 2.791 IN RA OF 
96 375 CYS CB 387 
MST SD 0.043 3.357 INTRA OF 
97 375 CYS CB 
387 MET CH 0.004 3.196 INTRA OF 
98 377 ALA CA 
380 MST CE 0.169 3.031 INTRA OF 
99 390 ASP CO 
391 GLY N 0.058 3.042 INTRR 
100 390 ASP 0 
391 GLY C0 014 2.786 INTRA 
101 395 TYR 0 396 218 C 0.022 2.776 Bº 
102 396 ILS 0 397 ALA C 0.01 2.79 TRA BP 
103 399 MN N 400 CYS N 0.019 2.581 INTRA BP 
104 405 VAL COl 406 LSU N 0.416 2.684 INTRA BP 
105 415 CYS N 632 CYS 80 0.209 3.091 INTRA BP 
106 416 LYS 0 637 ARG NH2 0.322 2.226 INTRA Bp 
107 416 LYS N 417 LYS N 0.016 2.562 INTRA BP 
108 431 LYS 0 432 HER C 0.164 2.636 INTRA BP 
109 432 HER 00 433 ASH N 0.135 2.565 INTRA or 
110 437 ASH 0 436 TRP C 0.006 2.794 TNTRA BP 
111 441 LBO 0 442 OLU C 0.171 2.629 INTRA Bp 
112 445 LYS NZ S24 ASP OD2 0.016 2,532 INTRA or 
113 457 TRP 0 458 ASN C 0.107 2.693 INTRA 
114 459 ILS N 460 PRO CD 0,131 2.869 INTRA 
115 459 ILR CB 460 PRO CD 0.059 3.141 INTRA 
116 465 TYR C 467 ARG N 0.152 2.746 INTRA Bp 
117 465 TSR 0 467 ARG N 0.103 2.597 INTRA HP 
118 465 TYR CS1 471 CIS BO 0.051 3.349 INTRA BP 
119 465 TYR CB1 660 CYS 90 0.048 3.352 INTRA SP 
120 472 ARO NB 475 OLU 091 0,197 2.353 INTRA HP 
121 472 ARG NS 475 OLU CD 0.077 3.023 INTRA Bp 
122 402 ALA 0 483 PRO C 0.075 2.775 2N776A BP 
123 486 GLN 0 488 ASN N 0.198 2.502 INTRA or 
124 486 OLN 0 487 LYS C 0,137 2.663 INTIUI BP 
175 490 SUR 0 492 CYS N 0.061 2.639 INTRA Bp 
126 490 SIR C 492 CYS N 0.024 2.676 INTRA BP 
127 492 CYS N 493 OLU N 0.106 2.494 INTRA BP 
128 495 CYS C 496 VAL 001 0.055 1.145 INTRA or 
129 495 CYS CB 507 OLU 021 0.028 7.172 INTRA UP 
130 496 VAL C02 497 OLY N 0.261 2.839 tlTRA or 
131 496 VAL 0 497 OLY C 0.242 2.858 INTRA Bp 
132 496 VAL C 497 OLY 0 0,138 2.662 1NTRA Bp 
133 496 VAL 0 497 OLY 0 0,079 2.321 INTRA HP 
134 496 VAL C 497 GLY C 0.004 7.796 TNTRA Hp 
135 497 01.0 0 498 PRO C 0.319 2.481 INTRA BP 
136 497 01.0 CA 50S OLY N 0.051 3.049 tNTRA or 
137 497 OLY C 498 PRO C 0,05 2.75 INTRA BP 
138 500 VAL 0 501 CYS Co 0.137 2.663 INTRA Bº 
139 505 ASN NO2 624 LBO CD2 0.088 3.012 INTRA 8º 
140 506 ARO N 507 OLU N 0.007 2.593 INTRA BP 
141 517 ARG 0 513 CYS C 0.225 2.575 INTRA HP 
142 521 OLU C 522 LYS CO 0.098 3.102 IN71tA SP 
143 543 GLU 0 544 PRO C 0.091 2.709 INTRA UP 
144 550 LYS C 552 OLO N 0.107 2,793 INTRA SP 
145 550 LYS 0 551 OLU C 0.061 2.739 INTRA SP 
146 550 LYS 0 552 OLU N 0.02 2.611 INTRA HP 
147 567 SIR N 560 OLU N 0.012 2.588 INTRA 113 
148 568 OLU 0 569 ALA C 0.224 2.576 INTRA 
149 569 ALA 0 570 HIS C 0.149 2.651 INTRA 
150 569 ALA 0 572 CYS N 0.021 2.529 INTRA NB 
151 579 ASH 0 580 HIS C 0.002 2.790 INIRA 
152 585 ARO 0 586 LYB C 0.067 2,733 INTRA Bp 
153 586 LYS 0 581 ASP C 0.359 2.441 INTRA Bº 
154 586 LYS C 587 ASP C 0.059 2.741 INTRA Bº 
155 586 LYS 0 589 ALA C 0.066 2.734 INTRA BP 
156 590 ALA 0 591 CYS C 0.37 2.43 INTRA BP 
157 590 ALA C 591 CYS C 0.11 2.69 INTRA  P 
158 592 VAL 0 593 LYS C 0.04 2.76 INTRA BP 
159 593 LYS 0 594 GIN C 0.13 2.67 INTRA BP 
160 593 LYS 0 596 LBU N 0.093 2.457 INTRA BP 
161 593 LYS NZ 635 ASP OD2 0.056 2.494 INTRA BP 
162 596 LSO 0 597 LRU C 0.043 2.757 INTRA or 
163 598 ASP 0 599 LSU C 0.025 7,775 INTRA or 
164 604 OLY 0 605 ASH C 0.096 2,707 INTRA BP 
165 605 ASH 001 606 THR N 0.163 2.387 INTRA By 
166 605 ASN CO 606 THR N 0.092 3.008 INTRA BP 
167 607 VAL CO1 615 CYS 80 0.149 3.251 INTRA HP 
168 613 LYS CO 614 PHB N 0.141 2.959 INTRA SP 
169 619 SER 0 620 LYS C 0.062 2.738 INTRA BP 
170 621 THR C02 622 LYS N 0.551 2.549 INTRA SP 
171 641 THR 0 645 TYR N 0.027 2.523 INTRA BP 
172 647 OLY 0 648 ALA C 0.023 2.777 INTRA BP 
173 646 ALA 0 649 ASP C 0.035 2.765 INTRA SP 
174 651 ILS 0 652 LYS C 0.092 2.708 INTRA BP 
175 655 SSR 0 656 ASN C 0.017 2.783 INTRA BP 
176 660 CYS 0 661 HIN C 0.129 2.671 INTRA BP 
177 660 CYS C 661 SIR 0 0.001 2.799 INTRA BP 
176 661 88R C 662 THR C02 0 08 3.12 INTRA BP 
179 662 THR N 663 SIR N 0.149 7.451 INTRA BP 
180 671 PHI 0 672 HIS C 0.05 2.75 TN7RA 1W 
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1.6. Observed frequencies of amino acid replacements between closely related 
proteins (Dayhoff et al 1978). 
10 37 
2 10 30 
7 66 25 
I 3 8 21 6 
3 3 2 
4S 77 4 3 2 2 12 
5 59 19 5 13 3 1 70 
10 11 1 4 4 43 17 
1 9 3 8 1 2 5 4 5 
10 15 2 1 10 6 53 8 
II 27 4 2 4 1 9 3 9 42 83 
6 6 2 4 4 9 17 20 32 15 10 
3 2 2 3 2 1 14 2 2 12 9 48 
2 3 4 I 3 1 23 24 4 2 2 10 
2 2 1 17 9 2 4 I I I 2 
2 2 2 1 3 2 2 4 I I 4 26 
2 3 FT 
5 35 5 4 1 1 27 7 3 9 1 4 4 7 5 
1.7. Peptide Library of TfR1 
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34 LVHANFGTKKDFE 59 AQRDAWGPGAAKS 84 ELNKVARAAAEVA 
35 TKKDFEDLYTPVN 60 PGAAKSGVGTALL 85 AAAEVAGQFVIKL 
36 LYTPVNGSIVIVR 61 VGTALLLKLAQMF 86 QFVIKLTHDVELN 
37 SIVIVRAGKITFA 62 KLAQMFSDMVLKD 87 HDVELNLDYERYN 
38 GKITFAEKVANAE 63 DMVLKDGFQPSRS 88 DYERYNSQLLSFV 
39 KVANAESLNAIGV 64 FQPSRSIIFASWS 89 QLLSFVRDLNQYR 
40 LNAIGVLIYMDQT 65 IFASWSAGDFGSV 90 DLNQYRADIKEMG 
41 IYMDQTKFPIVNA 66 GDFGSVGATEWLE 91 DIKEMGLSLQWLY 
42 FPIVNAELSFFGH 67 ATEWLEGYLSSLH 92 SLQWLYSARGDFF 
43 LSFFGHAHLGTGD 68 YLSSLHLKAFTYI 93 ARGDFFRATSRLT 
44 HLGTGDPYTPGFP 69 KAFTYINLDKAVL 94 ATSRLTTDFGNAE 
45 YTPGFPSFNHTQF 70 LDKAVLGTSNFKV 95 DFGNAEKTDRFVM 
46 FNHTQFPPSRSSG 71 TSNFKVSASPLLY 96 TDRFVMKKLNDRV 
47 PSRSSGLPNIPVQ 72 ASPLLYTLIEKTM 97 KLNDRVMRVEYHF 
48 PNIPVQTISRAAA 73 LIEKTMQNVKHPV 98 RVEYHFLSPYVSP 
49 ISRAAAEKLFGNM 74 NVKHPVTGQFLYQ 99 SPYVSPKESPFRH 
50 KLFGNMEGDCPSD 75 GQFLYQDSNWASK 100 ESPFRHVFWGSGS 
51 GDCPSDWKTDSTC 76 SNWASKVEKLTLD 101 FWGSGSHTLPALL 
52 KTDSTCRMVTSES 77 EKLTLDNAAFPFL 102 TLPALLENLKLRK 
53 MVTSESKNVKLTV 78 AAFPFLAYSGIPA 103 NLKLRKQNNGAFN 
54 NVKLTVSNVLKEI 79 YSGIPAVSFCFCE 104 NNGAFNETLFRNQ 
55 NVLKEIKILNIFG 80 SFCFCEDTDYPYL 105 TLFRNQLALATWT 
56 ILNIFGVIKGFVE 81 TDYPYLGTTMDTY 106 ALATWTIQGAANA 
57 IKGFVEPDHYVVV 82 TTMDTYKELIERI 107 QGAANALSGDVWD 
58 DHYVVVGAQRDAW 83 ELIERIPELNKVA 108. SGDVWDIDNEF 
Appendix II. Molecular Biology 
III. Bacterial Strains 
BL21 (DE3): hsdS, gal, (AcIts8S7, ind1, Sam7, ninS, lacUVS-T7 gene]) 
A strain employed for high-level expresson of genes cloned into expression vectors 
containing bacteriophage T7 promoter. bacteriophage T7 RNA polymerase is carried 
on the bacteriophage ? DE3, which is integrated into the chromosome of BL21 
DH5a: 80dlacZAMIS, recAl, endA1, gyrA96, thi-1, hsdR17, supE44, relAl, deoR, d(lac-ZYA-argF) U169, 
phoA 
DH5a is a well-known, versatile strain that can be used in many everyday cloning 
applications. In addition to supporting blue/white screening, recA1 and endAl 
mutations in DH5cz is thought to increase insert stability and improve the quality of 
plasmid DNA prepared from minipreps. 
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JM109: recAl, supE44, endAl, hsdRl7, gyrA96, relA1, thi, d(lac proAB), F'[traD36, proAB', lacl', 
lacZAMls] 
A recombination-deficient strain that will support growth of vectors carrying a 
number of mutations and will modify, but not restrict, transfected DNA (Yanisch- 
peron et al. 1985). 
OrigamiTM 
host strains are K-12 derivatives that have mutations in both the thioredoxinreductase 
(trxB) and glutathione reductase (gor) genes, which greatly enhances disulfide 
bondformation in the cytoplasm (13). Studies have shown that expression in 
Origami(DE3) yielded 10-fold more active protein than in a trxB single mutant host 
even though overall expression levels were similar(Prinz et al., 1997). Origami hosts 
are not compatible with kanamycin or tetracycline resistantplasmids. Origami hosts 
are ideal for use with pET-32 vectors, since the thioredoxin fusion tag further 
enhances the formation of disulfide bonds in the cytoplasm. OrigamiTM (DE3) strains 
are the same as Origami but are lysogenic for aX prophage that contains an IPTG 
inducible T7 RNA polymerase. 
XL-! Blue: recAl, endAl, gyrA96, thi-1, hsdR17(rr, mk+), supE44, relAI, lac, (f, proAB, 
lacllZAM1 S:: Tn10(tet')J 
Strain of choice for preparation of high-quality plasmid DNA, or use in difficult 
transformations. Allows blue-white color screening and single-strand rescue of 
phagemid DNA. Contains an tetracycline-resistant F episome, eliminating time- 
consuming selection on minimal media plates. 
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Appendix 
II. 2. Vectors 
pALTER-Ex l (Promega) 
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Appendix 
pDB2536 (Delta Biotechnology) 
11 
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11.3. DNA ladders 
i. Lambda / EcoRI / Hindill Marker 
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ii. 1 Kb DNA ladder 
DNA Mass 
K[b ses (n9) 
IQ 4DD 42 
- BD 42 
6.0 5ß 
5.0 42 







All oligonucleotides were supplied by Sigma-Genosys. 
Peter J Sargent 
CF 124 35 CCATGAGCTT GGATGGAAGA TTTGTCTACA TAGCG 
CF125 35 CGCTATGTAG ACAAATCTTC CATCCAAGCT CATGG 
DS181 24 CTCAACCAGG CCCAGGAACA TTTT 
DS 182 19 AGAGACCACC GAAGACTGC 
DS 185 22 GACAGAAACA CATATGAAAA AT 
DS 186 19 GGAGATGTGG CCTTTGTGA 
hLFRI 20 AGCACAGAGA TTAGATCTCG 
hLFFI 20 ACAGGGGAAA ACAAATGTGC 
hLFF2 19 ATCATGCCGT GGTGTCTCG 
hLFR2 19 TCTTTATGCA GCTGACAGG 
HLf PCR fwd 41 GGAATTCAGT ACTGGATCCA TGGGTCGACG 
HU PCRbck 45 TCCGCTCGAG CAATTGAAGC TTTACTTCCT 
hTrfFwd 41 GGAATTCTCG AGGCCGCCAC CATGAGGCTC 
HSTFRI 18 AGCAGCCACA CCCTGGAC 
HSTFFI 22 TTACTTTACT GTGACTTACC TG 
HSTFF2 19 ATGGATGCCA AGATGTACC 
HSTFF3 21 AACAACAAAG AGGGATACTA C 
hSTfp2ldFwd 33 CGCGGATCCA TGGTCCCTGA TAAAACTGTG AGA 
HSTfp2IdBck 33 CTGAAGATCT TCTTTTGACC CATAGAACTC TGC 
hTrfBck 38 TTTTCCTTTT GCGGCCGCTT AAGGTCTACG GAAAGTGC 
LFPompTK5-3 46 CTAGAAATAA TTTTGTTTAA CTTTAAGAAG 
LFPompTK3-5 46 TCGACCCATA TGTATATCTC CTTCTTAAAG 
PET2 I d-insert53 45 CTAGAAATAA TTTTGTTTAA CTTTAAGAAG 
PET2 I d-insert3 5 45 TCGACCATGG ATCCATCTCC TTCTTAAAGT 
TfG394R-CKF 20 GCTGTTTAAG GACTCTGCCC 
TfG394R-CKR 20 AGACAGCAAA ATACCCTGCC 
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11.5. The hSTf (N413Q, N611Q) cDNA insert present in the yeast expression 
vectors pDB2529 and pDB2536. Sequence in red highlights hSTf. 
1 atgaagtggg ttttcatcgt ctccattttg ttcttgttct cctctgctta ctctagatct ttggataaga gagtccctga 
MKWVFIVSILFLFSSAYSRSLDKRVP 
81 taaaactgtg agatggtgtg cagtgtcgga gcatgaggcc actaagtgcc agagtttccg cgaccatatg aaaagcgtca 
DKTVRWCAVSEHEATKCQSFRDHMKSV 
161 ttccatccga tggtcccagt gttgcttgtg tgaagaaagc ctcctacctt gattgcatca gggccattgc ggcaaacgaa 
IPSDGPSVACVKKASYLDCIRAIAANE 
241 gcggatgctg tgacactgga tgcaggtttg gtgtatgatg cttacctggc tcccaataac ctgaagcctg tggtggcaga 
ADAVTLDAGLVYDAYLAPNNLKPVVA 
321 gttctatggg tcaaaagagg atccacagac tttctattat gctgttgctg tggtgaagaa ggatagtggc ttccagatga 
EFYGSKEDPQTFYYAVAVVKKDSCFQM 
401 accagcttcg aggcaagaag tcctgccaca cgggtctagg caggtccgct gggtggaaca tccccatagg cttactttac 
NQLRGKKSCHTGLGRSAGWNIPIGLLY 
481 tgtgacttac ctgagccacg taaacctctt gagaaagcag tggccaattt cttctcgggc agctgtgccc cttgtgcgga 
CDLPEPRKPLEKAVANFFSGSCAPCA 
561 tgggacggac ttcccccagc tgtgtcaact gtgtccaggg tgtggctgct ccacccttaa ccaatacttc ggctactcgg 
DGTDFPQLCQLCPGCGCSTLNQYFGYs 
641 gagccttcaa gtgtctgaag gatggtgctg gggatgtggc ctttgtcaag cactcgacta tatttgagaa cttggcaaac 
GAFKCLKDGAGDVAFVKHSTIFENLAN 
721 aaggctgaca gggaccagta tgagctgctt tgcctggaca acacccggaa gccggtagat gaatacaagg actgccactt 
KADRDQYELLCLDNTRKPV0EYKDCH 
801 ggcccaggtc ccttctcata ccgtcgtggc ccgaagtatg ggcggcaagg aggacttgat ctgggagctt ctcaaccagg 
LAQVPSHTVVARSMGGKEDLIWELLNQ 
881 cccaggaaca ttttggcaaa gacaaatcaa aagaattcca actattcagc tctcctcatg ggaaggacct gctgtttaag 
AQEHFGKDKSKEFQLFSSPHGKDLLFK 
961 gactctgccc acgggttttt aaaagtcccc cccaggatgg atgccaagat gtacctgggc tatgagtatg tcactgccat 
DSAHGFLKVPPRMDAKMYLGYEYVTA 
1041 ccggaatcta cgggaaggca catgcccaga agccccaaca gatgaatgca agcctgtgaa gtggtgtgcg ctgagccacc 
IRNLREGTCPEAPTDECKPVKWCALSH 
1121 acgagaggct caagtgtgat gagtggagtg ttaacagtgt agggaaaata gagtgtgtat cagcagagac caccgaagac 
HERLKCDEWSVNSVGKIECVSAETTED 
1201 tgcatcgcca agatcatgaa tggagaagct gatgccatga gcttggatgg agggtttgtc tacatagcgg gcaagtgtgg 
CIAKIMNGEADAMSLDGGFVYIAGKC 
1281 tctggtgcct gtcttggcag aaaactacca aaagagcgat aattgtgagg atacaccaga ggcagggtat tttgctgtag 
GLVPVLAENYQKSDNCEDTPEAGYFAV 
1361 cagtggtgaa gaaatcagct tctgacctca cctgggacaa tctgaaaggc aagaagtcct gccatacggc agttggcaga 
AVVKKSASDLTWDNLKGKKSCHTAVGR 
1441 accgctggct ggaacatccc catgggcctg ctctacaata agatcaacca ctgcagattt gatgaatttt tcagtgaagg 
TAGWNIPMGLLYNKINHCRFDEFFSE 
1521 ttgtgcccct gggtctaaga aagactccag tctctgtaag ctgtgtatgg gctcaggcct aaacctctgt gaacccaaca 
GCAPGSKKDSSLCKLCMGSGLNLCEPN 
1601 acaaagaggg atactacggc tacacaggcg ctttcaggtg tctggttgag aagggagatg tggcctttgt gaaacaccag 
NKEGYYGYTGAFRCLVEKGDVAFVKHQ 
1681 actgtcccac agaacactgg gggaaaaaac cctgatccat gggctaagaa tctgaatgaa aaagactatg agttgctgtg 
TVPQNTGGKNPDPWAKNLNEKDYELL 
1761 ccttgatggt accaggaaac ctgtggagga gtatgcgaac tgccacctgg ccagagcccc gaatcacgct gtggtcacac 
CLDGTRKPVEEYANCHLARAPNHAVVT 
1841 ggaaagataa ggaagcttgc gtccacaaga tattacgtca acagcagcac ctatttggaa gccaagtaac tgactgctcg 
RKDKEACVHKILRQQQHLFGSQVTDCS 
1921 ggcaactttt gtttgttccg gtcggaaacc aaggaccttc tgttcagaga 
tgacacagta tgtttggcca aacttcatga 
GNFCLFRSETKDLLFRDDTVCLAKLH 
2001 cagaaacaca tatgaaaaat acttaggaga agaatatgtc aaggctgttg gtaacctgag aaaatgctcc acctcatcac 
DRNTYEKYLGEEYVKAVGNLRKCSTSS 
2081 tcctggaagc ctgcactttc cgtagacctt aataa 
LLEACTFRRp- 
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Appendix III: Crystallisation 
111.1. Crystal Screen 1: Hampton Research 
Salt Buffer pH Precipitant 
I 0 02M Calcium chloride dihydrate 0.1M Sodium acetate trihydrate 4.6 30 %v/v 2-methyl-2,4-pentenediol 
2 0 4M Potassium sodium tartrate tanhydrate 
3 0 4M Ammonium dihydrogen phosphate 
4 0.1M Tris hydrochloride 8.5 2M Ammonium sulfate 
5 0.2M tri-Sodium citrate dihydrate 0.1M Sodium HEPES 7.5 30 %v/v 2-methyl-2,4-pentanediol 
6 0 2M magnesium chloride hexahydrate 0.1M Tris hydrochloride 85 30 %w/v PEG 4000 
7 0 IM sodium cacodylate 6.5 I. 4M sodium acetate trihydrate 
8 0.2M tri-sodium citrate dihydrate 0.1 M sodium cacodylate 6.5 30 %v/v iso-propanol 
9 0 2M ammonium acetate 0.1 M tri-sodium citrate dihydrate 5.6 30 3w/v PEG 4000 
10 0 2M ammonium acetate 0.1 M Sodium acetate trthydrate 46 30 %w/v PEG 4000 
11 0.1 M trrsodium citrate dihydrate 5.6 IM Ammonium dihydrogen phosphate 
12 0.2M magnesium chloride hexahydrate 0.1 M Sodium HEPES 7.5 30 %v/v iso-propanol 
13 0 2M tri-Sodium citrate dihydrate OA M Tris hydrochloride 8.5 30 %v/v PEG 400 
14 0 2M Calcium chloride dihydrate 0.1 M Sodium HEPES 7.5 28 %v/v PEG 400 
15 0 2M ammonium sulfate 0.1 M sodium cacodylate 6.3 30 %w/v PEG 8000 
16 0 1M Sodium HEPES 7.5 1 SM lithium sulfate monohydrate 
17 0 2M lithium sulfate monohydrate 0.1 M Tris hydrochloride 85 30 %w/v PEG 4000 
18 0.2M magnesium acetate tetrahydrate 0IM sodium cacodylate 6.5 20 %w/v PEG 8000 
19 0,2M ammonium acetate 0.1 M Tns hydrochloride 8.3 30 %v/v Iso-propanol 
20 0,2M ammonium sulfate 0.1 M Sodium acetate trihydrate 4.6 25 %w/v PEG 4000 
21 0.2M magnesium acetate tetrahydrate 0.1M sodium cacodylate 6.5 30 %v/v 2-methyl-2,4-pentanediol 
22 0 2M sodium acetate tnhydrate 0.1 M Tris hydrochloride 85 30 %w/v PEG 4000 
23 0 2M magnesium chloride hexahydrate 0.1 M Sodium HEPES 7.3 30 %v/v PEG 400 
24 0,2M Calcium chloride dihydrate 0.1 M Sodium acetate trihydrate 4.6 20 %v/v iso-propenol 
25 0.1M imidazole 6.5 IM sodium acetate trihydrate 
26 0 2M ammonium acetate 0 1M tri-sodium citrate dihydrate 5.6 30 %v/v 2-methyl-2,4-pentanediol 
27 0 2M tn-Sodium citrate dehydrate 01M Sodium HEPES 73 20 3v/v iso-propanol 
28 0.2M sodium acetate trihydrate 0.1 M sodium cacodylate 6.5 30 3w/ PEG 8000 
29 0.1 M Sodium HEPES 75 0 8M Potassium sodium tartrate tetrahydrate 
30 0 2M ammonium sulfate 30 %w/v PEG 8000 
31 0.2M ammonium sulfate 30 %w/v PEG 4000 
32 2M Ammonium sulfate 
33 4M sodium formate 
34 0 IM sodium acetate tnhydrate 46 2M sodium formate 
35 O. IM Sodium HEPES 7.3 0.8M sodium dihydrogen phosphate, 
0,8M potassium dthydrogen phosphate 
36 0.1M Tru hydrochloride 83 834w/v PEG 8000 
37 01 M Sodium acetate trihydrate 46 8 %w/v PEG 4000 
38 01M Sodium HEPES 75 1.4M tri-sodium citrate dehydrate 
39 0 IM Sodium HEPES 7.5 2 Yev/v PEG 400,2M ammonium sulfite 
40 0 IM tri-sodium citrate dihydrate 5.6 20 %v/v iso-propanol, 20% (w/v) PEG 4000 
41 0IM Sodium HEPES 75 10 %v/v iso-propanol, 20% (w/v) PEG 4000 
42 0.05M potassium dihydrogen phosphate 20 %w/v PEG 8000 
43 30 %w/v PEG 1 S00 
44 0.2M magnesium formate 
45 0 2M zinc acetate dthydrate 0. IM sodium cacodylate 6.5 18 3wh PEG 8000 
46 0.2M calcium acetate hydrate 0.1M sodium cacodylate 65 18 3w/v PEG 8000 
47 0.1M Sodium acetate trihydrate 46 2M Ammonium sulfate 
48 0 IM Tris hydrochloride 83 2M Ammonium dihydrogen phosphate 
49 IM lithium sulfate monohydrate 2yw/v PEG 8000 
50 0.5M lithium sulfate monohydrate I S3w/v PEG 8000 
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111.2. Crystal Screen 2: Hampton Research 
Salt Buffer pH Precipitant 
1 2M sodium chloride I0%w/v PEG 6000 
2 0.5M sodium chloride 0.01M heaadecyhrimethylammonium bromide 
0 01M magnesium chloride hexahydrate 
3 25%v/v ethylene glycol 
4 35%v/v dioxane 
5 2M ammonium sulfate 5%v/v iso-propanol 
6 7.0 IM imidazole 
7 10%w/v PEG 1000,10%w/v PEG8000 
8 1 SM sodium chloride 10Yev/v ethanol 
9 0. IM sodium acetate trihydrate 46 2M sodium chloride 
10 0 2M sodium chloride 0.1 M sodium acetate trihydrate 46 30 /. v/v MPD 
I1 0 OlM cobaltous chloride hexahydrate 0.1M sodium acetate trihydrate 4.61 M 1,6 hexanediol 
12 0IM cadmium chloride dihydrate 0.1 M sodium acetate trihydrate 46 30%w/v PEG 400 
13 0 2M ammonium sulfate 0. IM sodium acetate trihydrate 4,6 %0%v PEG monomethyl ether 2000 
14 0 2M potassium sodium tartrate tetrahydrate 0. IM tri-sodium citrate dihydrate 5.6 2M ammonium sulfate 
15 0 5M ammonium sulfate 0 IM tri-sodium citrate dihydrate 5.6 IM lithium sulfate monohydrate 
16 0 5M sodium chloride 0. IM tri-sodium citrate dihydrate 5.6 2%v/v ethylene imine polymer 
17 O. 1M tn-sodium citrate dihydrate 5.6 35%v/v tart-butanol 
18 0. OIM ferric chloride hexahydrate 0.1M tri-sodium citrate dihydrate 5.610%v/v jeffamine M-600 
19 O. lM tri-sodium citrate dihydrate 5.6 2. SM 1,6 hexanediol 
20 O. 1M MES 6.5 1.6M magnesium sulfate heptahydrate 
21 0 IM sodium dihydrogen phosphate 0. IM MES 6.5 2M sodium chloride 
0. IM potassium dihydrogen phosphate 
22 0.1 M MES 6.5 12°/ow/v PEG 20,000 
23 1 6M ammonium sulfate 0 IM MES 6.5 10°/av/v dioxane 
24 0 05M cesium chloride O. 1M MES 6.5 30%v/v jeffamine M-600 
25 0.01M cobaltous chloride hexahydrate 0. IM MES 6.5 1.8M ammonium sulfate 
26 0,2M ammonium sulfate 0 IM MES 6.5 30Yaw/v PEG monomethyl other 5000 
27 0 OIM zinc sulfate heptahydrate O. IM MES 6.5 25%v/v PEG monomethyl ether 530 
29 6.5 1.6M tri-sodium Citrate dihydrate 
29 0 SM ammonium sulfate O. IM HEPES 75 30%v/v MPD 
30 0.1M HEPES 7.5 10%w/v PEG 6000, S%v/v MPD 
31 0 IM HEPES 7.5 20%v/v jeffamine M-600 
32 0 IM sodium chloride 0 IM HEPES 7.5 1.6M ammonium sulfate 
33 O. 1M HEPES 7.5 2M ammonium formate 
34 0 05M cadmium sulfate hydrate 0 IM HEPES 7.5 1M sodium acetate trihydrate 
35 0 IM HEPES 7.5 70%v/v MPD 
36 0.1M HEPES 7.5 4.3M sodium chloride 
37 0.1M HEPES 7.5 10%w/v PEG 8000 
38 0.1M HEPES 7.5 20%w/v PEG 10,000,8%v/v ethylene glycol 
39 0.2M magnesium chloride hexahydrate 0 IM trig 853.4M 1,6 hexanediol 
40 0. I M tris 8.5 25%v/v tert-butanol 
41 0oiM nickel (II) chloride hexahydrate 0.1M iris 8.5 IM lithium sulfate monohydrste 
42 1 5M ammonium sulfate 0 IM iris 8.5 12%v/v glycerol anhydrous 
43 0 2M ammonium dihydrogen phosphate 0 IM iris 85 50%v/v MPD 
44 O, IM trig 8.3 20°/. v/v ethanol 
45 001M nickel (H) chloride hexahydrate 0 IM iris 8.5 20%w/v PEG monomethyl ether 2000 
46 0 IM sodium chloride 0.1M bicine 9.0 20%v/v PEG monomethyl ether 550 
47 0. IM bicine 9,0 2M magnesium chloride hexahydrate 
48 0. IM bicine 9.0 2%v/v dioxane, I0%w/v PEG20000 
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111.3. Crystallisation Screen 3: hLf-In3+ 
Salt Buffer pH Precipitant 
1 0 OI M Tria Base 7.5 5% (v/v) Ethanol 
2 0.01M Tris Base 7.5 10% (v/v) Ethanol 
3 0.01M Iris Base 7.5 15% (v/v) Ethanol 
4 0.01M Tris Base 75 20% (v/v) Ethanol 
5 0.01 M Trio Base 7.5 25% (v/v) Ethanol 
6 0.01M Tris Base 7.5 30% (v/v) Ethanol 
7 O. OIM Tru Base 8.0 5% (v/v) Ethanol 
8 0.01M Tris Base 8.0 10%(v/v) Ethanol 
9 0.01M Tru Base 8,0 15% Iv/v) Ethanol 
10 O. OIM Tru Base 8.0 20%(v/v) Ethanol 
I1 0.01M Tris Base 80 25% (v/v) Ethanol 
12 0.01M Trio Base 8.0 30% (v/v) Ethanol 
13 0 OIM Tns Base 8,5 5% (v/v) Ethanol 
14 0.01M Tns Base 8.5 10% (v/v) Ethanol 
15 0.01M Tris Base 8.5 15% (v/v) Ethanol 
16 0 01 M Trls Base 85 20% (v/v) Ethanol 
17 0OIMTrioBase 8.5 25% (vtv) Ethanol 
18 0.01M Trio Base 8.5 30"/. (v/v) Ethanol 
19 0.01 M Tris Base 90 5% (v/v) Ethanol 
20 0 OIM Trio Base 9.0 10% ON) Ethanol 
21 0 01M Tris Base 9.0 I5%"(v/v) Ethanol 
22 0.01M Trio Base 9.0 20% (v/v) Ethanol 
23 0 OIM Tris Base 9.0 25% (v/v) Ethanol 
24 0.01M Trio Base 9.0 30% (v/v) Ethanol 
25 0.01M Tris Base 7.5 5% (v/v) Iso-propanol 
26 0.01M Tris Base 7.5 10% (v/v) ISO-propanol 
27 0 OI M Tns Base 7.5 15% (v/v) lso-propanol 
28 0 OIM Tris Base 75 20°h (v/v) lso-propanol 
29 O. OIM Trio Base 7.5 25%(v/v) Iso-propanol 
30 0.01M Tris Base 7.5 30% (v/v) Iso-propanol 
31 0 Ol M Trio Base 8.0 5% (v/v) lao-propanol 
32 0 Ol M Tris Base so 10% (v/v) lso-propsnol 
33 0.01M Trio Base 8.0 I S% (v/v) Iso-propanol 
34 0 OIM Tris Base 8,0 20% (v/v) Ito-propsnol 
35 0.01M Trio Base 90 25%(v/v) lso-propsnol 
36 0.01M Tns Base 80 30%(v/v) Ito-propanol 
37 0 01M Tris Base 95 5% (v/v) I50-propanol 
38 0.01M Tns Base 8.5 10% (v/v) Iso-propanol 
39 O. OI M Tris Base 95 I s% (v/v) ISO-propanol 
40 O. OI M Tns Base 8.5 20% (v/v) lso-propanot 
41 O. 01M Trio Base 8.5 25% (v/v) [so-propanot 
42 0,01M Tris Base 8.5 30% (v/v) Iso-propanol 
43 0.01 M Tris Base 9.0 5% (v/v) Iso-propanol 
44 0.01M Tns Base 9.0 10%(v/v) Iso-propenol 
45 0.01M Trio Base 9.0 15% (v/v) lao-propanol 
46 0.01M Trio Base 9.0 20% (v/v) Iso-propanol 
47 0.01M Tris Base 9.0 25% (v/v) Iso-propanol 
48 0.01M Trio Base 9.0 30% (v/v) Iso-propanol 
49 0 Ol M Tns Base 7.5 5% (v/v) PEG 6000 
30 0 O1 M Tris Base 7.5 15% (v/v) PEG 6000 
51 0 OI M Tno Base 7.5 20% (v/v) PEG 6000 
52 0 OI M Tris Base 7.5 25% (v/v) PEG 6000 
53 0 OIM Tris Base 7.5 30%(v/v) PEG 6000 
54 0.01M Trio Base 75 35% (v/v) PEG 6000 
55 0 OI M Tns Base 90 5% (v/v) PEG 6000 
56 0 OIM Tru Base 8.0 15% (v/v) PEG 6000 
57 0 OIM Tru Base 8.0 20°/s (v/v) PEG 6000 
58 0 OI M Tres Base 90 25% (v/v) PEG 6000 
59 0 Ol M Us Base 8.0 30% (v/v) PEG 6000 
60 0 Ol M Tns Base 80 35% (v/v) PEG 6000 
61 0 Ol M Tris Base 8.5 5% (v/v) PEG 6000 
62 0 Ol M Tris Base 85 15% (vtv) PEG 6000 
63 0 OIM Tris Base 8.5 20% (v/v) PEG 6000 
64 0.01 M Tris Base 95 25% (v/v) PEG 6000 
65 0 olM Tris Base 8.5 30^4 (v/v) PEG 6000 
66 0.01M Tris Base 85 35% (v/v) PEG 6000 
67 0 01 M Tria Base 90 S% (v/v) PEG 6000 
68 0 01 M Tris Base 90 15% (v/v) PEG 6000 
69 0 OIM Tris Base 9.0 20% (v/v) PEG 6000 
70 0 OI M Tru Base 9.0 25% (v/v) PEG 6000 
71 0.01M Tris Base 90 30% (v/v) PEG 6000 
72 0.01 M Trio Base 90 35% (v/v) PEG 6000 
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111.4. Crystallisation of hLf-In 3+: Screen 1 
No Crystals Precipitate Crystals (3 weeks) Crystals (4 weeks) Crystals /± ýr ", "A i 
Ethanol 
ýIl I Ome/mi 
1 2 3 4 5 6 
7 8 9 10 11 12 
13 14 15 16 17 18 
19 20 21 22 23 24 
3Umg/ml 
2345 
7 10 11 12 
13 14 15 16 17 18 
19 20 21 22 23_4 
ý1Zý lOmv/mI 
1 2 3 4 5 6 
7 8 9 10 11 12 
13 14 15 16 17 18 
19 20 21 22 23 24 
30mg/ml 
23456 
789 l0 Il 12 
13 14 15 16 17 18 
97 20 21 22 23 24 1 
Isopropanol 
-W' IOmQ/mI 
25 26 27 28 29 30 
31 32 33 34 35 36 
37 38 39 40 41 42 
43 44 45 46 47 48 
ýiifý 311mQ/ml 
25 26 27 28 29 30 
31 32 34 35 36 
37 38 40 41 42 
43 44 45 46 47 48 
ýý lOma/mI 
25 26 27 28 29 30 
31 32 33 34 35 36 
37 38 39 40 41 42 
43 44 45 46 47 48 
PUL 30m&/mI 
25 26 27 28 29 30 
31 32 33 34 35 36 
37 38 39 40 41 42 
43 44 45 46 47 48 
20mg/ml 
1 2 3 4 5 6 
7 8 9 10 11 12 
13 14 15 16 17 Ix 





7 9 10 II 12 
13 14 15 to 17 18 
19 20 21 22 23 --3747d 
20me/ml 
2 3 4 5 6 
7 8 9 10 II 12 
13 14 15 16 17 18 
19 20 21 22 23 24 
20mg/ml 
26 27 28 29 30 
7 
32 33 34 35 36 
37 38 39 40 41 42 
44 45 46 47 48 
40mg/ml 
25 26 27 28 29 30 
31 32 33 34 35 36 
37 38 39 40 41 42 
43 44 45 46 47 48 
20mg/ml 
25 26 27 28 29 30 
31 32 33 34 35 36 
37 38 39 40 41 42 
43 44 45 4 47 48 
40mg/ml 
25 26 27 28 29 30 
31 32 33 34 35 36 
37 38 39 40 41 42 
43 44 45 46 47 48 
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PEG6000 
10me/ml 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 65 66 
67 68 69 70 71 72 
20me/mI 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 55 66 
67 68 69 70 11 72 
30mg/ml 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 65 66 
67 68 69 70 71 72 
10mg/ml 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 65 66 
67 68 69 70 71 72 
"i 3Umg/ml 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 65 66 
67 68 69 70 71 72 
111.5. SDS ladders 
mg/ml 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 65 66 
67 68 69 70 71 72 
20mo/ml 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 65 66 
67 68 69 70 7I 72 
yvmgi mi 
49 50 51 52 53 54 
55 56 57 58 59 60 
61 62 63 64 65 66 
67 68 69 70 71 72 
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Structure/Function Overview of Proteins Involved in Iron Storage and 
Transport 
Peter J. Sargent, Sebastien Famaud and Robert W. Evans' 
Metalloproteur Research Group, Randall Research Division of Cell and Molecular Biophysics, Kings College 
London, New Hunt'sdouse, Guy's Campus. London SEI I UL UK 
Abstract: Iron, the major trace element in the body, is an essential component of many proteins and enzymes, As 
low-molecular-weight iron is potentially toxic b calls, higher organisms axpress a nutnber of proteins for the 
transport and storage of iron We review our current urderstending of the intestinal absorption of iron in the 
light of recently identified membrane proteins, namely the ferric reducase, Dcytb, the two iron(U) transport 
proteins, DMTI and ferroportm/lregl, and hepheestun the membrane-bound homologue of the fartomdaee 
ceruloplasmm. Two types of mammalian transferrin receptor. TfRI and TfR12, are now known to aast. The 
structure ofTtRl and its role in the process of receptor-mediated cellular uptake of ban are presented together 
with structural information on the iron storage protein tannin. Mechanisms for the regulation of levels of TfRI 
and ferritm, as well as other proteins involved in iron homeostasis, are discussed Our current knowledge and 
understanding of the structure of members of the transfemn family of iron-binding proteins and the nature of the 
iron-binding centres in trensfernns is presented, together with information on the processes of iron-uptake and 
iron-release by transfecnn and a summary of the elements that have been found to bind to tremferri ne, 
Keywords: Trensferrin, ferritir, transferrin receptor. iron metabolism. 
INTRODUCTION 
With rare exceptions, virtually all organisms fruit 
Arehaeoto man are dependent on iron for survival [1]. The 
functional roles for iron include provision of a specific 
binding site for oxygen in the haem moiety of haemoglobin 
and conferment of redox activity on the cytochromes of the 
respiratory chain and on numerous enzymes, some of which 
are involved in DNA synthesis [2]. However, even though 
iron is an essential trace metal it is also toxic under certain 
conditions, for example in its non-chelated, labile form. 
Cellular iron deficiency is known to arrest cell growth and 
ultimately lead to cell death [3]. Organisms have therefore 
evolved highly sophisticated mechanisms to control on 
homeostasis in order to provide the sufficient iron to support 
life, whilst at the same time minimising its toxic effects. In 
mammals this regulation is at many levels. 
The daily iron requirement mainly for haemoglobin 
synthesis in a healthy individual is approximately 25mg. 
This varies from person to person. For instance, growing 
children and menstruating women have much higher iron 
demands. This demand increases even more for pregnant 
individuals. Iron requirements are three times higher in 
pregnancy than they are in menstruating women [4]. On 
average though, the production of 200 billion new 
erythrocytes every day requires -20mg of iron for 
haemoglobin synthesis, accounting for nearly 80% of the 
iron demand [3]. The remaining 20V. of the iron is used as a 
constituent in the production of other haemoproteins, iron- 
sulphur (Fe-S) proteins, and proteins that use iron in other 
functional groups. 
'Address correspondence to the author at the McWloprotan Research 
croup, Randall Division of Colt and Molecular Biophysics. King's College 
London, Guy's Campus, London SEI IUL; Tot: +44-20-7848-6481; Fat: 
+0420.7848.6483: E-mut: robat. ev kdlcuk 
A typical Western diet provides on average 6mg of this 
iron (both haem and non-haem) per 4120 kJ of energy intake 
[5]. However, the amount of iron absorbed is regulated 
depending on the iron status of the individual. An individual 
with high levels of iron will not absorb iron so readily as 
someone with low levels. Also, the form of iron is 
important. Food iron occurs in two forms, harm iron and 
non-haem iron. Nearly 50% of iron in meat is of the haem 
form [4]. This form is the most important dietary source of 
iron, as it is more readily absorbed than non-hum iron 
Hence vegetarians can be at a relatively greater risk for iron 
deficiency [5]. 
In normal individuals total body iron amounts to 
approximately 35 and 45mg/kg of body weight in adult 
women and men, respectively [6]. The majority of the iron. 
60-70°/., is present in haemoglobin in circulating 
erythrocytes, 10% in the form of myoglobin, cytochromes, 
and iron-containing enzymes, and the remaining 20-30% is 
stored in ferritin and haemosiderin in hepatocytes and 
reticuloendothelial macrophages [7]. This distribution of 
iron varies, for example in situations of iron deficiency, 
erythroid precursors have priority and the production of red 
blood cells continues at the expense of other tissues. The 
body is, however, economical in its handling of iron Only 
0.5-2mg enters and leaves the body on a daily basis [2] thus 
the majority of the iron is recycled, 
IRON ABSORPTION AND TRANSPORT 
Intestinal absorption of iron is thought to be the critical 
step in iron homeostasis 8]. The enterocytes found in the 
epithelial cell layer of the duodenum are specialised for 
absorption and transportation of iron. These cells differ from 
other cells in that they express a number of proteins related 
to iron uptake and transport (Fig. 1). 
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III. p). Amodelfar imaarrpataaoss &wdonalepilwhal cells 
pnooe ns sl oaai an tYuse propose dto be frmo1 ed in the nbsoxpt i1 
ct<vlamom. Adtiptedfma [2]. 
it has been proposed tha nan-ham iron (pk3,1, ) in the 
duodc am s re duce d by a feuic roductase (Dcytb: duodenal 
cy[oci¢ome b) in the beult border, bef one being tanspe¢ted 
rto the era mcyte dwough the tonumbaut ran 
srmsportar DUU (divsitr¢metaluynspar r 1). Owe inside 
tie cel, the iron (F11') is either sund mfe tin, or passes 
twoughthe basoW ere1 nemtase'be to reach the pksma by on 
ran exporter known as feaoporem or kegl. This sup is 
*tout to be foliamd by the reoid on c F! 2* by the 
pkma fenoxidase cemloplasmm (or es memörme- 
essocisted honologae, hep stin) [9]. F23+ is then 
sequesundvpbyepo-tmtideim, akbou tthedetailsc(this 
step on notyetfulytaudersmod. In romanal Jedividuals, this 
e acelhilu ion cäcukLes it the phm bound to wean 
tmsIeum (ü) and it ts fans no longer toxic, as i is 
neble to genaaefree radicals. 
CELLULAR Dl ON UPTAKE 
k, vezub¢des, 4u major protein nvohnd m änn uptake 
of zam-loaded if into celk is the plemu memDrme 
mduuupon of imfro® the pgrotr+aidmIttut(diet) to the 
tauf rrmreceptor (IfRI) (8]. l otypes of IM1, IfR1 end 
'IIR12, are lawa+v2t. 'hu ktbr molecule his or* recardly 
been ide tiied and its function reine s inu1ear (10]. It is 
lewwn, however, that both receptors bimd dfemc IIeuieatA 
ne pH-dependera nanu and de liver ion to the ce Ils 
'QR12 his t much lower baedn afficty this MR1, 
spp oxffitely 25 bores lower, end is di t olm eo oid 
the body varies eigjfxadly (11]. The but dvzicteruedot 
tu two is TIR1 (12], a 160-emäw-acid CkycopaotaM. Me 
furxL egal receptors composed of tiro idaaical monomers, 
larked by Iwo dsuthide bridges to fawn a molecule of 
molecular mass 190,000 Da. The crystal stnutn of the 
ectodoaiamoft1w IIRI, resolved at3.2A, [13] u cl nt 
PIC. (2A). Virtually all cells, except mºn e red blood cels, 
hive tue receptor on ttu i suace , 
but the lap st member 
at atthe erytkao, placeea and liver [14]. 
AL prrysiob0c &I pH, *& tra sfemn receptor has a hýjft 
biidiig e Lty for dücric reran mmsfetrii. PbUot 
brLdmC of %A two protenu, the complex zaamalicee 
tcoutcktlat-coatedpis rdo epeciaäsedendosomes (Ph. 
3). Upon mmsatio t and bee of the clatkait coo, t Im 
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50u"OlAreAm Ovmitw 4'Prafinr 6natwL in hm welt 
endosome becomes competent to pump protons in a protest 
energised by ATPase [15]. This causes the endosomal 
lumen to rapidly acidify to a pH arourri 5.5. At this pH, the 
binding of the iron to serum transfemn is weakened, leading 
to iron release. The free Fe3* is then reduced to Fee' on the 
cis-side of the endosomal membrane, before being 
transported out of the endosome by DMFI Once in the 
A) 
B) 
L]nrntJAFik6 t! dwtzn. X05.14 i1 11 Na 27 I 
cytosol, iron is either stored or utilised by the can. 
Following release of the iron, the ttirsfemn-Ml complex 
is then recruited through exocytic vesicles beck to the cell 
surface. At physiological pH-l, epo-treraferrindiseocietee (tom 
the receptor and returns to the circulation where it is 
reutilised [16]. It has been calculated that tranefemn is 




Fig, (Z) A) The crystal stmcbrs of the ectodemain of tlu trara feain receptor (Tfit 1) resolved at 3.21 
Each MI numcmr can be divided up ua rnmber of domain; Cytoplasmic domun, N-temurus corsisttsig of 61 anarn acids; 
Transnicmbram domain, 26 anuiv acids long lydrop1ubic seian; and the tattsfernn binding domai: 4 671 atnro acids bra. One 
monomer is depicted inblae, whilst the other morons is shown in red, jai yellow depicting th. profiase dornaitt apical denture 
and helical domain respectively. Adapted fl+om [13]. 
B) A nbb on diagram of Lchain hone apofenitin (1.95x) (1 AEW) created using Deep Viewer ! Swiss PD B Viewer 
Each of the 24 subunits is colaared differently to eve an idea oftla complaxityof tlhe nolec. L. 
CD Rsbbondiagram of rabbit serum tramfenut (1JNFA) 
Pictise was created using Deep Viewer! Swiss PDB Viewer. Both lobes an labelled and both domuns lighluiled Doman I Bkr 
and Domainll. Red. 
D) I. The H-lobe birdirt-site of Iranian Iac9oferrin and II. Schematic diagram of the co-ordination ernisoreeerd and the I 'drogen 
b ordins network around Fe 
3' in the N-bb e of hen s arum tram £enin 
This Few inn is bound to this side chairs of Asp6Q Tyr92, Tyr192, and His253 and the bidentate C032 Ios, witch is lydmran- 
bonded to Argl2l and to peptide NH groups from the N-tarminu of antic-helix. 
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1 G1rreýtya%ýriCiass 2M9S, V. I2, Jk 21 
CABS may ilso teke up ion in olur protein-board 
farms, such as &cidic safeaim, cr haemoglobin, aQ t rou 
plugocycoszs of red bbod cells by mumpheges. 
ochemiial dde also sweets tha eddlia el rn Wteke 
n dmru s may e xxt (3]. This demmwa*es Out mm 
*Oughthe Wmsfeai<-mediued endocywsis is tout to be 
4, e major tptake syetnu of ra, cells karre evokred e 
- nmmber of other me cherias for te uptake of 
IRON STORAGE AND RELEASE 
Not all body on s uLifised n metabolx processes. 
Some of ä is stared as a reserve m case body inn ]eels 
became low. As free k+on would aWagate uto tDxic 
pncip aaes (17] kon is red infeafsu andhaemosiderau 
n 1, hpttocyoes gd reticuberudotixlial macrophages. This 
stared on aenaurvs to shot 20-30% of the total body irm 
n normal mdvibis1e . 
P nArk is a ubiquiow and h oly cansewed ron- 
bE, dwgpcot*m. A rw nber cf Mena fom s exist ä chdi4, 
cywsoäc fentsn, =lod=&iel feu do std stri- featÄ. 
The =mum of the cytosohc form of L-ckAtft horse 
apafeaIDn is drown in ft. (2E). lienfethais ire all 
C; U? tvn 
rYk'l1A(7 : It 
4i 
I. - 
hAaopolymrs of 24 aibwuts of two Vpts, desiputed Hfor 
heavy (71,000 Da) or heart, and L for lien (19300 Da) or 
äver [11. Tust molecuLshave t1w eAi1Wtuagwstartc to 
4pproxmaae ly 4500 won amm su f emi e Fe'+ 1181, An 
zaatut ft Cat of far1n is 9; abil*' to cttayse *0 
oxidation of 1R 1; he pre damaneat ianfawn it the cytosol, 
cowtrt gt to 113+bdaxe t is ngnesteed in 4u fentm 
amxnl con. 
Humosidaai is a poorly defaud sari-prom ca=plex 
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tissue sc ont* arty bw amowads of hannosidck%, however, 
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pt tic laly m organs nuh is the liver, pauaeas, cud lust 
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Their expression can be up- or down-regulated depending on 
the availability of iron. This control involved modulation of 
transcription, mRNA stability, translation, and post. 
translational modification 
Post-transcriptional modification is the best characterised. 
This involves the iron regulatory proteins (lRPs) and iron 
responsive elements (IREs). IRPI and IRP2 are involved in 
the coordinate postuanscriptional regulation of iron 
metabolism by binding to IRE$ [20] These IRF. v are stem- 
shaped structures located in the 5' and 3' untranslated 
regions (UTRs) of mRNA encoding proteins. Their structure 
includes a terminal hexanucleotide loop region with the 
sequence 5'-CAGUGX-3', where X can be A. C, or U. but 
never G, and a base-paired stem structure that is interrupted 
by a conserved unpaired cytosute, six nucleotides down from 
the loop. Table 1 shows examples of some of the proteins 
under IRE control. These include proteins involved in iron 
storage, erythroid haem synthesis, the TCA cycle, iron 
export and iron uptake. 
The binding of IRPs to single IREs in the 5' UrRs of 
mRNA has been found to block translation. Whereas, 
binding of IRPs to IREs in the 3' UTRs stabilises the 
mRNA, therefore having a positive effect on translation. Fig. 
(4) shows some of the proteins that are regulated in this way, 
and also the effect iron levels have on the translation of their 
mRNAs. 
The actual binding of IRPs to IREs is regulated by a 
number of different factors. When iron levels are high, a 
cubane iron sulphur cluster assembles in IRPI, inhibiting 
IRE binding and converting IRPI to an aconitase [9]. Under 
iron limiting conditions this iron sulphur cluster does not 
form, and IRPI is able to bind to IREs. This is different for 
IRP2 as this protein does not contain an iron sulphur 
cluster. IRP2 has been found to contain an iron-dependent 
degradation domain. In the presence of iron, proteosomes 
bind to this protein and degrades it, thus preventing its 
interaction with IREs. Even though these two IRPs have 
MmAUUd Chomi oy JODS, Yd IA N& 11 1 
been identified, little is known about their individual 
contribution to the maintenance of cellular iron homeostasis. 
It has been shown in vitro that both proteins do not differ in 
their ability to be able to regulate ferritin and TfRI 
expression [24]. However, it has been suggested (25) that 
IRP2 dominates post-transcriptional regulation of iron 
metabolism in mammals. The actual control of IRP 
expression is poorly understood A number of factors that 
influence their expression are known. These include the 
influence of reactive oxygen species, shown to disassemble 
the iron sulphur cluster of IRPI, as well as nitric oxide and 
hypoxia having an effect on both IRPs [3). 
Many other regulatory mechanisms exist that are 
independent of the IRPIIRE mechanisms. A number of 
cytokines have been reported to have an effect on the 
expression of some of the proteins involved in iron 
homeostasis. For example, tumor necrosis factor-aa, 
interleukin-1, interleukin-6, and interferon-y all stimulate H. 
ferritin expression but reduce TfRI expression (26). 
Interferon-y has also been shown to induce DMf-1 
expression and inhibit ferroportin expression. 
Another example of regulation is the proposed role of the 
haemochromatosms protein HFE in iron homeostasis. HFE is 
a heterodimeric membrane protein that has the ability to 
form noncovalent associations with ßj-microglobulin and 
has been shown to bind to TfRI. Two molecules of HFE 
can bind to the dimeric TIRI, or just one molecule 
simultaneously with a diferric If. When both proteins are 
bound. FIFE has been found to reduce the binding affinity of 
Tf for TtRI. Two possible reasons for this reduction in 
affinity exist Either HFE, on binding to one polypeptide 
chain of the TIRI duner, can transmit structural changes to 
other TfRI chains, or it competes with Tf for the TIRI 
binding site [27]. However, how HFE actually contributes to 
the regulation of cellular iron homeostasis is still unknown. 
Expression of HFE in the cell reduces iron uptake by 331/e, 
but does not affect the endocytic or exocytic rates of TIRI 
cycling [28]. 
Table L Examples of Iron Responsive Element (IRE)-Contalnlag Genes and their Fanctloo 
Gene IRE location Fundion Reference 
&Mgt* IRF, 
Farnen L chain 5' Iron Store (211 
Fetritn H chain 5' Iron Store 
MRochandnal AconBno 5' Enzyme in Citric Acid cycle 
Eiythrotd S-ALA"synthese 5' Specdic key enzyme in heue synthesis 
Nnmp2 3' Iron Importer (221 
Ferroportin I (REGI) 5' Iron Exporter (23) 
DMTI 3' Iron Transporter (31 
Sucnnae dehydrogenw Involved in the citric acid cycle 191 
Moinple REa 
TIRI 3' M-0indmgand-treneport (211 
TM Io . hO of 1N )ill. whether is the 3' a5' rttrmAabd'pm (UTR). Is sin II,. t Only W TAI SANA Mlrw eW6pI$ IR L 
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Fig. (4). The IRP-IRE regulation system showing the effect iron, NO, H201 and Oz levels has on the binding of IRPs to IREs, and the 
subsequent effect this has on translation on a number of proteins 
IRPs binding to IREs in the 3' UTR portion of mRNA has been found to protect the mRNA from degradation, whereas, the binding of 
IRPs to IREs in the 5' UTR portion has been found to block translation. Adapted from [3). 
TRANSFERRINS on the surface of melanoma cells. These proteins are found in 
a wide range of organisms, in both vertebrate and 
The transferrins are a family of homologous monomeric 
bilobal glycoproteins of molecular mass approximately 
80kDa that have an important role in iron homeostasis. Even 
though the first isolation of a member of the transfemn 
family, ovotransferrin came in 1900 [29] it was not until 
1944 that it a role was proposed for it [30]. Soon after, a 
similar protein, now known as serum transferrin, was 
isolated from blood plasma [31]. The transferrin family 
comprising four main members, each exhibiting a high 
affinity for iron (Kd- 10-221) [32], includes the serum 
transferrins, which transport iron from its site of absorption 
to the site of utilisation or storage, the lactoferrins, which 
possess antimicrobial properties, the ovotransferrins, a major 
component of egg white, and the melanotransferrins, found 
invertebrate groups Table 2 lists some of the trunsfemns 
that have either fully or partially sequenced 
General Structure 
The transferrin polypeptide is approximately 670 amino 
acids long folded into two lobes that exhibit high levels of 
homology, the N- and C-lobe. The two lobes of human 
serum transferrin are 48°%o homologous [33] and for both 
porcine and rabbit serum transferrin, 45.5% and 42.9% 
respectively [34} This high degree of homology is 
consistent with the theory that both lobes arose from a gene 
duplication process [35] 
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Table l Trandemini that have been Identified and Sequenced 
Chordate Anthropoda $dthgdermde 
T an. tmrln M. mmdia Area Amphbla Aetlnopterytll Insects Mdecoalnce FAINDIdes 
Serum 
TYsmffcrtin 
Human African clawed toed Medakt Moagwto (Aedei) 
Mouse Atlantic cod Cockroach 
Rat Haddock Silkworm 
Rabbit Coho nlmon Fndl fly 
Cow Cherry salmon Picture winit fly 












Hippo Brown trout Wax moth 
Bowhead 
Whale 
Brook trout Tic to fly 




Spam Whale Japanese char 

























Othan Red urchin 
ctreen urchin 
Sea le rbin 
Haws tin urchin 
Saxt ihn (bulltring) 
Panttitin 
(crayfish) 
PuhY and vulmit we ban ie i1Wu. mii Me wuli updund is 2003 hmc www. t4ýhm. ýA dusds dutlýEiMmbKlAtmdwAVYmdmr4RA1ý 
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Within the secondary structure of these proteins, there are 
six conserved disulphide bridges in each lobe, with an extra 
three semi-conserved bridges in the C-lobe [35]. Chicken 
and duck ovotransferrin have only fifteen bndges, whereas 
human lactoferrin has a further disulphide bridge in the C- 
lobe and human Tf has a further four bridges, two in the N- 
lobe and two in the C-lobe. 
Since the first report of the structure of transferrins in 
1979, from a 6A electron density map [361 the tertiary 
structure of these proteins has been elucidated at much higher 
resolution. For example, the crystal structure of hold hen 
ovotransferrin N-lobe has been elucidated recently at 1.65A 
[37], human apo-lactoferrin at 20A [38] and rabbit serum 
transferral at 2.6A [31]. These structures show that the 
transferrins are folded into two lobes of approximately 330 
trlwrt tat 
amino acids that are joined together by a short connecting 
peptide and also make contact vu a 'cushion' of 
hydrophobic residues packed between them. Each lobe can 
be further split into two dissimilar domains (CI, CII, NI and 
NIT) (Fig. 2C). These domains consist of mixed right- 
handed (-sheets (-25'/. ) and m-helices (--401/6). 
Most of the transfemns, except for Xmopus laevls 
transferrin, contain a varying number of N-linked 
glycosylation sites. For example, rabbit scrum tnvufenin has 
only one [39]. bovine lactoferrin has four (40] and human 
serum transferrin has two [41 ]. No 0-linked giycosylations 
have been identified on transferrins. The fact that not all 
transferrins are glycosylated suggests that there r no specific 
role for these sugars. 
Table3. Comparison of the Residues Involved In Iron Binding, Their Position and 1M Amino Acid Either Side of M (-land +1) 
for Both Lobes Amongst Different Tranderrine 
GLobe N-tube 
Tranfkrrln -1 Fea'/Qaad +1 -1 FOS+II`and +1 
Human Scum Transferrln Lau A>p62 Ala Lou Asp392 Oly 
Phe T'r9S Tyr Oly 7yr426 Phe 
Oly 7yrlgt Set Oly TyrS11 71r 
Bar M*249 "r Am 11101113 Alt 
Oly Arg124 Set Oly Ar54M 71u 
Human Gdoferrlu Lou A. p66 Oly Lou A. p19S Oly 
His Tyr92 Tyr Oly 7yr435 Lou 
Sc 7pr192 Set Oly TyrS2e The 
Ser Tyr253 Alt Am Ff191 Ala 
Arg Arg121 Thr Asp Arg66S 71u 
Rabbit Serum Ttanlerln Lau Aep63 Ala Lou Aap3 2 Oly 
Phe 7yr93 Tyr Oly Tyr42S Lou 
Oly 7yrllS Sur Oly lyrSl4 Thr 
Sur iyr2e9 Ala Am H1082 Ala 
Oly ArJ124 Bar Asp Arge33 71V 
Purdue Serum Trandarrln Lau AQ62 Ala Lou Aap396 Oly 
His Tyr% Tyr Oly 7yrU1 Lou 
Oly Tyr192 Ala Oly 7yr326 Thr 
Ser 15a253 Ala Am 1011594 Ala 
Oly Ar{l22 Set Asp Arg162 The 
Camel LartoferA. Lau A4p Oly Lou Asp39S Oly 
His Tyr92 Try Oly 7yr433 Lou 
Oly Tyr 192 Ser Oly TyrS26 1111, 
Sir HIa253 Ala Am HIa195 Ala 
Oly Argl2l Set ASP Artr63 lM 
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Iron-Binding Sites 
The transferrins have the ability to bind reversibly two 
ferric ions, one in each lobe. The two iron-binding sites are 
42A apart and buried deep in the interdomain cleft in a 
highly polar environment (42]. The iron-binding sites in 
both lobes are very similar and comprise a distorted 
octahedral coordination involving four protein Uganda and a 
bidentate synergistic carbonate anion [34] (Fig. 2DI). These 
protein ligands comprise two tyrosine residues, one aspartate 
residue and one histidine residue. Amongst all known 
transferrmsthe aspartate and the histidine are provided by 
domain 1, whereas the two tyrosines and the bidentate 
carbonate anion is provided by domain H. All four of these 
ligands, along with an arginine involved in the anchoring of 
the carbonate anion to the protein, are conserved between 
lobes and amongst higher transfemns. Table 3 illustrates to 
what degree these five residues, along with their neighbors, 
are conserved amongst the higher transfemns. 
In order to understand the binding of Fe3+ by transferrin, 
it is important to note that Fe3+ has the ability to bind six 
ligands. This arises from the fact that the atom has five 
unpaired electrons in its 3d orbital and an empty 4s orbital. 
When Fe" is bound by transferrin, a possible way these two 
orbitals are filled up is by an electron from one carboxylate 
oxygen (aspartate), an electron frown each of the two 
phenolate oxygens (two tyrosines), an electron from each of 
the two oxygens from the carbonate anion, and two electrons 
from the imidazole nitrogen (histidme) (see Fig 2DI1) It is 
also important to note that the three positive charges of the 
Fe3+ arc matched by the 3 negative charges of the aspartate 
and the two tyrosines. Also, the charge on the amon is 
compensated for by the positively charged arginine side 
chain and a positive charge at the N-terminus of an a-helot 
[43]. 
Iron Binding and Release 
A feature common to all transferrins is the closing of the 
interdomam clefts upon incorporation of iron into the iron- 
binding saes, bringing the von-binding ligands on both 
domains together, 'grasping' the iron. In the apo form, the 
domains have been shown to be open [44]. 
The actual mechanism of iron binding is still not 
completely clear. It is thought that iron-binding starts with 
the binding of the carbonate anion to domain II, followed 
closely by the binding of the metal by the two tyrosines on 
the same domain. Once bound, a conformational change 
occurs, causing domain I to close over domain II This 
closure allows the histidine and aspartate ligands to come 
into contact with the iron, allowing them to bind the irons 
remaining two coordinates. 
The extent in which the two domains open and close is 
reported in a recent study [45] which also demonstrates how 
highly conserved the rotation angle of domains is across the 
transfeam family When domain I from the closed form of 
hen serum transferrm N-lobe is superimposed with the open 
form, a rotation of52.7° difference can be seen. Similarly in 
the C-lobe, a rotation of 35° was seen. The rotations in the 
N-lobe of human lactoferrin and human serum transferrin are 
also similar, 54° and 63° respectively. 
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The actual affinity for the Fei` ion varies between both 
lobes and also members of the transferrin family. One 
explanation for this is that the iron-ligand bond distances are 
known to vary. The longer bond length is thought to be the 
reason why the N-lobe of serum transfcrrin releases iron more 
readily than the C lobe on increasing acidity. Iron is released 
from the N-lobe of serum transferrin at around pH 5.7, 
whereas the C lobe retains uon until around p1I 4.8 (46]. A 
difference in the pH dependence of iron release can also be 
seen between transferrin family members as. for example, 
lactofetrin retains iron at it pH as low as 3.5. The higher 
iron-binding affinity seen in lactofetrms could also be due to 
the greater number of interdomain hydrogen bonds [34]. 
These differences in iron affinity between the serum 
tranesferrtns and the lactoferrvis has also been proposed to be 
due to particular residues found only in the N terminal lobe 
of the serum transfenins, away from the iron-binding site, at 
the interdomain interface. In this region, two lystnes have 
been proposed to play a role in iron-release. These residues 
are on opposite faces of the iron-binding cleft and are thought 
to be budged by a single proton when the protein is in its 
closed form. The theory is that at low pli these two lysine 
are protonated, leading to the subsequent release of the 
proton bridge and causing the two domains to repel each 
other [4] As the domains flip open, the von is released 
This theory is known as the dilysine trigger. The 
importance of these lysines was highlighted in a study [47] 
that showed that mutation of these two lysine had a 
significant effect on iron binding and release. 
However, a primary role of this dilyaine trigger has been 
questioned It is thought that the protonauon of the 
carbonate anion and the histidine iron-binding ligand 
constitutes the primary stages of iron release, with the 
dilysinc trigger being important once the iron binding 
ligands are weakened [34]. This dilysine trigger does explain 
though, at least in part, the in vitro release of iron more 
readily from the N-lobe compared to the C"lobe of serum 
transfetrin. 
Hinding of Other Metals 
Although the transferrms have evolved to bind iron QII) 
with high affinity at neutral pH, their metal-binding sites are 
able to bind a wide range of different metal ions. As serum 
transferrin in normal mdividuals is only partially iron. 
saturated transferrin could in theory bind and transport 
metals other than iron that could ultimately be taken up into 
cells by receptor-mediated endocytosis. 
By 1992 thirty elements, in addition to iron, were 
known to be able to bind to one or both of the m etal"bindug 
sites in human serum transferrin in vitro (48). Since then s 
further four metal ions, cerium (IV) (49), bismuth (III) [50], 
lutetium (III) [51] and ytterbium (III) [52) have been shown 
to bind to members of the transferrin family of proteins. The 
elements now proven to bind to transfemns are highlighted 
in Fig. (S). Despite the large number of metal ions that are 
now known to bind to the transferrins, crystal structures of 
transfetrins complexed to metals other than iron (III) are 
limited to human lactoferrin with copper (It) [53] and cerium 
(IV) [54], and mare lactofemn with samarium (III) (55]. The 
availability of further crystal structures for metal complexes 
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